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Abstract 
Chronic HCV infection (CHC) is a significant cause of both liver related and non-
liver related morbidity and mortality worldwide. Disease progression through to 
cirrhosis and hepatocellular carcinoma is highly variable, and once chronicity of 
infection has been established, the likelihood of spontaneous clearance without 
antiviral treatment is extremely low. Safe and highly effective oral antiviral 
therapy is now available for the treatment of CHC, however price and 
accessibility may limit the global use of these agents. Furthermore, concerns 
have been raised regarding the incidence of hepatocellular carcinoma in HCV-
infected individuals receiving oral antiviral regimens, and there appears to be a 
‘point of no return’ beyond which cirrhotic HCV-infected individuals fail to 
benefit from antiviral treatment. Thus, there remain a number of unanswered 
questions on the natural history of HCV infection. 
Ageing of the immune system, or immunosenescence, appears to contribute to 
poorer clinical and treatment outcomes, however robust, non-invasive, clinically 
relevant biomarkers are lacking. MicroRNAs (miRNAs) are short, endogenous non-
coding RNAs responsible for post-transcriptional control of host gene expression. 
Specific patterns of miRNA deregulation have been described in the serum, liver 
tissue and peripheral immune cells of HCV-infected subjects, and it is 
hypothesised that they may be suitable as both diagnostic and prognostic 
biomarkers.  
We interrogated 3 patient cohorts (providing access to local and national clinical 
data) to identify patient factors associated with disease progression and both 
spontaneous and treatment-associated clearance of CHC. We found that 
chronological age and elevated BMI had the strongest association with hepatic 
cirrhosis. Co-morbid type 2 diabetes mellitus was associated with poor clinical 
outcomes during antiviral therapy. Spontaneous clearance of CHC occurred 
rarely (0.36 per 100 person-years follow up), and was associated with female 
gender, earlier age at infection, low HCV viral load and co-infection with HBV. 
Current injecting drug use was negatively associated with spontaneous 
clearance.  
We also explored the use of miRNAs as biomarkers in these cohorts. We 
correlated miRNA expression with cellular markers of immunosenescence to 
identify novel prognostic biomarkers for disease outcomes in CHC. Our findings 
demonstrated that CHC was associated with a distinct miRNA signature in the 
serum and peripheral immune cells. Serum miR-21-5p, miR-122-5p and miR-885-
5p levels correlated with the expression of previously described biomarkers of 
ageing, however these miRNAs performed poorly as biomarkers of cirrhosis in 
CHC. Elevated serum miR-21-5p expression was an independent predictor of 
virologic relapse following antiviral therapy, together with HCV genotype. MiR-
21-5p also appeared to predict the likelihood of an adverse clinical event during 
treatment. We identified a further microRNA, miR-345-5p, elevated baseline 
expression of which correlated with negative clinical outcome during treatment, 
and was associated with the presence of both hepatic and extra-hepatic 
malignancy. We explored the regulation of miRNA expression in an in vitro 
model, and found that interferon-stimulated gene expression is necessary for 
IFN-induced miR-21-5p expression.  
Finally, we performed pathway analysis for target genes regulated by miRNAs 
deregulated during CHC, and found that pathways in cancer were highly 
enriched. Pathway enrichment was similar between HCV-infected cirrhotic 
subjects and non-cirrhotic, immunosenescent subjects, suggesting that non-
cirrhotic individuals with elevated biomarkers of immunosenescence may be at 
an increased risk of hepatocellular carcinoma and may benefit from enhanced 
surveillance and prioritisation for antiviral treatment. Overall, the wealth of 
clinical and molecular data provided the opportunity to explore possibilities for 
integrating novel biomarkers into clinical decision-making for monitoring liver-
related disease in HCV-infected subjects.  
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IDU   Intravenous drug use     1-36 
IGF2BP1  Insulin-like growth factor 2 mRNA-binding protein 1 1-111 
IFITM1  Interferon-induced transmembrane protein 1  1-43 
IFNAR   Type I IFN-α/Β receptor     1-42 
IFN   Interferon       1-32 
IFN-α   Interferon-alpha      1-68 
IGF-1   Insulin-like growth factor 1    1-95 
IHHs   Immortalised human hepatocytes   1-110 
IKKε   Inhibitor of kappa B kinase-related kinase   1-41 
IL   Interleukin       1-40 
IMPDH   Inosine monophosphatase dehydrogenase  1-69 
INK4   Inhibitors of CDK4      1-89 
IR   Insulin resistance      1-59 
IRAK1   IL-1 receptor associated kinase 1    1-107 
IRES   Internal ribosome entry site    1-29 
IRF-3   Interferon regulatory factor 3    1-41 
ISDR   Interferon sensitivity determining region  1-32 
ISG   Interferon-stimulated gene    1-40 
ISRE   Interferon-sensitive response element   1-42 
JAK   Janus kinase       1-42 
JNK   c-Jun terminal kinase     1-54 
KCs   Kuppfer cells       1-52 
KEGG   Kyoto Encyclopaedia of Genes and Genomes  2-135 
KIR2DL3  Killer gene immunoglobulin-like receptor 2DL3  1-44 
LCMV   Lymphocytic choriomeningitis virus   1-47 
LDLr   LDL-receptor       1-33 
LDLs   Low-density lipoproteins     1-29 
LMICs   Low- and middle-income countries   1-38 
LPS   Lipopolysaccharide      1-62 
LT-ΒR   Lymphotoxin Β receptor     1-29 
LVPs   Lipoviroparticles      1-29 
MAIT   Mucosal-associated invariant T cells   1-48 
MAPK   Mitogen-activated protein kinase    1-92 
MAVS   Mitochondrial antiviral signalling protein  1-41 
MCM5   Mini-chromosome maintenance protein 5  4-177 
Mda5   Melanoma differentiation-associated gene  1-41 
MDM2   Mouse double minute 2 homolog protein  1-90 
MELD   Model for end-stage liver disease    5-214 
MHC   Major histocompatibility complex   1-57 
MiR   MicroRNA       1-34 
MiRNA   MicroRNA       1-66 
MMP   Matrix metalloproteinase     1-29 
MPTP   Mitochondrial permeability transition pore  1-100 
mRNA   Messenger RNA      1-25 
MSM   Men who have sex with men    1-37 
MTCT   Mother to child transmission    1-37 
mTOR   Mammalian target of rapamycin    4-177 
MW   Membranous web      1-31 
MyD88   Myeloid differentiation primary-response gene 88 1-41 
NAFLD   Non-alcoholic fatty liver disease    1-57 
NANBH  Non-A, non-B hepatitis     1-24 
NASH   Non-alcoholic steatohepatitis    1-51 
NF-κB   Nuclear factor-kappa B     1-41 
NHSGGC  NHS Greater Glasgow & Clyde Health Board  3-139 
NK cells  Natural killer cells      1-40 
NPHV   Non-primate hepaciviruses    1-25 
NPM   Nucleophosmin      1-90 
NRES   National Research Ethics Service    5-214 
NS   Non-structural      1-27 
nt   Nucleotides       1-24 
NTPase  Nucleoside triphosphatase     1-28 
OCLN   Occludin       1-33 
OMM   Outer mitochondrial membrane    1-29 
ORF   Open reading frame     1-27 
PAMPs   Pathogen associated molecular patterns  1-40 
PBMC   Peripheral blood mononuclear cell   1-48 
PD-1   Programmed cell death-1     1-48 
PDGF   Platelet derived growth factor    1-52 
PDGFR  Platelet derived growth factor receptor   1-52 
PEG   Polyethylene glycol      1-70 
pegIFN-α  PEGylated interferon-alpha    1-70 
P-gp   P-glycoprotein      1-73 
PKR   Protein kinase R      1-32 
Poly (I:C)  Polyinosinic:polycytidylic acid    2-118 
PPARγ   Peroxisome proliferator – gamma    1-53 
Pre-miRNA  Precursor miRNA      1-103 
PT   Prothrombin time      1-66 
PTEN   Phosphatase and tensin homolog    4-173 
PWID   Persons who inject drugs     1-36 
RANKL   Receptor activator of NFκB ligand   1-66 
RAS   Resistance associated substitutions   1-73 
Rb   Retinoblastoma      1-89 
RBV   Ribavirin       1-68 
RdRp   RNA-dependent RNA polymerase    1-28 
RIG-I   Retinoic acid-inducible gene I    1-41 
RIN   RNA integrity numbers     2-122 
RISC   RNA-induced silencing complex    1-103 
RLRs   Retinoic acid-inducible gene-like receptors  1-41 
RNA   Ribonucleic acid      1-24 
ROC   Receiver operating characteristic   2-137 
ROS   Reactive oxygen species     1-51 
RR   Responder-relapsers     5-215 
RSV   Respiratory syncytial virus     1-69 
RT   Reverse transcriptase     1-33 
SAE   Serious adverse event     5-215 
SASP   Senescence-associated secretory phenotype  1-91 
Sen-Β-Gal  Senescence associated Β-galactosidase   1-66 
siRNA   Short interfering RNAs     1-105 
SIRT1   Sirtuin 1       1-95 
SMAD2  Sma- and Mad-related protein 2    1-109 
SNP   Single nucleotide polymorphism    1-45 
SoC   Standard of care      1-69 
SOCS1   Suppressor of cytokine signalling 1   1-109 
SOCS3   Suppressor of cytokine signalling 3   1-111 
SR-B1   Scavenger receptor class B type 1   1-33 
STAT   Signal transducer and activator of transcription 1-42 
STI   Sexually transmitted infection    1-37 
SVR   Sustained virologic response    1-45 
SVR12   Sustained virologic response at 12 weeks  1-68 
SVR24   Sustained virologic response at 24 weeks  1-68 
TAB1   TGF-Β activated kinase 1 binding protein 1  1-112 
TAB2   TNF-Β activated kinase 1 binding protein 2  1-109 
TBK1   NF-κB activator binding kinase 1    1-41 
TE   Transient elastography     1-65 
TE    Tris-EDTA buffer      2-117 
TGF-Β   Transforming growth factor-Β    1-52 
TIMP   Tissue inhibitors of metalloproteinase   1-52 
TLRs   Toll-like receptors      1-40 
TNF-R1  Tumour necrosis factor receptor 1   1-29 
TNF-α   Tumour necrosis factor-α     1-29 
TRAF   TNF receptor-associated factor     1-41 
TRBP   TAR RNA binding protein      1-103 
Treg   Regulatory T cell      1-47 
TRF   Telomere repeat binding factors    1-83 
TRIF   TIR domain containing adaptor inducing interferon-Β 1-41 
TRIM25  Triple motif-containing protein 25   1-41 
UGT   Uridine 5’-diphosopho-glucuronosyltransferase  1-74 
ULN   Upper limit of normal     1-24 
UTR   Untranslated region      1-25 
VEGF   Vascular endothelial growth factor   1-109 
VIF   Variance inflation factor     2-137 
VLDLs   Very-low-density lipoproteins    1-29 
WoSSVC  West of Scotland Specialist Virus Centre  3-139 
XPO5   Exportin 5       1-103 
αSMA   alpha-smooth muscle actin    1-52 
Β-ME   2-Mercaptoethanol      2-116 
ΔCT   Normalised cycle threshold    2-134
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1 Introduction 
1.1 Background 
1.1.1 ‘Non-A, Non-B’ Hepatitis 
‘Non A, non B hepatitis (NANBH)’ was first described in the 1970s as a form of 
transfusion-associated hepatitis which could not be identified with the use of 
serological tests for hepatitis A virus (HAV), hepatitis B virus (HBV), 
cytomegalovirus (CMV) or Epstein-Barr virus (EBV) (Feinstone et al., 1975, Alter 
et al., 1975, Prince et al., 1974). Researchers postulated that it was caused by a 
third type of human hepatitis virus with an incubation period of two to 15 weeks 
(Feinstone et al., 1975, Hoofnagle et al., 1977).  
Further research led investigators to propose that: 
i) the epidemiology of NANBH resembled that of HBV infection 
ii) an infectious carrier state must exist in relatively asymptomatic hosts 
iii) it was more common in lower socio-economic groups 
iv) it was significantly associated with the development of chronic liver 
disease (Feinstone and Purcell, 1978).  
The causative agent was proven to be transmissible, as inoculation of 
chimpanzees with serum or plasma from patients with NANBH resulted in 
hepatitis, defined as a serum alanine aminotransferase (ALT) of greater than 3 
times the upper limit of normal (ULN), histopathological changes consistent 
with viral hepatitis, or both (Shimizu et al., 1979, Yoshizawa et al., 1980).  
Despite an active research programme, scientists struggled to identify specific 
viral antigens and antibodies with standard immunological methods and it was 
over a decade before the infectious agent was characterised. Choo and 
colleagues (1989) utilised elegant recombinant DNA cloning techniques to 
identify a positive-stranded ribonucleic acid (RNA) molecule of around 10,000 
nucleotides (nt) which they termed the hepatitis C virus (HCV) (Choo et al., 
1989).  
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1.1.2 Classification of HCV 
HCV is now known to be an enveloped, positive-sense, single-stranded RNA virus. 
Based on these characteristics, it was initially presumed to be related to the 
Togaviridae or Flaviviridae. Members of the Flaviviridae family have virions 
composed of the following basic components:  
1. A nucleocapsid containing a positive-sense, single-stranded RNA genome, 
96000 – 123000 nt in length 
2. An enveloped lipid bilayer, in which ≥ 2 envelope proteins are anchored. 
The RNA genome serves as messenger RNA (mRNA) and, together with modified 
cell membranes as well as virus and host factors, acts as a template for 
replication through negative-strand full length intermediates.  
Phylogenetic analysis ultimately classified HCV as a new member of the genus 
Hepacivirus within the family Flaviviridae (figure 1-1) (Simmonds et al., 1993). 
Other members of the Hepacivirus genus include GB virus B (GBV-B), a virus 
recovered from a tamarin killed in captivity (Simons et al., 1995), and the 
rodent, bat and non-primate hepaciviruses (NPHV) (Reuter et al., 2014, Lyons et 
al., 2014, El-Attar et al., 2015, Drexler et al., 2013). The list of hepaciviruses 
continues to grow with additional members recently identified in domestic 
cattle and catsharks (Hartlage et al., 2016). 
HCV is divided into 7 separate phylogenetic groups, or genotypes, which display 
marked sequence diversity (figure 1-2). On average, the genotypes differ by 30-
35% at the nucleotide sequence level over the complete genome (Smith et al., 
2014) with most variability concentrated in regions such as the E1 and E2 
envelope glycoproteins. The lowest variability between genotypes is seen in the 
5’ untranslated region (UTR). The genotypes can be further divided into more 
closely related subtypes, which diverge by around 20-25% of nucleotide sites. 
HCV subtypes are also epidemiologically distinct, demonstrating different 
distributions according to geographical range and risk factor group (chapter 
1.1.6).  There is considerable genetic diversity in those genotypes seen in sub-
Saharan Africa and Southeast Asia, leading researchers to suggest that HCV has 
been endemic in these regions for periods spanning hundreds of years 
(Simmonds, 2001, Pybus et al., 2009). 
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Figure 1-1: Phylogenetic tree of members of the family Flaviviridae. The scale bar depicts a 
divergence of 0.1 (10% amino acid sequence divergence). HCV, hepatitis C virus; NPHV, non-
primate hepacivirus; GBV, GB virus B. Extracted from Simmonds (2013) 
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Figure 1-2: Evolutionary tree of NS5B sequences of HCV genotypes 1-7. The scale bar depicts 
an evolutionary distance of 0.05nt. Extracted from Smith et al. (2014)  
 
1.1.3 Structure of the HCV virion 
The length of the HCV genome is approximately 9600 base pairs (bp), consisting 
of a 5’ UTR, a single open reading frame (ORF) and a 3’ UTR (Moradpour and 
Penin, 2013, Choo et al., 1991, Kolykhalov et al., 2000). Most of the genome 
forms the ORF which encodes the entire HCV polyprotein, consisting of 3 
structural (core, E1, E2) and 7 non-structural (NS) proteins (Simmonds, 2004). 
The 3 structural proteins are encoded by the amino-terminal segment of the 
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ORF. The NS proteins are encoded by the remainder, and include the p7 
viroporin, the NS2 protease, the NS3-4A complex (nucleoside triphophatase 
(NTPase)/RNA helicase and protease activities), the NS4B and NS5A proteins, and 
the NS5B RNA-dependent RNA polymerase (RdRp) (Moradpour and Penin, 2013). 
The 5’ and 3’ UTRs contain the signals for replication and translation of the viral 
RNA (figure 1-3).  
The 5’ UTR is the most conserved part of the HCV genome, sharing 60% sequence 
homology with GBV-B. It is 341 nt long and contains 4 highly structured domains. 
Domains II, III and IV together with a segment of the core-coding region make up 
the internal ribosome entry site (IRES), consisting of 4 distinct stem loops (Honda 
et al., 1996).  
 
Figure 1-3: The HCV genome and gene products, extracted from Abdel-Hakeem and Shoukry 
(2014). Cleavage sites of the HCV polyprotein by host and viral proteases are indicated with 
arrows. The purple arrows indicate the cleavage sites for the host signal peptidases, the 
green arrow indicates auto-cleavage by NS2/3 and the lilac arrows indicate cleavage by the 
NS3 protease. IRES, internal ribosome entry site; UTR, untranslated region. 
 
The viral genomic RNA together with the capsid protein (core) forms the 
nucleocapsid, which is spherical and approximately 30 nm in diameter. The 
nucleocapsid is surrounded by a lipid-containing envelope derived from host 
endoplasmic reticulum (ER) membranes. The morphological structure of HCV 
remains obscure as a consequence of the complex lipid envelope, however 
electron microscopy has demonstrated that the infectious virion is 40-100 nm in 
size (Gastaminza et al., 2006, Catanese et al., 2013). Virions circulate in 
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association with low-density lipoproteins (LDLs) and very-low-density 
lipoproteins (VLDLs) as lipoviroparticles (LVPs) (Catanese et al., 2013). These 
LVPs also contain apolipoproteins, including apolipoprotein B (APOB), 
apolipoprotein C (APOC) and apolipoprotein E (APOE).   
1.1.4 Viral proteins 
1.1.4.1 Core protein 
The RNA-binding core protein forms the viral capsid, as described above. It 
contains 3 distinct domains: i) domain D1, an N-terminal predominantly 
hydrophilic domain of ~120 amino acids (aa), ii) domain D2, a 50 aa C-terminal 
hydrophobic domain, and iii) domain D3, a highly hydrophobic 20 aa domain 
serving as a signal sequence for E1 (McLauchlan, 2000). D1 is involved in RNA 
binding and nuclear localisation, whereas D2 is mainly responsible for binding 
with ER membranes, outer mitochondrial membranes (OMM) and lipid droplets. 
Core protein directly interacts with a number of cellular proteins, including 
lymphotoxin β receptor (LT-βR), tumour necrosis factor receptor 1 (TNF-R1) and 
the DEAD box polypeptide 3 (DDX3), and plays an important role in diverse 
cellular processes. Core protein can promote oxidative stress, steatosis and 
apoptosis, leading to fibrogenesis independently of the immune response and 
inflammation (Missiha et al., 2008). Both core and NS5A proteins are able to 
upregulate expression of the pro-fibrogenic genes cyclo-oxygenase 2 (COX-2) and 
matrix metalloproteinase (MMP)-9 in hepatocyte-derived cell lines (Nunez et al., 
2004). The effects of core protein on apoptosis are conflicting; both increased 
and reduced Fas-mediated apoptosis by core have been reported in vitro 
(McLauchlan, 2000) and it may have both pro- and anti-apoptotic functions. The 
picture is no clearer for the effect of core protein on tumour necrosis factor-α 
(TNF-α) or LT-βR mediated apoptosis (Shimizu et al., 1996, Farci et al., 1996). 
Core associates with lipid droplets, and transgenic mice expressing core have 
been shown to develop hepatic steatosis (defined as an accumulation of lipid 
droplets in the liver) from an early age (Moriya et al., 1997). These transgenic 
mice lines were subsequently found to develop hepatic tumours, with histology 
demonstrating adenomata initially followed by transformation into poorly-
differentiated hepatocellular carcinomas (Moriya et al., 1998). Core protein has 
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previously been shown to regulate the transcription of the cellular oncogenes c-
myc and c-fos, supporting a role in hepatic carcinogenesis (Ray et al., 1995).  
1.1.4.2 E1 and E2 envelope glycoproteins 
The type I transmembrane glycoproteins E1 and E2 are essential for virus 
attachment and entry (see Chapter 1.1.5.1). They consist of an N terminal 
domain (160 and 334 aa, respectively) and a short C terminal transmembrane 
domain of ~30 aa. Both E1 and E2 are highly glycosylated. E2 contains 
hypervariable region (HVR) 1, a 27 aa region at the N terminus which is the 
major HCV neutralising epitope, and HVR2, a 9 aa region downstream of HVR1. 
The hypervariable regions demonstrate the highest sequence variability between 
HCV genotypes and subtypes. The interaction between HVR1 and negatively 
charged molecules at the cell surface is thought to facilitate host cell 
recognition and attachment (Bartosch et al., 2005). 
1.1.4.3 Frameshift protein 
The frameshift protein or ARFP (alternate reading frame protein) is produced 
during chronic HCV infection (CHC). Specific antibodies proving the existence of 
this protein were first detected in 2001 (Walewski et al., 2001). It is encoded by 
a reading frame that overlaps the N-terminal core-encoding region of the HCV 
polyprotein and is generated by a -2/+1 ribosomal frameshift during translation, 
hence the name (Xu et al., 2003). Similarly to core protein, it appears to localise 
to the ER membrane but its exact role in the HCV life cycle is as yet 
undetermined.  
1.1.4.4 P7 protein 
P7 is an integral membrane-associated ion channel protein of approximately 63 
aa. It is comprised of 2 transmembrane domains connected by a cytoplasmic 
loop. As p7 monomers are able to assemble into hexamers or heptamers, forming 
ion channels in lipid bilayers, it is thought to belong to the viroporin family 
(Gonzalez and Carrasco, 2003). P7 is now known to be critical for HCV infectivity 
as mutant polypeptides with deletions of all or part of p7 were not viable in a 
chimpanzee model (Sakai et al., 2003). 
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1.1.4.5 NS2 protein 
NS2 is a non-glycosylated transmembrane protein which contains 2 internal 
signal sequences responsible for association with the ER membrane (Santolini et 
al., 1995). It is released from the HCV polyprotein by proteolytic cleavage; the 
N-terminus is separated from the E2/p7 polypeptide by host signal peptidase, 
whereas the C-terminus is cleaved at the NS2-3 junction by auto-proteolysis 
(figure 1-3). NS2 loses its protease activity after self-cleavage from the amino-
terminal domain of NS3 and is quickly degraded by the proteasome (Franck et 
al., 2005).  
1.1.4.6 NS3-NS4A complex 
The NS3 protein contains a serine protease domain at the N-terminus, and a 
helicase/NTPase in the C-terminal region. The protease activity of NS3 is 
enhanced by an activator, NS4A. NS4A is a 54 aa protein which stabilises the 
NS3-NS4A complex (Bartenschlager et al., 1995). The NS3-4A protease is 
essential for productive infection, and consequently is a target for the new 
direct-acting antivirals (DAAs). It is responsible for cleavage at the NS3/4A, 
4A/4B, 4B/5A and 5A/5B junctions (figure 1-3).  
The NS3 helicase has NTPase and 3’-5’ RNA unwinding functions, making it 
essential for HCV RNA synthesis (McGivern et al., 2015). It plays a critical role in 
separating template and nascent RNA strands during HCV replication (Scheel and 
Rice, 2013). Genetic evidence also implicates the NS3 helicase in early HCV 
particle assembly (Ma et al., 2008). 
1.1.4.7 NS4B protein 
NS4B is a 261 aa integral membrane protein which is essential for the 
organisation of the replication complex. It induces the formation of the 
membranous web (MW), consisting of vesicles in a membranous matrix, that 
harbours the replication complex (Egger et al., 2002). NS4B has also been shown 
to directly activate pro-oncogenic signalling pathways (Jiang et al., 2017), 
supporting a potential role in hepatocarcinogenesis. 
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1.1.4.8 NS5A protein 
NS5A is an important regulator of HCV replication. It consists of a 30 aa 
amphipathic α-helix anchor at the N-terminus which is required for assembly of 
the replication complex and membrane localisation, together with a further 3 
domains. Domain I contains a zinc-binding motif at the N-terminal end formed by 
4 cysteine residues. Mutations which disrupted either membrane localisation or 
zinc binding were shown to block RNA replication (Tellinghuisen et al., 2004). 
The crystal structure of domain I was solved in 2005, and suggested potential 
protein, RNA and membrane binding sites, with significant implications for 
antiviral drug development (Moradpour et al., 2005).  
The mechanism by which NS5A regulates HCV replication is not fully understood. 
Both domains I and II are known to be required for HCV replication, however the 
function of domain III was less clear. Subsequently, a deletion in domain III was 
shown to be able to disrupt virus production independently of replication. It was 
demonstrated that a serine residue within the deletion was responsible for the 
observed phenotype, and that phosphorylation at that position was required for 
early virion production (Tellinghuisen et al., 2008). Studies of inhibitors 
targeting NS5A have suggested that NS5A may have both phosphorylation 
dependent and independent functions in RNA replication: a cis-acting function in 
the context of the replication complex, and a further trans-acting function 
requiring hyperphosphorylation (Fridell et al., 2011). 
NS5A interacts directly with cellular proteins, and is postulated to play a role in 
regulation of cellular growth and signalling, as well as response to interferon 
(IFN)-based therapy. The amino acid sequence of a region of NS5A, the 
interferon sensitivity-determining region (ISDR), has been shown to correlate 
with IFN sensitivity. Gale et al. (1998) were able to demonstrate that NS5A binds 
directly to the protein kinase catalytic domain of protein kinase R (PKR), which 
is a mediator of the IFN-induced antiviral response, and that the ISDR was 
required for this interaction (see chapter 1.2).  
1.1.4.9 NS5B (RdRp) 
NS5B is a tail-anchored protein, with a 21 aa α-helical transmembrane domain in 
the C-terminal region which may be involved in important protein-protein 
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interactions as well as acting as a membrane anchor. This membrane association 
is essential for HCV replication (Moradpour et al., 2004). The 530 aa N-terminal 
region forms a ‘fingers, palm and thumb’ polymerase structure, similar to the 
human immunodeficiency virus (HIV) reverse transcriptase (RT) (Ago et al., 
1999). Uniquely, extensive interactions between the fingers and thumb result in 
a completely encircled enzyme active site (Lesburg et al., 1999). NS5B may also 
interact with other cellular proteins to regulate HCV replication. Similar to the 
NS3 protease and NS5A protein, NS5B is a target for the DAAs. Both nucleoside 
and non-nucleoside inhibitors potently block NS5B-directed HCV RNA synthesis 
(chapter 1.5.1.5).   
1.1.5 HCV life cycle 
1.1.5.1 Virus attachment and entry 
HCV primarily infects and replicates within hepatocytes. The mechanism by 
which HCV enters the hepatocyte has not been fully elucidated, but involves 
interaction between the HCV envelope glycoproteins E1 and E2 and a number of 
host cell surface molecules. A major breakthrough came with the identification 
of the cell surface receptor CD81 as a binding partner for HCV in 1998 (Pileri et 
al., 1998). Subsequently, a number of further molecules have been identified 
with roles in HCV attachment and entry, including the LDL-receptor (LDLr) 
(Agnello et al., 1999), scavenger receptor class B type 1 (SR-B1) (Scarselli et al., 
2002, Bartosch et al., 2003), claudin-I (CLDN1), occludin (OCLN) (Evans et al., 
2007, Mensa et al., 2011), CD36 (Cheng et al., 2016) and the apolipoproteins.  
Glycosaminoglycans and the LDLr appear to be involved in the initial binding 
step. E1-E2 then interacts with CD81 and SR-B1, and the co-receptor CD36. 
Proof-of-concept studies evaluating monoclonal antibodies directed against CD81 
and SR-B1, and direct inhibition of CD36, have demonstrated that blockage of 
these receptors is associated with protection against HCV infection in vivo, 
confirming their essential role in the HCV life cycle (Meuleman et al., 2008, 
Meuleman et al., 2012, Cheng et al., 2016). Viral entry appears to be dependent 
on the tight junction factors CLDN1 and OCLN. The association between tight-
junctions and HCV-receptor complexes facilitates cell-to-cell transmission; a 
combination of receptors is also involved in cell-free transmission.   
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Subsequent HCV entry into the hepatocyte results in clathrin-mediated 
endocytosis. The E1 envelope glycoprotein mediates fusion between the viral 
and endosomal membranes under acidic pH, facilitating release of the 
nucleocapsid into the cytoplasm.  
1.1.5.2 Translation and replication 
Following uncoating of the viral nucleocapsid, the positive-strand RNA genome is 
released into the cytosol where it serves as mRNA for the synthesis of the HCV 
polyprotein. Translation, which is initiated at the IRES on the 5’ UTR, takes 
place at the ER membrane. The IRES is responsible for cap-independent 
translation of the genomic RNA, through the recruitment of cellular proteins, 
including the eukaryotic initiation factors (eIF) 2 and 3. The structural proteins 
are cleaved from the HCV polyprotein by two host proteases, signal peptide 
peptidase, responsible for maturation of core, and signal peptidase (McLauchlan 
et al., 2002). Viral peptidases (NS2-3 and NS3-4A) are responsible for the 
processing of the non-structural proteins, as described above (figure 1-3).  
The HCV protein NS4B induces the formation of the ER-derived membranous 
web, rich in cholesterol, sphingolipids and fatty acids, which is essential for HCV 
replication (Bartenschlager et al., 2004). In the first step, negative-strand 
intermediates are synthesised from the RNA genome. The negative-strand RNA 
then serves as a template for the production of multiple positive-strand progeny 
for polyprotein translation, the synthesis of new template RNA strands or 
packaging into virus particles (Lohmann, 2013). NS5B is the key catalyst of RNA 
synthesis, and the RNA-binding NS5A protein is an essential part of the viral 
replication complex, the phosphorylation status of which may determine the 
balance between replication and virion production (as discussed above).  
A number of other molecules have been shown to have important roles in the 
HCV life cycle. The liver specific microRNA-122 (miR-122) is able to bind to 
conserved sites in the IRES, and is essential for HCV replication (chapter 1.7.4). 
Cyclophilin A induces conformational changes in NS5A and NS5B which are 
required for HCV replication. The cholesterol and fatty acid synthesis pathways 
are also implicated in productive infection (Lindenbach, 2013). 
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1.1.5.3 Assembly and release 
Our understanding of the mechanism of viral assembly and release is limited. 
Viral particle assembly is believed to be initiated by the interaction of core and 
NS5A with genomic RNA on the surface of lipid droplets. Biogenesis of VLDL 
occurs in the ER and Golgi apparatus, followed by secretion of mature VLDL 
particles through the Golgi secretory route (Hossain et al., 2014). HCV hijacks 
the VLDL production pathway, and fuses with APOB, APOE and other nascent 
VLDL particles in the ER to form LVPs. The LVPs bud off from the ER and are 
transported to the Golgi in COP-II vesicles (Syed et al., 2017) before being 
secreted through the Golgi secretory pathway. 
 
1.1.6 Epidemiology and transmission of HCV 
It is estimated that around 130-210 million individuals globally are anti-HCV 
antibody positive, i.e. roughly 3% of the world’s population, although accurate 
determination of the true prevalence is problematic (Manns et al., 2017). The 
majority of individuals infected with HCV are asymptomatic and may be unaware 
of their infection, and groups at high risk of infection may be less likely to 
access clinical care. Additionally, the use of anti-HCV antibody testing to 
determine prevalence will not exclude those patients who have cleared the virus 
spontaneously or through treatment. The estimated prevalence of HCV viraemia 
is consequently lower, at around 0.8-1.14% worldwide ('Global prevalence and 
genotype distribution of hepatitis C virus infection in 2015: a modelling study,' 
2017).  
The prevalence (figure 1-4) and risk factor for acquisition of HCV varies from 
country to country. 
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Figure 1-4: Geographical distribution of HCV infection. Extracted from Manns et al. (2017) 
 
The major route of HCV transmission is parenteral - through blood and plasma 
product transfusion, the use of unsterilized medical equipment, vaccination 
programmes and intravenous drug use (IDU). Prior to the implementation of 
universal screening of blood products in 1991, a large cohort of patients 
contracted the virus through contaminated blood or blood products, e.g. 
haemophiliacs and patients receiving anti-rhesus D immunoglobulin (Power et 
al., 1995, CDC, 2014), and the highest prevalence of HCV infection is seen in 
countries with a high rate of iatrogenic infections. The re-use of glass syringes 
for injections remains a key risk factor for transmission in Pakistan (Qureshi et 
al., 2010), and in the Nile Delta the prevalence is > 10% of the population as a 
consequence of the re-use of needles during a widespread provision of 
intravenous tartar emetic to control Schistosomiasis spp. in the latter half of the 
1900s (CDC, 2014, Frank et al., 2000). Increased HCV (and HIV) prevalence in 
China has also been attributed to procedural error during an officially 
encouraged plasma donation campaign (Lu et al., 2013). 
In recent years, the predominant risk factor for the acquisition of HCV in the UK 
has been IDU. In Scotland, of those cases of HCV-antibody positivity in whom a 
risk factor was identified, 91% were among persons who inject drugs (PWID) 
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(HPS, 2016). Transmission through the sharing of equipment for intranasal drug 
use is also recognised, and this risk is often underappreciated by patients and 
care-providers (Karmochkine et al., 2006). A number of public health initiatives 
raising awareness of the disease and encouraging individuals to access testing 
have been developed, for instance, the Big Red C campaign in Scotland and 
‘Tune In to Hep C’ in the US. 
Transmission of HCV through mother to child transmission (MTCT) or sexual 
contact is uncommon in the absence of HIV co-infection (Wasley and Alter, 2000) 
and national guidelines do not recommend the use of barrier contraception for 
HCV-infected individuals (Bradshaw et al., 2013). However, in recent years an 
epidemic of acute HCV following sexual intercourse has been reported in 
industrialised countries amongst HIV-positive men who have sex with men (MSM) 
(Bradshaw et al., 2013, van der Helm et al., 2011, Wandeler et al., 2012). The 
reported incidence amongst HIV-negative MSM remains low, and the increase in 
incidence amongst HIV-infected individuals is thought to reflect both behavioural 
and biological factors, i.e. serosorting, mucosally traumatic practices, the use of 
mucosally administered recreational drugs, intercurrent sexually transmitted 
infections (STIs) and HIV itself (Bradshaw et al., 2013). 
Health Protection Scotland (HPS) reported a cumulative number of HCV 
diagnoses in Scotland at 38577 cases (data to 31 Dec 2015), 17% of whom were 
known to have died (HPS, 2016). Infections in Scotland are primarily due to 
genotype (Gt) 1 and Gt3, as seen in Europe, Australia and the USA (McLeod A, 
2014, Simmonds, 2004). The prevalence of each genotype varies according to 
geographical region, and has evolved over time with the changing epidemiology 
of infection. Interestingly, a recent phylogeographic reconstruction using 
Bayesian inference methods showed that HCV Gt1a lineage expansion in Scotland 
occurred between 1940 and 1965. The investigators hypothesised that this may 
have occurred through the introduction of independent Gt1a lineages to 
Scotland as a consequence of the mass population mixing during World War II, 
the first use of large scale parenteral treatments and the subsequent 
dissemination of HCV worldwide as individuals returned to their countries of 
origin (McNaughton et al., 2015).  
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Whilst Gt1 and Gt3 infections are the most prevalent worldwide, Gt4 and Gt5 
are overrepresented in resource-limited countries (figure 1-5). In Europe, about 
90% of infections are due to Gt1-3 (Messina et al., 2015, Esteban et al., 2008). 
Infection with subtypes classically associated with iatrogenic spread (1b, 2a and 
2b) are found more commonly in the elderly, whereas subtypes 1a, 3a and 4d are 
more closely linked with IDU. Rare/novel strains of HCV may gain increasing 
prominence in the DAA era, with highly effective antiviral regimens now 
available for the more commonly seen genotypes. Recent data have suggested 
that rare subtypes and strains which cannot be assigned to known subtypes 
circulate in low- and middle-income countries (LMICs) and these may respond 
less effectively to DAA therapy (da Silva Filipe et al., 2017). 
 
Figure 1-5: Distribution of HCV genotype by country according to economic status (extracted 
from Manns et al. (2017)). 
 
1.1.7 Viral diversity and quasispecies 
The diversity of HCV reflects both sequence drift over time and the rapid, 
adaptive changes the virus undergoes in a single individual in response to 
immunological pressures and antiviral therapy (chapter 1.5.2). Sequence drift is 
largely responsible for the diversity seen between different genotypes and is 
referred to as ‘neutral’ as it has little effect on phenotype and becomes fixed in 
the population by chance (Kimura, 1979, Simmonds, 2004). This differs from the 
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‘Darwinian’ theory of evolution in which changes result in improved viral fitness 
and are therefore sustained and ultimately predominate.  
Evidence for both theories of evolution can be seen in the HCV genome 
sequences: rapid changes in HVR1 may allow the virus to evade the antibody 
response to infection, demonstrating ‘Darwinian’ evolution, whereas the 
sequence variability between geographically or epidemiologically distinct 
genotypes demonstrates marginal phenotypic change, consistent with neutral 
theory (Simmonds, 2004).  
CHC results in a population of highly diverse variants, named ‘quasispecies’, 
which typically differ by 1-3%. A lack of proof-reading, coupled with a relatively 
high rate of virus production, results in the continuous generation of mutant 
virions, with implications for drug and vaccine development (Timm and 
Roggendorf, 2007). RNA copying by the HCV-encoded RNA polymerase is error 
prone, with error rates of between 1 in 10 000 and 1 in 100 000 bp copied 
(Domingo et al., 1996). This heterogeneity has already been shown to lead to 
viral escape during DAA treatment (Susser et al., 2009, da Silva Filipe et al., 
2017). Genetic heterogeneity is found throughout the genome, however certain 
regions demonstrate more variability. HVR1 at the N-terminus of E2 is one such 
segment, with > 80% sequence variability between genotypes (Manns et al., 
2017). 
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1.2 Immune response to HCV infection 
The host immune response to infection consists of innate and adaptive 
components, the adaptive consisting of cellular and humoral responses. Innate 
immunity comprises physical barriers, cellular components (e.g. granulocytes, 
macrophages and natural killer (NK) cells), and soluble components (Neumann-
Haefelin et al., 2005). Adaptive cellular immunity, mediated through CD4+ and 
CD8+ lymphocytes, is important in the control of viral infection.  
1.2.1 Innate immune response 
Interferons are members of the cytokine family which play a crucial role in the 
cellular defence against viral infection. Those of relevance in HCV infection 
include the type I IFNs (IFN-α subtypes and IFN-β), type II IFNs (IFN-γ) and type 
III IFNs (IFN-λ, otherwise known as interleukin (IL)-29, IL-28A and IL-28B). IFN-α 
and IFN-β induce the innate immune response, and can directly inhibit viral 
replication. Additionally, they are able to direct the adaptive immune response 
by priming cytotoxic T cells and T helper cells. IFN-γ has immunomodulatory 
activity and is secreted by NK cells and cytotoxic T cells (Lemon S, 2010).  
HCV RNA replication induces type I IFN within 48 hours of infection in a 
chimpanzee model (Bigger et al., 2001). It is postulated that this early IFN 
response may restrict viral replication in acute infection (Neumann-Haefelin et 
al., 2005). However, despite this early response, type I IFN does not play a 
major role in viral clearance and HCV is largely eliminated by non-cytolytic 
effects through the IFN-γ driven interferon-stimulated gene (ISG) expression in 
hepatocytes. IFN-γ may also inhibit HCV infection by downregulating claudin-1 
and CD81 (Wei et al., 2009).  
The host innate immune response is induced upon recognition of conserved 
molecular patterns expressed on microbial and viral structures (pathogen 
associated molecular patterns; PAMPs) by resident membrane and cytosolic 
receptor molecules (Olivieri et al., 2013a). Amongst these molecules are the 
toll-like receptors (TLRs) which are transmembrane proteins of mammalian cells. 
In humans, viral nucleic acids are recognised by the endosomal TLRs -3, -7, -8 
and -9, by PKR, and by the cytosolic retinoic acid-inducible gene-like receptors 
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(RLRs) retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-
associated gene (Mda5).  
HCV RNA contains specific PAMPs, including stem-loop double-stranded RNA 
(dsRNA) and poly-uridine motifs in the 3’-UTR (Tuplin et al., 2002). Cell culture 
studies have suggested that two distinct PAMP receptors, TLR-3 and RIG-I, direct 
the host response to HCV infection (Ishii and Koziel, 2008, Lemon, 2010). TLR-3 
acts through the TIR domain containing adaptor inducing interferon-β (TRIF) 
molecule, whereas TLR-7, -8 and -9 act through myeloid differentiation primary-
response gene 88 (MyD88) (Olivieri et al., 2013a). The association of TLR-3 with 
TRIF leads to the recruitment of TNF receptor-associated factor (TRAF) 6, TRAF3 
and the nuclear factor-kappa B (NF-κB) activator binding kinase 1 (TBK1), 
resulting in phosphorylation of interferon regulatory factor 3 (IRF-3) by TBK1 and 
inhibitor of kappa B kinase-related kinase (IKKε). RIG-I is a DEAD box helicase 
able to sense short HCV replication intermediate dsRNAs with free 5’-
triphosphatases. On recognition of the HCV PAMP, it is recruited to the 
mitochondrial surface where it interacts with MAVS (mitochondrial antiviral 
signalling protein, also known as IPS-1, VISA and Cardif) through shared caspase 
recruitment domains (CARDs) resulting in recruitment of TBK1 and IKKε. Both the 
E3 ubiquitin ligase triple motif-containing protein (TRIM) 25 and the 
mitochondrial targeting chaperone protein 14-3-3ε are involved in this process; 
TRIM25 mediates the ubiquitination of RIG-I at position Lys-63 which facilitates 
MAVS binding and is important for IFN production (Loo et al., 2006). RIG-I also 
interacts with apoptosis-associated speck like protein containing CARD resulting 
in activation of a caspase-1-dependent inflammasome (Nitta et al., 2013) (figure 
1-6). 
Cellular recognition of the HCV PAMPs by various PAMP receptor pathways leads 
to the activation and nuclear translocation of NF-κB and IRF-3. IRFs control the 
induction of IFN at the transcriptional level by binding to specific promotor 
elements. Although IRF-5 and IRF-7 are also important in the host response to 
viral infection, their role in HCV infection has not been characterised. Together 
with NF-κB and ATF2/c-Jun, IRF-3 forms an enhanceosome complex on the IFN-
α/β promoter, resulting in IFN-β expression and secretion from the infected cell. 
IRF-3 also controls the transcription of the IFN-λs.  
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Both IFN-α and IFN-β are recognised by the type I IFN-α/β receptor (IFNAR) 
resulting in activation of the JAK (Janus kinase)/STAT (signal transducer and 
activator of transcription) signalling pathway. Following IFNAR binding, STAT1 
and STAT2 are phosphorylated to form a heterodimer, resulting in recruitment of 
IRF9 and formation of the ISGF3 transcription factor complex. ISGF3 binds to the 
interferon-sensitive response element (ISRE) and results in high level of 
expression of ISGs (Ishii and Koziel, 2008, Lemon, 2010). Upregulation of ISGs has 
been demonstrated in the liver biopsy specimens of patients with CHC (Sarasin-
Filipowicz et al., 2008), and is associated with an increase in circulating 
cytokines, including chemokine IFN-γ inducible protein-10 (CXCL10/IP-10) 
(Askarieh et al., 2010). Interestingly, Robinson and colleagues (2015) found that 
Gt1-infected biopsies demonstrated an upregulation of genes regulated by type I 
and III IFNs, whereas Gt3-infected biopsies displayed upregulation of IFN-γ 
induced transcripts.  
 
Figure 1-6: Induction of innate immunity by HCV in hepatocytes. Extracted from Wong et al. 
(2016). IFNAR, type 1 IFN-α/Β receptor; TLR3; toll-like receptor 3; P, phosphorylated; ISGF3, 
interferon-stimulated gene factor 3. 
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The gene products of ISGs are able to limit HCV replication at different phases of 
the virus life cycle, as well as having direct effects on cellular processes. Many 
PAMP receptors and related molecules are also ISGs, for instance, RIG-I and PKR. 
Interferon-induced transmembrane protein 1 (IFITM1) is an important ISG 
effector, which is induced during IFN-α treatment and accumulates at hepatic 
tight junctions where it interacts with CD8 and OCLN to disrupt HCV entry 
(Wilkins et al., 2013).  
ISG15 is another important ISG, which modulates host antiviral responses 
through ‘ISGylation’ of viral and host proteins and inhibition of virus release. 
IRF3, RIG-I and PKR are all modified by ISGylation, resulting in positive 
regulation of type I IFN signalling. ISG15 also targets many proteins involved in 
the innate immune response to viral infection, including JAK1, STAT1 and other 
ISGs (Morales and Lenschow, 2013). The stability of HCV NS5A protein is 
decreased by IFN-mediated ISGylation, leading researchers to suggest that ISG15 
could be used as a therapeutic adjunct to IFN-α treatment in CHC (Kim and Yoo, 
2010). Additionally, knockdown of ISG15 expression is associated with increased 
HCV replication in various cell lines (Jones et al., 2010, Domingues et al., 2015). 
Conversely, it has also been proposed that increased ISG15/ISGylation may 
promote HCV infection (Chen et al., 2010). Early PKR-dependent induction of 
ISG15 may inhibit RIG-I ubiquitination, blocking subsequent HCV RNA-mediated 
RIG-I activation and leading to negative regulation of the host immune response 
and promotion of HCV replication (Arnaud et al., 2011).  
HCV utilises a number of additional strategies to evade host immune 
surveillance. Core protein is able to downregulate IFN signalling by blocking 
STAT1 phosphorylation, preventing heterodimerisation with STAT2 (Lin et al., 
2006). Foy et al. (2003) demonstrated that the NS3/4A protein complex is able 
to block IRF-3 activity in vitro through preventing accumulation of the 
phosphorylated IRF-3 isoform, and the nuclear translocation of IRF-3, thus 
promoting viral persistence. Additionally, NS3/4A is able to cleave host proteins 
including TRIF and the adaptor protein MAVS, releasing it from the mitochondrial 
membrane and blocking its ability to signal (Lemon, 2010, Bowie and 
Unterholzner, 2008). Recent data suggest that immune evasion may also be 
mediated through NS3-4A targeting of importin β1 and related modulators of 
IRF3 and NF-κB nuclear transport (Gagne et al., 2017). Abe et al. (2007) showed 
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that the NS5A protein was able to inhibit TLR-MyD88-induced signalling in mouse 
macrophage cells by binding to the death domain of MyD88. Overexpression 
studies have suggested that the viral protein NS4B may also interfere with RIG-I 
signalling (Tasaka et al., 2007).  
A key component of the IFN antiviral response is PKR. PKR phosphorylates serine 
51 of the alpha subunit of the eukaryotic initiation factor 2 (eIF-2α) leading to 
blockage of protein synthesis initiation and inhibition of viral replication (Gale et 
al., 1998). PKR is also a mediator of stress-induced apoptosis and repression of 
PKR leads to malignant transformation of mammalian cells (Koromilas et al., 
1992). The viral protein NS5A is able to bind to and inhibit PKR, blocking 
apoptosis through sequestration of p53, modulation of intracellular electrolyte 
levels, binding to growth factor receptor-bound protein 2 and induction of IL-8. 
The E2 protein also appears to bind to and inhibit PKR through molecular 
mimicry, as a result of sequence similarity to the phosphorylation domains of 
PKE and eIF-2α (Taylor et al., 1999).  
NK and NKT cells are an important component of the innate immune response 
and contribute to suppression of viral replication through cytolysis of infected 
cells, production of immunomodulatory cytokines, such as IFN-γ, and activation 
of dendritic and T cells (Ishii and Koziel, 2008). It has been shown that certain 
NK cell receptor genes (killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) 
and human leukocyte antigen (HLA)-C1) are associated with resolution of HCV 
infection, suggesting that inhibitory NK cell interactions are important in 
determining outcome of infection (Khakoo et al., 2004). In CHC, NK cells 
demonstrate alterations in phenotype and function (Rehermann, 2013), with 
higher levels of STAT1, increased degranulation and decreased production of 
IFN-γ and TNF-α compared to NK cells from healthy controls. DAA therapy is 
associated with a rapid normalisation of NK cell cytotoxic effector functions, a 
decrease in the expression level of the ISG STAT1, and a decrease in serum 
levels of CXCL10/IP-10 and CXCL11 (Serti et al., 2015).  
Several genetic polymorphisms have been shown to influence the outcome of 
HCV infection, namely those encoding IFN-λ, IFN-γ, and the NK receptor KIR2DL3 
and its HLA ligand as described above (Lemon, 2010). Genome wide association 
studies (GWAS) found a strong correlation between single nucleotide 
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polymorphisms (SNPs) near the IL-28B (recently renamed the IFN-λ3 or IFNL3) 
gene (rs12979860 and rs8099917) and rates of spontaneous and IFN-based 
treatment-associated clearance of HCV (Ge et al., 2009, Rauch et al., 2010, 
Suppiah et al., 2009). HCV Gt1-infected patients with the unfavourable IFNL3 
rs12979860 TT genetic polymorphism had significantly lower sustained virologic 
response (SVR) rates in response to IFN-based treatment than patients with the 
CC genotype. It has previously been demonstrated that patients with IFNL3 non-
responder genotypes (non-CC) have higher hepatic ISG expression at baseline 
than those with responder genotypes (Urban et al., 2010), and that this 
correlates with a poorer response to IFN-α based therapy (Asselah et al., 2008). 
Furthermore, analysis of transcription factors in the peripheral blood of patients 
with CHC suggests that those with IFNL3 responder genotypes have a Th1/NK 
dominant state favouring viral clearance (O'Connor et al., 2016). 
In 2013, a new polymorphism rs368234815 (previously ss469415590; TT or ΔG) 
upstream from the IFNL3 gene on chromosome 19q13 was found to result in a 
frameshift mutation, creating the ORF for a novel inducible protein-coding gene, 
IFNL4, and resulting in transient expression of the IFN analogue, IFN-λ4 
(Prokunina-Olsson et al., 2013). The rs368234815-ΔG allele was found to 
correlate with the previously identified rs12979860-T allele, and more strongly 
predicts HCV clearance in Gt1 infection (O'Brien et al., 2015). These SNPs can 
result in the production of no IFN-λ4 protein (TT genotype), a mutant IFN-λ4 
protein with reduced antiviral activity (called P70S), or the wild type IFN-λ4 
protein. Counterintuitively, individuals with the rs368234815-ΔG allele who 
produce the active wild type IFN-λ4 protein have significantly lower rates of 
spontaneous viral clearance. IFN-λ4 induces STAT1 and STAT2 phosphorylation, 
and activates ISGs. This pre-activation of IFN-signalling may prevent further 
activation in response to viral infection, and may impair the response to 
exogenous IFN-α as described above (Prokunina-Olsson et al., 2013). In Gt1-
infected biopsies, the presence of the IFNL4 ΔG variant was associated with 
higher expression of the ISGs IFIT1, ISG15, RSAD2 and USP18. However, IFNL4 
genotype did not influence baseline ISG expression in Gt3-infected biopsies, 
perhaps explaining the reduced predictive power of IFNL3 genotype in Gt3 
infection (Mansoor et al., 2016, Cariani et al., 2016).  
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1.2.2 Adaptive immune response 
1.2.2.1 Humoral response to HCV infection 
Circulating antibodies against various HCV proteins become detectable in the 
serum within several weeks of exposure to the virus (Ishii and Koziel, 2008, 
Neumann-Haefelin et al., 2005). The majority of antibodies have minimal 
relevant activity against HCV due to its high sequence variability, however rapid 
induction of virus-neutralising antibodies was associated with spontaneous 
clearance in one outbreak whilst chronic infection was associated with low titre 
or absent early phase antibody response (Pestka et al., 2007). Induction of cross-
neutralising antibodies in the late phase of infection has been reported in 
chronically HCV-infected individuals, but is rarely associated with viral 
eradication (Alter et al., 1989). 
The first detectable antibodies against HCV proteins usually target NS3 and core 
protein, followed by development of antibodies against NS4 and the 
glycoproteins E1 and E2. The HVR-1 of E2 is a major epitope for neutralising 
antibodies and the variability observed in this region may well reflect a viral 
mechanism evolved to evade B cell responses (Simmonds, 2004). HCV is also able 
to evade the antibody response through cell-to-cell spread via tight junctions 
between hepatocytes (Swadling et al., 2013).   
Protective immunity to HCV remains a controversial subject. In vivo studies 
involving chimpanzees have demonstrated protection against HCV reinfection 
following vaccination or previous exposure (Farci et al., 1994, Farci et al., 
1995). However, multiple re-infections with HCV have been reported in both 
immunocompetent and immunocompromised patients (Proust et al., 2000, 
Martin et al., 2013, Prince et al., 1992).  
1.2.2.2 Cellular response to HCV infection 
At 4-8 weeks following HCV infection, HCV-specific T cells are recruited to the 
liver. Both CD4+ and CD8+ T cell responses are crucial for an effective immune 
response to HCV infection. The HCV specific CD8+ T cell response and presence 
of neutralising antibodies is insufficient to suppress viraemia without the CD4+ T 
cell response (Kaplan et al., 2007). Without sustained CD4 T cell support, CD8 T 
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cells cannot control replication and escape mutations are able to develop (Ishii 
and Koziel, 2008). 
CD4+ T cells act through secreting antiviral cytokines and through activation of 
viral specific B cells and CD8+ T cells. A fall in HCV RNA titre is associated with 
vigorous HCV-specific T cell responses and the induction of IFN-γ in liver and 
peripheral blood cells (Ishii and Koziel, 2008).  
Studies have demonstrated that the hallmark of chronic infection is a weak, 
dysfunctional and narrowly targeted T cell response against a minimal number of 
epitopes (Neumann-Haefelin et al., 2005). As viral persistence is common in 
acute HCV, with around 80% of individuals progressing to chronic infection, a 
number of theories have been developed to explain this failure of the T cell 
response. 
Data from the lymphocytic choriomeningitis virus (LCMV) model suggests that T 
cell ‘exhaustion’ may develop as a consequence of a high rate of viral 
replication (Ishii and Koziel, 2008). HCV is able to produce up to 1012 virions 
daily (Neumann et al., 1998), postulated to exceed the capacity of host 
immunity with resultant inability to maintain CD4+ T cells during acute 
infection. Additionally, in the chimpanzee model HCV-specific CD8+ T cells in 
the acute phase display a ‘stunned’ phenotype and are unable to secrete IFNγ in 
response to HCV infection (Ishii and Koziel, 2008). 
Other groups have described impaired T cell maturation in chronic HCV, 
demonstrating that HCV-specific CD8+ T cells exhibit phenotypic changes 
characteristic of early stages of differentiation (CD28+ and/or CD27+) (Neumann-
Haefelin et al., 2005) and are functionally impaired (Ishii and Koziel, 2008). HCV 
is also able to retard the normal maturation of non-HCV-specific cells. Lucas and 
colleagues (2004) demonstrated that in HCV-infected individuals, CMV specific 
CD8+ cells (which demonstrate a highly differentiated phenotype in CMV mono-
infected subjects) also had higher expression of CD28 and CD27.  
Rushbrook et al. (2005) demonstrated that marked CD4+ CD25+ FoxP3+ 
regulatory T cell (Treg) activity is present in patients with CHC, and this may 
contribute to weak CD8+ T cell responses. Ebinuma et al. (2008) observed an 
attenuated antigen-specific T cell proliferative response in FoxP3+ cells and 
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Cusick et al. (2011) demonstrated that depletion of CD4+ CD25+ cells restored 
peripheral blood mononuclear cell (PBMC) proliferative responses to the HCV NS3 
protein. Additionally, Cabrera et al. (2004) found that HCV-specific IFN-γ was 
enhanced in PBMCs depleted of CD4+CD25+ and suppressed in PBMCs enhanced 
with CD4+ CD25+.  
Interestingly, CD8+ T cell responses can be restored by blocking the programmed 
cell death-1 (PD-1)/PD-1 ligand pathway (Radziewicz et al., 2007). PD-1 is a cell 
surface receptor of the CD28 family and when bound to its ligand generates an 
immunomodulatory effect. Urbani et al. (2006) demonstrated that CD8+ 
lymphocyte expression of PD-1 was maintained at high levels in individuals 
demonstrating viral persistence, compared with rapid downregulation in those 
individuals who cleared the virus. Inhibition of this pathway was briefly under 
consideration as a therapeutic adjunct to HCV treatment (Urbani et al., 2008), 
however the efficacy of the new DAA regimes has rendered manipulation of this 
pathway largely obsolete in the HCV treatment landscape. Research into the use 
of PD-1 blockade for checkpoint inhibition has however gained pace in the field 
of chronic HBV infection (Liu et al., 2014). 
Whilst early treatment of HCV with IFN may prevent the development of T-cell 
exhaustion (Abdel-Hakeem et al., 2010, Badr et al., 2008), IFN-based treatment 
of CHC is not associated with restoration of HCV-specific CD8+ T cell function 
(Barnes et al., 2002). It has been postulated that the IFN-based therapy itself 
contributes to the ongoing impairment of immune cell function through its 
inhibitory effect on the lymphocyte population. Conversely, viral eradication 
with an IFN-sparing regime was shown to be associated with a restoration of 
CD8+ T cell function, and a decrease in PD-1 expression on HCV-specific CD8+ T 
cells. 
More recently, it has been shown that mucosal-associated invariant T cells (MAIT 
cells; innate-like effector T cells) are reduced in frequency in CHC, and display 
an activated phenotype (high expression of HLA-DR, granzyme B, PD-1 and CD69) 
with reduced response to antigen stimulation, and that this MAIT cell 
dysfunction is not reversed following successful DAA treatment (Hengst et al., 
2016).  
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The importance of the cytotoxic T cell response in the clearance of HCV 
infection is further highlighted by the association between the HLA class I 
alleles, which are responsible for restricting the cytotoxic T lymphocyte 
response, and the likelihood of spontaneous and treatment-associated viral 
eradication. In a cohort of iatrogenically infected females with Gt1b infection, 
HLA-B*27 was found to be the strongest predictor of clearance, although A*03, 
and the class II alleles DRB1*04:01, DRB1*01:01 and DRB1*15, were all associated 
with viral eradication (McKiernan et al., 2004). Additionally, carriage of HLA-
B*57 (associated with elite control in HIV infection (Asher et al., 2013)) has been 
associated with spontaneous clearance of HCV (Kim et al., 2011). 
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1.3 Natural history of HCV infection 
1.3.1 Outcome following exposure to HCV 
After exposure to HCV, there is a window period of 1-3 weeks before HCV RNA is 
detectable in the serum (Negro, 2012). Acute infection is only symptomatic in 
~15% of individuals, complicating its diagnosis. If symptoms are present they 
tend to be non-specific, requiring a high index of suspicion from the healthcare 
provider and knowledge of an individual’s risk exposure (table 1-1). 
Table 1-1: Signs and symptoms associated with acute HCV infection 
Weeks from exposure to HCV Signs and symptoms 
 
 
2-12 
Fatigue 
Jaundice 
Flu-like symptoms 
Dyspepsia 
Abdominal pain 
4-10 Seroconversion 
4-12 Elevated or fluctuating liver enzymes 
 
Clinical hepatitis coincides with the appearance of viral-specific T cells in the 
liver and blood (Missiha et al., 2008). Interestingly, if acute HCV infection is 
symptomatic there is a much higher chance of spontaneous clearance 
(approximately 50% compared with <20% in asymptomatic patients), presumably 
due to the more vigorous immune response.  Subjects who spontaneously clear 
HCV infection remain HCV IgG antibody positive, but HCV RNA is undetectable.  
Spontaneous clearance of HCV requires a broad, sustained CD4+ and CD8+ T cell 
response (chapter 1.2.2.2). Individuals who fail to mount a vigorous immune 
response develop CHC, defined as viral persistence beyond 6 months post 
exposure. Spontaneous clearance beyond 6 months infection occurs rarely and is 
poorly understood. In chronically infected individuals, the immune response is 
insufficient to eradicate the virus but results in chronic liver inflammation. 
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These individuals are at risk of progressive liver disease and hepatocellular 
carcinoma (HCC) (figure 1-7). 
 
Figure 1-7: Natural progression of chronic liver disease. Extracted from Pellicoro et al. 
(2014). NASH, non-alcoholic steatohepatitis. 
 
Chronic liver inflammation results in fibrosis, due to the accumulation in the 
liver of extracellular matrix (ECM) proteins including collagen, laminin, elastin 
and fibronectin. In liver disease secondary to chronic viral infection, fibrosis 
occurs mainly around portal tracts. It is a complex process, best viewed as a 
wound healing response to chronic liver injury (Sebastiani et al., 2014). Fibrosis 
may actually confer a protective benefit to hepatocytes as deposition of type I 
collagen protects the cells against toxic stimuli (Bourbonnais et al., 2012), 
however persistent inflammation results in scarring and ultimately loss of 
function. 
Although multiple cell types contribute to the pathogenesis of liver cirrhosis, 
hepatic stellate cells (HSCs) are the primary cells responsible for fibrogenesis. 
HSCs are vitamin A storing cells which reside in the peri-sinusoidal space of Disse 
and are usually quiescent. Infection with HCV results in damage to liver 
parenchymal cells, including hepatocytes and cholangiocytes, and the release of 
reactive oxygen species (ROS) and other inflammatory mediators. Apoptosis both 
initiates and perpetuates the inflammatory cascade, and is mediated by several 
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stimuli including Fas and TNF-α. Oxidative stress results in cell death, 
lipotoxicity, immune infiltration and activation of HSCs, with transformation into 
proliferative myofibroblasts (Zoubek et al., 2017). These cells are the main 
source of ECM proteins, and are characterised by enhanced contractility, 
increased proliferation and migration, and the release of pro-inflammatory and 
pro-fibrogenic factors.  
Monocytes are directed to the site of injury through the CC-chemokine ligand 2 
(CCL2)-CC-chemokine receptor 2 (CCR2) pathway, whereas neutrophils are 
recruited by High-Mobility-Group-Protein B1 (HMGB1) (released following 
necroptosis) together with the chemokine CXCL12 (Kubes and Mehal, 2012). 
Phagocytosis of necrotic or apoptotic cells results in further release of pro-
inflammatory cytokines, including TNF-α, IL-6 and IL-1Β, recruitment of T cells 
and perpetuation of myofibroblast activation. Activated Kuppfer cells (KCs, 
specialised macrophages) are involved in activation of HSCs and KC-mediated 
inflammation is thought to aggravate hepatic injury and contribute to the 
development of cirrhosis (Lopez-Navarrete et al., 2011). Importantly, KCs can 
elicit expression of platelet derived growth factor receptor (PDGFR) on HSCs in 
vitro (Zhou et al., 2014). Platelet derived growth factor (PDGF) stimulation 
results in proliferation of myofibroblasts via extracellular signal-regulated kinase 
(ERK) dependent and independent pathways, whereas transforming growth 
factor Β (TGF-Β) released by stimulated immune cells promotes myofibroblast 
survival through activation of protein kinase B (AKT) and focal adhesion kinase 
(FAK). TGFΒ also upregulates type I collagen synthesis and alpha-smooth muscle 
actin (αSMA) by myofibroblasts leading to fibrogenesis. Interestingly, FAK 
inhibition reduces HSC migration and expression of αSMA and collagen, and 
manipulation of this pathway is under scrutiny for the development of anti-
fibrotic therapies (Zhao et al., 2017).  
The balance between ECM protein deposition and dissolution is dependent on the 
interplay between matrix metalloproteinase (MMP) enzymes and their inhibitors, 
tissue inhibitors of metalloproteinase (TIMP). An unfavourable MMP: TIMP ratio 
results in fibrogenesis and scarring, ultimately leading to cirrhosis. Hepatic 
myofibroblasts express TIMP1 which inhibits MMP activity and leads to the 
deposition of ECM proteins (Zoubek et al., 2017). Macrophages play important 
and opposing roles; restorative macrophages (characterised by low Ly6C 
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expression) display increased MMP-9 and MMP-13 production as well as 
expression of phagocytosis-associated receptors (Ramachandran et al., 2012) 
whereas pro-fibrotic macrophages (Ly6Chi) promote hepatocellular injury 
through the release of pro-inflammatory cytokines as discussed above. The 
switch in macrophage phenotype from a fibrogenic to a restorative population is 
thought to occur in response to hepatic expression of CX3CL1 and other anti-
inflammatory signals (Pellicoro et al., 2014). Dendritic and NK cells are also 
involved in resolution of fibrosis, through promotion of MMP-9 dependent ECM 
degradation (Ramachandran et al., 2012).  
Cytokines and their signalling pathways play important roles in hepatic 
fibrogenesis. PDGF, TGF-Β and TNF-α have well described pro-inflammatory and 
pro-fibrogenic activity in the pathogenesis of chronic liver disease. A number of 
other molecules, including the adipokine leptin and connective tissue growth 
factor (CTGF), promote fibrogenesis through TGF-Β1 signalling (Sebastiani et al., 
2014). Leptin acts as a suppressor of the anti-fibrotic nuclear receptor 
peroxisome proliferator-γ (PPARγ), promoting HSC activation (Zhou et al., 2009).  
IFNs are well recognised for their antiviral activity (chapter 1.2.1) and appear to 
also have anti-fibrotic activity. Leukocyte-derived IFN-Β is able to inhibit the 
TGF-Β and PDGF pathway in mice, resulting in decreased αSMA and collagen 
production by myofibroblasts (Rao et al., 2010). IFN-γ release by T cells may 
also reduce ECM deposition through the TGFΒ1/Smad3 pathway (Baroni et al., 
1996).  
Interleukins have both pro- and anti-fibrogenic activity, and can be produced by 
many cells types, including KCs and liver sinusoidal epithelial cells, in response 
to injury. IL-1 and IL-17 have pro-inflammatory roles; IL-1 directly activates HSCs 
and IL-17 is able to upregulate TNF-α, TGF-Β1 and collagen via the STAT3 
signalling pathway. Conversely, IL-10 downregulates the inflammatory response 
and modulates fibrogenesis through inhibition of HSC activity (Zhang et al., 
2007). High PBMC expression of IL-10 has been associated with progression to 
chronicity after acute HCV infection, whereas low IL-10 expression is associated 
with clearance (Flynn et al., 2011). 
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The HCV viral proteins are able to directly trigger HSC activation. Incubation of 
NS3 and core protein with activated HSCs resulted in increased intracellular 
calcium concentration and reactive oxygen species (ROS) production (Bataller et 
al., 2004). The increased intracellular calcium concentration and ROS production 
results in the activation of cellular kinases and induction of osteopontin. 
Osteopontin activation results in phosphorylation of AKT and GSK-3Β, promoting 
mesenchymal transformation of hepatocytes (Iqbal et al., 2013). The NS3 and 
NS5 proteins stimulate pro-inflammatory pathways (through NFκB and c-Jun 
terminal kinase (JNK) induction) whereas core protein was associated with 
increased cell proliferation through PI3K/AKT and Ras/ERK pathways. The E2 
envelope glycoprotein is also able to promote fibrogenesis by activating MMP-2 
upon binding to CD81 on HSCs, resulting in degradation of ECM, parenchymal 
damage and influx of inflammatory cells (Mazzocca et al., 2005). HCV infection 
also leads to HSC activation indirectly through the induction of immune 
responses and pro-inflammatory cytokines as previously described.  
1.3.2 Factors contributing to disease progression in CHC 
Liver disease progression in CHC is highly variable. Various modifiable and non-
modifiable factors are postulated to influence the rate of disease progression; 
the most important factors identified appear to be gender, age at acquisition 
and alcohol consumption (Missiha et al., 2008). However, in a prospective study 
from the Trent Hepatitis C study group only age at biopsy and pre-existent 
fibrosis were found to correlate with increased progression (Ryder et al., 2004).  
1.3.2.1 Non-modifiable factors 
1. Age at acquisition and duration of infection: 
Older age at acquisition is independently associated with a faster 
progression to fibrosis, even when controlling for duration of infection 
(Missiha et al., 2008). The rate of disease progression following liver 
transplantation correlates with increasing age of the donor (Rayhill et al., 
2007). Furthermore, children who are vertically infected appear to have a 
very slow progression to cirrhosis (Tovo et al., 2000).  
1-55 
 
Fibrosis progression accelerates with time, even after controlling for age 
(Poynard et al., 2001). A cohort study of Italian patients with bleeding 
disorders found that both age and duration of infection were associated 
with severity (Franchini et al., 2001). The reasons for the importance of 
age as a predictor of progressive fibrosis are undetermined, but may 
include changes in immune function and reduced hepatic blood flow. The 
relationship between ageing and HCV infection is reviewed in chapter 
1.6.3. 
2. Gender: 
Male sex is associated with a faster progression to cirrhosis, even when 
accounting for age, duration of infection, alcohol intake and metabolic 
factors. Fibrosis progression is known to accelerate following the 
menopause, and exogenous oestrogen exposure slows the rate of fibrosis 
in postmenopausal women, suggesting a hormonal explanation for these 
differences (Codes et al., 2007, Di Martino et al., 2004, Villa et al., 2012). 
In vitro, oestrogen inhibits proliferation and activity of HSCs, reducing 
fibrogenesis (Bissell, 1999). It has also been shown that the post-
menopausal increase in progression of fibrosis may be due to steatosis 
(Codes et al., 2007). A further contribution may be made by a sex-specific 
IL-10 promoter polymorphism, leading to reduced fibrosis in females 
(Paladino et al., 2006). 
3. Race: 
Black patients are less likely to progress to cirrhosis when compared with 
white patients, despite a higher incidence of HCC and increased liver-
related mortality. They also have lower activity scores on biopsy, and 
lower ALT levels (Sterling et al., 2004, Wiley et al., 2002). Other racial 
differences are less robustly characterised, although Latino patients in 
the US demonstrate a faster progression to cirrhosis compared to whites 
(Missiha et al., 2008). North American Aboriginal populations have a 
higher rate of spontaneous clearance of the virus, thought to be 
secondary to a differing response to IFN-α and reduced production of IL-10 
in response to viral core protein (Aborsangaya K, 2007, Rempel et al., 
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2009). It is thought that differences in immune response may underlie 
racial variations. 
4. Host genetic factors:  
The ‘favourable’ IFNL responder genotype is associated with accelerated 
disease progression in CHC as a result of higher hepatic inflammatory 
activity (Bochud et al., 2012). It is also associated with a two-fold 
increased mortality, and an increased incidence of adverse clinical 
outcomes (Noureddin et al., 2013).  Interestingly, this effect is more 
pronounced in Gt3-infected individuals (Eslam et al., 2015).    
CHC is associated with increased serum and intrahepatic levels of IP-
10/CXCL10 (Mascia et al., 2017). IP-10 levels have been shown to predict 
both fibrosis stage and outcomes with IFN-based HCV treatment (Askarieh 
et al., 2010, Harvey et al., 2003).  
A number of additional host polymorphisms have been reported in 
association with disease progression in HCV infection, including 
polymorphisms of TGF-β1, angiotensin, CCR5-δ32 and IL-10 promoter 
regions (Paladino et al., 2006, Powell et al., 2000, Patin et al., 2012). 
However, these results have not been consistent across studies. For 
instance, Powell and colleagues (2000) were unable to demonstrate any 
association between different IL-10 genotypes and severity of liver 
disease and Goyal et al. (2006) found that the CCR5-δ32 mutation did not 
affect susceptibility to infection or fibrosis stage. Historically, these 
studies have been limited by small size and failure to control for other 
factors influencing disease progression (Missiha et al., 2008). 
A GWAS for functional single nucleotide polymorphisms (SNPs) was 
conducted by Huang et al. (2006) on 916 HCV-infected individuals and 
identified a SNP in the DEAD box polypeptide 5 (DDX5) gene (p68), an RNA 
helicase. DDX5 is able to bind to the HCV NS5B RNA polymerase, reducing 
HCV replication in vitro (Goh et al., 2004). Individuals with the DDX5 
minor allele or DDX5-POLG2 haplotypes demonstrated more rapid fibrosis, 
although age and steatosis were not controlled for. Further 
polymorphisms identified through GWAS are currently under investigation, 
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including SNPs in genes that regulate apoptosis (Patin et al., 2012) and 
those within the major histocompatibility complex (MHC) on chromosome 
6p21 (Urabe et al., 2013). Polymorphisms in the adiponutrin/patatin-like 
phospholipase domain-containing protein 3 which determines liver fat 
content have been shown to predict fibrosis progression in non-alcoholic 
fatty liver disease (NAFLD) as well as CHC (Tamaki et al., 2015). 
Richardson et al. (2005) have demonstrated that more rapid disease 
progression correlates with increasing number of fibrotic polymorphisms, 
highlighting the complexity of the role played by genetic variation in the 
pathogenesis of HCV-related fibrosis. 
5. Viral factors: 
Assessing the effect of viral genotype on pathogenicity has proven 
challenging given the difficulties in estimating duration of infection and 
the bias towards recruitment of individuals with clinically apparent 
disease, thus the impact of viral factors remains controversial.  
Cohort studies of specific risk factor groups, for instance, haemophiliacs, 
have suggested that HCV Gt1 is more likely to establish persistent 
infection and to be associated with disease severity (Franchini et al., 
2001, Yee et al., 2000). Conversely, Grebely (2014) described an 
increased likelihood of spontaneous clearance of acute infection 
associated with Gt1 infection, as has also been described in the chronic 
setting (Scott et al., 2006). In HBV co-infected patients, a higher 
incidence of HCC has been described with Gt1 infection, and in mixed 
infection with Gt 1 and Gt2 (Oh et al., 2012). However, Wright et al. 
(2003) found that non-1 genotypes were independently associated with 
disease progression. Gt3 infections are associated with a higher incidence 
of steatosis which may be associated with accelerated fibrosis progression 
(Rubbia-Brandt et al., 2000). As described above, the effect of IFNL 
genotype may also be more pronounced in Gt3-infected subjects.  
High quasispecies diversity is associated with elevated liver 
transaminases, and may contribute to accelerated fibrosis progression 
(Asselah et al., 2002).  
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6. Iron overload: 
Iron overload develops in 30-40% of patients with HCV infection as a 
consequence of liver inflammation and is associated with increased 
fibrosis (Haque et al., 1996). It is attributed to deregulation of the iron 
regulatory hormone hepcidin, which is downregulated in response to HCV-
induced oxidative stress (Sebastiani et al., 2014). Elevated serum ferritin, 
reduced hepcidin level and iron accumulation in the liver have all been 
associated with accelerated disease progression or poor outcome with 
IFN-based therapy (Tsochatzis et al., 2010, Lange et al., 2012).  
1.3.2.2 Modifiable factors affecting disease progression in CHC 
I. Alcohol consumption: 
Chronic alcohol intake is associated with accelerated fibrosis progression, 
increased incidence of HCC and higher overall mortality in patients with 
HCV infection (Negro, 2012, Ostapowicz et al., 1998, Seeff et al., 2001, 
Wiley et al., 1998). Poynard et al. (2001) showed that patients who 
consumed over 50 g alcohol/day were more likely to develop progressive 
fibrosis. The effect of low level alcohol consumption on the history of HCV 
infection is as yet unknown. However, in cirrhotic patients even moderate 
alcohol consumption increases the incidence of HCC (Vandenbulcke et al., 
2016). 
II. Co-infection: 
a. HBV 
 
Co-infection with HBV leads to greater liver inflammation, accelerated 
progression to cirrhosis and a high risk of HCC (Gaeta et al., 2003, Zarski 
et al., 1998). Additionally, a retrospective cohort study performed by the 
International Interferon-α Hepatocellular Carcinoma Study Group ('Effect 
of interferon-alpha on progression of cirrhosis to hepatocellular 
carcinoma: a retrospective cohort study. International Interferon-alpha 
Hepatocellular Carcinoma Study Group,' 1998) demonstrated that 
hepatitis B core antibody (HBc+) positivity is associated with an ongoing 
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risk of HCC even in the absence of active infection (hepatitis B surface 
antigen (HBsAg) negative). HBV reactivation has been described in 
individuals undergoing HCV treatment with both IFN-based therapy 
(Potthoff et al., 2009) and DAAs (Bersoff-Matcha et al., 2017) and may 
result in a hepatitis flare. Patients should be monitored closely, and 
commenced on HBV nucleoside/nucleotide analogue therapy if HBV 
replication is detected. 
 
b. Human Immunodeficiency Virus (HIV) 
 
As with HBV infection, coinfection with HIV results in more rapid 
progression to cirrhosis and a higher incidence of HCC (Sulkowski et al., 
2007, Garcia-Samaniego et al., 2001). Graham and colleagues (2001) 
showed that HIV-1 co-infection significantly increased the relative risk of 
cirrhosis and decompensated liver disease. Co-infection is also associated 
with reduced likelihood of spontaneous clearance and correlates with a 
poorer response to IFN-based therapy (Thomas and Seeff, 2005).  
 
c. Schistosomiasis:  
 
Coinfection with HCV and schistosomiasis is common in countries where 
both infections are endemic and is associated with increased 
inflammation and progression to fibrosis (Angelico et al., 1997). 
 
III. Metabolic factors: 
The relationship between HCV, obesity, fatty liver disease and insulin 
resistance (IR) is complicated. Non-alcoholic fatty liver disease 
incorporates both simple steatosis and steatohepatitis, the latter 
characterised by hepatocyte ballooning, lobular inflammation and 
progression to fibrosis (Firneisz, 2014). Steatohepatitis is thought to result 
from oxidative damage generated from fat accumulation in hepatocytes 
leading to influx of inflammatory cytokines and activation of stellate 
cells.  
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Steatosis is more common in HCV-infected patients when compared with 
the general population, and as described earlier, the incidence and 
severity may be increased in Gt3 infections (Rubbia-Brandt et al., 2004, 
Hwang et al., 2001). Body mass index (BMI) is an independent predictor of 
both steatosis and fibrosis in HCV-infected individuals (Friedenberg et al., 
2003). However, steatosis in Gt3 infections can occur independently of 
obesity and IR and is thought to be secondary to core protein effects on 
lipid oxidation and LPL assembly. In non-Gt3 infections, incidence of fatty 
liver correlates with the usual metabolic risk factors (Monto et al., 2002, 
Rubbia-Brandt et al., 2004). Non-SVR in Gt1-infected individuals is 
associated with IR, steatosis, more advanced fibrosis and higher 
circulating levels of the adipokine lectin, which correlates with steatosis 
severity (Klok et al., 2007, Pavlidis et al., 2011). Interestingly, in Gt3-
infected subjects, only fibrosis stage and IR predicted non-SVR. However, 
Westin and colleagues (2007) found that steatosis was associated with a 
slower fall in HCV viral load in response to treatment in both Gt3 and non-
Gt3 infection.  
Both viral and metabolic steatosis may occur in an individual patient, and 
have a different but additive effect on HCV disease (Adinolfi et al., 2013). 
In an analysis by Moucari et al. (2008) fibrosis was independently 
associated with severe steatosis. The presence of hepatosteatosis is 
associated with enhanced Fas-mediated hepatocyte apoptosis which 
correlates with increased disease severity (Ribeiro et al., 2004). 
Concordantly, Schwabl and colleagues (2017) found that hepatic steatosis 
and higher BMI were associated with increased mean liver stiffness, a 
lower hepatic venous pressure gradient (HVPG) decrease and persistent 
elevation of fibrogenic and angiogenic biomarkers following treatment in 
an HIV/HCV co-infected cohort.   
The relationship between liver fibrosis and IR is difficult to assess given 
the role of the liver in carbohydrate metabolism and insulin degradation. 
However, studies have suggested that individuals with chronic HCV have 
an increased incidence of IR and type 2 diabetes mellitus (DM 2) when 
compared with healthy controls, regardless of cirrhosis (Allison et al., 
1994, Fraser et al., 1996). Conversely, Friedenberg (2003) found that 
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when controlling for age, BMI and family history of diabetes this signal 
was lost. A later study by Moucari et al. (2008) found a higher frequency 
of IR in patients with HCV compared with the general population. 
Infection with HCV Gt1 or Gt4 was independently associated with IR. 
Serum HCV RNA levels also correlated with IR, suggesting a role for viral 
replication in the development of IR (Moucari et al., 2008). IR is also 
known to negatively impact response to HCV treatment (Romero-Gomez 
et al., 2005, EASL, 2011). 
IV. Tobacco and cannabis smoking: 
Tobacco smoking is well recognised as a risk factor for HCC, and may be 
independently associated with fibrosis progression (Hutchinson et al., 
2005). The precise mechanisms are currently unknown although lifestyle 
factors such as smoking may be associated with accelerated cellular 
ageing.   
A recent study by Ishida et al. (2008) also demonstrated that daily 
cannabis use was associated with moderate to severe fibrosis and they 
recommended that individuals with HCV should be dissuaded from 
cannabis use. Conversely, Brunet et al. (2013) were unable to 
demonstrate a significant association between cannabis use and disease 
progression in their HIV/HCV co-infected population. 
The cannabinoid system consists of two receptors, CB1 and CB2, to which 
cannabinoids may bind. Depending on which receptor is expressed, 
cannabinoids can have opposite effects on the liver. Cannabis use leads to 
accelerated fibrosis through its effects via the CB1 receptor, promoting 
steatosis (Hezode et al., 2005, Hezode et al., 2008). In animal models, 
antagonism of the CB1 receptor reduced fibrosis whereas stimulation of 
the CB2 receptor demonstrated anti-inflammatory and anti-fibrogenic 
effects (Teixeira-Clerc et al., 2006). Levels of CB1 are 6 times higher in 
patients with CHC compared with healthy controls, and twice as high in 
individuals with cirrhosis compared to those with low level fibrosis 
suggesting that alteration of the CB1/CB2 ratio in HCV infection may 
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underlie the effect of cannabis ingestion on disease progression (van der 
Poorten et al., 2010). 
V. Coffee intake: 
Coffee consumption has been associated with lower mortality and reduced 
progression to fibrosis in patients with chronic liver disease (Masterton 
and Hayes, 2010). It is also associated with a reduction in the incidence of 
HCC regardless of aetiology (Gelatti et al., 2005). The underlying 
protective mechanism remains obscure, although a recent study has 
demonstrated that this beneficial effect may be mediated through a 
reduction in oxidative damage, which correlated with increased telomere 
length and lower collagen synthesis in patients with CHC (Cardin et al., 
2013). Coffee may also reduce intestinal permeability, which may inhibit 
the promotion of fibrogenesis through bacterial lipopolysaccharide (LPS)-
dependent TLR4 signalling (Schnabl and Brenner, 2014). 
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1.4 Assessment of liver disease severity in CHC 
An important part of risk stratification is assessment of fibrosis stage and there 
are a number of methodologies in use in clinical practice. It is vital that patients 
with more advanced disease are offered surveillance for oesophageal varices and 
hepatocellular carcinoma, and where appropriate, are prioritised for antiviral 
treatment. All patients should receive interventions targeting modifiable factors 
influencing disease progression (chapter 1.3.2.2), for instance, counselling 
regarding lifestyle modifications (i.e. abstinence from alcohol, diet, exercise, 
weight loss), optimisation of glycaemic control and treatment of co-infection. 
1.4.1 Invasive methods 
Liver biopsy is the gold standard for assessing liver disease severity. Liver biopsy 
for fibrosis staging is usually performed under radiological guidance, and can be 
percutaneous or transjugular, with the transjugular route preferred for patients 
with ascites, or at high risk of complications. Laparoscopic liver biopsy is also 
performed. Liver biopsy is associated with a low mortality, however 
complications including pain, bleeding, infection and damage to other structures 
may occur (Grant and Neuberger, 1999). Histological scoring systems have been 
developed to report the grade (degree of inflammation) and stage (fibrosis), 
with Metavir (Bedossa and Poynard, 1996) and Ishak (Ishak et al., 1995) the most 
commonly used in clinical practice. 
The Metavir activity score for chronic hepatitis grades hepatic inflammation into 
3 categories, with A1 indicating minimal or mild disease, A2 indicating moderate 
hepatitis, and A3 reserved for severe disease. The principle observational 
features are the degree of periportal interface hepatitis (‘piecemeal necrosis’) 
and parenchymal injury (Goodman, 2007).   
The stage of fibrosis is reported as below (figure 1-8):  
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Figure 1-8: Histological scoring systems for hepatic fibrosis severity using Sirius red staining 
for collagen. Extracted from Standish et al. (2006). 
 
The European Association for the Study of the Liver (EASL) suggest that non-
invasive methods can be used instead of liver biopsy, with examination of liver 
tissue reserved for cases of suspected mixed aetiology or in the case of 
contradictory results ('EASL Recommendations on Treatment of Hepatitis C 2015,' 
2015). 
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1.4.2 Non-invasive methods 
1.4.2.1 Transient elastography 
Transient elastography (TE) is a non-invasive technique which uses ultrasound 
and low-frequency elastic waves to estimate liver fibrosis. It may be affected by 
age, obesity and necro-inflammatory activity, and although has excellent 
diagnostic accuracy for the diagnosis of cirrhosis, it is less discriminant at 
intermediate fibrosis stages (Friedrich-Rust et al., 2008). Liver stiffness values 
have been shown to correlate strongly with Metavir fibrosis stage in CHC (figure 
1-9). 
 
Figure 1-9: Box plots of liver stiffness values (kPa) for each Metavir fibrosis stage. Figure 
extracted from Castera et al. (2008). The vertical axis is in logarithmic scale. Panel A was 
adapted from Ziol et al. (2005) and panel B from Castera et al. (2005).  
 
Researchers have suggested that diagnostic accuracy may be improved by 
combining TE with serum biomarker panels, particularly at the lower stages of 
fibrosis.  
1.4.2.2 Biomarker panels 
Well established panels of biomarkers are in use, for instance, FibrotestTM and 
the Enhanced Liver Fibrosis Test (ELFTM) ('EASL Recommendations on Treatment 
of Hepatitis C 2015,' 2015). These tests rely on a combination of biochemical and 
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haematologic parameters, such as aminotransferase level, bilirubin, prothrombin 
time (PT) and platelet count, with or without additional markers of liver fibrosis, 
including α2-macroglobulin, haptoglobin and apolipoprotein A1. Other factors 
influencing fibrosis progression, for instance, age and gender, are factored into 
several of the scoring systems.  
Castera and colleagues (2008) found that a combination of TE and FibroTestTM 
offered the best diagnostic performance, and when concordant, matched the 
histological stage in > 90% of cases of severe fibrosis (≥F3) and cirrhosis (F4), and 
> 80% of cases with significant fibrosis (≥F2). When used individually FibroTestTM 
was shown to overestimate disease when compared with histology, whereas TE 
may underestimate fibrosis stage (Castera, 2015). The aspartate 
aminotransferase (AST) to platelet ratio (APRI) is a simple scoring tool which 
performs as well as TE in predicting advanced fibrosis (Wong et al., 2017). 
Novel scoring panels consisting of angiogenic biomarkers have recently been 
developed for assessment of liver fibrosis in CHC. The Angio-Index panel includes 
angiopoietin-2, basic fibroblast growth factor, hepatocyte growth factor and 
endostatin, and was found to have an excellent predictive value for significant 
fibrosis (Toson et al., 2017). There has been considerable interest in the role of 
endogenous non-coding RNAs, such as microRNAs (miRNAs), as biomarkers of 
hepatic fibrosis and they will be discussed in chapter 1.7. 
Interestingly, a number of biomarkers of cellular senescence also function as 
biomarkers of fibrosis in CHC. Replicative senescence has been associated with 
expression of senescence associated β-galactosidase (Sen-β-Gal) in liver cells of 
patients with CHC, and Paradis et al. (2001) showed that the presence of liver 
cells positive for Sen-β-Gal correlated with age and increasing levels of fibrosis 
in HCV infection. Recently, the use of osteoprotegerin and collagen IV in a blood 
test to identify liver fibrosis has been shown to improve diagnostic accuracy 
(Bosselut et al., 2013). Osteoprotegerin is a member of the TNF receptor 
superfamily which acts as a decoy receptor for receptor activator of NFκB ligand 
(RANKL) and is known to be upregulated at senescence, making it an interesting 
marker for further study and supporting the association between ageing and 
faster progression to fibrosis. Additionally, chronically HCV-infected individuals 
have shorter CD4 T cell and hepatocyte telomere lengths compared with healthy 
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controls, and this has been shown to correlate with both advanced disease stage 
and poorer response to IFN-based therapy (Hoare et al., 2010b, Sekoguchi et al., 
2007). 
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1.5 Treatment of CHC 
1.5.1 History of HCV treatment 
The primary goal of HCV therapy is cure, which was historically defined as 
undetectable HCV RNA 24 weeks after cessation of therapy (SVR24). Over 95% of 
patients who achieved SVR24 remained non-viraemic long term (Yoshida et al., 
2015). More recently it has been demonstrated that an undetectable HCV RNA at 
12 weeks post end-of-treatment (SVR12) is equivalent to SVR24 as an efficacy 
endpoint, and this has now become the standard marker of success in clinical 
trials (Yoshida et al., 2015). For many years, the standard of care (SoC) 
consisted of IFN and ribavirin (RBV), with treatment duration based on genotype 
and treatment response. However, the recent characterisation of the viral 
proteins and their role in the HCV life cycle has enabled the development of 
DAAs with marked improvements in tolerability and treatment response.  
1.5.1.1 Aciclovir 
The antiviral aciclovir was trialled for the treatment of chronic NANBH in 1985 in 
a small pilot study of only 5 patients (Pappas et al., 1985). Patients were treated 
with IV aciclovir at a dosage of 5mg/kg 8 hourly for 10 days. In 2 patients, serum 
aminotransferase levels decreased by more than 50%, however levels in the 
remainder were unchanged or increased relative to baseline. The 2 patients in 
whom aminotransferase levels improved were re-treated with a higher dose of 
aciclovir; aminotransferase levels rose in both patients. During follow up, no 
patient demonstrated lasting clinical or biochemical improvement, leading 
researchers to conclude that aciclovir was not effective in the treatment of 
chronic NANBH (Pappas et al., 1985). 
1.5.1.2 Interferon-alpha 
Human leukocyte interferon alpha (IFN-α) had been shown to be effective in the 
treatment of patients with chronic HBV infection and chronic active hepatitis as 
early as 1976 (Greenberg et al., 1976), and it was demonstrated subsequently 
that prolonged courses of recombinant IFN-α were associated with loss of HBsAg 
in a proportion of patients (Dusheiko et al., 1985). It was first used for the 
treatment of NANBH in 1986, before the identification of HCV as the aetiologic 
agent (Hoofnagle et al., 1986).  
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The use of thrice weekly IFN-α for 48 weeks was associated with 10-20% SVR 
(Poynard et al., 1998, McHutchison et al., 1998). Despite significant side effects 
and poor virologic response, IFN-α monotherapy remained the SoC for the best 
part of a decade.  
1.5.1.3 Ribavirin 
The antiviral activity of the synthetic guanosine analogue RBV was first 
described in 1972 (Witkowski et al., 1972). It has activity against both RNA and 
DNA viruses after intracellular phosphorylation, and was first approved for the 
treatment of severe respiratory syncytial virus (RSV) infection in children 
(Eggleston, 1987). 
RBV was trialled in the treatment of CHC in the early 1990s, and was associated 
with a transient reduction in serum aminotransferases (Bodenheimer et al., 
1997), however mean HCV RNA levels were not significantly decreased after 4 or 
24 weeks of therapy (Tong et al., 1994), suggesting that RBV as monotherapy 
was insufficient. Subsequently, the combination of IFN-α and RBV was found to 
improve virologic outcomes, resulting in an SVR24 of 20-40%, although at the 
cost of a significant side effect profile (Bellobuono et al., 1997, McHutchison et 
al., 1998, Chemello et al., 1995). Older age, stage of liver disease, high pre-
treatment HCV RNA and aminotransferase levels, and HCV genotype were found 
to influence treatment response (Chemello et al., 1995, Sherlock, 1995).  
The antiviral mechanism of RBV against HCV is not fully understood. It is 
proposed to act by a) immunomodulation through induction of a shift from a Th2 
to a Th1 immune response, b) inhibition of host inosine monophosphate 
dehydrogenase (IMPDH), c) direct inhibition of HCV replication and d) induction 
of mutagenesis (figure 1-10). 
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Figure 1-10: Sites of RBV action. Extracted from Feld and Hoofnagle (2005). Th, T-helper 
cell; IFN-γ, interferon-gamma; TNF-α, tumor necrosis factor-alfa; RMP, ribavirin 
monophosphate; RDP, ribavirin diphosphate; RTP, ribavirin triphosphate; IMP, inosine 
monophosphate; IMPDH, inosine monophosphate dehydrogenase; RdRP, RNA-dependent RNA 
polymerase; CTL, cytotoxic T-lymphocyte; es, equilibrative nucleoside transporter; GMP, 
guanosine monophosphate; GTP, guanosine triphosphate.  
1.5.1.4 Pegylated IFN-α (pegIFN-α) 
The next advance in the treatment of CHC came through the discovery that the 
half-life of IFN could be prolonged through PEGylation, the modification of a 
biological molecule through covalent conjugation with a polyethylene glycol 
(PEG) polymer.  
The use of pegIFN-α in place of standard IFN-α monotherapy was associated with 
an improvement in SVR rate, but it was the combination of weekly pegIFN-α and 
daily RBV which became the SoC for the next decade. Two pegylated IFN-α 
molecules were developed, pegIFN-α2a and pegIFN-α2b. In their pivotal study, 
Fried and colleagues (2002) demonstrated that the combination of weekly 
pegIFN-α2a and daily RBV for 48 weeks was associated with an overall SVR24 of 
46%, compared with 36% for thrice weekly non-pegylated IFN-α2b plus daily RBV, 
and 29% for weekly pegIFN-α2a alone. The alternative combination of pegIFN-
α2b and RBV was associated with a slightly lower SVR rate of 42% (Manns et al., 
2001). 
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The most important predictors of SVR with pegIFN-α and RBV were found to be 
HCV genotype, stage of hepatic fibrosis and host IFNL3 genotype, particularly in 
Gt1 infection. Patients with HCV Gt2 or Gt3 infection had an overall SVR rate of 
65-80% with the combination of peg-IFNα and RBV for 24 weeks, compared with 
just 40-50% in HCV Gt1 infected patients receiving 48 weeks of therapy (EASL, 
2011).  
The combination of pegIFN-α and RBV was associated with significant side 
effects. The use of RBV is associated with the development of a dose-limiting 
reversible haemolytic anaemia (Bodenheimer et al., 1997), possibly as a 
consequence of oxidative damage to erythrocyte membranes (De Franceschi et 
al., 2000). Other haematological and biochemical side effects of combination 
therapy include neutropenia, thrombocytopenia and ALT flares. Thyroid function 
abnormalities are reported with pegIFN-α, and adequately controlled thyroid 
function is a prerequisite for treatment. Both pegIFN-α and RBV are contra-
indicated in patients with severe pre-existing cardiac disease and 
electrocardiogram monitoring is recommended during their use. 
Neuropsychiatric side effects are also described secondary to both drugs, for 
instance, ‘riba rage’, and they are contra-indicated in individuals with severe 
psychiatric disorders. Additionally, their use in patients with depression and 
comorbid substance use disorders must be judged on an individual basis, under 
expert guidance. Importantly, RBV is teratogenic; pregnancy must be excluded 
before it is used, and effective contraception is essential during treatment and 
for 6 months beyond (EASL, 2011). Both drugs must be used with caution in 
patients with cirrhosis, and pegIFN-α is contra-indicated in decompensated 
disease.  
As a consequence of the side effects and poor tolerability, the use of pegIFN-α is 
now rarely recommended as first line therapy for acute or chronic HCV infection, 
but the addition of pegIFN-α to a DAA combination may still be considered as 
salvage therapy for patients who have failed an IFN-sparing DAA regimen (Feld, 
2014). One exception is in the treatment of IFN-eligible, treatment-naïve Gt2 
HCV-infected individuals, in whom 16-24 weeks of pegIFN-α with RBV may still 
be considered due to the extremely high SVR rates seen with this combination 
(circa 90%) (Dillon et al., 2017). Additionally, the use of weight-based RBV in 
patients who have baseline predictors of poor response to DAA treatment is still 
1-72 
 
recommended ('EASL Recommendations on Treatment of Hepatitis C 2016,' 2016) 
(see chapter 1.5.2).  
1.5.1.5 Direct-acting antivirals 
Advancements in understanding of the HCV viral proteins and their role in the 
HCV life cycle (chapter 1.1.4) opened the door for the development of antiviral 
compounds active against these proteins. Four different classes of DAAs are now 
available, with activity against 3 essential viral proteins: the NS3/4A protease, 
the NS5A protein and the NS5B polymerase. Combinations of these DAAs (+/- 
RBV) now lead to cure rates of 90-100%, largely irrespective of genotype. 
I. NS3/4A protease inhibitors 
The first DAAs licensed for use in the treatment of CHC were the NS3/4A serine 
protease inhibitors, telaprevir and boceprevir. These first generation protease 
inhibitors were only licensed for use in Gt1 infection, and improved the SVR rate 
to 65-75% in combination with pegIFN-α and RBV (Lawitz et al., 2008, Jacobson 
et al., 2011, Kwo et al., 2010, Poordad et al., 2011, Zeuzem et al., 2011). 
Although these combinations were more effective, they were poorly tolerated 
and associated with significant adverse effects leading to an increased rate of 
discontinuation. Both were associated with dermatologic side effects including 
rash and pruritis, and telaprevir was particularly associated with the 
development of Stevens-Johnson syndrome and toxic epidermal necrolysis. 
Haematologic side effects including anaemia, leukopenia and neutropenia were 
commonly reported, as were gastrointestinal side effects including dysgeusia and 
proctalgia. 
The next protease inhibitor to be approved for the treatment of chronic Gt1 HCV 
infection was simeprevir. The use of simeprevir in combination with pegIFN-α 
and RBV was associated with an SVR of 85-95% in treatment-naïve patients, and 
was associated with an improved side effect profile (Fried et al., 2013, Hayashi 
et al., 2014, Manns et al., 2014, Jacobson et al., 2014, Scott et al., 2015). This 
combination was also effective in patients who had previously failed pegIFN-α 
based treatment, demonstrating SVR rates of 61-80% compared to just 23% with 
pegIFN-α/RBV alone (Zeuzem et al., 2014a, Forns et al., 2014). The presence of 
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the resistance-associated substitution (RAS) Q80K in the NS3 protease sequence 
was found to be associated with significantly lower SVR rates. 
In general, NS3/4 protease inhibitors have a high antiviral efficacy, but have a 
low barrier to resistance and must be prescribed as part of combination therapy. 
Currently, there are 3 NS3/4A protease inhibitors recommended as part of DAA 
regimens for the treatment of CHC in adults in Scotland: simeprevir, paritaprevir 
and grazoprevir (Dillon et al., 2017). A further protease inhibitor, voxilaprevir, is 
showing promise in the treatment of NS5A-inhibitor experienced patients in 
combination with sofosbuvir and velpatasvir (Bourliere et al., 2017). 
All 3 currently available protease inhibitors are metabolised by cytochrome P450 
3A4, and co-administration with drugs that induce or inhibit CYP3A4 should 
usually be avoided. This interaction is exploited however by the co-
administration of paritaprevir with low dose ritonavir (a potent CYP3A4 
inhibitor) which acts as a pharmacokinetic enhancer and allows once-daily 
dosing. Simeprevir and paritaprevir are inhibitors of the efflux transporter P-
glycoprotein (P-gp) and the uptake transporter OATP1B1, and simeprevir and 
grazoprevir are mild inhibitors of CYP3A. Transient increases in bilirubin may be 
observed during treatment with simeprevir and paritaprevir (Zeuzem et al., 
2014b) due to the inhibition of the bilirubin transporter OATP1B1. Both 
paritaprevir and grazoprevir additionally inhibit breast cancer resistance protein 
(BCRP), another ATP binding cassette (ABC) efflux transporter. All 3 drugs are 
transported by P-gp, OATP1B1 and OATP1B3 in addition to others. Drug 
interactions are common and should be actively sought prior to treatment, with 
consideration given to illicit recreational drug use ('EASL Recommendations on 
Treatment of Hepatitis C 2016,' 2016). Protease inhibitors should not be used in 
patients with advanced cirrhosis (Child-Pugh stage B or C) because of the 
substantially higher drug concentrations in this patient group. 
II. NS5B polymerase inhibitors 
Sofosbuvir, a nucleoside analogue inhibitor of the NS5A RdRp, was approved in 
January 2014. Sofosbuvir has pan-genotypic activity; the combination of 
sofosbuvir, pegIFN-α and RBV for 12 weeks for HCV Gt1, Gt4, Gt5 and Gt6 
infection was evaluated in the NEUTRINO study. The study cohort consisted of 
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primarily Gt1 and Gt4 infected patients (98%) and the combination was 
associated with an SVR rate of ~90%. The combination was well tolerated, the 
most common side effects being fatigue and headache. Patients with cirrhosis 
did less well on treatment, with an overall SVR rate of 80% (Yoshida et al., 
2015). 
Sofosbuvir is not metabolised by CYP450 or uridine 5'-diphospho-
glucuronosyltransferase (UGT), but it is transported by P-gp and should not be 
co-administered with drugs that inhibit P-gp, for instance, rifampicin. It does 
not inhibit or induce the drug transporters described previously and drug-drug 
interactions are minimal. One notable exception is amiodarone, co-
administration of which may result in extreme bradycardia (Renet et al., 2015). 
Dasabuvir is a non-nucleotide inhibitor of the HCV RdRp, which acts by changing 
the 3D conformation of the enzyme and inhibiting its function. It is metabolised 
in the liver by CYP2C8 and CYP3A4, and inhibits UGT1A4, BCRP and P-gp in vivo. 
It is co-prescribed with paritaprevir, ritonavir and ombitasvir +/- RBV for the 
treatment of HCV Gt1 infection. The response rate in patients with Gt1b 
infection was extremely high (97-100%), regardless of prior pegIFN-α experience 
or presence of compensated cirrhosis (Ferenci et al., 2014, Dore et al., 2016, 
Zeuzem et al., 2014b, Andreone et al., 2014, Feld et al., 2016). Individuals with 
HCV Gt1a infection had lower responses, but benefited from the inclusion of RBV 
(SVR rates of 90% and 97%, respectively) (Ferenci et al., 2014). 
Failure to achieve an SVR with dasabuvir-containing regimens is associated with 
the development of RASs in the polymerase sequence. However, sofosbuvir has a 
high barrier to resistance and persistent, clinically relevant RASs have not been 
reported in treatment failure (Sarrazin, 2016). The S282T mutation, conferring 
2.4-18.1 fold reduced susceptibility to sofosbuvir, is selected for in vitro (Gane 
et al., 2017a), but rarely emerges in clinical trials (Gane et al., 2013). It is 
therefore recommended that sofosbuvir forms the backbone of any re-treatment 
strategies.   
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III. NS5A replication complex inhibitors 
There are 5 NS5A inhibitors currently recommended as part of DAA combinations 
in treatment guidelines ('EASL Recommendations on Treatment of Hepatitis C 
2016,' 2016): daclatasvir, ledipasvir, ombitasvir, elbasvir and velpatasvir. The 
use of daclatasvir in the treatment of CHC was approved in 2014. It is a 
substrate of CYP3A4, and a substrate and inhibitor of P-gp. Daclatasvir has pan-
genotypic activity, and the combination of sofosbuvir and daclatasvir was 
associated with high SVR rates in both treatment-naïve patients and those who 
had previously failed regimens containing first generation NS3/4A protease 
inhibitors (Sulkowski et al., 2014). The combination of daclatasvir, pegIFN-α and 
RBV was non-inferior to pegIFN-α/RBV (Dore et al., 2015, Hezode et al., 2015) 
but has been superseded by more efficacious regimens and is not recommended 
in international guidelines ('EASL Recommendations on Treatment of Hepatitis C 
2016,' 2016).  
Ledipasvir and velpatasvir are both administered as part of fixed-dose 
combinations (FDC) with sofosbuvir, with or without additional RBV depending on 
pre-treatment profile. Ledipasvir is a weak inducer of CYP3A4, CYP2C and 
UGT1A1 in vitro, and inhibits intestinal CYP3A4, UGT, P-gp and BCRP. Caution is 
therefore recommended when co-prescribing ledipasvir and P-gp substrates, for 
instance, digoxin. The solubility of ledipasvir is pH-dependent and real-world 
data suggest reduced SVR rates in patients receiving high dose proton-pump 
inhibitor therapy (Terrault et al., 2016). Velpatasvir is metabolised by CYP2B6, 
CYP2C8 and CYP3A4. It is a weak inhibitor of P-gp, OATP1B1 and OATP1B3, and a 
moderate inhibitor of BCRP, and is transported by the same.  
The combination of ledipasvir and sofosbuvir for HCV Gt1 infection was studied 
in the ION Phase III trials. It was found to be extremely effective in treatment-
naïve and treatment-experienced cohorts, and in patients with compensated 
cirrhosis (Afdhal et al., 2014a, Afdhal et al., 2014b, Kowdley et al., 2014). 
The once daily, pangenotypic FDC of sofosbuvir and velpatasvir was investigated 
as treatment for CHC in the ASTRAL studies. ASTRAL-1 included treatment naïve 
and treatment-experienced patients with HCV genotypes 1, 2, 4, 5 and 6 
infection, including patients with compensated cirrhosis. The combination was 
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found to be extremely effective, with an overall SVR of 99% (Feld et al., 2015). 
In the ASTRAL-2 and ASTRAL-3 studies, a 12 week course of 
sofosbuvir/velpatasvir was compared to the same duration of sofosbuvir/RBV in 
a cohort of both untreated and treatment-experienced patients with HCV Gt2 
and Gt3 infection. For Gt2 infection, the SVR with sofosbuvir/velpatasvir was 
99%, compared with 94% in the sofosbuvir/RBV arm. Individuals with HCV Gt3 
infection had SVR rates of 95% and 80%, respectively (Foster et al., 2015). The 
combination was also studied in HCV Gt1-6 infected patients with 
decompensated cirrhosis (Child-Pugh B and above). Patients were assigned in a 
1:1:1 ratio to receive sofosbuvir/velpatasvir for 12 weeks, sofosbuvir/velpatasvir 
plus RBV for 12 weeks or sofosbuvir/velpatasvir for 24 weeks. The overall SVR 
rates were 83% (95% CI, 74-90%), 94% (95% CI, 87-98%) and 86% (95% CI, 77-92%), 
respectively. Serious adverse events were similar between groups, and anaemia 
was common in patients receiving RBV (Curry et al., 2015). More recently, the 
combination of sofosbuvir/velpatasvir/RBV for 24 weeks has been studied in a 
cohort of HCV-infected patients who had previously failed a DAA containing 
regimen, and resulted in an overall SVR of 91% (95% CI, 82-97%) (Gane et al., 
2017b). A 12 week course of sofosbuvir/velpatasvir is the preferred first line 
therapy for HCV Gt3 infected individuals in Scotland, with the consideration of 
additional RBV in those with cirrhosis (Dillon et al., 2017).   
Finally, the NS5A inhibitor elbasvir is available as part of a FDC with the NS3/4A 
serine protease inhibitor grazoprevir for the treatment of HCV Gt1, Gt4 and Gt6 
infection. Elbasvir is metabolised by CYP3A4 and inhibits P-gp and BCRP. It is 
transported by P-gp. Elbasvir/grazoprevir was shown to be highly effective in the 
treatment of CHC in both treatment-naïve and -experienced patients (Kwo et 
al., 2017, Zeuzem et al., 2015, Lawitz et al., 2015, Buti et al., 2016). The 
combination of elbasvir/grazoprevir for 12 weeks is the preferred first line 
therapy for individuals with HCV Gt1 infection in Scotland, with the addition of 
RBV for patients with compensated cirrhosis (Dillon et al., 2017). The duration 
should be extended to 16 weeks in patients with a high baseline HCV viral load 
and/or the presence of baseline NS5A RASs as these factors were found to 
determine treatment response (Komatsu et al., 2017). This combination is safe 
for use in patients with end stage renal failure (ESRF) (Roth et al., 2015), 
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including those on haemodialysis, but it is contraindicated in patients with 
decompensated cirrhosis (Child-Pugh stage B or C).  
1.5.2 Factors influencing treatment response 
1.5.2.1 IFN-α based treatment 
In general, the modifiable factors influencing treatment response to IFN-based 
therapy mirror those affecting disease progression (chapter 1.3.2). Prior to the 
advent of the DAAs, the most important factors influencing response were HCV 
genotype, host IFNL3 genotype, and disease stage (Sherlock, 1995). It is now 
recognised that the functional variant lies within the INFL4 gene locus upstream 
of the IFNL3 locus on chromosome 19q13 (O'Brien et al., 2015). Expression of the 
wild type IFN-λ4 protein (associated with the unfavourable rs368234815-ΔG 
allele) is associated with increased basal antiviral ISG expression (see chapter 
1.2.1) and a reduced response to exogenous IFN-α (Murakawa et al., 2017). 
Other genetic polymorphisms of interest include SNPs in SPP1, the gene encoding 
osteopontin. Osteopontin is an important protein with cytokine functions that is 
crucial for initiation of the Th-1 immune response. Serum osteopontin level was 
found to correlate with treatment response, and SNPs in the promotor region of 
SPP1 have been shown to predict SVR rates with IFN-based therapies (Naito et 
al., 2005, Shaker et al., 2013). Other predictors of response included baseline 
HCV RNA level, age, IR, gender, ALT level or co-infection with HIV or another 
hepatotropic virus (Manns et al., 2006).  
1.5.2.2 DAA combination therapy 
Whilst DAA combinations are extremely effective and associated with excellent 
SVR rates in the majority of patients, there remain a number of negative pre-
treatment factors. An individualised approach to treatment is necessary, with 
consideration of HCV genotype/subtype, baseline resistance variants, presence 
of cirrhosis, prior treatment experience, and potential drug-drug interactions. 
The presence of cirrhosis is associated with a poorer response to combination 
DAA therapy (Majumdar et al., 2015). The addition of RBV to 
sofosbuvir/velpatasvir was associated with a significant improvement in SVR in 
patients with decompensated cirrhosis (Curry et al., 2015). The real-world 
benefit of additional RBV in decompensated cirrhosis was also demonstrated in 
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the NHS England expanded access programme (EAP) (Foster et al., 2016). RBV 
may also be of value in the treatment of individuals with baseline RASs 
conferring reduced susceptibility to DAAs.  
As previously described, RASs are amino acid substitutions in the viral RNA which 
confer resistance to DAA therapy. The first clinically important RAS identified in 
the DAA era was the naturally occurring Q80K mutation in the NS3 protease 
sequence which negated the effect of adding simeprevir to pegIFN-α/RBV in 
Gt1a HCV-infected individuals. Gt1a-infected subjects with a Q80K substitution 
had significantly lower SVR rates following treatment with pegIFN-α, weight-
based RBV and simeprevir (overall SVR 58% in treatment-naïve patients, and 47% 
in IFN-α experienced) (Jacobson et al., 2014, Forns et al., 2014). This mutation 
was seen in ~13% of Gt1 infected, treatment naïve patients in a Scottish cohort 
(Shepherd et al., 2015). Additional NS3 resistance variants include the 
substitutions R155K and A156T/V (Tong et al., 2006, Halfon and Locarnini, 2011). 
Variants with natural RASs conferring resistance to DAAs may be present at low 
level as part of the circulating quasispecies population, but be selected for 
under antiviral pressure (Abdelrahman et al., 2015). Many RASs in the NS3 
sequence confer a loss of replicative fitness (excepting Q80K) and are replaced 
quickly by wild-type virus when protease-based antiviral therapy is discontinued. 
In contrast, RASs in the NS5A sequence do not appear to affect viral fitness and 
may persist long-term (Krishnan et al., 2015). Naturally occurring variants 
conferring resistance to NS5A inhibitors also appear to occur more frequently 
(Sarrazin, 2016, Welzel et al., 2017, Hirotsu et al., 2015).  
Persistence of variants conferring resistance to sofosbuvir have not been 
described. The S282T variant results in markedly impaired viral fitness, however 
rapid reversion to wild-type virus is described after relapse, with the variant 
becoming undetectable 24-48 weeks post-sofosbuvir (Hedskog et al., 2015, da 
Silva Filipe et al., 2017, Gane et al., 2017a). However, naturally occurring 
variants associated with low-level resistance have been described, including 
C316N and S556G, and may persist long-term (Krishnan et al., 2015). S556G is 
the natural variant in HCV genotypes 2, 3, 4 and 5, explaining dasabuvir’s 
genotype-specific activity (Di Maio et al., 2014).   
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International guidelines currently recommend sequencing only the NS5A region, 
and using a deep sequencing cut-off of 15% (i.e. only RASs present in >15% of 
generated sequences should be considered) ('EASL Recommendations on 
Treatment of Hepatitis C 2016,' 2016). A number of clinically important NS5A 
RASs have now been identified (table 1-2). 
Table 1-2: Clinically important RASs 
NS5A aa position Ledipasvir RASs 
(Gt1a) 
Elbasvir RASs 
(Gt1a) 
Velpatasvir RASs 
(Gt3) 
M28 M28A 
M28G 
M28T 
M28A 
M28G 
M28T 
 
Q30 Q30E 
Q30G 
Q30H 
Q30K 
Q30R 
Q30D 
Q30E 
Q30G 
Q30H 
Q30K 
Q30L 
Q30R 
 
L31 L31M 
L31V 
L31F 
L31M 
L31V 
 
P32 P32L 
P32S 
  
H58 H58D H58D  
Y93 Y93C 
Y93H 
Y93N 
Y93S 
Y93C 
Y93H 
Y93N 
Y93S 
Y93H 
 
Whilst RASs may be associated with suboptimal efficacy of DAAs, treatment 
failure usually occurs only in the context of other negative predictive factors, 
for instance high baseline HCV viral load and advanced liver disease (Sarrazin, 
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2016). Extending the duration of treatment or intensification with the addition 
of RBV may negate the effect of baseline RASs on treatment outcomes (Sarrazin 
et al., 2016). 
Interestingly, IFNL4 genotype may also be relevant in determining response to 
IFN-sparing regimens. Meissner and colleagues (2014) found that the IFNL4-ΔG 
allele was associated with slower early viral decay in response to sofosbuvir and 
RBV, and reduced treatment efficacy. The IFNL4 genotype may also influence 
the development of RASs: it is hypothesised that patients with the IFNL4-TT/TT 
genotype have a more efficient antiviral response to HCV infection, resulting in 
selection for viral adaptations (Akamatsu et al., 2015). In support of this, the 
IFNL4-TT/TT genotype has been shown to correlate with the presence of NS5A 
RASs at Y93H in HCV Gt1 infected subjects (Peiffer et al., 2016). 
One major advantage of IFN-sparing combinations has been in the treatment of 
HCV in patients co-infected with HIV. Prior to the advent of DAAs, HIV/HCV co-
infection was associated with a significantly poorer response to IFN-based 
treatment (Laguno et al., 2004, Moreno et al., 2005). The PRESCO trial found an 
overall SVR rate of 50% in response to pegIFN-α/RBV in HIV/HCV co-infected 
subjects (35% in HCV Gt1, and 72% in HCV Gt3) (Nunez et al., 2007). The 
combination was associated with significant side effects, including a reduction in 
CD4 count leading to increased susceptibility to opportunistic infection. HIV co-
infection is no longer considered a negative predictor of response to treatment; 
HIV/HCV co-infected patients respond as well as HCV mono-infected patients to 
DAA combinations (Milazzo et al., 2016, Rockstroh et al., 2015, Schwabl et al., 
2017, Sulkowski et al., 2015). 
Older age, independent of fibrosis stage, does not appear to confer a negative 
prognostic impact on virologic outcomes with DAA treatment, however it may 
affect the incidence of adverse clinical events. Although age at baseline was not 
significantly associated with adverse outcome, Cheung et al. (2016) found that 
even in subjects with baseline albumin > 35g/L, only 50% of individuals aged ≥ 65 
years remained free from adverse event during follow up (death, hospitalisation, 
transplantation, decompensation or sepsis), compared with 63.5% of patients < 
65 years old.  
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It is clear that even in the DAA era, the relationship between ageing and 
negative clinical and treatment outcomes in CHC warrants further scrutiny. 
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1.6 Biological ageing in CHC 
1.6.1 Biological ageing 
Ageing is a complex physiological process that is mediated by genetic, 
epigenetic, cellular and environmental factors resulting in organ damage, an 
increased susceptibility to disease, decreased stress response and ultimately 
death (Deeks, 2011). Evidence is accumulating to suggest that cellular 
senescence may function as an essential mechanism to limit the proliferation of 
damaged cells, and that ageing may result partly from the efforts of the cellular 
stress response programme to reduce the risk of neoplastic change following 
insult (Hoare et al., 2010a, Kim and Sharpless, 2006). Cellular senescence may 
be triggered by telomere dysfunction, mitochondrial deterioration, DNA damage 
and chromatin instability, oxidative and oncogenic signals (Coppe et al., 2010, 
Hoare et al., 2010a) (figure 1-11).  
 
Figure 1-11: Overview of cellular senescence, extracted from Hoare et al. (2010a)  
Depending on the level of stressors, cell populations will react in different ways 
with increasing levels of stress leading to senescence, apoptosis or necrosis. 
Senescent cells remain metabolically active, but display an altered phenotype 
and elevated Sen-β-Gal activity.  
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Accelerated senescence is now recognised in a number of chronic medical 
conditions, and both elucidation of the pathways involved and identification of 
modifiable factors has come under intense scrutiny. 
1.6.1.1 Cellular senescence  
I. Telomere dysfunction 
Telomeres are repeating hexanucleotide sequences with telomere binding 
protein complexes that function to cap the chromosomal ends and prevent 
chromosomal instability (Hoare et al., 2010a, von Figura et al., 2009). In 
humans, telomeres consist of tandem repeats of the DNA sequence TTAGGG over 
an area of 10-15 kb together with a 3’ single strand overhang (Kitay-Cohen et 
al., 2008). The 3’ overhang forms a T loop through insertion in the upstream 
double strand telomere sequence, protecting the telomere from developing a 
DNA damage response. The shelterin complex includes telomere repeat binding 
factors 1 and 2 (TRF1 and TRF2) and binds to the double-stranded telomere to 
protect and regulate this unique structure (figure 1-12). 
 
 
Figure 1-12: Structure of the human telomere. Extracted from Hoare et al. (2010a). RAP1, 
repressor/activator protein 1; TIN2, TRF1-interacting nuclear protein 2; TRF2, telomere 
repeat binding factor 2; TRF1, telomere repeat binding factor 1; POT1, protection of 
telomeres 1. 
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Telomeres act to protect chromosomes from recombination, end-to-end fusion 
and recognition by DNA damage checkpoints and contribute to the organisation 
of the chromosomes within the nucleus. They are also involved in the regulation 
of gene expression and control the replication capacity of the cell (Cong et al., 
2002). 
 
Figure 1-13: End replication problem, extracted from Cong et al. (2002). DNA replication by 
the conventional polymerase proceeds in the 5′-to-3′ direction. The newly synthesized 
leading strands would not generate overhangs, but the newly synthesized lagging strands 
would lose their extreme 3′ end after RNA primers are removed. Both parental strands may 
also be subject to nuclease processing. 
In the absence of compensatory mechanisms, telomeres of proliferating cells 
shorten with each cell division (figure 1-13). On reaching a critical length, 
telomeres lose the ability to cap the chromosomal ends and DNA damage 
checkpoints are activated. Telomere dysfunction has been shown to activate 
p53/p21-dependent cell cycle arrest or apoptosis in vivo, dependent on cell type 
(von Figura et al., 2009). This was first formally described by Hayflick in 1965 as 
the process that limits the proliferation of human cells in culture and has thus 
been termed the ‘Hayflick limit’ (Hayflick, 1965) or cellular senescence 
(mortality stage I (M1)). Studies in mice revealed a cell cycle arrest response in 
liver cells, and an apoptotic response in lymphocytes (Satyanarayana et al., 
2003).  
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Studies on fibroblasts have shown that interruption of p53-mediated senescence 
leads to an increased lifespan of cells, but that ongoing telomere shortening 
induces a second p53 independent checkpoint, named crisis or mortality stage II 
(M2). This stage is associated with marked chromosomal instability secondary to 
telomere dysfunction and ultimately cell death (Cong et al., 2002). Crisis results 
from a loss of inhibitors of DNA damage response elements with subsequent 
recruitment of the PI3 kinases ATM and ATR, phosphorylation of histone 2A at 
serine 139 (γ-H2AX) and stabilisation of p53 and p21. Cellular senescence and 
crisis are important functions to prevent the replication and growth of 
genomically unstable cells.  
Telomere shortening has been described in many tissues during ageing, including 
peripheral blood cells, hepatocytes and lymphocytes (Jiang et al., 2007). It is 
postulated to contribute to the age-related accumulation of cytogenetic 
abnormalities recognised in human lymphocytes (Ramsey et al., 1995). Longer 
telomeres are associated with protection from age related diseases, improved 
cognition and better lipid profiles (Atzmon et al., 2010). Accelerated telomere 
shortening has also been described in a number of chronic inflammatory 
conditions, including cirrhosis, chronic HIV infection and inflammatory bowel 
disease (Deeks, 2011, Kinouchi et al., 1998, Kitada et al., 1995). Lifestyle 
factors commonly associated with ill health have also been shown to be 
associated with accelerated telomere shortening, for instance, smoking and a 
sedentary lifestyle (Song et al., 2010).   
II. Telomerase activity 
Telomerase is an RNA-dependent DNA polymerase that adds telomeric DNA to 
eukaryotic telomeres (Cong et al., 2002) to prevent telomere shortening with 
cell replication (von Figura et al., 2009). Telomerase consists of two essential 
components: a catalytic protein with reverse transcriptase activity (hTERT), and 
an RNA component (hTERC) which serves as the template for the synthesis of 
telomeric DNA. It includes several other proteins, including heat-shock protein 
90 and dyskerin, which are known to be important for activity, stability and 
maturation of telomerase.  
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In human cells, activity of telomerase is tightly regulated. Expression of 
telomerase is high in cells with a high proliferative potential, such as germ cells 
and activated lymphocytes, yet most human somatic cells are telomerase 
negative. Overexpression of telomerase enables the cell to circumvent the DNA 
damage checkpoints M1 and M2, resulting in unlimited proliferation and 
‘immortalisation’ of cell lines. It is recognised in approximately 90% of tumour 
samples (Cong et al., 2002, Kim et al., 1994). In support of this, whilst telomere 
dysfunction in telomerase knockout mice (Terc-/-) was associated with 
tumorigenesis secondary to chromosomal instability, tumour progression was 
impaired due to induction of cell cycle arrest and apoptosis (Lechel et al., 
2007).  
However, telomerase dysfunction is also associated with impaired organ 
maintenance and suppressed stem cell function (Rudolph et al., 1999, von Figura 
et al., 2009). Reduced telomerase function (as seen in dyskeratosis congenita) is 
associated with premature greying of the hair, osteoporosis, immune senescence 
and other conditions associated with frailty. More than 50% of cases of 
dyskeratosis congenita result as a consequence of mutations in genes encoding 
proteins that maintain telomere function, resulting in markedly shortened germ 
line telomeres (Cong et al., 2002, Savage and Alter, 2009).  
1.6.1.2 Immunosenescence  
Ageing results in changes to both the innate and adaptive immune system (figure 
1-14). A number of characteristic changes are described, including i) reduced 
number and functionality of hematopoietic stem cells, ii) thymic involution, iii) 
increased frequencies of well-differentiated CD28-CD57+ T cells, iv) increased 
pro-inflammatory cytokines, v) reduced circulating naïve T cells and vi) 
decreased CD4/CD8 ratio (Deeks, 2011).  
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Figure 1-14: Changes in immune cell compartments with ageing. Ageing of the innate and 
adaptive immune system results in chronic low grade inflammation which drives 
immunosenescence. Extracted from Nguyen et al. (2017). DCs, dendritic cells. 
 
Immune cells derive from bone marrow-derived haematopoetic stem cells 
(Nguyen et al., 2017). Senescent haematopoetic stem cells are less able to self-
renew to prevent clonal exhaustion, and demonstrate myeloid skewing of 
differentiation and increased apoptosis (Janzen et al., 2006). Levels of the 
cyclin-dependent kinase inhibitor p16INK4A (chapter 1.6.1.3) accumulate in 
ageing stem cells, inhibition of which is associated with improved stress 
tolerance and reduced apoptosis (Janzen et al., 2006). 
Ageing is associated with changes in humoral immunity resulting in the 
generation of less effective antibodies with poor affinity and reduced diversity. 
These changes occur due to alterations in the bone marrow environment with 
consequent defects in B cell development (Labrie et al., 2004). T cell 
maturation also demonstrates age-associated changes; T lymphocytes in the 
elderly show loss of functional capacity and cellular diversity, with reduced 
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immune response to antigens. There is an increase in the ratio of helper: 
cytotoxic T cells and ratio of memory: naïve T cells (Holcar et al., 2015). The 
age-related loss of naïve T cells is more marked in the CD8+ compartment, as is 
the expansion of the end-differentiated population. The thymus plays a crucial 
role in immunity, and is the primary organ facilitating T cell maturation. Ageing 
is associated with a dramatic reduction in the size of the thymus, characterised 
by reduced cellularity and epithelial space as well as fat infiltration and an 
increase in perivascular space (Li et al., 2003). 
Telomere length and telomerase activity correlate with activation of B and T 
cells, and stage of differentiation. Ageing is associated with telomere attrition in 
T cells as a consequence of telomerase activity, naïve T cell percentage and 
health conditions (Lin et al., 2015). Loss of the costimulatory cell surface marker 
CD28 is a recognised marker of ageing T cells. Well differentiated CD4+ CD28- T 
cells are less able to proliferate and have shortened telomeres, and chronic 
antigen exposure and inflammation leads to dramatic clonal expansion of these 
cells. CD4+ CD28- T cells are pre-activated, and have a unique DNA methylation 
landscape, associated with higher expression of inflammasome related genes, 
release of IL-1Β on activation and increased production of IFN-γ (Suarez-Alvarez 
et al., 2017), contributing to a pro-inflammatory state. The proportion of 
defective effector memory T cells also increases with age, and these cells are 
characterised by shorter telomeres and the expression of the cell surface 
receptor CD57 (Tarazona et al., 2000). Expression of CD57 is also associated with 
lack of proliferative ability and lower secretion of IL-2 (Manfras et al., 2004, 
Monteiro et al., 1996). 
1.6.1.3 Regulation of INK4/ARF in ageing 
The INK4/ARF locus on chromosome 9p21 contains genes encoding important 
tumour suppressor proteins, the cyclin dependent kinase inhibitors (CKIs) (Kim 
and Sharpless, 2006, Sherr, 2000). Cyclin dependent kinase inhibitor 2A 
(CDKN2A) encodes two transcripts which are translated in different open reading 
frames to yield two distinct proteins – p14ARF (also known as ARF) and 
p16INK4A, or CDKN2A (figure 1-15). In addition, the INK4/ARF locus encodes a 
third tumour suppressor protein, p15INK4B (CDKN2B), as well as a noncoding 
RNA, ANRIL (Broadbent et al., 2008, LaPak and Burd, 2014). ANRIL runs antisense 
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to CDKN2B and is thought to function as an epigenetic regulator of INK4/ARF 
gene transcription.  
 
 
Figure 1-15: CDKN2A gene contains two upstream exons, 1α and 1Β. The two exons are 
driven by distinct promoters, resulting in alternative transcripts. The transcript initiated 
from the proximal 1α promoter encodes INK4A (CKDN2A), whilst the transcript initiated by 
the 1Β promoter encodes ARF. INK4 inhibits CDK4/6-cyclin-D-mediated hypophosphorylation 
of retinoblastoma family members, ultimately resulting in cell cycle arrest. ARF stabilises 
p53 levels through binding to and inactivating MDM2. Extracted from Chin (2003). RB, 
retinoblastoma; P, phosphoryl group 
 
Both CDKN2A and CDKN2B are members of the INhibitors of CDK4 (INK4) class of 
CKIs and act by binding to and inactivating the cyclin-dependent kinases (CDKs) 
CDK4 and CDK6. CDK4 and CDK6 promote proliferation through binding to D-type 
cyclins, mediating subsequent phosphorylation of retinoblastoma (Rb) family 
members (Kim and Sharpless, 2006). The binding of CDKN2A and CDKN2B to the 
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cyclin dependent kinases therefore maintains the Rb-family proteins in a 
hypophosphorylated state resulting in E2F binding and cell cycle arrest. In 
humans, the induction of CDKN2A has been reported in association with critically 
short telomere length, and it is thought to exert a protective function in 
proliferative cells (Jacobs and de Lange, 2004, Wang et al., 2013).  
 
Germline mutations of ARF are associated with melanoma and other 
malignancies (Murphy et al., 2004). ARF interacts with a number of targets to 
effect tumour suppression. One pathway is through the regulation of p53 in 
response to oncogenic stress signals or irregular proliferation. ARF binds to and 
inactivates the mouse double minute 2 homolog protein (MDM2), also known as 
E3 ubiquitin protein ligase, an important negative regulator of p53. MDM2 
targets p53 for proteasomal degradation hence inactivation by ARF results in p53 
stabilisation. ARF is able to interact with multiple other proteins, including E2F-
1, topoisomerase I, MYC and nucleophosmin (NPM). Interaction of NPM with ARF 
causes sequestration of ARF in the nucleolus of the cell and prevents ARF from 
binding to MDM2. Mutant forms of NPM which are localised to the cytoplasm have 
been documented in approximately a third of cases of primary adult acute 
myelogenous leukaemia (Colombo et al., 2006) and are believed to compromise 
the ARF-p53 pathway by localising ARF to the cytoplasm where it is unable to 
interact with MDM2, decreasing its stability. 
 
Recent evidence has suggested that the INK4/ARF locus may be implicated in 
ageing. Expression of CDKN2A increases with ageing in rodent, baboon and 
human tissues (Herbig et al., 2006, Nielsen et al., 1999, Zindy et al., 1997). 
Inactivation of CDKN2A but not ARF in a progeroid mouse strain is able to 
partially rescue certain age-related phenotypes (Baker et al., 2008). 
Additionally, Melzer et al. (2007) were able to demonstrate an association 
between SNPs near the INK4/ARF locus and physical function (Melzer et al., 
2007). Increased expression of CDKN2A has been demonstrated in association 
with risk behaviours including smoking and physical inactivity, and is negatively 
correlated with telomere length (Liu et al., 2009). Furthermore, increased 
CDKN2A expression correlates with that of IL-6, a soluble biomarker of 
senescence. 
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1.6.1.4 Senescence associated secretory phenotype 
Cellular senescence is an important tumour suppressor mechanism to limit 
replication in the presence of dysfunctional telomeres, chromatin instability, 
oncogenic signalling and expression of cell cycle inhibitors (Coppe et al., 2010). 
However, senescent cells may develop altered secretory phenotypes which 
influence the tissue microenvironment and paradoxically may promote 
tumorigenesis. This phenotype is termed the senescence-associated secretory 
phenotype (SASP). Senescent cells shown to develop this phenotype include HSCs 
(Schnabl et al., 2003) and endothelial cells (Shelton et al., 1999). 
 
Senescent cells activate downstream signalling pathways resulting in the release 
of ROS, pro-inflammatory cytokines, chemokines and growth factors (Nelson et 
al., 2012). Nelson et al. (2014a) were able to demonstrate that co-culture of 
senescent fibroblasts with young, replication-competent fibroblasts resulted in a 
DNA damage response in the young cells. The number of surrounding cells 
positive for Sen-β-Gal and other markers of senescence was also higher following 
co-culture, indicating that senescent cells are able to induce senescence in 
adjacent cells in vitro. The authors also provided evidence for this phenomenon 
in vivo by using a marker of oxidative stress to demonstrate that senescent 
hepatocytes cluster in mouse liver. 
 
SASP factors can be divided into soluble signalling pathways, proteases, and 
secreted insoluble proteins/ECM components (Coppe et al., 2010). The major 
cytokine of the SASP is IL-6. IL-6 is known to be associated with the DNA damage 
response (in particular, signalling through ATM and the protein kinase CHK2), 
and expression of IL-6 is able to induce senescence in neighbouring cells in a 
paracrine fashion. IL-1 is also overexpressed by senescent cells and acts through 
the IL-1 receptor/TLR family to trigger the NF-κB pathway. Other factors 
upregulated at senescence include prostaglandin E2, COX-2, colony-stimulating 
factors and osteoprotegerin. The IGF pathway and various chemokines are also 
thought to be important in the promotion of senescence. Proteases involved in 
the SASP include the MMPs, serine proteases and regulators of the plasminogen 
activation pathway. Fibronectin, an insoluble glycoprotein which interacts with 
cell surface receptors to promote adhesion, survival, migration and growth, is 
also upregulated in senescence. 
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The SASP is increasingly recognised as a major contributor to the spectrum of 
immunosenescence and to ‘inflamm-aging’, a term coined by Franceschi et al. 
(2000) to describe the upregulation of the inflammatory response with ageing. 
Inflamm-aging is a major driving force of frailty and has been described in a 
range of diseases, including chronic HIV infection and cardiovascular disease. For 
example, the SASP of senescent endothelial cells has been postulated to 
contribute to atherosclerosis development (Balistreri et al., 2013). It has been 
hypothesised that alteration of TLRs and/or their ligands could contribute to 
inflammation imbalance (Olivieri et al., 2013a).  
 
Pattern recognition receptors, including TLRs, are able to detect altered 
endogenous ligands released by damaged, necrotic or senescent cells and PAMPs 
expressed by micro-organisms. A pro-inflammatory pathway is activated, 
resulting in the downstream activation of NF-κB, mitogen-activated protein 
kinases (MAPKs) and members of the IRF family (Olivieri et al., 2013a) This 
process is usually tightly regulated, and loss of this control can result in chronic 
inflammation (figure 1-16).  
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Figure 1-16: Activation of pro-inflammatory pathways by senescent cells. Extracted from 
Olivieri et al. (2013a). PAMPs, pathogen associated molecular patterns; DAMPs, damage 
associated molecular patterns; ROS, reactive oxygen species; SASP, senescence associated 
secretory phenotype 
Interestingly, the SASP differs depending on the pathway driving cellular 
senescence. Cells induced to senescence through telomere dysfunction or 
replicative exhaustion express similar phenotypes, whereas senescence induced 
by CDKN2A overexpression is thought not to result in the full SASP despite being 
associated with other hallmarks of ageing and increased plasma levels of IL-6 
(Coppe et al., 2010, Liu et al., 2009). The kinase inhibitor CDKN2A is an 
effective inhibitor of NF-κB which may partly explain why senescence induced by 
CDKN2A overexpression is not associated with development of the SASP.  
1.6.1.5 Biomarkers of ageing 
Biomarkers of ageing (BoA) have come under intense scrutiny in recent years. It 
is postulated that various biomarkers may be used to predict an individual’s risk 
of age-related disease. As accelerated immune senescence is increasingly 
recognised in a number of chronic inflammatory diseases, such as HIV infection, 
cirrhosis and inflammatory bowel disease, these markers may also contribute to 
risk stratification and have a role in monitoring response to various therapies. 
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1.6.2 The ageing liver 
The ageing process leads to functional and structural changes in the liver, 
affecting the liver’s ability to withstand hepatic insults. Hepatocyte size and the 
number of binucleated cells increase with age, and there is a reduction in the 
number of mitochondria (Gan et al., 2011, Premoli et al., 2009). These changes 
are postulated to affect liver morphology and physiology in addition to oxidative 
capacity (Sheedfar et al., 2013) (figure 1-17).  
 
 
Figure 1-17: Schematic illustration of the pattern of liver disease progression during ageing, 
extracted from Sheedfar et al. (2013). NASH, non-alcoholic steatohepatitis; ROS, reactive 
oxygen species; ER, endoplasmic reticulum; HCC, hepatocellular carcinoma. 
 
Macroscopically, there is approximately one-third loss of hepatic volume 
between the ages of 30 and 100 years, thought to be mediated by reduced  
perfusion with Wynne et al. (1989) reporting a 35% loss in hepatic blood flow in 
subjects over 65 when compared to subjects below 40 years. 
 
A significant decrease in the regenerative property of the liver is seen with 
ageing (Hoare et al., 2010a, Sanz et al., 1999, Timchenko et al., 2006). Stocker 
& Heine (1971) demonstrated that in young rats, all hepatocytes are able to 
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enter the cell cycle after a 70% hepatectomy, whereas in aged rats only one-
third did. More recent evidence suggests that there is an active age-related 
change in the regulation of hepatocyte proliferation and that the CCAAT-
enhancer-binding protein (C/EBP) family members, glycogen synthase kinase 3 
beta (GSK3β), histone deacetylase 1 (HDAC1) and sirtuin 1 (SIRT1) epigenetic 
and signalling pathways play an important role (Iakova et al., 2003, Sheedfar et 
al., 2013). C/EBP family members are known to have a profound impact on fat 
cell differentiation (Chiu et al., 2004). In addition, C/EBPα represses hepatocyte 
proliferation through inhibition of CDKs.  
 
Downregulation of C/EBPα is reported after hemi-hepatectomy, resulting in 
hepatic regeneration. However, in aged rats the chromatin remodelling protein 
Brm is expressed at higher levels and interacts with C/EBPα leading to the 
formation of a high molecular weight complex also containing HDAC1, HP1α, 
E2F4 and Rb. This ‘repression switch’ from CDKs to E2F-promoted genes results 
in impaired proliferation following hepatectomy (Iakova et al., 2003). A recent 
paper by Zhu et al. (2014a) also found that expression of CDKN2A was 
significantly higher in older patients undergoing hepatectomy for liver cancer, 
and that it negatively correlated with liver regeneration in these patients.  
 
An important feature of ageing is the reduction in circulating growth hormone 
(GH) and insulin-like growth factor 1 (IGF-1). Components of the IGF-1 pathway 
such as GSK3β and PI3K/AKT are important in hepatocyte senescence. Age 
associated elevation of C/EBPα-Brm complex is mediated by 
hyperphosphorylation of C/EBPα at S193 which occurs following activation of 
CDK4 (Wang et al., 2006). CDK4 is activated by increased levels of cyclin D3 
which are present in aged mice due to protein stabilisation and declining levels 
of GSK3β (Jin et al., 2009). This senescence phenotype has been mimicked 
through inhibition of GSK3β in human liver-derived Chang cells (Seo et al., 
2008). Further support for the role of C/EBP in the ageing process was provided 
by Chiu et al. (2004) who demonstrated that transgenic mice expressing C/EPBΒ 
in place of C/EPBα do not develop fatty liver and are longer lived.  
 
Targeting GSK3β, HDAC1 and SIRT1 pathways has also been reported to improve 
the course of age-related diseases. HDAC1 is responsible for deacetylating 
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histone H3 on E2F-dependent promoters and appears to have a critical role in 
the regulation of liver regeneration in aged rodents. Aged livers contain high 
levels of the RNA binding protein CUGBP1 in a complex with eIF2. This complex 
is able to bind to the 5’ regions of several mRNAs including HDAC1 and C/EBPα, 
resulting in increased translational activity (Willis-Martinez et al., 2010). 
Overexpression of HDAC1 in the livers of old rodents appears to lead to 
suppression of gene expression via epigenetic silencing (figure 1-18).  
 
 
Figure 1-18: The dual function of HDAC1 in young and old livers is regulated by association 
with different protein complexes. Extracted from Willis-Martinez et al. (2010)  
 
Ageing is associated with increased lipid deposition in the liver, and it is worth 
noting that overexpression of HDAC1 also leads to the development of hepatic 
steatosis, potentially through interaction with C/EBP (Willis-Martinez et al., 
2010) (figure 1-18). Accumulation of the lipid in the liver is strongly associated 
with IR, and oxidative stress is thought to play a role in this ‘lipotoxicity’ (Slawik 
and Vidal-Puig, 2006). The commonest histological change on liver biopsy with 
ageing is the cytoplasmic accumulation of highly oxidised insoluble proteins, 
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known as lipofuscin (Jung et al., 2007) as a consequence of oxidative stress. 
Lipofuscin appears to promote free radical formation through the trapping of 
metallic cations (Jolly et al., 1995) and thus contributes to further oxidative 
damage. 
 
As discussed previously, there is often a trade-off between cellular senescence 
and restriction of tumorigenesis. The development of hepatic senescence, whilst 
associated with failure of cellular proliferation and regeneration, may be 
protective against the development of HCC. Uncontrolled activation of cell 
proliferation through the C/EBPα pathway is associated with development of 
HCC. The decline of P13K/AKT and GSK3 axis with ageing drives the cell to enter 
a protective mode against HCC (Wang et al., 2004). The age associated increase 
in C/EBPα/Brm complex can be corrected by the use of GH (Timchenko et al., 
2006) but upregulation of GH/IGF-1, whilst allowing for better recovery from 
injury, may lead to HCC development.  
 
1.6.3 Ageing and CHC 
CHC is associated with elevated expression of a number of biomarkers of cellular 
senescence, leading researchers to suggest that HCV infection may result in an 
aged phenotype. CHC is associated with increased mortality from both hepatic 
and extra-hepatic disease suggesting increased susceptibility to disease (Lee et 
al., 2012) – a recognised consequence of the normal ageing process. Ageing itself 
also appears to have a negative impact on the history of HCV infection (chapter 
1.3.2.1); older patients experience more rapid disease progression and a poorer 
response to IFN-based treatment (Hoare et al., 2010a). Additionally, the 
morbidity and mortality associated with HCV infection increases exponentially 
with age (Grebely and Dore, 2011). 
1.6.3.1 Cellular senescence in CHC 
CHC is associated with telomere shortening in numerous cell types (Kitay-Cohen 
et al., 2008, Sekoguchi et al., 2007). In chronic liver disease, hepatocyte cell 
cycle turnover results in hepatocyte telomere shortening and induction of 
replicative senescence (Wiemann S, 2002), linked to progressive fibrosis and 
cirrhosis. Moreover, chronic inflammation is associated with the generation of 
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ROS with attendant effects upon telomere length. Sekoguchi et al. (2007) 
demonstrated that active HCV infection was associated with hepatocyte 
telomere shortening, but that this signal was lost in patients with normal ALT 
levels. Telomere shortening also correlated with lower platelet counts and 
higher levels of serum hyaluronic acid, markers of increased hepatic fibrosis. As 
Sekoguchi and colleagues (2007) were unable to identify hepatocytes with 
evidence of oxidative damage independent of telomere length, the investigators 
proposed that the primary cause of cellular senescence in CHC was telomere 
shortening due to cell turnover. They also observed more hepatocytes 
demonstrating morphological features of senescence suggesting the rate of 
senescence is increased in CHC (Sekoguchi et al., 2007). Although oxidative 
stress was not considered the main mechanism of cellular senescence, it was 
postulated to contribute to accelerated telomere shortening in advanced 
fibrosis.  
Interestingly, Hartmann et al. (2011) demonstrated that telomerase gene 
mutations were more frequent in cirrhotic patients than in healthy controls, or 
HCV-infected patients with indolent disease, leading them to postulate that 
telomere shortening may represent a causal factor accelerating fibrosis and 
impairing liver regeneration in response to chronic liver injury. 
1.6.3.2 Immunosenescence in CHC 
Both HCV and ageing are associated with effects on the immune system. Chronic 
immune activation may result in the development of T cells that are capable of 
cytokine secretion yet demonstrate failure to proliferate. CD57 is a cell marker 
commonly expressed on such T cells and correlates with senescence (Kern et al., 
1996). Manfras et al. (2004) found that increased oligoclonality and expression of 
CD57 on peripheral lymphocytes was associated with increased levels of fibrosis 
and reduced response to treatment in patients with HCV infection, perhaps 
explaining the poorer treatment outcomes classically seen in older patients 
(Sherlock, 1995). 
HCV-infected individuals also have shorter lymphocyte telomeres (characteristic 
of immunosenescence) in comparison with healthy controls, and subjects in 
whom HCV has been eradicated (Kitay-Cohen et al., 2008, Grady et al., 2016). In 
contrast to the findings in hepatocytes, Kitay-Cohen and colleagues (2008) 
1-99 
 
demonstrated similar cell turnover in HCV-infected and healthy individuals, 
suggesting lymphocyte telomere shortening is not a result of shorter cell cycles. 
They also demonstrated that rates of aneuploidy persisted despite normalisation 
of ALT, suggesting that genomic instability secondary to telomere shortening 
endures despite disease remission (Kitay-Cohen et al., 2008). 
Chronically HCV-infected individuals have reduced CD4 T lymphocyte telomere 
lengths compared to healthy controls (Grady et al., 2016). Hoare and colleagues 
(2010b) also demonstrated this association, and estimated the overall difference 
in telomere length to be equivalent to 10 years additional ageing. Furthermore, 
they showed that CD4 T lymphocyte telomere length correlated with predictors 
of morbidity and mortality (increased fibrosis stage, increased portal tract 
inflammation, prolonged PT and increased bilirubin) and suggested that 
individuals with mild disease but shortened telomeres should be offered antiviral 
therapy at the earliest opportunity.  
Reduced hTERT mRNA expression, which is reflective of telomerase activity, has 
been reported in the peripheral lymphocytes of patients with HCV infection, and 
is unrelated to activity or stage of disease. Reduced telomerase activity 
represents premature ageing, and Satra and colleagues (2005) have suggested 
that deregulated hTERT mRNA expression may be involved in the 
immunopathogenesis of HCV infection. In contrast to this, Hoare et al. (2010a) 
were unable to demonstrate a failure of telomerase induction in peripheral 
lymphocytes of patients with CHC.  
1.6.3.3 INK4/ARF regulation in HCV 
CKDN2A has been suggested as a potential BoA, expression of which correlates 
with ageing in a number of animal tissues (Herbig et al., 2006, Nielsen et al., 
1999, Zindy et al., 1997) (chapter 1.6.1.3). CDKN2A accumulates with ageing in 
haematopoetic stem cells, and CDKN2A inhibition is associated with reduced 
apoptosis and improved stress tolerance (Janzen et al., 2006). Robinson and 
colleagues (2013) observed higher expression of CDKN2A mRNA and the related 
transcripts ARF and CDKN2B in the PBMCs of chronically HCV-infected subjects 
compared with matched controls, and found that expression of CDKN2A and ARF 
mRNA correlated with disease stage. Elevated expression of CDKN2A mRNA 
correlated with increased p16 protein levels. They also demonstrated a trend 
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towards shorter telomere length in the PBMCs of patients with CHC compared 
with healthy controls but this failed to reach statistical significance.  
1.6.3.4 Oxidative stress in HCV 
Conditions causing a mismatch between production and removal of ROS lead to a 
change in the redox state of the cell, known as oxidative stress. Oxidative stress 
promotes cellular senescence both directly and indirectly through effects on 
telomere function. Mitochondria are an important source of ROS, and it has been 
postulated that HCV may contribute directly to mitochondrial dysfunction 
(Finkel, 2011).  
HCV viral proteins, notably core and NS3/4A, localise to the OMM (Kasprzak et 
al., 2005, Horner et al., 2011). A number of in vitro studies have reported an 
increase in ROS production and mitochondrial dysfunction in association with 
HCV proteins, particularly the core protein (Korenaga et al., 2005, Okuda et al., 
2002). Korenaga et al. (2005) demonstrated that incubation of core protein with 
control mitochondria caused glutathione oxidation and increased ROS 
production. These changes are thought to relate to enhanced mitochondrial 
uptake of calcium ions (Korenaga et al., 2005, Piccoli et al., 2007, Quarato et 
al., 2013).  
Barbaro et al. (1999) found a higher prevalence of ultrastructural alterations of 
mitochondria in Gt1b infected patients together with depletion of mitochondrial 
DNA, and postulated that impaired oxidative phosphorylation in these patients 
may promote hepatotoxicity. 
Quarato and colleagues (2013) proposed the existence of a positive feedback 
loop with increased Ca2+ flux from the ER into the mitochondria leading to 
increased ROS production and enhanced opening of the mitochondrial 
permeability transition pore (MPTP). Activation of the MPTP leads to further 
alteration of the redox state with subsequent effects on ER-mitochondrial Ca2+ 
homeostasis. Opening of the MPTP results in depletion of the low molecular 
weight molecules (carnitine, coenzyme A (CoA) and NAD+) required to import 
long chain acyl-CoA for β-oxidation. Accumulating acyl-CoA molecules are thus 
forced towards triglyceride synthesis leading to hepatic lipid deposition and 
steatosis, with consequent effects on fibrosis progression (chapter 1.3.2.2). 
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Differing levels of oxidative stress appear to lead to different pathogenic 
outcomes; low production of ROS reportedly favours pro-survival adaptation, 
whereas high levels of ROS lead to permanent opening of the MPTP and resultant 
osmotic swelling, rupture of the OMM and ultimately, cell death. 
1.6.3.5 Lifestyle factors 
Studies have demonstrated a high prevalence of various risk behaviours amongst 
HCV-infected individuals. For instance, Zani et al. (2009) gathered self-reported 
data on smoking and alcohol use amongst 229 patients attending a clinic in Italy. 
Over half of the male patients consumed alcohol and around 44% were current 
smokers. Of the female patients, approximately 35% consumed alcohol and 27% 
were current smokers. Additionally, PWIDs make up the majority of the HCV-
infected population in the UK (HPS, 2015).  
Shorter telomere length has been reported in association with alcohol use, 
substance misuse and smoking (Pavanello et al., 2011, Song et al., 2010, Yang et 
al., 2013). Smoking also accelerates the age-dependent accumulation of 
cytogenetic abnormalities in lymphocytes (Ramsey et al., 1995). Grady et al. 
(2016) found that HCV-infected PWIDs had significantly reduced CD4+ T 
lymphocyte telomere lengths in comparison to healthy controls (Grady et al., 
2016). This accumulation of DNA damage and accelerated cellular senescence 
(Song et al., 2010) may lead to faster disease progression and HCC development 
in individuals with HCV (chapter 1.3.2.2). 
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1.7 The role of microRNAs in HCV pathogenesis 
MiRNAs are short endogenous non-coding RNAs approximately 22 nt in length 
which are responsible for post-transcriptional gene regulation. Specific 
alterations in circulating miRNA expression have been described in a number of 
diseases (Edwards et al., 2010) and these signatures are increasingly being 
exploited as biomarkers for diagnosis and staging as well as demonstrating 
prognostic implications (Calin and Croce, 2006, Witwer et al., 2012, Fognani et 
al., 2013). 
1.7.1 MiRNA biogenesis and function 
In 1993, Lee and colleagues (1993) discovered a gene involved in the timing of C. 
elegans larval development (lin-4) that did not code for a protein but rather 
produced a pair of short RNA transcripts 22 nt and 61 nt in length, with the 
longer transcript thought to be the precursor of the shorter. It was noted that 
both transcripts had antisense complementarity with multiple sites in the 3’ UTR 
of the lin-14 gene, and it was subsequently shown that base pairing of the lin-4 
RNA at these sites resulted in down-regulation of lin-14 translation (Wightman et 
al., 1993). The shorter 22nt transcript is now known to be a member of the 
miRNA family, a class of endogenous, non-coding RNAs involved in post-
transcriptional gene regulation. MiRNAs are widespread in nature, having been 
described in both plants (Emery et al., 2003) and animals (Leaman et al., 2005, 
Pasquinelli et al., 2000). Currently, the human miRNA family includes 2588 
mature miRNAs (miRBase v21.0, http://www.mirbase.org/). Each miRNA is able 
to regulate many different mRNAs and thus they exhibit crucial regulatory 
functions in diverse biological processes including immune response, cellular 
differentiation and aging (Bartel, 2004). 
MiRNAs are transcribed as long primary transcripts (pri-miRNA), typically 
hundreds to thousands of nucleotides in length, by RNA polymerase II and RNA 
polymerase III. They may be transcribed from dedicated genes, or processed 
from introns of other genes. Pri-miRNAs then undergo cleavage in the nucleus 
into shorter 70-110 nt hairpin structures by the action of a microprocessor 
complex containing the RNAase III ribonuclease Drosha (Lee et al., 2003), also 
known as ribonuclease 3, and the microprocessor complex subunit DiGeorge 
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syndrome critical region 8 (DGCR8) (Kim, 2005) (figure 1-19). DGCR8 stabilises 
the pri-miRNA and determines the cleavage site for Drosha. Following cleavage, 
the shortened molecule is referred to as a precursor miRNA (pre-miRNA). The 
pre-miRNA is exported into the cytoplasm by exportin 5 (XPO5) where it is 
cleaved by another RNAse III nuclease called Dicer, generating a partially dsRNA 
structure. Dicer and its interaction-domain protein (TAR RNA binding protein, 
TRBP) dissociate from the miRNA to form the RNA-induced silencing complex 
(RISC). The dsRNA structure is unwound, leaving a mature functional strand 
which is complementary to the target mRNA and is incorporated into the RISC 
together with a member of the Argonaute (AGO) protein family, AGO2 
(Chendrimada et al., 2005). The other strand is designated miRNA* and is 
degraded. The mature strand then guides RISC to target mRNA to inhibit 
translation or promote degradation. The specificity of miRNA to the target mRNA 
is determined by its seed sequence, a 6-8 nt sequence in the 5’ region of the 
miRNA which binds to a complementary sequence in the 3’ UTR of the target 
gene (Bartel, 2009). The degree of complementarity between the sequences 
determines the outcome of RISC binding; imperfect complementarity generally 
leads to impaired translation whereas perfect complementarity results in 
cleavage (Sullivan and Ganem, 2005). 
The extracellular circulating miRNA population is heterogeneous; miRNAs can be 
carried in association with membrane vesicles (including exosomes, apoptotic 
bodies and shedding vesicles), packaged into high density lipoprotein particles, 
or bound to Argonaute family proteins (Turchinovich et al., 2012). It is thought 
that miRNAs contained within membrane vesicles may be specifically sorted and 
may aid communication between cells or play a role in regulation of gene 
expression in target cells (Shrivastava et al., 2015). In contrast, protein-bound 
miRNAs are thought to be released passively into the circulation on cell death.  
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Figure 1-19: MiRNA biogenesis, extracted from Issler and Chen (2015). DGCR8, DiGeorge 
syndrome critical region 8; XPO5, exportin 5; GTP, guanosine triphosphate; RISC, RNA-
induced silencing complex; AGO2, argonaute-2; ORF, open reading frame 
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1.7.2 MiRNA nomenclature 
A uniform system for miRNA annotation was developed to ensure that miRNA 
could be distinguished from other small RNAs including short interfering RNAs 
(siRNAs). MiRNAs are identified using a combination of expression and biogenesis 
criteria (Ambros et al., 2003): 
Expression criteria: 
A. Detection of a distinct ~22 nt RNA transcript by hybridisation to a size-
fractionated RNA sample 
B. Identification of the sequence in a cDNA library made from size-
fractionated RNA, which must precisely match the genomic sequence of 
the organism from which it was cloned 
Biogenesis criteria: 
C. Prediction of a fold-back precursor structure containing the ~22nt miRNA 
sequence within 1 arm of the hairpin 
D. Phylogenetic conservation of the ~22nt miRNA sequence and its predicted 
fold-back precursor secondary structure 
E. Detection of increased precursor accumulation in organisms with depleted 
Dicer function 
Novel miRNAs should meet both biogenetic and expression criteria. If the miRNA 
cannot be detected, a candidate gene can still be annotated as a miRNA gene if 
the phylogenetically conserved hairpin precursor can be detected, and it 
accumulates in organisms with reduced Dicer function (Ambros et al., 2003). 
MiRNAs are named using the ‘miR’ prefix and assigned numbers sequentially 
according to date of identification, and identical miRNA are given the same 
number regardless of organism. Pre-miRNA are differentiated by using the 
uncapitalized prefix ‘mir’. The species in which the miRNA was observed is 
distinguished by a 3 letter annotation, for example, hsa-miR-21 in Homo sapiens. 
MiRNAs with closely related mature sequences are annotated with lower case 
letters (for example, miR-26a and miR-26b). If the mature sequences are 
1-106 
 
generated from distinct precursor sequences or genomic loci then this is 
indicated with an additional number, e.g. miR-26a-1.  
MiRNA sequences which originate from the same predicted precursor in equal 
abundance are denoted with a ‘-3p’ or ‘-5p’ suffix, for example, miR-21-5p, to 
indicate whether the sequence is originating from the 3’ or 5’ end. Alternately, 
if the relative abundancies indicate that there is a predominant miRNA then it is 
assigned a name in the form miR-56, and the opposite arm is designated miR-
56*.       
1.7.3 ‘Inflamma-miRs’ and ‘onco-miRs’ 
The inflammatory response against pathogens must be tightly controlled: the 
production of inflammatory mediators is essential to clear infection, however 
unrestrained inflammation leads to tissue damage. MiRNAs play pivotal roles in 
regulating immune responses, and nearly all the miRNA involved in immune 
regulation demonstrate altered expression in ageing (Olivieri et al., 2013b). 
These miRNA have been termed ‘inflamma-miRs’ and act mainly as negative 
regulators of pro-inflammatory signalling pathways.  
MiRNAs are suggested to modulate TLR signalling through several different 
mechanisms (figure 1-20). MiRNAs are able to directly activate the RNA-sensing 
TLR or to target components of the TLR signalling pathway. Additionally, miRNAs 
are directly regulated by TLRs. Evidence suggests that a number of miRNAs are 
involved in regulating this process, in particular, miR-155, miR-21 and miR-146a 
(Olivieri et al., 2013a, Quinn and O'Neill, 2011). 
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Figure 1-20: MiRNAs modulating TLR pathways, extracted from Olivieri et al. (2013a). LPS, 
lipopolysaccharide; GPI, glycosylphosphatidylinositol; RSVF proteins, respiratory syncytial 
virus fusion proteins; TLRs, toll-like receptors 
MiR-146a is highly expressed in aged mice and higher circulating levels have 
been described in certain diseases of ageing, including cardiovascular disease, 
Alzheimer’s dementia and osteoarthritis (Olivieri et al., 2013a). Induction of 
miR-146a by TNF-α and IL-1Β is dependent on NF-κB. MiR-146a then acts as a 
negative feedback regulator by targeting IL-1 receptor associated kinase 1 
(IRAK1) and TRAF6, resulting in downregulation of NF-κB activity (Taganov et al., 
2006, Bhaumik et al., 2008). MiR-146a expression in primary human fibroblasts 
was also shown to downregulate IRAK1 as well as levels of the SASP mediators IL-
6 and IL-8. Levels of miR-146a are increased in senescent fibroblasts, suggesting 
miR-146a induction may be part of a compensatory mechanism to modulate 
inflammation (Bhaumik et al., 2009). MiR-146a also has an important regulatory 
role in oncogenesis through reducing the metastatic potential of cancerous cells 
(Bhaumik et al., 2008). 
MiR-21 is a well described ‘onco-miR’, aberrant expression of which is described 
in numerous cancers (Fouad et al., 2017, Supic et al., 2017, Nakka et al., 2017). 
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It is central to a number of inflammatory pathways, including TLR signalling 
(Olivieri et al., 2012, Quinn and O'Neill, 2011). MiR-21 is upregulated in PBMCs, 
macrophages and fibroblasts in response to bacterial LPS and is induced by IFN 
stimulation in a number of cell lines (Sheedy et al., 2010, Pedersen et al., 2007). 
IFN stimulation does not result in miR-21 induction in cell lines with a genetic 
deletion of the STAT3 locus, suggesting that STAT3 is an important regulator of 
miR-21 expression. There are several potential binding sites for NF-κB within the 
miR-21 promoter region, and IFN-induction of miR-21 has previously been shown 
to be NF-κB dependent. Importantly, IFN-induced NF-κB binding to the miR-21 
promoter was abrogated by STAT3 knock down, suggesting crosstalk between the 
signalling pathways (Yang et al., 2015). MiR-21 plays a dual role, inhibiting as 
well as inducing TLR signalling. Transfection of cells with a precursor of miR-21 
has been shown to suppress NF-κB activity and to promote secretion of the anti-
inflammatory IL-10 in response to LPS stimulation. Induction of miR-21 results in 
a decrease in levels of the tumour suppressor PDCD4 protein, acting as a 
molecular switch from a pro-inflammatory to an anti-inflammatory response 
(Sheedy et al., 2010). However, miR-21 can also function as an agonist of single-
stranded RNA-binding TLRs, resulting in NF-κB activation (Fabbri et al., 2012). 
Circulating levels of miR-21 have been shown to correlate with C-reactive 
protein (CRP) and fibrinogen and are positively associated with ageing, making 
miR-21 an attractive biomarker of ageing.  
Elevated miR-155 expression is associated with diseases of ageing and 
inflammation, including acute myocardial infarction and atherosclerosis (Olivieri 
et al., 2013a). Like miR-21, it is a well characterised onco-miR, with deregulated 
expression in various cancers. It was first described in chickens suffering from 
avian leucosis virus-associated lymphoma and is now recognised to promote B-
cell lymphomas, in particular Hodgkin lymphoma and diffuse large B-cell 
lymphoma, as well as being associated with solid organ tumours (Eis et al., 
2005). MiR-155 appears to exert both positive and negative regulatory effects on 
NF-κB activity. MiR-155 is upregulated as part of the inflammatory response to 
LPS stimulation, and is associated with increased production of TNF-α (Tili et al., 
2007). It is also downregulated by the anti-inflammatory cytokine IL-10, in 
contrast to miR-146a and miR-21 (McCoy et al., 2010). However, Ceppi et al. 
(2009) showed that miR-155 also exerts negative feedback through targeting 
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TGF-Β activated kinase 1 binding protein 2 (TAB2), a signal transduction 
molecule in the TLR/IL1-R pathway, leading to inhibition of TAK1, and 
consequently NF-κB and MAPK. MiR-155 may also downregulate MyD88, as well as 
Iκκε, Sma- and Mad-related protein 2 (SMAD2) and Fas-associated death domain 
protein (Xiao et al., 2009), as well as targeting the suppressor of cytokine 
signalling 1 (SOCS1) gene.  
MiR-16, miR-195, miR-15 and miR-457 are related miRNA sequences from the 
miR-15 family. MiR-16 has tumour suppressor functions and has been shown to 
bind to both B-cell lymphoma 2 (BCL2) (Cimmino et al., 2005) and vascular 
endothelial growth factor (VEGF) (Hua et al., 2006), resulting in suppression of 
anti-apoptotic and angiogenic signalling. Downregulation of miR-16 is recognised 
in many tumour types (Lu et al., 2005). Interestingly, unstimulated human B 
cells from elderly individuals demonstrate increased miR-155 and miR-16 
expression compared with young subjects, and this is associated with elevated 
serum and intrinsic B cell TNF-α expression (Frasca et al., 2015). This pre-
activated B cell phenotype is associated with the suboptimal responses to 
exogenous antigens and vaccines classically seen in immunosenescence. Frasca 
and colleagues (2015) found that miR-155 and miR-16 are able to target the 
transcription factor E47 and activation-induced cytidine deaminase (AID), 
contributing to the age-associated decline in B cell function.  
Other miRNAs implicated in the ageing process include MiR-200, known to show 
markedly increased expression when exposed to ROS. This upregulation is known 
to involve p53 and retinoblastoma proteins, essential in the mechanisms 
underlying cellular senescence (Magenta et al., 2011). 
1.7.4 MiRNA deregulation in CHC 
MiRNAs have been implicated in various stages of HCV pathogenesis. HCV viral 
proteins may directly modulate miRNA expression: the NS3 complex is able to 
upregulate miR-27a and downregulate miR-335 and miR-150 (Khanizadeh et al., 
2017), whilst HCV core protein suppresses miR-138. MiR-138 targets hTERT, thus 
inhibiting cellular senescence and promoting proliferation and oncogenesis (Shiu 
et al., 2017). 
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Cellular miRNA play important roles in regulating HCV replication and 
pathogenicity. Sequestration of the endogenous liver-specific miRNA miR-122 
was shown to lead to a significant reduction in HCV RNA (Jopling et al., 2005). 
MiR-122 binds to 2 adjacent sites in the HCV IRES in association with AGO2 
forming an oligomeric complex. The miR-122 binds to the 5’UTR of the HCV RNA, 
protecting it from nucleolytic degradation and promoting stability (Shrivastava 
et al., 2015). Cell culture studies demonstrated the key role that miR-122 plays 
in the HCV life cycle, as exogenous miR-122 was able to rescue infectious virion 
production in a non-permissive cell line (Narbus et al., 2011). MiR-122 also 
demonstrates tumour suppressor activity through inhibiting cell proliferation and 
neoplastic transformation of hepatocytes (Hu et al., 2012), and target analysis 
suggests it may bind to the HCV receptor OCLN. Antagonists of miR-122 including 
miravirsen, a locked nucleic acid-modified DNA phosphorothioate antisense 
oligonucleotide able to sequester mature miR-122, reached clinical trials as 
therapeutic adjuncts for the treatment of CHC (Janssen et al., 2013), although 
the efficacy of newer DAA combinations has rendered them largely redundant. 
There had been additional safety concerns as miR-122 knock-out in mice was 
associated with the development of hepatic steatosis and tumorigenesis (Tsai et 
al., 2012).   
Several other cellular miRNAs are able to bind directly to the HCV genome, but 
in contrast to miR-122 they appear to attenuate HCV replication (figure 1-21). 
 
Figure 1-21: Cellular miRNAs targeting the HCV genome. MiR-122 binds to 2 sites within the 
5’UTR, enhancing viral replication. Let-7b also binds at the 5’UTR as well as the NS5A coding 
site. The binding of miR-199a at the 5’UTR inhibits replication. MiR-448 targets core and 
miR-181c is able to inhibit viral replication through binding at E1 and NS5A coding regions. 
Extracted from Shrivastava et al. (2015) 
Murakami et al. (2009) found that overexpression of miR-199a inhibited HCV 
genome replication in immortalised human hepatocytes (IHHs), and inhibition 
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was associated with accelerated replication. MiR-199a has been shown to bind 
directly to the 5’UTR of the HCV genome, and may have both direct and indirect 
antiviral effects. MiR-196 and miR-448 are induced by IFN in hepatoma cell lines, 
and synthetic mimics of these miRNA have been shown to inhibit HCV replication 
in vitro (Pedersen et al., 2007).  
As well as directly interacting with the HCV genome, cellular miRNA are able to 
regulate genes involved in the innate immune response to HCV infection. For 
instance, let-7b is able to bind to the HCV genome at the 5’UTR and NS5A 
sequences, but is additionally able to target insulin-like growth factor 2 mRNA-
binding protein 1 (IGF2BP1) resulting in inhibition of HCV replication and viral 
protein translation (Cheng et al., 2013).  
Shrivastava et al. (2015) showed that miR-130a expression is upregulated in liver 
tissue from HCV-infected individuals, and in HCV-treated IHH. Knockdown of 
miR-130a was associated with upregulation of IFITM1 (Bhanja Chowdhury et al., 
2012). As IFITM1 is an important ISG effector which interacts with CD81 and 
OCLN to disrupt HCV entry, researchers postulated that induction of miR-130a 
represents a strategy by which HCV is able to evade the IFN-signalling pathway 
(Bhanja Chowdhury et al., 2012).  
HCV infection induces miR-155 expression, resulting in hepatocyte proliferation 
and oncogenesis through Wnt signalling (Zhang et al., 2012). The onco-miR miR-
21 is also upregulated in IHH in response to HCV infection. MiR-21 is elevated in 
the liver tissue of individuals with CHC, and is strongly expressed in tumour 
biopsies from patients with HCC. Chen and colleagues (2013) showed that 
upregulation of miR-21 suppressed MyD88 and IRAK1 expression, abrogating the 
type I IFN-mediated antiviral response. Overexpression of miR-122 is also 
associated with disruption of the IFN-signalling pathway; MiR-122 overexpression 
is associated with reduced ISRE activity, whereas suppression of miR-122 
downregulates suppressor of cytokine signalling 3 (SOCS3), resulting in enhanced 
IFN-induced ISRE activity. MiR-221 and miR-30 are also able to target SOCS3, and 
additionally SOCS1. SOCS1 and SOCS3 are members of the STAT-induced STAT 
inhibitor family, and are cytokine-inducible negative regulators of cytokine 
signalling. They are able to inhibit JAK tyrosine kinase activity and STATs in the 
JAK-STAT signalling pathway. The miR-30 cluster is downregulated in HCV-
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infected Huh7.5 cells, and upregulated in response to IFN-α, and inhibition of 
miR-30c increased HCV RNA levels in vitro (Zhang et al., 2013a).  
MiRNAs have both pro- and anti-fibrotic roles in the pathogenesis of chronic liver 
disease, depending on the nature of the stimuli and the cellular context (figure 
1-22). MiR-29 is recognised as an important regulator of fibrosis, decreased 
expression of which is associated with fibrosis in many tissues. MiR-29a is 
downregulated following TLR4 stimulation, and has been shown to target 
important fibrotic genes, including TGF-Β activated kinase 1 binding protein 1 
(TAB1, the gene regulating TIMP-1) and PDGFR (O'Reilly, 2016, Ciechomska et 
al., 2014). The miR-29 family is also able to target the DNA methyltransferases, 
resulting in further epigenetic modification of genes involved in ECM regulation.    
 
Figure 1-22: MiRNAs have both profibrotic and antifibrotic roles in liver disease. Extracted 
from Szabo et al. (2013). HSC, hepatic stellate cell. 
As described previously, miR-21 is upregulated in the liver tissue of individuals 
with CHC and modifies the type I IFN inflammatory response. Downregulation of 
miR-21 is associated with suppression of TGF-Β signalling and HSC activation 
(Zhang et al., 2013b). MiRNA target prediction analysis suggests that miR-21 may 
bind to the HCV receptor CLDN1. 
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The pro-fibrotic miRNA miR-181b is induced by TGF-Β1, and regulates HSC 
proliferation through targeting the cell cycle regulator p27 (Wang et al., 2012). 
MiR-221 and miR-222 expression in liver tissue also correlates with fibrosis stage. 
MiR-222 binds to CDKN1B, also regulating the expression of p27, and is induced 
in response to TNF-α signalling (Ogawa et al., 2012). MiR-199a and miR-199b 
were also found to be upregulated in fibrotic liver tissue. MiR-199a has a role in 
regulating the TLR signalling pathway (figure 1-20) and a direct HCV antiviral 
effect. Murakami and colleagues (2011) found that overexpression of miR-199a 
was associated with upregulation of fibrosis related genes in HSCs in both 
humans and mouse models. MiR-16 is postulated to downregulate hepatocyte 
growth factor (HGF) and Smad7 expression levels, contributing to liver fibrosis 
(Zhu et al., 2015). MiR-221 is induced in response to apoptosis, and protects 
hepatocytes from apoptosis through binding to and regulating expression of pro-
apoptotic genes. MiR-221 also regulates hepatocyte proliferation through 
targeting Arnt, resulting in an increased risk of HCC (Szabo and Bala, 2013).  
A number of miRNAs have been shown to be upregulated in the sera of subjects 
with HCV infection and to correlate with necro-inflammation, including miR-122 
and miR-21 (Bihrer et al., 2011b, Bihrer et al., 2011a). Trebicka and colleagues 
(2013) also showed that miR-122 expression positively correlated with enhanced 
inflammatory activity, but found that there was a negative correlation with 
fibrosis stage which they attributed to the loss of hepatocytes in advanced 
disease. Conversely, Cermelli et al. (2011) found that serum miR-122 levels 
positively correlated with disease severity. Elevated circulating miR-34a has 
been described in patients with liver fibrosis secondary to multiple aetiologies, 
including CHC and NAFLD (Cermelli et al., 2011, Salvoza et al., 2016). Increased 
serum miR-16 levels have also been described in both CHC and NAFLD (Cermelli 
et al., 2011).  
Many of the miRNAs implicated in inflamm-aging are deregulated in HCV 
infection, and correlate with necro-inflammatory activity and fibrosis stage. We 
hypothesised that we could identify novel diagnostic and prognostic biomarkers 
for clinical and virologic outcomes in CHC by correlating miRNA expression with 
previously validated BoA.  
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1.8 Aims and objectives 
Disease progression in CHC is highly variable and poorly understood, and there 
are little real-world data regarding predictors of treatment outcome with DAA 
therapy. Robust, non-invasive biomarkers able to identify HCV-infected subjects 
at high risk of progression to cirrhosis and HCC, or at risk of poor clinical and 
virologic outcomes with DAA therapy, are required. The primary aims of this 
research were: 
1. To explore factors associated with spontaneous clearance of CHC in a 
large Scottish cohort   
2. To gain further insights into modifiable and non-modifiable factors 
associated with disease progression and treatment outcomes in CHC 
3. To explore the role of BoA as predictors of disease progression in CHC 
4. To characterise patterns of miRNA deregulation during DAA treatment, in 
order to identify novel biomarkers associated with adverse clinical and 
virologic outcomes during DAA treatment  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cells 
Table 2-1: Cell lines 
Cells Description Source 
HepaRG Human hepatocyte cell line Elihu Aranday Cortes 
ISG15 KO HepaRG Human hepatocyte cell line – 
ISG15 -/- 
Elihu Aranday Cortes 
 
2.1.2 Kits 
Table 2-2: Kits  
Kit Source 
exoRNeasy Serum/Plasma Starter Qiagen 
MiRNeasy Micro Qiagen 
MiRNeasy Serum/Plasma Qiagen 
Qubit® HS RNA Assay Kit Thermo Fisher Scientific 
Qubit® MicroRNA Assay Kit Thermo Fisher Scientific 
RNeasy Mini Plus Qiagen 
TaqMan® Advanced miRNA cDNA 
Synthesis Kit 
Thermo Fisher Scientific 
TaqMan® Array Human MicroRNA A+B 
Cards Set v3.0 
Thermo Fisher Scientific 
TaqMan® MicroRNA Reverse 
Transcription Kit 
Thermo Fisher Scientific 
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2.1.3 Reagents 
Table 2-3: Reagents 
Reagent Source 
10X Poly A Buffer Thermo Fisher Scientific 
10X RT Buffer Thermo Fisher Scientific 
10X RT Enzyme Mix Thermo Fisher Scientific 
20X miR-Amp Primer Mix Thermo Fisher Scientific 
20X Universal RT Primer Thermo Fisher Scientific 
25X Ligation Adaptor Thermo Fisher Scientific 
2-Mercaptoethanol (B-ME) Sigma-Aldrich 
2X miR-Amp Master Mix Thermo Fisher Scientific 
50% PEG 8000 Thermo Fisher Scientific 
5X Ligase Buffer Thermo Fisher Scientific 
5X RT Buffer Thermo Fisher Scientific 
ATP, 10mM Thermo Fisher Scientific 
Buffer RLT Qiagen 
Buffer RPE Qiagen 
Buffer RWT Qiagen 
Chloroform Sigma-Aldrich 
DNAZapTM Thermo Fisher Scientific 
dNTPs with dTTP (100 mM) Thermo Fisher Scientific 
Ethanol Sigma-Aldrich 
hIFN-α Invivogen 
MegaplexTM PreAmp Primers – Human 
Pool A and B 
Thermo Fisher Scientific 
Megaplex™ RT Primers (10X) – Human 
Pool A and B 
Thermo Fisher Scientific 
MgCl2 (25 mM) Thermo Fisher Scientific 
Multiscribe™ Reverse Transcriptase 
(50U/µL) 
Thermo Fisher Scientific 
Nuclease-free water Thermo Fisher Scientific 
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Poly A Enzyme, 5 U/µL Thermo Fisher Scientific 
Poly(I:C) Sigma-Aldrich 
Qiazol® Lysis Reagent Qiagen 
RNA Ligase, 10 U/µL Thermo Fisher Scientific 
RNase Inhibitor (20 U/µL) Thermo Fisher Scientific 
RPMI-1640 Media Sigma-Aldrich 
TaqMan® Fast Advanced Master Mix Thermo Fisher Scientific 
TaqMan® PreAmp Master Mix (2X) Thermo Fisher Scientific 
TaqMan® PreAmp Primers (10X) Thermo Fisher Scientific 
TaqMan® Universal PCR Master Mix, 
No AmpErase® UNG, 2X 
Thermo Fisher Scientific 
Tris-EDTA (TE) Buffer pH 8 Ambion 
 
2.1.4 MiRNA assays 
The TaqMan® Advanced miRNA assays were ordered from Thermo Fisher 
Scientific. 
Table 2-4: MiRNA assays 
Assay name Mature miRNA sequence (5’ – 3’) 
hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA 
hsa-miR-122-5p UGGAGUGUGACAAUGGUGUUUG 
hsa-miR-885-5p UCCAUUACACUACCCUGCCUCU 
hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU 
hsa-miR-155-5p UUAAUGCUAAUCGUGAUAGGGGU 
hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC 
hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG 
hsa-miR-345 GCCCUGAACGAGGGGUCUGGAG 
miR-146b-3p UGCCCUGUGGACUCAGUUCUGG 
hsa-miR-195-5p UAGCAGCACAGAAAUAUUGGC 
hsa-miR-574-3p CACGCUCAUGCACACACCCACA 
hsa-miR-451a AAACCGUUACCAUUACUGAGUU 
cel-miR-39-3p UCACCGGGUGUAAAUCAGCUUG 
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2.1.5 MiRNA mimic 
Table 2-5: MiRNA mimic 
cel-miR-39-3p UCACCGGGUGUAAAUCAGCUUG 
 
2.1.6 Cell culture growth media 
All cell culture steps were performed by Dr. Elihu Aranday-Cortes, MRC-
University of Glasgow Centre for Virus Research. HepaRG cell lines were cultured 
in William’s E Medium (Invitrogen Life Technologies), supplemented with 10% 
fetal bovine serum gold (PAA), 2 mM L-glutamine, 100 IU/mL of penicillin, 100 
µg/mL of streptomycin, 5 µg/mL insulin and 0.5 µM hydrocortisone. Cells were 
grown to confluency in 6 well plates before treatment. Cells were treated with 
recombinant hIFN-α2b (100 IU/mL), the TLR3 agonist polyinosinic: polycytidylic 
acid (poly (I:C)) (1 µg/mL) or mock-treated, and incubated for 24 hrs before 
being harvested.  
2.1.7 Equipment 
Table 2-6: Equipment 
Equipment Source 
10/20 µL TipOne® Graduated Filter Tip Starlab 
1000 µL TipOne® Graduated Filter Tip Starlab 
200 µL TipOne® Graduated Filter Tip Starlab 
7500HT Fast Real-Time PCR System Applied Biosystems 
7900HT Fast Real-Time PCR System Applied Biosystems 
Eppendorf® Centrifuge 5424R Sigma-Aldrich 
Eppendorf® MiniSpin® Microcentrifuge Sigma-Aldrich 
GeneAmp® PCR System 9700 Applied Biosystems 
Heraeus™ Megafuge™ 40R Thermo-Fischer Scientific 
MicroAmp® 8-Cap Strip Applied Biosystems 
MicroAmp® 8-Tube Strip, 0.2mL Applied Biosystems 
MicroAmp® Fast Optical 96-Well Reaction 
Plate 
Applied Biosystems 
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MicroAmp® Optical Adhesive Film Applied Biosystems 
Sorvall® Legend RT Centrifuge Thermo-Fischer Scientific 
TaqMan® Array Microfluidic Card Sealer Applied Biosystems 
Vortex-Genie 2 Sigma-Aldrich 
 
 
2.2 Methods 
2.2.1 Manipulation of RNA 
Samples of PBMCs, serum and plasma were available from pre-existing cohorts 
(see Chapter 4.2 and Chapter 5.2 for details). For the Outcome study (chapter 
4), blood was processed on the day of venepuncture to ensure highest yield and 
quality of PBMCs. For the EAP study (chapter 5), samples were shipped to 
Glasgow overnight by courier before being stored at -70oC. 
2.2.1.1 Optimisation of serum miRNA extraction 
In preliminary experiments, the yield of RNA from 150-200µL of serum was 
variable (6-22 ng/µL). Therefore, the following experiment was performed to 
compare the yield of RNA from different volumes of serum. The kit manufacturer 
(Qiagen) advised that processing serum volumes of > 200 µL can lead to 
contaminants which interfere with the purification process. Hence, the samples 
were separated into aliquots of 100 µL and then processed individually. The 
aqueous phases were subsequently pooled, and the washing steps were 
performed according to the manufacturer’s protocol. RNA was eluted using 16 µL 
of RNase-free water, and quantified using a Qubit HS RNA kit. 
Table 2-7: Yield of RNA according to starting volume of serum (µL) 
Starting volume (µL) Yield of RNA (ng/µL) 
100 2.76 
200 5.72 
300 12.44 
400 20.4 
500 31.6 
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On the basis of this experiment, a starting volume of 500 µL serum, processed in 
100 µL aliquots as above, was used for miRNA expression profiling with the 
TaqMan® MicroRNA Arrays (Chapter 2.2.2.1). 
2.2.1.2 Extraction of miRNA from serum 
Serum and plasma had been previously separated from whole blood using 
centrifugation and stored at -70oC. For both the pilot and expanded Glasgow 
Outcomes Study cohorts (Chapter 4.2), a starting volume of 500 µL serum was 
used.  
In the EAP analysis (Chapter 5), the starting volume was restricted by sample 
availability. A volume of 150 µL was used for the individual miRNA assays. 
Additionally, aliquots of 50 µL from each patient sample were pooled and 
homogenised, and 500 µL pooled sample per patient group was used for the 
TaqMan® MicroRNA Array. Starting volumes > 150 µL were processed in aliquots 
as described in Chapter 2.2.1.1.  
Samples were thawed at room temperature prior to being mixed with 5 volumes 
of Qiazol and then incubated at room temperature for 5 minutes. At this stage, 
3.5 µL of the exogenous control cel-miR-39-3p (MiRNeasy Serum/Plasma Spike-In 
Control, 1.6 x 108 copies/µL) was added to a subset of samples. Next, 1 volume 
of chloroform was added, and the sample was mixed by shaking vigorously. The 
samples were incubated at room temperature for a further 2-3 minutes before 
being centrifuged at 4oC at 12000G for 15 minutes. The upper aqueous phase was 
transferred to a new tube and mixed with 1.5 volumes of 100% ethanol. RNA was 
then extracted using the MiRNeasy Serum/Plasma column-based technique. On-
column DNase treatment is not recommended for plasma/serum samples; these 
body fluids do not typically contain significant amounts of DNA and treatment 
may reduce recovery of small RNA. Additionally, assays for mature miRNA are 
not affected by the presence of small amounts of genomic DNA. Washing steps 
were performed according to the manufacturer’s protocol. The RNeasy spin 
column was then placed in a new collection tube, and a volume of 16 µL RNase-
free water added to the membrane. The column was incubated at room 
temperature for 10 minutes before being centrifuged at >12000rpm for 1 minute 
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using the Eppendorf® MiniSpin® centrifuge. A second elution step was 
performed using the same eluate, resulting in a final volume of 14 µL.  
RNA extracted from serum/plasma was analysed by spectrophotometry 
(NanoDropTM 1000, Thermo Fisher Scientific) or QubitTM fluorometric 
quantification (Thermo Fisher Scientific) according to starting volume of sample.  
2.2.1.3 Extraction of miRNA from PBMCs 
Samples of PBMCs were available from a pre-existing study (study details 
described in Robinson et al. (2013)). PBMCs had been collected following 
separation over a density gradient (Histopaque®-1077, Sigma Aldrich), 
suspended in freezing medium and stored in liquid nitrogen. For a subset of 
patients, aliquots of 5x106 PBMCs previously lysed in 600 µL Buffer RLT (Qiagen) 
and stored at -70oC were also available.  
Cryopreserved samples were thawed in a waterbath at 37oC before being 
resuspended in 2 volumes RPMI-1640 medium pre-warmed to ambient 
temperature. The diluted cell suspension was then added to 8 mL RPMI at room 
temperature. The supernatant was decanted following centrifugation at 250G for 
10 minutes at 20oC, and the pellet was reconstituted in 600 µL Buffer RLT with 
1% Β-ME (Qiagen). Aliquots previously stored in Buffer RLT were thawed on ice. 
Homogenised lysate was placed in a gDNA Eliminator spin column (RNeasy Mini 
Plus Kit, Qiagen) and centrifuged for 30 s at > 12000rpm using the Eppendorf® 
MiniSpin®. The flow-through was retained and mixed with 900 µL (1.5 volumes) 
of 100% ethanol by vortexing. Subsequent steps were performed according to the 
amended manufacturer’s protocol (Appendix D), avoiding the use of Buffer RW1 
which is incompatible with the extraction of small RNAs. RNA was eluted using 
30 µL RNase-free water. 
RNA extracted from PBMCs was analysed for quantity and purity using 
spectrophotometry (NanoDrop 1000, Thermo Fisher Scientific). The average 
260/280 ratio for the RNA extracted from cryopreserved PBMCs was 2.035 
compared with a ratio of 2.025 for RNA extracted from PBMCs stored in lysis 
buffer. For a selection of samples, the quality of the RNA was also assessed by 
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Dr. Elihu Aranday-Cortes, University of Glasgow-MRC Centre for Virus Research 
using the Agilent 2200 TapeStation and the High Sensitivity R6K ScreenTape.  
RNA integrity numbers (RIN) indicated that there was increased RNA degradation 
in the cryopreserved samples compared to the samples stored in lysis buffer 
(figure 2-1).   
 
 
 
Figure 2-1: Comparison of RIN for RNA extracted from cryopreserved PBMCs and PBMCs in 
RLT lysis buffer. Results obtained by running different RNA samples on the R6K ScreenTape. 
The gel image shows the separation profile of each of the individual samples showing 28S, 
18S, small rRNAs and lower marker     
 
2.2.1.4 Extraction of miRNA from exosomes 
For a subset of serum samples (n=8), miRNA was extracted from exosomes. 
Extraction was performed using the ExoRNeasy Serum/Plasma Midi Kit, suitable 
for starting volumes of 100 µL to 1 mL. Samples of 500 µL serum (stored at -
70oC) were thawed at room temperature prior to being mixed with 1 volume 
Buffer XBP. The sample was mixed gently and transferred to the ExoEasy spin 
column before being centrifuged for 1 minute at 500G. The flow-through was 
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discarded and the sample was centrifuged for a further minute at 500G. The 
column was washed by adding 3.5 mL Buffer XWP and spinning for a further 5 
minutes at 5000G. The spin column was then transferred to a fresh tube, and 
700µL Qiazol added to the membrane. The sample was centrifuged at 5000G for 
5 minutes to collect the lysate, which was subsequently vortexed and incubated 
at room temperature for 5 minutes. The lysate was incubated for a further 2-3 
minutes at room temperature following the addition of 90 µL chloroform, and 
then centrifuged at 4oC for 15 minutes at 12000G. The upper aqueous phase was 
mixed with 2 volumes 100% ethanol before being transferred to an RNeasy 
MinElute spin column. Washing steps with Buffer RWT and Buffer RPE were 
performed according to the manufacturer’s instructions. As previously, 16 µL 
RNase-free water was added to the membrane and incubated at room 
temperature for 10 minutes before being centrifuged at >12000rpm using the 
Eppendorf® MiniSpin® for a further minute. A second elution step was 
performed using the same eluate, resulting in a final volume of 14 µL.  
2.2.1.5 Extraction of miRNA from HepaRG cells 
MiRNA was extracted from a monolayer of HepaRG cells (1x106 cells) using a 
column based protocol, the MiRNeasy Micro kit (Qiagen). Firstly, 700 µL Qiazol 
was added to each cell culture dish; the lysate was mixed by vortexing for 1 
minute and transferred to a tube to incubate at room temperature for 5 
minutes. The lysate was incubated for a further 5 minutes at room temperature 
following the addition of 140 µL chloroform and then centrifuged at 4oC for 15 
minutes at 12000G. The aqueous phase was transferred to a new tube and mixed 
with 1.5 volumes of 100% ethanol. Washing steps were performed according to 
the manufacturer’s protocol. A further 5 minute centrifugation step was 
performed to dry the spin column membrane. The spin column was then placed 
in a new collection tube, and 16 µL of RNase-free water was added to the 
membrane. The column was incubated at room temperature for 10 minutes 
before being centrifuged at 12000 rpm in the Eppendorf® MiniSpin® for 1 
minute. A second elution step was performed using the eluate resulting in a final 
volume of 14 µL. Samples were then diluted with RNase-free water to a final 
concentration of 5 mg/µL for downstream cDNA synthesis.  
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2.2.2 MiRNA expression profiling 
2.2.2.1 MiRNA expression profiling using TaqMan® MicroRNA Arrays 
The TaqMan® MicroRNA Array consists of two 384-well microfluidic cards pre-
loaded with TaqMan® primers and probes, allowing quantification of 754 
individual miRNAs. Each card also contains 3 endogenous controls (the small 
nucleolar RNAs U6snoRNA, RNU44 and RNU48) and 1 negative control assay. Each 
card was used in conjunction with the matching MegaplexTM Pool of stem-looped 
RT primers. 
In the Outcomes study (Chapter 4), the starting amount of total RNA was 
133.2ng (44.4 ng/µL) for the PBMC analysis and 69 ng (23 ng/µL) for the serum 
analysis. In the EAP cohort (Chapter 5), the starting amount of total RNA was 
104ng (34.7 ng/µL). In all cases, a pre-amplification step was included according 
to the manufacturer’s recommendations. A control experiment was performed 
for each card type using 3 µL RNase-free water in place of sample to control for 
background contamination. 
I. RT reaction 
For the RT reaction, the following reagents were combined and gently mixed by 
inverting the microcentrifuge tube.  
Table 2-8: RT reaction mix components 
RT reaction mix component Volume for 1 sample (µL) 
MegaplexTM RT Primers (10X) 0.8 
dNTPs with dTTP (100 mM) 0.2 
MultiScribeTM Reverse Transcriptase (50 U/µL) 1.5 
10X RT Buffer 0.8 
MgCl2 (25 mM) 0.9 
RNase Inhibitor (20 U/µL) 0.1 
Nuclease-free water 0.2 
Total 4.5 
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A total of 4.5µL RT reaction mix was pipetted into a PCR tube, followed by 3µL 
total RNA. The tubes were sealed and incubated on ice for 5 minutes prior to 
cDNA synthesis. Thermal-cycling conditions on the GeneAmp® PCR System 9700 
were as follows: 
Table 2-9: Thermal cycling conditions for RT reaction 
Stage Temperature Time 
Cycle 
(40 cycles) 
16oC 2 minutes 
42oC 1 minute 
50oC 1 s 
Hold 85oC 5 minute 
Hold 4oC ∞ 
 
II. Pre-amplification reaction 
For the PreAmp reaction mix, the following reagents were thawed and 
combined: 
Table 2-10: PreAmp reaction mix 
PreAmp reaction mix component Volume for 1 sample (µL) 
TaqMan® PreAmp Master Mix (2X) 12.5 
MegaplexTM PreAmp Primers (10X) 2.5 
Nuclease-free water 7.5 
Total 22.5 
 
A total of 22.5 µL of the PreAmp reaction mix was added to 2.5 µL of the RT 
product from the previous reaction in a new PCR tube. The tubes were mixed 
gently, spun briefly and incubated on ice for 5 minutes. The following thermal 
cycling parameters were used for the preamplification reaction: 
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Table 2-11: Thermal cycling conditions for PreAmp reaction 
Stage Temperature Time 
Hold 95oC 10 minutes 
Hold 55oC 2 minutes 
Hold 72oC 2 minutes 
Cycle (12 cycles) 95oC 15 s 
60oC  4 minutes  
Hold 99.9oC 10 minutes 
Hold 4oC ∞ 
 
Each 25µL reaction product was diluted with 75 µL 0.1X Buffer TE and stored at -
20oC prior to running the real-time quantitative PCR. 
III. Real-time quantitative PCR  
In this step, the pre-amplified target cDNA was amplified by DNA polymerase 
using the sequence specific primers and probe on the TaqMan® MicroRNA Array. 
The PreAmp reaction product was thawed and mixed with TaqMan® Universal 
PCR Master Mix and nuclease-free water as follows. 
Table 2-12: RT-qPCR reaction mix 
PCR reaction mix component Volume for 1 array (µL) 
TaqMan® Universal PCR Master Mix, No 
AmpErase® UNG, 2X 
450 
Diluted pre-amp product 9 
Nuclease-free water 441 
Total 900 
 
The TaqMan® Array cards were stored at 4oC; each card was allowed to 
equilibrate at room temperature for 15 minutes prior to use. Each port of the 
microfluidic card was then loaded with 98 µL of the PCR reaction mix, and the 
cards were then centrifuged for 2 minutes using the Heraeus™ Megafuge™ 40R at 
331G before sealing. 
2-127 
 
The cards were run on the 7900HT Fast Real-Time PCR system using the thermal-
cycling conditions described in Table 2-13: 
Table 2-13: Thermal cycling conditions for RT-qPCR reaction  
Stage Temperature Time 
Hold 50oC 2 minutes 
Hold 95oC 10 minutes 
Cycle  
(40 cycles) 
95oC 15 s 
60oC 1 minute 
Hold 4oC ∞ 
 
2.2.2.2 MiRNA profiling using individual miRNA assays 
The cDNA templates were prepared using the TaqMan® Advanced MiRNA cDNA 
Synthesis Kit. Mature miRNAs from total RNA are modified by adding a poly (A) 
tail to the 3’ end of the transcript, then lengthening the 5’ end by adaptor 
ligation to provide a forward-primer binding site for the miR-Amp reaction. The 
specificity of this system for miRNAs relies on the 5’adapter, which can only be 
ligated to the free phosphorylated 5’ end of a miRNA molecule. Other cellular 
RNAs have 5’ modifications that will not allow ligation of the adapter and so will 
not be reverse transcribed.  The specificity is such that even other small RNAs 
such as small nuclear and small nucleolar RNAs, which often possess 5’ 
modifications, are not recognised. As a consequence, the small RNA endogenous 
control assays used with the standard chemistry TaqMan miRNA assays are not 
compatible with the TaqMan Advanced miRNA workflow (B Revill 2018, personal 
communication, 28 March). 
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Figure 2-2: cDNA template preparation using TaqMan® Advanced MiRNA cDNA Synthesis Kit. 
PAP, poly (A) polymerase; Lig, ligase; RT, reverse transcriptase; P, hot-start DNA 
polymerase. Extracted from: Thermo Fisher Scientific (Inc, 2016). 
I. 3’ poly(A) tailing reaction 
Samples and reagents were first thawed on ice. Two microlitres of sample was 
used for each reaction; for tissue samples a maximum of 10 ng total RNA was 
used. Reagents were mixed as follows before being added to each sample. 
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Table 2-14: Poly (A) tailing reaction mix 
Poly(A) tailing reaction mix component Volume for 1 sample (µL) 
10X Poly (A) Buffer 0.5 
ATP 0.5 
Poly (A) Enzyme 0.3 
RNase-free water 1.7 
Total 3.0 
 
The samples were incubated according to the following thermal-cycling settings: 
Table 2-15: Thermal cycling conditions for poly (A) tailing reaction 
Stage Temperature Time 
Polyadenylation 37oC 45 minutes 
Stop reaction 65oC 10 minutes 
Hold 4oC ∞ 
 
II. Ligation reaction 
The 5’ ligation reaction mix was prepared as follows: 
Table 2-16: Ligation reaction mix 
Ligation reaction mix component Volume for 1 sample (µL) 
5X DNA Ligase Buffer 3.0 
50% PEG 8000 4.5 
25X Ligation Adaptor 0.6 
RNA Ligase 1.5 
RNase-free water 0.4 
Total 10.0 
 
The reaction mix was vortexed, centrifuged briefly, and transferred to the 5 µL 
poly (A) tailing reaction product. The reaction tubes were incubated according 
to the following settings: 
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Table 2-17: Thermal cycling conditions for ligation reaction 
Stage Temperature Time 
Ligation 16oC 60 minutes 
Hold 4oC ∞ 
 
III. RT reaction 
The RT reaction mix was prepared as follows: 
Table 2-18: RT reaction mix 
RT reaction mix component Volume for 1 sample (µL) 
5X RT Buffer 6.0 
dNTP Mix (25mM) 1.2 
20X Universal RT Primer 1.5 
10X RT Enzyme Mix 3.0 
RNase-free water 3.3 
Total 15.0 
 
The reaction mix was transferred to the reaction tube containing the adaptor 
ligation reaction product (30 µL total). The RT reaction was performed under the 
following thermal-cycling conditions: 
Table 2-19: Thermal cycling conditions for RT reaction 
Stage Temperature Time 
Reverse transcription 42oC 15 minutes 
Stop reaction 85oC 5 minutes 
Hold 4oC ∞ 
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IV. MiRNA amplification step 
Table 2-20: MiR-Amp reaction mix 
MiR-Amp reaction mix component Volume for 1 sample (µL) 
2X miR-Amp Master Mix 25.0 
20X miR-Amp Primer Mix 2.5 
RNase-free water 17.5 
Total 45.0 
  
The above reagents were combined in a microcentrifuge tube and mixed 
thoroughly. For each sample, 45 µL of the reaction mix was combined with 5 µL 
of the RT reaction product obtained in the previous step. The tubes were placed 
in a thermal cycler and incubated using the following settings and MAX ramp 
speed. 
Table 2-21: Thermal cycling conditions for miR-Amp reaction 
Stage Temperature Time Cycles 
Enzyme activation 95oC 5 minutes 1 
Denature 95oC 3 s 14 
Anneal/extend 60oC 30 s 
Stop reaction 99oC 10 minutes 1 
Hold 4oC ∞ 1 
 
V. Real-time quantitative PCR 
For the RT-PCR, a 1:10 dilution of cDNA template was prepared using 0.1X TE 
Buffer. The TaqMan® Advanced miRNA Assays were thawed on ice before being 
mixed with TaqMan® Fast Advanced Master Mix 2X and RNAse-free water as 
follows. Samples were run in quadruplicate.  
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Table 2-22: RT-qPCR mix 
PCR reaction mix component Volume for 1 reaction (µL) 
TaqMan® Fast Advanced Master Mix (2X) 10 
TaqMan® Advanced MiRNA Assay (20X) 1 
RNase-free water 4 
Total 15 
  
The reaction mix components were mixed well by vortexing and centrifuged 
briefly. A total of 15 µL was transferred to each well of a PCR reaction plate 
followed by 5 µL diluted cDNA template, giving a total volume of 20 µL per 
reaction. The reaction plate was sealed with an optical adhesive cover and 
centrifuged for 1 minute at 1000G using the Sorvall® Legend RT centrifuge. The 
RT-qPCR was performed using the 7500 Fast Real-Time PCR system, with the 
following thermal cycling settings. 
Table 2-23: Thermal cycling conditions for RT-qPCR 
Stage Temperature Time Cycles 
Enzyme activation 95oC 20 s 1 
Denature 95oC 3 s 40 
Anneal/extend 60oC 30 s 
 
2.2.2.3 Analysis of miRNA expression profiling 
I. Array-based profiling 
Data from the TaqMan® MicroRNA Arrays were collected with the manufacturer’s 
SDS software (SDS 2.4, Applied Biosystems). Thresholds, set automatically, were 
checked individually and corrected as required. Quantitative data analysis was 
performed using ExpressionSuite Software v1.0.3 (Applied Biosystems) which 
uses the comparative cycle threshold (CT) method (ΔΔCT). Global normalisation 
was applied as there was high variation of expression of the small RNA controls 
between samples. Global normalisation uses the median CT value of assays 
common to every sample as the normalisation factor, on a per sample basis and 
is appropriate for profiling a large number of miRNA targets (Mestdagh et al., 
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2009). The maximum CT was set at 35, and wells were rejected if there was low 
amplification in the linear phase, bad passive reference signal, Cq confidence < 
0.8, baseline algorithm failure, noise spikes or noise higher than others in the 
plate, and if there was no signal in the well or the fluorescence was offscale. 
TaqMan® MicroRNA Assays have an amplification efficiency of 100% ± 15% across 
5 logs10 and a dynamic range of ≥ 7 logs10 with ≥ 0.98 linearity.  
A control experiment was run with nuclease-free water in place of sample. MiR-
601, miR-1290, miR-1243, miR-30a-5p, miR-151-3p, miR-520d-3p and miR-1274B 
were detected on control Card B (run with 3 µL nuclease-free water) and were 
excluded from all other analyses. No miRNAs were detected on Card A in the 
control experiment. 
II. Identification of endogenous miRNA controls 
Global normalisation is only appropriate when profiling a large number of genes 
(Mestdagh et al., 2009). Endogenous miRNA controls for the individual miRNA 
assays were therefore identified from the TaqMan® array data using 
ExpressionSuite software v1.0.3 (Applied Biosystems). All miRNAs were assessed 
for suitability as controls. CT values for each gene were plotted, and miRNAs 
showing the greatest stability of expression between samples were identified. 
Additionally, the average pairwise variation of each miRNA was calculated 
compared to all the other candidate miRNA to give a stability score 
(Vandesompele et al., 2002). Student’s t-tests were then performed to confirm 
that there were no significant differences in expression of the endogenous 
controls between experimental groups. 
For the PBMC analyses, miR-451a and miR-26a-5p were used as endogenous 
controls, and for the serum analyses, miR-574-3p was selected. 
A further validation experiment was performed for the serum analyses, 
comparing the detection of the endogenous internal control miR-574-3p with 
spiked cel-miR-39-3p expression. This comparison demonstrated good correlation 
(R2 = 0.829) between the endogenous and exogenous control (figure 2-3).  
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Figure 2-3: Correlation between endogenous miR-574-3p and spiked cel-miR-39-3p CT values 
in serum samples from subjects with CHC. 
 
III. Validation 
TaqMan® Advanced MiRNA Assays were performed in quadruplicate, according to 
the manufacturer’s recommendations. Data from the assays were collected using 
the manufacturer’s SDS software. Thresholds were set automatically, and 
individually reviewed. Mean CT values were accepted if the standard deviation 
(SD) was < 0.5; outliers were removed. If the CT SD remained > 0.5 despite the 
removal of 1 outlier, the experiment was repeated. The expression level of each 
miRNA was quantified using the mean normalised threshold cycle number (ΔCT) 
and the relative expression level was calculated as 2−(ΔΔCt) (Livak and Schmittgen, 
2001, Schmittgen and Livak, 2008). As described above, the endogenous miRNAs 
miR-451a and miR-26a-5p were used as internal controls for PBMC samples, and 
miR-574-3p was used for the serum experiments. 
2.2.2.4 Reproducibility of TaqMan® Advanced MiRNA Assays 
An experiment was performed to assess the reproducibility of the individual 
miRNA assays over time. We analysed the expression of miR-21-5p, miR-122-5p, 
miR-885-5p and miR-574-3p in 4 serum samples. The experiment was repeated a 
week later on the same extracted RNA and under the same conditions. 
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Figure 2-4: MiRNA assays demonstrate good reproducibility over time.   
2.3 In silico target prediction and functional analysis 
Validated targets for individual miRNAs were identified using MiRTarbase 2016 
(http://mirtarbase.mbc.nctu.edu.tw/ (Chou et al., 2016)) and Tarbase v7.0 
(http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index 
(Vlachos et al., 2015)). Analysis was restricted to targets appearing in both 
databases, and miRNA target genes validated only by weaker experimental 
methodology, i.e. microarray or pulsed stable isotope labelling by aa in cell 
culture, were excluded. STRING v10.5 (http://string-db.org/) was used for the 
functional analysis of validated or predicted targets of selected miRNAs 
(Szklarczyk et al., 2015). Interaction scores are calculated by the software by 
combining the probabilities from different evidence sources and correcting for 
the probability of randomly observing an interaction. Experimental data are 
extracted from 7 databases: BIND, DIP, GRID, HPRD, IntAct, MINT and PID, and 
curated data are extracted from a further 5 databases: Biocarta, BioCyc, GO, 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) and Reactome. Only high 
confidence interactions (≥0.9) are included and figures are simplified by the 
removal of unconnected nodes from the interaction network. Up to 5 first shell 
interactors (i.e. proteins directly interacting with the input protein) were 
included to inform the pathway analysis. The Markov clustering algorithm was 
miR-21-5p miR-122-5p miR-885-5p miR-574-3p 
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applied with an inflation factor of 3 to extract relevant modules (Brohee and van 
Helden, 2006). Genes involved in the most significantly enriched KEGG pathway 
for each miRNA are highlighted in red for clarity. 
Pathway analysis for complete miRNA datasets was performed using the online 
tool DIANA-miRPath (http://diana.imis.athena-
innovation.gr/DianaTools/index.php). DIANA-miRPath performs an enrichment 
analysis of input datasets by comparing each set of genes to KEGG pathways 
utilising experimentally validated miRNA interactions derived from DIANA –
TarBase v6.0 (Vlachos et al., 2012). The input dataset enrichment analysis is 
performed by a Pearson's chi-squared test (χ2 = Σ[(O − E)2/E]), where O 
(Observed) is the number of genes in the input dataset found to participate in a 
given pathway and E (Expected) is the number of genes expected by chance, 
given the pathway and input list size, to be a member of that pathway 
(Papadopoulos et al., 2009).  Correction for multiple testing was done using the 
Benjamini–Hochberg method and significantly enriched pathways were selected 
according to a false discovery rate (FDR) <0.001. The input dataset enrichment 
in each KEGG pathway is represented by the negative natural logarithm of the P-
value (–ln P). The comparison of pathway analyses was performed using 
Ingenuity® Pathway Analysis (IPA®, Qiagen). 
2.4 Statistical analysis 
Data from the TaqMan® MicroRNA Arrays were analysed using the 
ExpressionSuite Software v1.0.3 (Applied Biosystems).  Only miRNA transcripts 
expressed in ≥ 2 biological replicates in each group were included in downstream 
analysis. Mathematical correction for multiple comparisons was not applied due 
to the small group size and the risk of increasing the type II error for those 
associations that were not null, and as all targets of interest underwent 
validation. Subsequent statistical analyses were performed using IBM® SPSS® 
Statistics v22 and GraphPad Prism® v7.03. 
Continuous variables are expressed as medians and interquartile ranges, and 
categorical variables are recorded as number and percentages. Categorical 
variables were compared using chi-square testing and continuous variables were 
analysed using the exact Wilcoxon Mann-Whitney test or Student’s t-test, 
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depending on distribution. Normality was assessed using the Shapiro-Wilk 
normality test. Differences between two paired sets of normally distributed 
variables were examined using the paired t-test, and differences between > 2 
paired sets of variables were analysed with one-way ANOVA. Dunnett’s multiple 
comparisons test was used to compare the mean of each set to the mean of the 
control for normally distributed data, whilst Dunn’s multiple comparison’s test 
was used for non-parametrically distributed data. Pearson correlation 
coefficients were calculated for pairs of variables; missing data were handled by 
pairwise deletion.  
Where it was not possible to express miRNA expression with reference to a 
healthy control population, miRNA expression was dichotomised into ‘positive’ 
or ‘negative’ dependent on the ΔCT relative to the mean/median of the group. 
MiRNA expression was defined as positive when the ΔCT was lower than the 
mean/median (i.e. increased expression) and negative when the ΔCT was higher 
than the mean/median. 
The relationship between biomarker expression, clinical characteristics and 
biochemical variables was assessed using binary logistic regression. Models were 
fitted using multiple logistic regression, starting with factors significant at the 
10% level in univariate analysis. Collinearity diagnostics were performed; 
tolerance of <0.2 and variance inflation factor (VIF) > 2.5 were considered 
evidence of collinearity.  Nagelkerke R2 values are reported. Cook’s distance was 
calculated to identify any cases unduly influencing the model. The diagnostic 
accuracy of each biomarker was evaluated using the area under the receiver 
operating characteristics (ROC) curve (AUC), and cut-offs were calculated 
according to the highest Youden index to maximise sensitivity and specificity.  
P values are 2-sided and values of <0.05 were considered significant. For all 
statistical analysis other than calculation of correlation coefficients, missing 
variables were handled by listwise deletion, i.e. subjects with missing data were 
excluded. 
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3 Spontaneous clearance of CHC 
3.1 Introduction 
Spontaneous clearance of HCV during acute infection (< 6 months) occurs in 20-
40% of people who acquire infection (Grebely et al., 2014, Vispo et al., 2014). 
Predictors of clearance are poorly understood, however there is concordance 
with factors known to be associated with improved clinical and treatment 
outcomes. Host factors, including gender (Grebely et al., 2014, Micallef et al., 
2006, Hsi et al., 2014, van den Berg et al., 2011) and immune response (Lemon, 
2010, Thomson et al., 2011), and viral factors, such as HCV genotype and 
quasispecies diversity (Grebely et al., 2014), are thought to influence disease 
progression and may also predict chance of spontaneous clearance (Westbrook 
and Dusheiko, 2014). Host genetics are relevant, and one of the strongest host 
factors associated with clearance (and response to HCV treatment) is a 
favourable IFNL3 gene polymorphism (chapter 1.2.1) (Grebely et al., 2014, 
Rembeck and Lagging, 2015). 
Spontaneous clearance of HCV in the chronic phase is less well described 
(Watanabe et al., 2003). It has been reported in the literature following 
superinfection with HBV (Sagnelli et al., 2009, Gruener et al., 2002) or following 
HDV infection of HIV-HBV co-infected subjects (Maida et al., 2008).  Additional 
studies have described clearance following the withdrawal of immunosuppressive 
medication (Somsouk et al., 2003), in the context of liver transplantation or 
surgery (Samonakis et al., 2005, Yoshikawa et al., 2001), following the 
development of hepatocellular carcinoma (Minami et al., 2014) and during 
pregnancy/parturition (Hattori et al., 2003, Zein et al., 2001). Additionally, 
spontaneous HCV RNA negativity has been described in HIV-HCV co-infected 
patients, including those with hepatic decompensation, following initiation or 
optimisation of antiretroviral therapy (Mora-Peris et al., 2015, Kaung et al., 
2014, Stenkvist et al., 2014). 
Host factors may be important predictors of clearance in the chronic phase as 
well as the acute phase; Raghuraman et al. (2012) reported a case of HCV 
clearance at 65 weeks post infection which was associated with reversal of T cell 
exhaustion and the appearance of neutralising antibodies, and two recent 
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studies looking at HIV-HCV co-infected patients found that late clearance was 
associated with a favourable IFNL3-CC genotype (Vispo et al., 2014, Stenkvist et 
al., 2014). However, interpretation of these studies is limited by the small 
number of cases. 
In this study, the incidence and factors associated with spontaneous clearance of 
CHC were established amongst a large Scottish cohort. 
3.2 Patient selection 
3.2.1 Study design and population 
The West of Scotland Specialist Virus Centre (WoSSVC) is part of the NHS Greater 
Glasgow & Clyde Health Board (NHSGGC) which serves a population of > 1 million 
individuals. Of the 35474 cases of HCV antibody positivity diagnosed in Scotland 
as of December 2013, 14076 (40%) reside within NHSGGC (McLeod A, 2014). The 
WoSSVC provides the majority of the diagnostic virology service for the West of 
Scotland and is the sole provider of HCV RNA testing. Data were obtained from 
the WoSSVC on HCV testing over a 20 year period between 1994 and 2013. The 
study followed a retrospective case-control design; cases were individuals who 
spontaneously resolved CHC, and controls were individuals who did not.   
3.2.2 Identification of cases and controls 
All patients included in the study must have been tested on either serum or 
dried blood spot (DBS) for HCV RNA as part of their clinical care. Patients with a 
minimum of 2 sequential samples positive for HCV RNA at least 6 months apart, 
followed by at least one negative test for HCV RNA, were identified. These 
patients were linked with national treatment data obtained from the Scottish 
Hepatitis C Clinical Database. This database is held by HPS and contains clinical 
and treatment data for HCV-infected patients attending outpatient specialist 
clinics across Scotland (McDonald et al., 2012). Patients with a history of HCV 
treatment were then excluded to create a cohort of individuals with potential 
spontaneous clearance of CHC. Clinical records of potential spontaneous clearers 
were reviewed to confirm the clinical scenario. Individuals in the spontaneous 
clearance group with > 1 negative HCV RNA sample were subcategorised as 
‘confirmed’ clearers. 
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Patients with 2 positive HCV RNA samples at least 6 months apart with no 
subsequent negative samples were selected as our comparison group. To create 
a control group of chronically infected patients, individuals were randomly 
selected from the comparison group using number generation with a frequency 
of 4 controls per patient of interest. 
3.2.3 Clinical, demographic and exposure data  
Demographic patient data (age at infection, sex, ethnicity, alcohol intake, BMI, 
source of infection), HCV markers (liver enzymes, HCV genotype, IFNL3 
genotype, HCV RNA and history of cirrhosis), and HIV, HBV and HDV serostatus 
were obtained from the Scottish Hepatitis C Clinical Database, augmented by 
case note review. Where available, biochemical and haematologic variables 
were recorded at the time of the last positive HCV RNA test for all patients, and 
concurrently with the first negative HCV RNA test for spontaneous clearers. The 
date of HCV clearance was estimated using the midpoint between the time at 
which the last positive HCV RNA and the first negative HCV RNA samples were 
collected. Duration of diagnosis (which serves as a proxy of duration of infection) 
was calculated as the interval between the first positive HCV RNA and the time 
of HCV clearance for spontaneous clearers; for the control group this was 
defined as the interval between the first positive and the last positive HCV RNA 
results. Follow up was censored at the last positive HCV RNA test for the control 
group. Clinical records for case patients were reviewed and data were collected 
on hospitalisations or acute events in the 12 months prior to clearance. 
3.2.4 Incidence of spontaneous clearance of CHC 
The incidence density rate of spontaneous clearance of CHC amongst untreated 
individuals was calculated as the number of cases of spontaneous clearance over 
the total number of person-years follow up. 
3.3 Results 
3.3.1 Clinical laboratory testing 
All patients had been tested for HCV RNA as part of their clinical care. Viral load 
samples logged as ‘positive’ or ‘detectable’ were recorded as the upper limit of 
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sensitivity for the given assay. Patients also underwent HCV genotyping as part 
of their routine clinical care. 
3.3.2 Derivation of sample set for analysis 
A total of 25113 samples were positive for HCV RNA, relating to 10318 patients. 
Of these, 1430 patients had 2 sequential positive results followed by a negative 
result. Following linkage to the Scottish Hepatitis C Clinical Database 1314 
patients were identified as treatment-experienced and were thus excluded, 
leaving 116 patients of interest. Ten patients were excluded following case note 
review as examination of full laboratory data showed that the HCV RNA positive 
samples were not sequential, suggesting fluctuating viraemia or 2 or more 
episodes of spontaneous clearance during acute infection rather than 
spontaneous clearance of CHC.  A further 48 patients had exposure to HCV 
treatment that had not yet been recorded on the national database. For 7 
patients, patient identifiers held in the database did not link with a clinical 
record. One patient had been incorrectly coded as negative, but on review of 
the laboratory data was found to have quantifiable HCV RNA. After these 
exclusions, 50 case patients remained and were included in downstream 
analysis, contributing 241 person-years follow up. Two patients were classified 
as spontaneous clearers solely on the basis of DBS testing, one of whom went on 
to have a positive serum HCV RNA test in the absence of ongoing risk exposure. A 
further two patients who were classified as spontaneous clearers on the basis of 
serum HCV RNA testing developed HCV RNA positivity > 1 year post probable 
clearance; one patient admitted to ongoing IDU. Twenty-seven patients went on 
to have at least 1 further negative HCV RNA test (26 serum samples and 1 DBS) 
and were subcategorised as ‘confirmed’ clearers. 
For the comparison group, 3329 patients with 2 positive HCV RNA samples at 
least 6 months apart with no subsequent negative samples were identified of 
whom 955 were treatment-experienced. The remaining 2374 were untreated, 
contributing 13766 person-years follow up. Our control population comprised 200 
randomly selected patients from this untreated cohort. 
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Figure 3-1: Derivation of final sample. *Patients excluded following linkage to treatment 
data held in the Scottish Hepatitis C Clinical Database 
 
3.3.3 Incidence of spontaneous clearance of CHC 
The overall incidence density rate of spontaneous clearance of CHC amongst the 
untreated patient population was 0.36 per 100-person-years follow up. When 
restricting the analysis to patients with ‘confirmed’ clearance, the incidence 
rate was 0.19 per 100-person-years follow up. 
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3.3.4 Characteristics of cases and controls 
Table S1 summarises the main demographic and clinical characteristics of the 
study populations. The majority of patients were white, with a history of IDU as 
the risk factor for acquisition of HCV. There was a similar incidence of Gt1 and 
Gt3 infections. There were no significant differences in HCV genotype, ethnicity 
or risk group between the two populations. Ongoing IDU was positively 
associated with chronicity of infection (p=0.034).  
Patients who spontaneously cleared CHC were more likely to be female (p = 
0.001) and to have been diagnosed at a younger median age (28.5 years vs. 33 
years, p = 0.022). Median age at diagnosis in females was not significantly 
different between the two groups (27 years vs. 31.5 years, p=0.144). The age at 
which males and females were diagnosed in each group was similar (cases, 
p=0.200; controls, p=0.108). 
There was no difference in the distribution of duration of diagnosis between 
groups (median duration 50 months v 50 months, p= 0.854) (figure 3-2). The 
minimum duration of diagnosis in the spontaneous clearance group was 9 months 
and the maximum duration was 182 months, compared with 7 months and 195 
months in the comparator group. As spontaneous clearance may be more likely 
in early infection, a subgroup analysis was performed for case patients (n=41) 
and control patients (n=144) with at least 24 months confirmed viraemia and 
showed identical findings. 
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Figure 3-2: Duration of infection was not significantly different between spontaneous 
clearers and control patients. Data are represented as box-whisker plots; boxes represent 
the 25th and 75th percentile, whiskers the range, and horizontal lines represent the median. 
Outliers are shown as circles. 
Median ALT levels were similar between cases and controls at the time of the 
last positive HCV RNA test (47.5 IU/L v 42.5 IU/L, p=0.560). There was a 
significant decrease in the ALT level between the last positive and the first 
negative HCV RNA test for case patients, providing further evidence of 
spontaneous clearance (47.5 IU/L v 20 IU/L, p<0.001). 
Of those subjects who had been tested, quantitative HCV RNA levels were 
significantly lower amongst cases versus controls (p<0.001), however 
spontaneous clearance in the context of high-level viraemia (>100000 IU/mL) 
was observed in 7 patients. IFNL3 genotyping was performed on 1 case patient; 
this patient was found to carry the IFNL3-CC allele. 
Amongst those tested, patients who spontaneously cleared CHC were 
significantly more likely to be hepatitis B surface antigen (HBsAg) positive (5/48 
(10.4%) vs. 0/99 (0%), p<0.001). Eight case patients and 28 patients in the 
control group were positive for hepatitis B core antibody and negative for HBsAg 
indicating past infection. One HBsAg+ patient was co-infected with hepatitis 
delta virus. Rates of HIV IgG positivity were similar between the two groups 
(p=0.518). 
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Detailed review of medical notes was only possible for case patients due to time 
constraints. In 5 patients, 4 of whom had documentation of ongoing alcohol 
abuse, spontaneous clearance of CHC followed admission to hospital with 
decompensated liver disease. In 2 of these cases there was intercurrent sepsis 
and in 1 case the patient was admitted twice; once as a result of a staggered 
paracetamol overdose and several months later due to alcoholic hepatitis with 
queried spontaneous bacterial peritonitis. In the 4th case, the patient was 
admitted on 3 occasions with decompensation between the last detectable and 
first undetectable HCV viral load, on 2 occasions following intentional drug 
overdose and on 1 further occasion in the context of alcohol use. The abstinent 
patient decompensated due to gram negative bacteraemia. Of the 
decompensated patients, two had significant ALT rises (>5 times the upper limit 
of normal).  
One patient underwent major abdominal surgery (hysterectomy) following the 
last positive HCV RNA PCR and prior to the first undetectable HCV RNA test. A 
further 3 patients underwent minor surgical procedures. Six patients (excluding 
those with sepsis and decompensation previously described) required hospital 
admission for various infections, including groin abscess, pneumonia, cellulitis 
and infective endocarditis.  
Four patients had spontaneous vaginal deliveries during the period between their 
last detectable serum HCV RNA and the first negative test. A further individual 
underwent evacuation of retained products of conception following termination 
of pregnancy. 
Twenty-seven of the cases had repeated negative RNA testing. Demographic and 
virologic characteristics of these are compared with controls in Table S2. On 
analysis of this more strictly defined cohort of spontaneous clearers, only female 
gender (p=0.006) and a lower median HCV viral load (p=0.001) remained 
significantly associated with clearance of CHC. 
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3.4 Discussion 
This is the largest cohort of patients with evidence of spontaneous clearance of 
CHC studied to date.  We have demonstrated that spontaneous clearance of CHC 
is rare, with an incidence rate of 0.19 – 0.36 per 100-person-years follow up. We 
found that spontaneous clearance of CHC was associated with female gender, 
HBsAg positivity, younger age at diagnosis and lower HCV RNA titres. It was 
negatively associated with current IDU. We observed that a proportion of cases 
occurred in the context of significant intercurrent illness and hepatic 
decompensation. 
The incidence rate of spontaneous HCV clearance in our cohort is similar to that 
described in a previous Japanese study which demonstrated an annualized 
incidence rate of spontaneous CHC clearance of 0.5%/year/person and found 
that clearance was associated with milder liver disease (Watanabe et al., 2003).  
In contrast, a study by Scott et al. (2006) found that a significant percentage of 
Alaska Natives with CHC experienced HCV RNA negativity, corresponding to a 
rate of 1.15 per 100 persons per year. This variation in rate of spontaneous 
clearance may reflect the different genetic background of the study populations 
together with different incidences of factors associated with clearance of CHC.  
In addition, repeat HCV RNA testing in patients with established CHC in whom 
treatment is not immediately anticipated is performed rarely in our clinical 
practice, in accordance with international guidelines ('EASL Recommendations on 
Treatment of Hepatitis C 2015,' 2015). Therefore, infrequent repeat testing of 
HCV RNA may have led to an underestimate of the true incidence of spontaneous 
clearance in our cohort.  
Concordant with our study, Scott et al. (2006) found that spontaneous HCV 
clearance was associated with a lower HCV viral load and a trend towards 
younger age at infection. Older age at acquisition is independently associated 
with a faster progression to fibrosis, even when controlling for duration of 
infection (Missiha et al., 2008), and children who are vertically infected appear 
to have a very slow progression to cirrhosis (Tovo et al., 2000). The presence of 
significant fibrosis is associated with a poorer response to HCV therapy ('EASL 
Recommendations on Treatment of Hepatitis C 2015,' 2015) and may be 
negatively associated with spontaneous clearance of CHC (Watanabe et al., 
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2003). The reasons for the importance of age as a predictor of progressive 
fibrosis are undetermined, but may relate to changes in immune function and 
reduced hepatic blood flow (Sheedfar et al., 2013).  
Female sex was significantly associated with spontaneous clearance of CHC in 
our study. This result remained significant when restricting the analysis to 
‘confirmed’ clearers. These results mirror findings in the acute setting (Grebely 
et al., 2014, Vispo et al., 2014, Micallef et al., 2006, Hsi et al., 2014, van den 
Berg et al., 2011), and are supported by data from Scott et al. (2006) who found 
that all patients in their cohort with late sustained HCV RNA negativity were 
female. It has been postulated that gender-based differences in immunity may 
underlie the association between female sex and acute spontaneous clearance 
(Grebely et al., 2014), and the same may hold true for clearance in the chronic 
setting. Additionally, male sex is associated with a faster progression to 
cirrhosis, even after controlling for age, duration of infection, alcohol intake and 
metabolic factors (Poynard et al., 1997, Marabita et al., 2011). It is possible that 
male gender was associated with increased disease severity in our study, and 
therefore a lower rate of clearance. Furthermore, Grebely et al. (2014) 
demonstrated that the effect of IFNL3 and HCV genotype on clearance in the 
acute phase was greater among females than males. IFNL3-CC genotype has also 
been associated with spontaneous clearance of HCV in HCV-HIV co-infected 
patients (Vispo et al., 2014, Stenkvist et al., 2014), a finding we are unable to 
confirm due to infrequent testing amongst our cases. 
Gt1 and Gt3 were equally distributed in our cohort, reflecting the distribution in 
Scotland (McLeod A, 2014). We did not find an increased likelihood of 
spontaneous clearance associated with Gt1 infection, as has previously been 
described in both the acute and the chronic setting (Grebely et al., 2014, Scott 
et al., 2006). However, as only a third of patients in our cohort had viral 
genotyping performed it is possible that this null result reflects limited 
statistical power.  
Co-infection with HBV (HBsAg+) was significantly associated with spontaneous 
clearance of CHC (p = 0.001). HCV clearance in the context of HBV 
superinfection has been described in several case reports (Sagnelli et al., 2009, 
Gruener et al., 2002) and may occur as a bystander effect of antiviral cytokine 
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release. It has been suggested that release of type I IFNs from the liver during 
acute infection may contribute to clearance and that HBV may monopolise the 
synthetic machinery of the hepatocyte, thus interrupting the HCV replication 
cycle (Lauer and Kim, 2006).  
Despite the negative association previously described between fibrosis and 
spontaneous clearance of CHC (Watanabe et al., 2003), one third of our case 
patients had a diagnosis of cirrhosis. Additionally, we identified a unique cohort 
of patients who cleared HCV following decompensation of their cirrhosis, most 
commonly in the context of alcohol excess and bacterial infection. The 
mechanisms underlying spontaneous clearance in this setting are unclear. 
Cirrhosis is associated with a reduction in the number of functional hepatocytes, 
potentially limiting viral replication and whilst HCV RNA quantification was 
performed too infrequently in our study to explore this hypothesis, patients with 
cirrhosis have been found to have lower HCV viral loads than non-cirrhotic 
subjects in a large Scottish mixed infection database (McNaughton A, personal 
communication, 2015). Furthermore, cirrhosis is associated with immune 
dysregulation and predisposition to bacterial infection (Thalheimer et al., 2005). 
Bacterial translocation occurs as a result of intestinal bacterial overgrowth and 
increased intestinal permeability, and results in endotoxaemia (Thalheimer et 
al., 2005, Giannelli et al., 2014). Bacterial LPS triggers production of 
inflammatory cytokines, including IFN-γ from hepatic lymphocytes, resulting in 
acute hepatic injury. Chronic alcohol ingestion enhances immune cell sensitivity 
to LPS resulting in increased production of inflammatory cytokines (Mandrekar et 
al., 2009). We hypothesise that HCV RNA clearance may occur in this setting as a 
result of non-specific stimulation of the immune system, perhaps on a 
background of lower baseline viral load. In support of this, two of the 
decompensated patients in our study had significant hepatitis flares preceding 
clearance suggesting the development of a vigorous Th1 cytopathic immune 
response. A similar mechanism may also explain spontaneous clearance of HCV in 
the context of major surgery, as described in the literature (Samonakis et al., 
2005, Yoshikawa et al., 2001). 
Clearance of HCV has been described in the literature during 
pregnancy/parturition (Hattori et al., 2003, Zein et al., 2001). In our study, we 
observed that 5 patients in the spontaneous clearance group became pregnant 
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during the last positive and first negative HCV RNA test, 4 of whom went on to 
have spontaneous vaginal deliveries and 1 of whom had a termination. Normal 
pregnancy is associated with distinct immunological phases (Mor and Cardenas, 
2010). Late pregnancy is an immune-tolerant state and is associated with a Th2 
dominant immune response induced by progesterone and adrenal 
corticosteroids. In contrast, parturition is a pro-inflammatory event associated 
with an influx of immune cells into the myometrium, and rebound of the Th1 
response (Mor and Cardenas, 2010). Spontaneous clearance in this context is 
postulated to occur as a result of restoration of the immune system and HCV-
specific T-cell response (Hattori et al., 2003).  
Finally, we present the tentative finding that ongoing IDU is negatively 
associated with spontaneous clearance of CHC. PWIDs are at risk of 
superinfection with distinct HCV strains which may negatively impact the 
likelihood of spontaneous clearance (Blackard and Sherman, 2007, Herring et al., 
2004). We also accept the possibility that a high HCV re-infection rate post 
clearance amongst PWIDs may mask the incidence of spontaneous clearance in 
this cohort (Micallef et al., 2006, Aitken et al., 2008). However, a recent study 
based in NHSGGC reported a trend towards a lower incidence of re-infection 
following spontaneous clearance (McDonald et al., 2012), as described in 
previous studies (Grebely et al., 2006).  
There are a number of limitations to our study as a consequence of its 
observational and retrospective design.  Our study is strengthened by the 
inclusion of patients presenting and followed up over two decades. Inherent in 
this however, is considerable variation in the utilisation of different laboratory 
tests over time, reflecting changing advice from clinical guidelines (EASL, 2011, 
Palfreeman et al., 2009) and the development and introduction of new 
technologies.  As a consequence of missing data, multivariate analysis was not 
deemed appropriate and statistical inferences must be interpreted with caution. 
We accepted HCV RNA testing on both serum and DBS in the study design to 
increase our study population. DBS testing may increase the uptake of screening 
in PWIDs, in whom venepuncture is often difficult and who may be less likely to 
attend clinic (Bennett et al., 2012, Hickman et al., 2008). However, HCV RNA 
testing on DBS has reduced sensitivity compared to the serum assay; one patient 
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in our cohort who was classified as a spontaneous clearer on the basis of DBS 
HCV RNA testing was found to have detectable HCV RNA on a subsequent serum 
sample. Additionally, the sensitivity of the serum quantitative HCV RNA assays 
varied over the course of follow up and earlier samples may have been more 
likely to be falsely negative. Moreover, fluctuating and low level viraemia is 
common in the early stages of infection. As we relied on only one negative HCV 
RNA for the definition of spontaneous clearance, it is possible that we 
misclassified these patients as spontaneous clearers. However, restricting the 
analysis to patients with at least 24 months confirmed infection did not change 
our findings and the normalisation of liver biochemistry provides further support 
for clearance. 
Follow up of patients with presumed late spontaneous clearance was poor; only 
60% of spontaneous clearers had follow up HCV RNA testing performed at any 
time point to confirm clearance. To address this limitation we performed an 
additional analysis of patients with persistent HCV RNA negativity over time and 
found that only female gender and low HCV viral load remained significant. 
We used age at diagnosis as a surrogate marker for age at infection. Many 
patients self-identified as having been at risk of exposure to HCV many years 
before they were first tested and therefore it is likely that we overestimated the 
true age at infection. Also, for many case patients there was a considerable 
duration between the last positive and the first negative HCV PCR, making it 
difficult to ascertain the true date of HCV clearance.  
As previously discussed, a detailed review of the medical notes was performed 
for all potential spontaneous clearers in order to confirm the clinical scenario. 
We were able therefore to obtain information on intercurrent illnesses, 
hospitalisations and pregnancies for the case patients. Due to the time 
constraints of the project, we were unable to obtain the same information for 
the control cohort. As a consequence, data on intercurrent illnesses and 
pregnancies in the case patients are presented qualitatively, and firm 
conclusions cannot be drawn regarding the association between these events and 
spontaneous clearance of chronic HCV. 
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Finally, HCV RNA testing rates may be subject to bias. Repeat HCV RNA testing in 
CHC is only recommended in patients for whom treatment is anticipated (EASL, 
2011). Although we allowed testing on DBS to increase our study population, 
certain patient groups may have been less likely to have been tested, including 
patients with chaotic lifestyles who are not engaged in care, or patients with 
contraindications to therapy. However, despite the methodological drawbacks 
inherent in a retrospective study, the biological plausibility of our results and 
concordance with the precedent in the literature lead us to believe that our 
results are sound. 
We conclude that spontaneous clearance of CHC is more common in females and 
patients with a low HCV viral load, and that previously described factors 
including superinfection with HBV and younger age at infection may play a role. 
This study reveals novel findings of a negative association with ongoing IDU, and 
describes a cohort of spontaneous clearance in the context of decompensated 
liver disease.  Further work is required to identify the mechanisms underlying 
spontaneous clearance of chronic infection. Given that such clearance may occur 
after a prolonged duration of chronic infection, more regular serum HCV RNA 
monitoring may be warranted, particularly in females, HBV co-infected 
individuals, patients with low level viraemia and those with decompensated liver 
disease. 
Excerpts from this chapter have now been published (Bulteel et al., 2016).  
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4 Circulating miRNA expression in patients with 
CHC: association with disease stage and 
biomarkers of ageing 
4.1 Introduction 
Disease progression in CHC is highly variable, and is dependent on both 
modifiable and non-modifiable factors (Chapter 1.2.2). At present, patients with 
more advanced disease are prioritised for antiviral treatment whilst a ‘watchful 
waiting’ approach may be taken in individuals with normal liver stiffness and no 
extra-hepatic complications of HCV infection. Assessment of liver fibrosis 
(chapter 1.4) is essential for risk stratification and to ensure that individuals 
with advanced fibrosis are offered appropriate surveillance for oesophageal 
varices and HCC.  
It is recommended that individuals with ≥ F3 fibrosis undergo abdominal imaging 
+/- serum alpha-fetoprotein (AFP) monitoring at 6 monthly intervals to monitor 
for hepatoma development ('EASL Recommendations on Treatment of Hepatitis C 
2016,' 2016, Ryder, 2003). However, studies have shown that in rare cases HCC 
may develop in HCV-infected patients without cirrhosis (Yeh et al., 2010). 
Additionally, data are emerging to suggest that delaying treatment results in an 
increased risk of liver-related death, and reduced treatment effectiveness 
(McCombs et al., 2014). Therefore, prognostic biomarkers able to identify 
individuals at high risk of progressing to end-stage liver disease or HCC during 
HCV infection are urgently required.  
BoA are attractive candidates for prognostic biomarkers in CHC as 
immunosenescence has been associated with accelerated disease progression 
and poorer treatment outcomes with IFN-based therapy (Hoare et al., 2010b, 
Manfras et al., 2004). The cyclin dependent kinase inhibitor CDKN2A is a well 
characterised BoA, PBMC expression of which can be used to infer 
immunosenescence (chapter 1.6.1). Expression of CDKN2A in the liver tissue of 
patients with CHC has been previously shown to correlate with necro-
inflammation (Bieche et al., 2005), and Robinson and colleagues (2013) found 
that higher expression of CDKN2A, and the related transcripts ARF and CDKN2B, 
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was observed in the PBMCs of HCV-infected subjects compared with healthy 
controls. The authors found that CDKN2A and ARF expression correlated with 
disease stage, and suggested that CDKN2 locus transcripts could serve as 
surrogate markers for advanced liver disease. They also hypothesised that 
expression of these transcripts could be used as prognostic biomarkers for the 
development of both hepatic and extra-hepatic disease manifestations of CHC 
(Robinson et al., 2013). However, PBMC separation can be time consuming which 
restricts their use in clinical practice. Furthermore, the use of RNA biomarkers 
has proven challenging as mRNA is subject to degradation resulting in alteration 
of gene expression ex vivo (Baechler et al., 2004). 
Both membrane vesicle-associated and protein-bound miRNAs are remarkably 
stable in plasma and cell culture media (Turchinovich and Cho, 2014) compared 
with mRNA, making them excellent candidate biomarkers. Specific miRNA 
‘signatures’ have been described in liver disease of multiple aetiologies, and 
they are increasingly being exploited as diagnostic and prognostic biomarkers, as 
an alternative to measuring differences in telomere length or gene expression 
(chapter 1.7). 
In this chapter, we aimed to gain insights into the pathogenesis of HCV infection 
by characterising miRNA expression in the peripheral blood of subjects with CHC. 
The availability of matched serum and PBMC samples provided us with a unique 
opportunity to explore miRNA regulation at the level of the peripheral immune 
system as well as document serum miRNA expression. We postulated that we 
could identify non-invasive biomarkers for hepatic cirrhosis by correlating serum 
and PBMC miRNA expression with disease stage in HCV-infected subjects. 
Furthermore, we hypothesised that by correlating miRNA expression with PBMC 
CDKN2A expression (a biomarker of immunosenescence thought to have negative 
prognostic implications) we could identify novel prognostic biomarkers for non-
cirrhotic HCV-infected individuals at high risk of progression to cirrhosis. As it is 
thought that miRNA within exosomes may play a role in cell-cell communication, 
and regulate gene expression in target cells, we also examined the expression of 
potential biomarkers within exosomes in order to determine whether a role in 
cell-cell signalling was supported. Finally, we studied the expression of a 
selected miRNA in a hepatoma cell line in response to TLR3 agonism and IFN-α 
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stimulation to explore this approach as a possible model for studying the role of 
miRNAs in the immune response to infection. 
4.2 Patient selection 
Matched serum and PBMC samples were available from a pre-existing cohort 
together with relevant clinical and demographic patient data. The Glasgow 
Outcomes Study cohort consisted of individuals with chronic HCV Gt1 and Gt3 
infection (n=100) attending hospitals in Glasgow, together with healthy age and 
sex matched controls (n=25) who were negative for anti-HCV antibodies 
(Robinson M, 2013). Exclusion criteria included obesity (BMI> 30kg/m2), current 
IDU, chronic alcohol excess, co-infection with HBV or HIV, and the use of lipid 
lowering medication. Patients with metabolic disorders, including DM 2, were 
also excluded. No participants were receiving HCV treatment at the time of 
sample collection. 
The study protocol was approved by the NHS Greater Glasgow & Clyde Research 
Ethics Committee (REC) (REC project number 11/AL/0371; August, 2011). All 
study participants provided written consent for sample collection and 
subsequent analysis. 
4.2.1 Pilot study cohort 
For the pilot study, non-cirrhotic patients (n=16, liver stiffness < 7.1 kPa on TE 
(Boursier et al., 2012), F0-1 disease) and cirrhotic patients (n=9, liver stiffness > 
12.5kPa, F4 disease) who had previously had their CDKN2A mRNA expression 
levels determined were selected from the pre-existing cohort (Robinson M, 
2013). Healthy sex-matched controls (n=8) were also included in the pilot 
analysis.  
As CDKN2A is a biomarker of cellular senescence, non-cirrhotic patients were 
sub-divided into ‘high biological age (bio-age)’ and ‘low bio-age’ according to 
the relative expression of PBMC CDKN2A mRNA, i.e. subjects with ≥ 2 fold higher 
expression of CDKN2A mRNA compared to healthy controls were classified as 
‘high bio-age’, and those with < 2 fold change were classified as ‘low bio-age’.  
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Demographic patient data (age at enrolment, age at infection, sex, ethnicity, 
alcohol intake, current IDU, source of infection), HCV markers (liver enzymes, 
HCV genotype, IFNL3 genotype, HCV RNA, liver stiffness, history of cirrhosis), 
and data on co-morbidities had been previously obtained. Biochemical and 
haematologic variables were recorded at baseline. Duration of infection was 
calculated as the interval between age at infection and age at enrolment.  
All patients were of white ethnicity. The median age of the cohort was 42 years 
(IQR 39-49) and the majority were male (n=24; 72.7%). Full baseline 
characteristics of the included patients are shown in Table S3. 
Following the pilot study, promising results for serum biomarkers were validated 
in a larger patient cohort (chapter 4.2.2 below). The derivation of each patient 
group from the original Glasgow Outcomes study is shown in figure 4-1. 
4.2.2 Expanded patient cohort 
The expanded study consisted of a larger cohort of HCV-infected patients (n=51) 
together with healthy controls (n=10). Of the HCV-infected subjects, around a 
third had a liver stiffness >12.5kPa consistent with cirrhosis (n=15, 29.4%).  
Data on CDKN2A, CDKN2B and ARF PBMC mRNA expression were only available 
for a subset of HCV-infected subjects (n=40, 78.4%), therefore bio-age could not 
be estimated and patients were simply grouped according to fibrosis stage, i.e. 
‘cirrhotic’ and ‘non-cirrhotic’. Demographic and laboratory features of the 
patients are shown in Table S4. 
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Figure 4-1: Derivation of each patient group for miRNA analysis from the original Glasgow 
Outcomes cohort. Matched PBMC and serum samples from HCV-infected subjects (n=25) and 
healthy controls (n=8) were analysed in the first instance. Promising results from the serum 
pilot study were validated in a larger bank of samples from HCV-infected subjects (n=51) and 
healthy controls (n=10). Exosomes were extracted from a subset of serum samples (n=8) 
from the pilot group. CHC, chronic hepatitis C virus infection; HC, healthy controls.  
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4.3 PBMC miRNA expression in CHC 
4.3.1 Effect of PBMC storage method on miRNA expression profiling 
It is often impractical to extract RNA from fresh PBMC fractions. PBMCs can be 
cryopreserved in liquid nitrogen or added to lysis buffer and stored at -70oC prior 
to RNA extraction. It is not known which storage method yields better results in 
downstream miRNA analysis. 
Pre-separated PBMC samples were available for the Outcomes study cohort 
(Robinson et al., 2013). The PBMCs had been separated from fresh whole blood 
over a density gradient before being either suspended in 1 mL freezing medium 
(per 1x107 cells) and cryopreserved in liquid nitrogen in  aliquots, or lysed in 600 
µL RLT buffer (5x106 cells) and stored at -70oC. We extracted RNA from paired 
PBMC samples stored using each method for 4 HCV-infected individuals. RNA was 
extracted from PBMCs as described previously (chapter 2.2.1.3). 
We compared miRNA expression in PBMCs cryopreserved in liquid nitrogen with 
miRNAs from those lysed in RLT buffer and stored at -70oC (chapter 2.2.1.3). The 
average 260/280 ratio for the RNA extracted from cryopreserved PBMCs was 
2.035 compared with a ratio of 2.025 for RNA extracted from PBMCs stored in 
lysis buffer. Gel electrophoresis was performed for RNA extracted from 3 of the 
cryopreserved samples using the Agilent TapeStation and demonstrated a mean 
RNA integrity number (RIN) of 7.6 indicating a degree of degradation (figure 2-
1). In comparison, the mean RIN was 9.1 for the RNA extracted from PBMCs 
stored immediately in lysis buffer. 
Each sample was run individually on a TaqMan® MicroRNA array card (chapter 
2.2.2.1) and between group differences were explored. A total of 442 miRNA 
transcripts were reliably detected (i.e. expressed in ≥ 2 biological group 
replicates) in the PBMCs stored in RLT buffer, compared with only 274 
transcripts in the cryopreserved PBMCs. Two hundred and sixty-five transcripts 
were expressed in both groups, and there was good overall correlation between 
CT values (figure 4-2; r=0.82, 95% CI: 0.78-0.86, p<0.0001).  
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Generally, miRNA expression levels were lower in cryopreserved PBMCs than in 
PBMCs stored in RLT buffer; 99 miRNAs were detected at significantly lower 
levels whereas only 11 were increased in abundance.  
Although this analysis demonstrated reasonable overall correlation between 
miRNAs expressed in PBMCs stored in liquid nitrogen and frozen in RLT buffer, 
the data do suggest that there is a significant benefit to storing PBMCs 
immediately in lysis buffer for downstream RNA analysis. However, based on 
sample availability, further experiments were performed using PBMCs that had 
been cryopreserved in liquid nitrogen and the above findings should be taken 
into consideration when interpreting the data in the following section. 
 
Figure 4-2: Correlation between CT values for miRNAs detected in PBMCs stored in RLT 
buffer compared with cryopreserved samples.  
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4.3.2 PBMC miRNA profile in CHC 
The immune response to HCV infection is known to play an important role in 
disease progression in CHC (chapter 1.2) and PBMC miRNA expression has been 
shown to correlate with disease stage and treatment outcome (Hsi et al., 2014). 
It was therefore of interest to interrogate miRNA expression in the PBMCs of 
HCV-infected individuals within our cohort.  
We examined global miRNA expression in the PBMCs of 25 HCV-infected 
individuals together with 8 healthy controls. We detected 450 of the 754 miRNAs 
examined in the PBMCs of HCV-infected subjects (present in ≥ 2 samples), 
compared with 353 in the healthy controls. Of the 242 miRNAs which could be 
compared across both groups, 26 demonstrated greater than two-fold change 
with respect to healthy controls; 14 miRNAs were significantly upregulated and 
12 miRNAs were significantly downregulated (figure 4-3, table 4-1). We also 
found that miR-720 was significantly upregulated, however subsequent studies 
have demonstrated that the sequence annotated as miR-720 is likely to be a 
fragment of a tRNA, and it has been removed from the miRBase database 
(Schopman et al., 2010). It was therefore excluded from downstream analyses.  
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Table 4-1: MiRNA expression in the PBMCs of HCV-infected individuals compared with healthy 
controls 
 MiRNA Fold change P value 
Increased in 
CHC 
miR-95-3p 2.095 0.011 
miR-500a-5p 2.117 0.037 
miR-140-3p 2.14 0.011 
miR-629-3p 2.191 0.01 
miR-1248 2.227 0.027 
miR-138-5p 2.271 0.034 
miR-629-5p 2.294 0.0001 
miR-589-3p 2.354 0.038 
miR-590-3p 2.404 0.023 
miR-16-5p 2.554 0.001 
miR-532-5p 2.698 0.009 
miR-146b-3p 2.708 0.002 
miR-193a-5p 2.774 0.001 
miR-1244 2.847 0.01 
Decreased in 
CHC 
miR-136-3p 0.072 0.0001 
miR-656-3p 0.184 0.001 
miR-323-3p 0.197 0.002 
miR-374a-3p 0.242 0.006 
miR-26a-1-3p 0.263 0.008 
miR-374b-3p 0.306 0.0001 
miR-410-3p 0.336 0.01 
miR-597-5p 0.334 0.049 
miR-151a-5p 0.346 0.028 
miR-376a-3p 0.349 0.012 
miR-744-3p 0.39 0.047 
miR-411-5p 0.415 0.037 
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Figure 4-3: Volcano plot demonstrating p value against fold change for miRNAs deregulated 
in the PBMCs of subjects with CHC compared with healthy controls. Data points in red 
indicate miRNA upregulated compared with healthy controls and those in blue indicate 
downregulation. Fold change > 2 and p value < 0.05 were considered significant.  
 
Pathway analysis was performed in silico using DIANA-miRPath for those miRNA 
significantly deregulated in the PBMCs of patients with CHC (figure 4-4). We 
found that cancer pathways were highly represented; microRNAs in cancer, viral 
carcinogenesis and proteoglycans in cancer were the most significantly enriched 
pathways. These data suggest an important role for miRNAs in regulating 
oncogenesis in CHC. 
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Figure 4-4: In silico pathway analysis using DIANA-miRPath for miRNAs significantly 
deregulated in the PBMCs of HCV-infected subjects. Red bars indicate number of miRNA 
involved in each pathway and blue bars indicate the number of genes. The y axis 
demonstrates significantly enriched KEGG pathways sorted according to a descending 
enrichment statistical score (–ln P).  
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4.3.3 Intergenotypic differences in PBMC miRNA expression 
The effect of viral genotype on disease progression in CHC is unclear and data 
are conflicting (chapter 1.3.2.1). Some cohort studies have suggested that Gt1 
infection is associated with increased disease severity and likelihood of viral 
persistence (Franchini et al., 2001, Yee et al., 2000). Conversely, an increased 
likelihood of clearance in both the acute and chronic stage has been described in 
Gt1 infection, although we were unable to demonstrate an association between 
HCV genotype and late spontaneous clearance in our Scottish cohort (Chapter 3). 
Gt3 infections are associated with a higher incidence of steatosis which may be 
associated with disease progression and increased incidence of HCC (Rubbia-
Brandt et al., 2000). We hypothesised that profiling PBMC miRNA expression in 
Gt1 and Gt3 infection would provide important insights into the phenotypic 
differences between viral genotypes.  
We detected 424 miRNA transcripts in ≥ 2 PBMC samples of Gt1-infected subjects 
(n=13) compared with 343 miRNA transcripts in Gt3 infection (n=12). We 
examined miRNA expression between Gt1- and Gt3-infected individuals and 
found that of the 173 miRNAs which could be directly compared, 49 miRNA were 
significantly upregulated in the PBMCs of Gt1- vs. Gt3-infected subjects. The full 
comparison is shown in Table S6. Only 8 miRNA were upregulated in HCV Gt3 
infection compared to Gt1 infection (figure 4-5; table 4-2). 
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Table 4-2: Intergenotypic differences in PBMC miRNA expression 
 MiRNA Fold change P value 
Increased in Gt1 
infection 
miR-532-5p 29.41 0.0001 
miR-671-3p 5.43 0.0001 
miR-193b-3p 4.90 0.0001 
miR-193a-5p 3.61 0.0001 
miR-148a-3p 3.57 0.0001 
miR-324-3p 3.44 0.0001 
miR-423-5p 3.30 0.0001 
miR-328-3p 3.07 0.0001 
miR-502-3p 2.76 0.0001 
miR-744-5p 2.51 0.0001 
miR-30b-5p 2.39 0.0001 
miR-324-5p 2.08 0.0001 
miR-25-3p 2.03 0.0001 
miR-142-3p 6.33 0.001 
miR-296-5p 3.66 0.001 
miR-652-3p 2.79 0.001 
miR-106b-5p 2.16 0.001 
miR-451a 6.10 0.002 
miR-320a 3.53 0.002 
miR-331-3p 2.17 0.002 
miR-92a-3p 2.16 0.002 
miR-589-5p 2.06 0.002 
miR-629-5p 2.00 0.002 
miR-424-5p 3.95 0.003 
miR-221-3p 2.16 0.003 
miR-642a-5p 2.07 0.003 
miR-345-5p 2.61 0.004 
miR-484 2.07 0.005 
miR-19b-3p 2.27 0.007 
miR-142-5p 4.03 0.008 
let-7c-5p 2.68 0.008 
miR-374b-5p 4.31 0.009 
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miR-375 3.09 0.011 
miR-148b-3p 2.54 0.011 
miR-21-5p 2.33 0.011 
miR-597-5p 2.72 0.012 
miR-574-3p 2.67 0.012 
miR-362-3p 4.42 0.013 
miR-181a-5p 2.26 0.013 
miR-150-5p 2.18 0.015 
miR-28-3p 8.40 0.016 
miR-101-3p 2.04 0.016 
miR-330-3p 2.03 0.019 
miR-339-3p 2.39 0.025 
miR-29a-3p 2.35 0.026 
miR-369-5p 5.95 0.028 
miR-140-5p 2.01 0.031 
miR-10a-5p 3.73 0.044 
miR-222-3p 2.24 0.048 
Increased in Gt3 
infection 
miR-190a-5p  4.35 0.0001 
miR-195-5p 4.95 0.0001 
miR-548c-3p 5.65 0.001 
miR-483-5p 11.23 0.004 
miR-494-3p 3.175 0.005 
miR-422a 2.76 0.01 
miR-26b-5p 2.50 0.041 
miR-1-3p 3.64 0.047 
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Figure 4-5: Volcano plot demonstrating p value against fold change for miRNAs deregulated 
in the PBMCs of Gt1- compared with Gt3-infected subjects. Data points in red indicate 
miRNAs upregulated in Gt3 infection compared with Gt1 infection, and those in blue indicate 
downregulation. Fold change > 2 and p value < 0.05 were considered significant.  
 
We next compared the PBMC miRNA expression in each genotype to miRNA 
expression in the PBMCs of healthy controls. We found that 50 miRNAs were 
significantly upregulated in the PBMCs of HCV Gt1-infected subjects compared to 
healthy controls, and 27 were significantly downregulated. In Gt3-infected 
individuals only 8 miRNAs were significantly upregulated whilst 13 were 
significantly downregulated. 
Eight miRNAs were significantly deregulated in both genotypes, miR-597-5p, 
miR-376c-3p, miR-151-5p, miR-376a-3p, miR-126-5p, miR-411-5p, miR-138-5p 
and miR-16-5p.  All were downregulated apart from miR-138-5p and miR-16-5p 
which demonstrated > 2 fold upregulation compared to healthy controls.  
It is difficult to interpret the difference in miRNA expression between genotypes 
given the lower total number of miRNAs detected overall in the PBMCs of Gt3- 
compared with Gt1-infected subjects. However, the number of deregulated 
miRNAs in the PBMCs of Gt3-infected subjects does appear to be fewer, even 
accounting for the difference in global miRNA expression. 
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Based on biological relevance (chapter 1.7.3), we selected miR-21-5p, miR-195-
5p and miR-221-3p for validation with quantitative RT-PCR. We found that 
miRNA expression was highly variable between individual samples, particularly 
for miR-21-5p, and we were unable to reproduce the differences in miRNA 
expression between genotypes seen in the miRNA array. We identified 
considerable individual biological variance in PBMC miRNA expression.  
 
Figure 4-6: PBMC expression of miR-21-5p, miR-195-5p and miR-221-3p is not significantly 
different between Gt1 and Gt3 HCV-infected patients. Dot plot graphs depict mean/median 
expression +/- 95% CI; ns=non-significant.  
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There were no significant differences in miR-21-5p, miR-195-5p or miR-221-3p 
expression between genotypes (figure 4-6). This highlights an issue with 
interpretation of the TaqMan® MicroRNA Array data – as fold changes are 
calculated based on the average ΔCT value for biological replicates, transcripts 
are only required to be present in ≥ 2 samples to be included. We have observed 
significant variance in miRNA expression between biological replicates. The 
small group size combined with high inter-individual variability in miRNA 
expression may explain why we are unable to reproduce the differences in 
miRNA expression observed between groups in the TaqMan® MicroRNA Array 
data, and highlights the importance of validating preliminary findings using 
individual assays. 
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4.3.4 Correlation between PBMC miRNA expression and disease 
stage in CHC 
We hypothesised that we could identify non-invasive biomarkers for hepatic 
cirrhosis by correlating PBMC miRNA expression with disease stage. In our initial 
miRNA screen, we found that the well-characterised biomarker miR-16-5p 
(chapter 1.7.3) was significantly upregulated in the PBMCs of HCV-infected 
subjects compared to healthy controls (table 4-1 & table S5). We therefore 
selected this miRNA for validation with quantitative RT-PCR. We also examined a 
panel of related miRNAs present in the PBMCs of HCV-infected individuals which 
were known to be associated with inflamm-aging, as well as additional miRNAs 
that we had identified during our preliminary serum screen (chapter 4.4.3). 
Between-group differences are shown in Table S7. There were no significant 
differences in selected miRNA expression in the PBMCs of non-cirrhotic 
individuals classified as ‘high bio-age’ and ‘low bio-age’ (chapter 4.2.2) and the 
data are therefore grouped together under ‘non-cirrhotic’ (n=16). Cirrhotic 
patients (n=9) were significantly older at study enrolment than HCV-infected 
non-cirrhotic patients (49 v 40.5 years, p=0.012) and had a higher BMI (27.4 v 
24.6 kg/m2, p=0.027). There were no differences between groups in terms of 
gender, age at infection or duration of infection. As published previously, 
individuals with HCV-related cirrhosis have elevated PBMC CDKN2A mRNA 
expression (Robinson et al., 2013). 
We found that miR-16-5p (p=0.001), miR-155-5p (p=0.002), miR-885-5p (p=0.002) 
and miR-221-3p (p=0.001) were significantly upregulated in the PBMCs of 
patients with cirrhosis compared with non-cirrhotic HCV-infected patients (figure 
4-7). There were no significant differences in PBMC miR-21-5p and miR-195-5p 
expression between cirrhotic and non-cirrhotic patients.  
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Figure 4-7: Expression of miR-16-5p, miR-221-3p, miR-155-5p, miR-885-5p, miR-21-5p and 
miR-195-5p in the PBMCs of HCV-infected patients with and without cirrhosis. Dot plot 
graphs depict mean/median expression +/- 95% CI; **p<0.01, ****p<0.0001, ns=non-
significant.  
We found significant correlations between CDKN2A mRNA expression and the 
expression of miR-16-5p (r=-0.652, R2=0.425, p<0.001), miR-221-3p (r=-0.561, 
R2=0.315, p=0.004), miR-155-5p (r=-0.643, R2=0.414, p<0.001), miR-885-5p (r=-
0.684, R2=0.468, p<0.001) and BMI (r=0.486, R2=0.237, p=0.016) (figure 4-8).  
 
Figure 4-8: CDKN2A expression is positively correlated with expression of miR-16-5p, miR-
221-3p, miR-155-5p and miR-885-5p, and BMI (kg/m2). Panels show XY correlation plots with 
linear regression curve fitted. 
  
4-172 
 
4.3.5 Functional analysis of selected miRNAs in silico 
We analysed protein-protein interactions for genes targeted by the miRNA 
significantly upregulated in the PBMCs of cirrhotic HCV-infected subjects to gain 
insights into potential in vivo functions. The 4 miRNAs which were significantly 
differentially expressed in the PBMCs of cirrhotics vs. non-cirrhotics (miR-16-5p, 
miR-155-5p, miR-221-3p and miR-885-5p) are well described in the literature.  
Using miRTarbase 2016 (Chou et al., 2016) and TarBase v7.0 (as described in 
chapter 2.3) we identified 37 experimentally validated target genes for miR-16-
5p (figure 4-9). Predicted protein-protein interaction analysis (from STRING 
v10.5) suggested that cell cycle regulation and protein phosphorylation are the 
most significantly enriched biological processes. The most significantly enriched 
KEGG pathway was the PI3K/AKT pathway. Pathways in cancer and the p53 
signalling pathway were also significantly enriched. AKT3, CCND1, CDK4, CDK6, 
FGFR1, IGF1R and TP53 are involved in both the p53 signalling pathway and the 
PI3K/AKT pathway. The PI3K/AKT pathway is an important senescence 
associated pathway, and in vitro studies suggest that it is directly regulated by 
HCV core protein (Tacke et al., 2011). Target proteins and first shell interactors 
involved in the PI3K/AKT pathway are highlighted in red in the following 
illustration (figure 4-9). 
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Figure 4-9: Predicted protein-protein interactions for miR-16-5p target genes. Networks are 
clustered according to the Markov cluster algorithm (inflation factor 3); strength of 
association is shown by the line thickness: dotted lines indicate weaker support. Genes 
involved in the PI3K/AKT pathway are highlighted in red. 
 
We next explored potential functions of miR-221-3p. MiR-221-3p has 43 validated 
targets, including phosphatase and tensin homolog (PTEN) and TP53 (figure 4-
10). The most significantly enriched biological process is negative regulation of 
cellular processes. As with miR-16-5p, pathways in cancer are significantly 
enriched; the 5 most significantly enriched KEGG pathways are microRNAs in 
cancer, pathways in cancer, hepatitis B, Epstein-Barr virus infection and cell 
cycle.  
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Figure 4-10: Predicted protein-protein interactions for miR-221-3p target genes. Networks 
are clustered according to the Markov cluster algorithm (inflation factor 3); strength of 
association is shown by the line thickness: dotted lines indicate weaker support. Proteins 
involved in microRNAs in cancer are highlighted in red. 
 
For miR-155-5p, we identified 60 experimentally validated target genes (figure 
4-11). Functional analysis of protein – protein interactions showed that positive 
regulation of cellular metabolic process was the most significantly enriched 
biological process. The 5 most significantly enriched KEGG pathways were human 
T-cell lymphotropic virus (HTLV) type 1 infection, non-small cell lung cancer, 
cell cycle, PI3K/AKT signalling pathway and the NF-κB signalling pathway. As 
previously, proteins involved in the most significantly enriched KEGG pathway 
are highlighted in red. 
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Figure 4-11: Predicted protein-protein interactions for miR-155 target genes. Networks are 
clustered according to the Markov cluster algorithm (inflation factor 3); strength of 
association is shown by the line thickness: dotted lines indicate weaker support. Proteins 
involved in the HTLV infection pathway are highlighted in red. 
Only 3 validated targets for miR-885-5p were identified: CDK2, MCM5 and CASP3. 
Predicted protein-protein interactions with the identified nodes and first shell 
interactors are shown in figure 4-12. DNA replication and cell cycle were the 
most significantly enriched KEGG pathways, and DNA helicase activity was the 
most significantly enriched biological process.  
 
Figure 4-12: Predicted protein-protein interactions for miR-885-5p target genes. Networks 
are clustered according to the Markov cluster algorithm (inflation factor 3); strength of 
association is shown by the line thickness: dotted lines indicate weaker support. Proteins 
involved in DNA replication are highlighted in red.  
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4.3.6 Discussion 
In this pilot study, we performed PBMC miRNA expression profiling on a cohort of 
chronically HCV-infected subjects, together with healthy controls. This has 
potentially allowed us to gain insights into the pathogenesis of CHC at the level 
of the peripheral immune system.  
The risk of developing HCC is increased 15 to 17-fold in HCV-infected patients 
compared to uninfected individuals, and the risk of developing HCC in a patient 
with cirrhosis secondary to HCV is around 2-6% per year (El-Serag et al., 2009). 
The major determinant of the risk of HCC development is stage of liver disease, 
although a variety of modifiable and non-modifiable factors may contribute to 
disease progression (chapter 1.3.2). CHC is also associated with the development 
of haematological malignancy, particularly non-Hodgkin’s lymphoma, in addition 
to solid organ tumours and skin cancers (Mahale et al., 2017). 
The data show that miRNAs deregulated in the peripheral immune cells of 
patients with CHC are highly represented in cancer pathways; 19 of the 26 
deregulated miRNAs are involved in various cancer pathways, with roles in 
angiogenesis, proliferation and evasion of apoptosis. Understanding the 
mechanisms underlying cancer development in HCV infection is vital for the 
development of targeted anti-cancer therapies, as well as guiding the monitoring 
of patients for early stage cancers.  
We found that miR-16-5p, miR-221-3p, miR-155-5p and miR-885-5p were 
significantly upregulated in the PBMCs of HCV-infected subjects with cirrhosis 
compared to non-cirrhotic patients. We performed in silico analysis of predicted 
protein-protein interactions for target genes of each miRNA, and found that all 4 
miRNAs targeted genes implicated in the cell cycle and cancer pathways. 
Upregulation of miR-155 in intra-hepatic immune cells (KCs) is associated with 
an activated state and the release of TNF, promoting inflammation (Szabo and 
Bala, 2013). Alteration of the miRNAs in the peripheral immune cells of HCV-
infected individuals may mirror changes in the intrahepatic immune cells, 
reflecting an inflammatory, pro-fibrotic cellular environment secondary to CHC.  
MiR-155-5p is a well characterised onco-miR which is known to be increased in 
the liver tissue, serum and monocytes of HCV-infected patients compared with 
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healthy controls (Bala et al., 2012). HCV infection has been shown to upregulate 
miR-155-5p expression in hepatocytes, monocytes and KCs in vitro, and this 
elevated expression is thought to be mediated indirectly through enhanced NF-
κB transcription (Zhang et al., 2012, Bala et al., 2012). MiR-155-5p targets the 
tumour suppressor gene APC, responsible for inactivating Wnt/Β-catenin 
signalling, promoting cellular proliferation and inhibiting apoptosis. Zhang and 
colleagues (2012) concluded that the HCV/NF-κB/miR-155/Wnt axis is an 
important pathway linking hepatic inflammation and tumorigenesis. 
Interestingly, higher miR-155 expression in the liver tissue is associated with SVR 
and the favourable IFNL3-CC genotype, and negatively correlates with ISG15 
expression. Additionally, transfection of KCs in vitro with a miR-155 mimic was 
shown to abrogate the immunomodulatory effect of IL-10 and TGF-Β on TLR-3 
signalling (Jiang et al., 2014). It appears that miR-155-5p may have important 
pro-inflammatory and antiviral activities in CHC.  
Overexpression of miR-885-5p was associated with downregulation of CDK2 and 
mini-chromosome maintenance protein (MCM5) in a neuroblastoma cell line 
(Afanasyeva et al., 2011), and it is thought to have tumour suppressor functions 
in a number of malignancies. MiR-885-5p may also modulate the Wnt/Β-catenin 
signalling pathway; miR-885-5p overexpression results in inhibition of Wnt/Β-
catenin signalling, suppressing metastasis of malignant cells (Zhang et al., 2016). 
Functional analysis of predicted protein-protein interactions suggests that miR-
885-5p functions as a regulator of the cell cycle and DNA replication, supporting 
a role in regulation of oncogenesis. 
MiR-221-3p is upregulated by HCV infection in an NF-κB dependent manner in 
vitro (Ding et al., 2015). It is elevated in the serum of HCV-infected subjects and 
correlates with serum aminotransferase levels and miR-122-5p expression. MiR-
221-3p is a well described onco-miR, and is highly upregulated in HCC compared 
to normal liver tissue (Pineau et al., 2010). It has been shown to target the CKI 
p27 and may also downregulate DNA damage inducible transcript 4 (DDIT4), a 
modulator of the mammalian target of rapamycin (mTOR) pathway, promoting 
tumorigenesis. MiR-221 overexpression in myeloid dendritic cells is associated 
with downregulation of pro-apoptotic ISGs and SOCS1, promoting cell survival 
(Sehgal et al., 2015). Interestingly, IFN-α has been shown to downregulate miR-
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221 in dendritic cells via inhibition of STAT3, with consequent antiproliferative 
and immunomodulatory effects (Sehgal et al., 2015).  
MiR-16-5p functions as a tumour suppressor (chapter 1.7.3) (El-Abd et al., 2015). 
It binds to both BCL2 (Cimmino et al., 2005) and VEGF (Hua et al., 2006), 
resulting in apoptosis and inhibition of angiogenesis. Overexpression in vitro is 
associated with inhibition of PI3K and AKT phosphorylation, resulting in 
suppression of proliferation and metastasis of HepG2 cells, which are derived 
from HCC (Wu et al., 2015).  Elevated miR-16-5p has been described in various 
tissues along with ageing-associated disease (Li et al., 2015), and reflects the 
development of senescence as an important mechanism to limit cellular 
proliferation and neoplastic change. We found that miR-16-5p was elevated in 
the PBMCs of non-cirrhotic as well as cirrhotic HCV-infected individuals 
compared to healthy controls, supporting the association between CHC and 
immunosenescence. 
Elevated expression of both miR-16 and miR-155 is seen in the B cells of elderly 
individuals, and is associated with a pro-inflammatory state and reduced B cell 
function (Frasca et al., 2015). Additionally, both miR-16-5p and miR-155-5p are 
elevated in the PBMCs of individuals with HCV-related lymphomas compared to 
healthy controls, HCV-infected subjects and individuals with HCV-related HCC 
(Piluso et al., 2015) indicating that they may have a role as diagnostic 
biomarkers for HCV-related haematological malignancy as well as providing 
insights into the pathogenesis of HCV-related cancers.  
The effect of genotype on risk of HCC occurrence is unclear, and data are 
conflicting. Increased risk of HCC development has been described with both Gt1 
and Gt3 infection and further work is needed to elucidate the relationship 
between HCV genotype and carcinogenesis (Bruno et al., 1997, Rubbia-Brandt et 
al., 2004). Chang and colleagues (2014) found that expression levels of miR-16, 
miR-193b, miR-199a, miR-222 and miR-324 were significantly higher in the 
PBMCs of HCV-infected patients compared to healthy controls and suggested that 
these miRNAs could be used as diagnostic biomarkers. They also demonstrated 
significant differences in PBMC miRNA expression between Gt1 and non-Gt1 
infected individuals. In our initial miRNA screen we found that a greater number 
of miRNAs were expressed in the PBMCs of patients with HCV Gt1 infection than 
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in Gt3 infected patients with respect to healthy controls, and of those a greater 
number were significantly deregulated. Concordantly with Chang et al. (2014) 
we found that miR-193b, miR-222 and miR-324 were upregulated in PBMCs from 
Gt1 compared to Gt3 HCV-infected subjects in our initial screen. However, in 
subsequent experiments we were unable to demonstrate significant differences 
in expression between genotypes for any of the selected miRNAs. This may be 
due to the small sample size studied and high individual biological variance in 
miRNA expression. Additionally, mathematical correction for multiple 
comparisons was not applied to the initial screen, to avoid the risk of increasing 
the type II error for those associations that were not null. Naturally, this will 
have led to an increased incidence of type I error which may also explain our 
null findings. 
Reflecting our larger patient cohort, cirrhotic patients were older at enrolment, 
and had a significantly higher BMI. Both older age and elevated BMI have been 
shown to accelerate fibrosis progression in CHC (chapter 1.3.2) and contribute to 
immunosenescence. It is possible that these baseline demographic factors 
contributed to the elevated miRNA expression in the PBMCs of HCV-infected 
subjects with cirrhosis independently of HCV infection. A cohort of age- and BMI-
matched controls with chronic liver disease secondary to NAFLD would have 
been a preferable control group. The feasibility of setting up such a cohort was 
explored to control for these factors, but ultimately was not felt possible within 
the time frame of the project.  
PBMCs are a heterogeneous population of cells, reflected in the variability of 
miRNA expression and lack of consistency in published miRNA studies involving 
PBMCs. The identification of endogenous miRNA controls unaffected by disease 
stage or genotype proved challenging. For instance, to aid analysis all TaqMan® 
MicroRNA Array cards are pre-loaded with 3 endogenous small non-coding RNA 
controls - RNU44, RNU48 and U6 sRNA. However, questions have been raised 
about the reliability of these endogenous controls and it has been demonstrated 
that expression of these housekeeping genes may be as variable as miRNA 
expression in tumour samples (Gee et al., 2011, Schwarzenbach et al., 2015). 
Levels of U6 sRNA have been shown to be highly variable in the serum, and are 
downregulated in the serum of patients with hepatic fibrosis (Marabita et al., 
2016, Benz et al., 2013). Concordantly, we found that their expression was 
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significantly altered in the context of CHC and cirrhosis, precluding their use. 
We were unable to identify a reliably expressed endogenous control miRNA that 
was not differentially expressed in the PBMCs of patients with CHC compared 
with healthy controls; all candidate control miRNAs suggested by the 
manufacturer demonstrated significant between-group differences, and the pilot 
study did not yield an alternative. This discovery was not made until after the 
RNA had been extracted, at which stage an exogenous ‘spike-in’ control could 
not be utilised. We were able to utilise global normalisation for the miRNA 
array, however this technique is only appropriate when profiling a large number 
of genes and could not be used for validation in the pilot cohort (Mestdagh et 
al., 2009). Consequently, although miRNA expression in the PBMCs of HCV-
infected subjects could be quantified and compared using endogenous miRNAs, 
we were unable to include healthy controls in our validation analysis. 
It is known that high concentrations (>10%) of the cryoprotectant dimethyl 
sulfoxide (DMSO) found in freezing media can reduce Taq DNA polymerase 
activity by up to 50% and it is possible that this contributed to the poorer miRNA 
transcript yield in the cryopreserved group (chapter 4.3.1). We also found that 
storage method affected the miRNA expression profile, although overall 
correlation between detected transcripts was acceptable. RNA extracted from 
the cryopreserved PBMCs demonstrated more advanced degradation in 
comparison to RNA extracted from PBMCs frozen in lysis buffer. Our results 
suggest that there is a marked benefit to suspending PBMCs intended for 
subsequent miRNA analysis immediately in lysis buffer prior to storage at -70oC 
rather than cryopreserving in liquid nitrogen. Additionally, the storage method 
utilised should be taken into consideration when interpreting miRNA arrays. We 
were required to use the cryopreserved samples for our pilot study, and this may 
have led to an underestimation of fold changes in our analysis. It is also possible 
that differences in the quality of RNA between cryopreserved samples led to an 
overestimation of between group differences. This may explain why we were 
unable to reproduce differences in PBMC miRNA expression between genotypes 
in the validation analysis. 
Finally, isolation of PBMCs requires separation from whole blood using density 
centrifugation and is time consuming. This limits their appeal as a source of 
biomarkers for use in clinical practice. As a consequence of these limitations and 
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despite interesting preliminary findings, further analysis using a larger bank of 
PBMC samples was not prioritised during this time period.  
Specific serum miRNA signatures have been described in CHC, and as with PBMC 
miRNA expression, have been associated with stage of disease and treatment 
outcome (Shrivastava et al., 2015). Serum is easily collected by centrifugation of 
whole blood that has been allowed to clot, making it an attractive and clinically 
relevant medium to study. We therefore next examined miRNA profiles in the 
serum of patients with CHC compared to healthy controls. 
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4.4 Serum miRNA expression in CHC 
4.4.1 Serum miRNA profile in CHC 
We first examined global miRNA expression in the serum of patients with CHC 
compared to healthy controls using the TaqMan® MicroRNA Array Cards (chapter 
2.2.2.1).  
We detected 423 of the 754 miRNAs examined in the serum of HCV-infected 
subjects (present in ≥ 2 biological replicates), compared with 344 in the healthy 
controls. Of the 272 miRNA transcripts which could be compared between the 
groups, we found that 47 were significantly differentially expressed in the serum 
of CHC patients with respect to healthy controls, and of those 27 demonstrated 
greater than two-fold change. Twenty-two miRNAs were significantly 
upregulated and 5 were significantly downregulated (figure 4-13, table 4-3).  
 
 
Figure 4-13: Volcano plot demonstrating p value against fold change for miRNAs deregulated 
in the serum of chronically HCV-infected subjects compared with healthy controls. Data 
points in red indicate miRNAs upregulated in CHC, and those in blue indicate 
downregulation. Fold change > 2 and p value < 0.05 were considered significant.  
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Table 4-3: MiRNA expression in the serum of HCV-infected subjects compared with healthy 
controls 
 MiRNA Fold change P value 
Increased in CHC miR-885-5p 8.57 0.0001 
miR-193a-5p 2.90 0.0001 
miR-193b-3p 3.86 0.0001 
miR-21-5p 2.25 0.0001 
miR-122-5p 4.19 0.0001 
miR-192-5p 4.00 0.0001 
miR-30d-5p 3.20 0.0001 
miR-34a-3p 3.95 0.0001 
miR-875-5p 6.47 0.0001 
miR-375 3.55 0.001 
miR-455-5p 3.29 0.003 
miR-1291 3.01 0.003 
miR-625-5p 2.79 0.004 
miR-99b-3p 2.83 0.009 
miR-224-5p 2.29 0.009 
miR-200b-3p 3.53 0.011 
miR-146b-3p 3.16 0.012 
miR-1244 3.82 0.014 
miR-126-5p 5.18 0.019 
miR-26a-1-3p 2.94 0.019 
miR-483-5p 5.77 0.024 
miR-182-5p 2.59 0.037 
Decreased in 
CHC 
miR-671-3p 0.48 0.004 
miR-411-3p 0.35 0.005 
miR-654-3p 0.36 0.009 
miR-486-5p 0.36 0.042 
miR-93-3p 0.44 0.049 
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To explore potential biological processes underlying the observed changes in 
extracellular miRNA expression between HCV-infected subjects and healthy 
controls, significantly deregulated miRNAs were analysed for pathway 
enrichment (figure 4-14). As with PBMC miRNA expression, we found that 
pathways in cancer were the most significantly enriched by extracellular miRNAs 
deregulated in CHC. MicroRNAs in cancer had the highest enrichment in HCV-
infected samples, followed by proteoglycans in cancer, colorectal cancer, 
pathways in cancer and viral carcinogenesis.  
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Figure 4-14: In silico pathway analysis for miRNAs significantly deregulated in the serum of 
HCV-infected subjects. Red bars indicate number of miRNAs involved in each pathway and 
blue bars indicate the number of genes. The y axis demonstrates significantly enriched KEGG 
pathways sorted according to a descending enrichment statistical score (–ln P).  
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4.4.2 Intergenotypic differences in serum miRNA expression 
Previous studies have demonstrated significant differences in serum and PBMC 
miRNA expression between HCV Gt1 and Gt3 infected patients (Shwetha et al., 
2013, Chang et al., 2014). However, we were unable to identify intergenotypic 
differences using the PBMCs in this study (chapter 4.3.3). We hypothesised that 
differences in miRNA regulation detected in serum rather than PBMCs from our 
patient cohort may explain phenotypic differences between genotypes. 
We detected 394 miRNA transcripts in the serum of Gt1-infected subjects 
compared with 360 miRNA transcripts in Gt3 infection. We compared miRNA 
expression between Gt1- and Gt3-infected individuals and found that 5 miRNAs 
were significantly upregulated in Gt3 infection compared with Gt1 infection: 
miR-145-5p, miR-196b-5p, miR-500a-5p, miR-140-3p and miR-186-5p. A further 4 
miRNAs were significantly downregulated: miR-130a-3p, miR-142-3p, miR-151-5p 
and miR-145-3p (table 4-4). 
Table 4-4: Intergenotypic differences in serum miRNA expression 
 MiRNA Fold change P value 
Increased in Gt1 
infection 
miR-130a-3p 2.28 0.002 
miR-142-3p 2.06 0.005 
miR-151-5p 4.46 0.009 
miR-145-3p 2.02 0.043 
Increased in Gt3 
infection 
miR-145-5p 2.49 0.007 
miR-196b-5p 2.29 0.01 
miR-500a-5p 2.29 0.02 
miR-140-3p 3.56 0.02 
miR-186-5p 5.72 0.04 
 
We next subdivided the HCV infected subjects by genotype, and compared each 
group to the healthy controls to identify genotype-specific extracellular miRNA 
expression patterns.  
We found that 23 miRNAs were significantly upregulated in the serum of HCV Gt1 
infected patients (n=13) compared to healthy controls (n=8): miR-21-5p, miR-
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193a-5p, miR-885-5p, miR-375, miR-660-5p, miR-455-5p, miR-483-5p, miR-193b-
3p, miR-29c-3p, miR-122-5p, miR-100-5p, miR-182-5p, miR-101-3p, miR-130a-3p, 
miR-192-5p, miR-362-3p, miR-362-5p, miR-30d-5p, miR-875-5p, miR-34a-3p, 
miR-126-5p, miR-26a-1-3p and miR-99b-3p. A further 4 miRNAs were significantly 
downregulated: miR-671-3p, miR-486-5p, miR-654-3p and miR-93-3p. 
Sixteen miRNAs were significantly upregulated in the serum of Gt3 infected 
patients (n=12): miR-192-5p, miR-193b-3p, miR-885-5p, miR-625-5p, miR-193a-
5p, miR-200b-3p, miR-122-5p, miR-186-5p, miR-146b-3p, miR-224-5p, miR-375, 
miR-365a-3p, miR-30d-5p, miR-34a-3p, miR-1291 and miR-875-5p. Two miRNAs 
were significantly downregulated: miR-654-3p and miR-486-5p.  
Eleven miRNAs were significantly deregulated in both genotypes, and 
demonstrated similar patterns of expression (miR-193a-5p, miR-885-5p, miR-375, 
miR-486-5p, miR-654-3p, miR-193b-3p, miR-122-5p, miR-192-5p, miR-30d-5p, 
miR-875-5p and miR-34a-3p). 
Serum miRNA expression was similar between genotypes in the cohort. As a 
consequence, further exploration of inter-genotypic differences in extracellular 
circulating miRNA expression was not deemed to be worth pursuing with more 
samples. 
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4.4.3 Correlation between serum miRNA expression, disease stage 
and biomarkers of ageing in CHC 
One objective of this study was to identify candidate miRNAs which could be 
used as alternative prognostic biomarkers in CHC. Cellular and immune 
senescence is associated with increased disease severity and poorer response to 
treatment in HCV-infected individuals (Hoare et al., 2010b, Manfras et al., 
2004). We hypothesised that by correlating miRNA expression with biomarkers of 
immunosenescence we could identify novel prognostic biomarkers for non-
cirrhotic HCV-infected individuals at higher risk of disease progression.  
We therefore stratified miRNA expression by disease stage (presence or absence 
of cirrhosis) and bio-age (as described in section 4.2.1). We examined patterns 
of expression, specifically looking for miRNAs that demonstrated differential 
regulation in the cirrhotic and high bio-age groups compared to the low bio-age 
and healthy control patients.  
Five miRNAs were significantly elevated in all HCV-infected patient groups 
compared to healthy controls: miR-885-5p, miR-122-5p, miR-193a-5p, miR-193b-
3p and miR-30d-5p. A further 12 miRNAs were significantly upregulated in the 
serum of cirrhotic patients (miR-21-5p, miR-625-5p, miR-375, miR-150-5p, miR-
186-5p, miR-140-3p, miR-99b-3p, miR-1291, miR-320a, miR-146b-3p, miR-192-5p 
and miR-34a-3p) and 3 miRNAs were significantly downregulated (miR-454-5p, 
miR-16-1-3p and miR-411-3p) compared with healthy controls. Five miRNAs were 
significantly elevated in the cirrhotic but not the non-cirrhotic patients (miR-
625-5p, miR-150-5p, miR-186-5p, miR-140-3p and miR-320a). 
Excluding the 5 miRNAs elevated in all patient groups, a further 10 miRNAs were 
significantly upregulated in the serum of ‘high bio-age’ patients (miR-21-5p, 
miR-146b-3p, miR-192-5p, miR-34a-3p, miR-200b-3p, miR-183-5p, miR-363-3p, 
miR-19a-3p, miR-126-5p and miR-875-5p) and 5 were downregulated (miR-671-
3p, miR-28-3p, miR-191-3p, miR-181a-2-3p and miR-93-3p). Three miRNAs were 
significantly altered in both the cirrhotic and the high bio-age group (miR-146b-
3p, miR192-5p and miR-34a-3p).  
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Finally, 3 additional miRNAs were significantly upregulated in the low bio-age 
group (miR-875-5p, miR-455-5p and miR-182-5p) and 4 miRNAs were 
downregulated (miR-576-3p, miR-93-3p, miR-590-5p and miR-411-3p) compared 
to the control group. Only 1 miRNA was common to the cirrhotic and low bio-age 
group (miR-411-3p); it was significantly downregulated in both.  
Both miR-21-5p and miR-146b-3p were significantly elevated in the cirrhotic and 
the high bio-age group, but not the low bio-age group. Additionally, miR-885-5p 
expression was significantly increased in the cirrhotic and high bio-age groups 
(RQ 14.7 and 6.6 respectively), although it was also elevated in the low bio-age 
group (RQ=5.6). MiR-122-5p was significantly upregulated in all CHC patients 
compared to healthy controls, and showed a negative correlation with disease 
stage and biological age (table 4-5). These miRNAs were identified as potential 
biomarkers and selected for validation with quantitative RT-PCR.  
Table 4-5: Fold change of selected miRNAs in the serum of HCV-infected subjects stratified 
by disease stage, compared to healthy controls 
 Fold change compared to healthy controls 
Cirrhosis High bio-age Low bio-age 
miR-885-5p 14.66 6.55 5.63 
miR-122-5p 3.19 3.87 6.40 
miR-21-5p 2.45 2.47 1.96 
miR-146b-3p 4.93 3.38 1.90 
 
 
As proof of principle and to explore potential biological processes underlying the 
observed differences in extracellular miRNA expression according to bio-age 
between non-cirrhotic HCV-infected subjects, and between cirrhotic and non-
cirrhotic individuals, we performed in silico pathway analysis for the miRNAs 
significantly deregulated in each patient group (figure 4-15). We observed that 
canonical pathway enrichment was similar between cirrhotic subjects and non-
cirrhotic, immunosenescent individuals with potential implications for the 
clinical management of these subjects. 
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Figure 4-15: Comparison of pathway analyses for miRNAs deregulated in the serum of 
cirrhotic (dark blue), high bio-age (light blue) and low bio-age (turquoise) subjects.  
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In our pilot cohort, miR-885-5p showed significant upregulation in both cirrhotic 
(p=0.0008) and high bio-age patients (p=0.0132). MiR-122-5p was significantly 
upregulated in all patient groups compared to healthy controls (figure 4-16). As 
in the PBMC analysis, we observed high individual biological variance in serum 
miRNA expression. 
 
Figure 4-16: Expression of miR-21-5p, miR-122-5p and miR-885-5p in the serum of healthy 
controls and HCV-infected subjects with low bio-age, high bio-age and cirrhosis. Dot plot 
graphs depict mean/median expression +/- 95% CI; *p<0.05, **p<0.01, ***p<0.001, ns=non-
significant.  
 
 
4-192 
 
MiR-21-5p showed a non-significant trend towards upregulation in cirrhotic and 
high bio-age patients compared to healthy controls. However, miR-21-5p was 
significantly higher when comparing all high risk patients (cirrhotic and high bio-
age patients) to low risk patients (low bio-age and healthy controls) (p=0.0232, 
figure 4-17). 
 
Figure 4-17: Expression of miR-21-5p in the serum of ‘low risk’ (HCV-infected low bio-age 
patients and healthy controls) and ‘high risk’ (HCV-infected cirrhotic and high bio-age 
patients) subjects. Dot plot graphs depict mean expression +/- 95% CI; *p<0.05.  
 
Although miR-146b-3p correlated with disease stage and biological age in the 
initial miRNA screen, amplification was inconsistent in the validation analysis 
and this miRNA was not pursued further as a biomarker. 
Next, we examined the use of miR-21-5p, miR-122-5p and miR-885-5p as 
biomarkers of cirrhosis in a larger bank of patient samples (described in section 
4.2.2). 
MiR-122-5p and miR-885-5p were significantly elevated in the serum of patients 
with cirrhosis secondary to HCV infection, and miR-885-5p was also elevated in 
non-cirrhotic HCV-infected patients compared with healthy controls (figure 4-
18). Although there was a trend towards higher expression of miR-885-5p in 
cirrhotics vs. non-cirrhotics, we did not demonstrate significant differences in 
miRNA expression between cirrhotic and non-cirrhotic HCV-infected patients in 
this cohort (figure 4-18). 
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Figure 4-18: Expression of miR-21-5p, miR-122-5p and miR-885-5p in the serum of healthy 
controls (n=10) and HCV-infected subjects with (n=15) or without (n=36) hepatic cirrhosis. 
Dot plot graphs depict mean/median expression +/- 95% CI; *p<0.05, **p<0.01, ****p<0.0001, 
ns=non-significant.  
Cirrhotic patients were found to be significantly older at enrolment (48yrs vs 
41yrs, p=0.004) and to have higher BMI (27.4kg/m2 vs 24.3kg/m2, p=0.004). 
CDKN2A and ARF mRNA expression was significantly elevated in the PBMCs of 
HCV-infected subjects with cirrhosis, as known (Robinson et al., 2013).  
The relationship between miRNA expression, CDKN2A expression, liver stiffness 
and additional laboratory variables was examined further in correlation analyses. 
As previously described (Robinson et al., 2013), we found that CDKN2A mRNA 
expression correlated significantly with that of the related transcripts CDKN2B 
(r=0.636, p<0.001) and ARF (r=0.907, p<0.001).  
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MiR-21-5p expression correlated with that of miR-122-5p (r=0.599, p<0.001) and 
miR-885-5p (r=0.777, p<0.001). There was also significant correlation between 
miR-122-5p and miR-885-5p expression (r=0.646, p<0.001). 
All 3 miRNAs correlated weakly but significantly with CDKN2A, CDKN2B and ARF 
mRNA expression (figure 4-19). Of the 3 miRNAs, miR-885-5p correlated most 
strongly with CDKN2A mRNA expression (r=-0.369, p=0.008); miR-885-5p also 
correlated significantly with ALT (r=-0.355, p=0.005). 
 
Figure 4-19: PBMC CDKN2A expression significantly correlates with serum miR-21-5p, miR-
122-5p and miR-885-5p expression. Panels show XY correlation plots with linear regression 
curve fitted. 
Liver stiffness correlated with age (r=0.388, p=0.006) and expression of CDKN2A 
(r=0.406; p=0.009), CDKN2B (r=0.489, p=0.001) and ARF (r=0.495, p=0.001). We 
also found that CDKN2A mRNA expression correlated weakly but significantly 
with age (r=0.283, p=0.044) and BMI (r=0.313, p=0.029).  
We did not find significant correlation between miRNA expression and liver 
stiffness in this expanded cohort. Additionally, there were no significant 
differences in the expression of selected miRNAs between viral or host IFNL3 
genotypes.  
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Interestingly, in a more strictly controlled comparison in which missing data 
were handled by listwise deletion (n=39), miR-122-5p expression positively 
correlated with HCV RNA (r=-0.373, p=0.019). This is consistent with findings in 
the literature: MiR-122 is required for HCV replication (chapter 1.1.5.2) and miR-
122 level has been shown to correlate with HCV viral load during DAA therapy 
(Waring et al., 2016).  
We used a two stage approach to identify factors associated with cirrhosis in our 
cohort. Univariate statistical tests were performed to assess key risk factors for 
potential associations (chapter 2.3). Models were then fitted for factors 
significant at the 10% level using multiple logistic regression analysis and 
reviewed.  
As data on CDKN2 locus transcription were only available for a limited number of 
patients in the expanded cohort and to avoid bias in the model, 2 analyses were 
performed. The first analysis included all HCV-infected patients (n=51) and 
CDKN2 transcript expression was excluded. In the univariate analysis, older 
chronological age (p=0.004) and higher BMI (p=0.005) were significantly 
associated with the presence of cirrhosis (table S9). These factors remained 
significantly associated with cirrhosis in multivariate analysis. A model 
containing chronological age and BMI correctly classified 81.6% of individuals and 
explained 40.4% of variation in the dependent variable. The model was 
statistically significant (Χ2 = 16.5, p<0.001). The inclusion of ALT (significant at 
the 10% level in univariate analysis) did not significantly improve the model 
(p=0.279) (table S10). A ROC curve analysis was performed using predicted 
probabilities for this model and demonstrated an AUC of 0.839 (95% CI: 0.717-
0.962, p<0.001). 
The second analysis included only patients who had had their CDKN2 locus status 
determined (n=40). In the univariate analysis, older chronological age (p=0.002), 
higher BMI (p=0.003), higher ALT levels (p=0.012), and both elevated PBMC 
CDKN2A mRNA (p=0.007) and ARF mRNA (p=0.006) expression were significantly 
associated with cirrhosis (table S11). Given the correlation between CDKN2A and 
ARF expression and to avoid collinearity bias, models were fitted using each 
transcript independently and in combination (unified into a single variable 
‘CDKN2 transcript expression’; high transcript expression was classified as either 
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CDKN2A expression ≥ 2 fold higher than healthy controls, or ARF expression ≥ 2 
fold higher than healthy controls, or both).  
A model containing chronological age, BMI and ALT correctly classified 92.1% of 
cases, and explained 69.4% of the variation in the dependent variable. The 
model was statistically significant (Χ2 = 26.5, p<0.001). Neither the inclusion of 
CDKN2 transcript expression nor the individual biomarkers significantly improved 
the diagnostic accuracy of the model (p=0.200) (table S12). Although inclusion of 
ALT improved the overall fit of the model, it was not significantly associated 
with cirrhosis when controlling for age and BMI (p=0.052). A ROC curve analysis 
was also performed using predicted probabilities for the final model (containing 
chronological age, BMI and ALT) and demonstrated an AUC of 0.935 (p<0.001, 
95% CI 0.849 – 1.000).  
Validated miRNAs were explored as potential diagnostic biomarkers using ROC 
curve analysis. We first examined the accuracy of each miRNA for the diagnosis 
of HCV infection. The AUCs for miR-21-5p, miR-122-5p and miR-885-5p were as 
follows: 0.620 (95% CI: 0.453 – 0.787, p=0.235), 0.733 (95% CI: 0.593 – 0.874, 
p=0.02) and 0.855 (95% CI: 0.751 – 0.959, p<0.001) respectively.  
We next compared individual miRNAs with ALT and CDKN2 transcript expression 
as potential diagnostic biomarkers for the presence of cirrhosis in CHC. None of 
the selected miRNAs nor ALT performed well as diagnostic biomarkers for 
cirrhosis (table S13). CDKN2A and ARF mRNA expression appeared to have better 
diagnostic potential. A fold change of ≥ 1.97 in PBMC CDKN2A mRNA expression 
was associated with a sensitivity of 84.6% and specificity of 66.7% in the 
diagnosis of cirrhosis in CHC, whilst a fold change of ≥ 7.19 in PBMC ARF mRNA 
expression was associated with 61.5% sensitivity and 85.1% specificity (cut-offs 
calculated according to highest Youden index). 
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4.4.4 Functional analysis of selected miRNAs in silico 
We analysed protein-protein interactions for the genes targeted by miR-122-5p 
and miR-21-5p to gain insights into potential in vivo functions. The predicted 
protein-protein interactions for miR-885-5p target genes have been documented 
previously (chapter 4.3.5). 
MiR-122-5p is a well characterised miRNA. We identified a total of 248 validated 
target genes (figure 4-20). We found that viral carcinogenesis was the most 
significantly enriched canonical pathway, including 10 of the validated miR-122 
target genes: BAX, CDK4, CREB1, GTF2B, GTF2H2, PKM, RAC1, RHOA and SRF. 
The hypoxia-inducible transcription factor-1 (HIF-1) signalling pathway (through 
genes AKT3, ALDOA, HMOX1, IGF1R, PFKFB2 and VHL), AMP-activated protein 
kinase (AMPK) signalling pathway (AKT3, CREB1, G6PC3, GYS1, IGF1R, PFKFB2 
and PRKAB1) and insulin signalling pathway (through AKT3, G6PC3, GYS1, PHKA1, 
PRKAB1, PTPN1 and SOCS1) were also significantly enriched. Insulin resistance is 
thought to be more common in CHC, and has been shown to correlate with 
serum HCV RNA level, suggesting that viral replication promotes IR (Moucari et 
al., 2008). Additionally, HIFs are thought to regulate hepatic lipogenesis 
although the exact role of each factor is unclear, and data are conflicting 
(Jungermann and Kietzmann, 2000). It has also been suggested that HIF-
dependent changes in hepatocyte metabolism may favour viral transmission and 
replication (Wilson et al., 2014).  
In the case of miR-21-5p, we identified 83 experimentally validated target 
genes, including BCL2, BMPR2, CDC25A, E2F1, EGFR, ERBB2, HNRNPK, MARCKS, 
PDCD4, PTEN, RECK, SERPINB5, SPRY2, STAT3, TIMP3, TP63, VEGFA. Target 
genes connected to a network are shown on the diagram below (figure 4-21). 
The most significantly enriched biological pathway is regulation of molecular 
function, and pathways in cancer are again highly represented. The 5 most 
significantly enriched KEGG pathways are microRNAs in cancer, pathways in 
cancer, pancreatic cancer, proteoglycans in cancer and the FoxO signalling 
pathway.  
 
4-198 
 
 
Figure 4-20: Predicted protein-protein interactions for miR-122-5p target genes. Networks 
are clustered according to the Markov cluster algorithm (inflation factor 3); strength of 
association is shown by the line thickness: dotted lines indicate weaker support. Proteins 
involved in the viral carcinogenesis pathway are highlighted in red. 
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Figure 4-21: Predicted protein-protein interactions for miR-21-5p target genes. Networks are 
clustered according to the Markov cluster algorithm (inflation factor 3); strength of 
association is shown by the line thickness: dotted lines indicate weaker support. Proteins 
involved in the microRNAs in cancer pathway are highlighted in red. 
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4.4.5 MiRNA expression in the exosomes of patients with CHC 
We examined the expression of miR-21-5p, miR-122-5p and miR-885-5p in the 
exosomes of matched serum samples in order to identify whether our candidate 
biomarker miRNAs were associated with membrane vesicles.  
Quantitative analysis was not possible as the endogenous control miR-574-3p had 
not been validated for use with exosomes and therefore unadjusted CT values 
are shown. All 3 miRNAs were detected within the exosomes of patients with 
chronic HCV. MiR-122-5p and miR-885-5p were expressed at significantly lower 
levels in the exosome fractions compared to whole serum, however miR-21-5p 
expression was not significantly different between groups (figure 4-22).  
 
Figure 4-22: Expression of miR-21-5p, miR-122-5p and miR-885-5p expression in the serum 
and exosomes of 8 HCV-infected patients. Dot plot graphs depict mean expression +/- 95% CI; 
**p<0.01, ***p<0.001, ns = non-significant.  
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4.4.6 Discussion 
In our pilot study, we identified a panel of miRNAs that showed significantly 
elevated expression in the serum of patients with CHC. Of these, we identified 3 
miRNAs that correlated with disease stage and bio-age which we hypothesised 
could be used to identify individuals at higher risk of disease progression: miR-
21-5p, miR-122-5p and miR-885-5p. Consistent with previous studies (Waring et 
al., 2016), we did not demonstrate significantly different miR-122-5p expression 
between Gt1 and Gt3 infection. MiR-21-5p and miR-885-5p levels were also 
similar between genotypes, suggesting that they are suitable for use as 
biomarkers in both Gt1 and Gt3 HCV-infected patients.  
We found that miR-21-5p, miR-122-5p and miR-885-5p were all expressed within 
exosomes. The extracellular circulating miRNA population is heterogeneous, and 
both immune and non-immune cells are thought to release miRNAs into 
extracellular environments. MiRNAs may be released actively or passively, and it 
is thought that miRNAs contained within exosomes play a role in cell-cell 
communication and act as ‘hormones’ to regulate gene expression in target 
cells, whereas protein-bound miRNAs are released passively into the circulation 
on cell death. Interestingly, miR-122-5p and miR-885-5p were downregulated in 
the exosome fraction compared to whole serum whilst miR-21-5p was expressed 
at the same level in both groups. This may indicate that miR-21-5p is 
predominantly exosome-bound in the serum whereas miR-122-5p and miR-885-5p 
are mainly released passively into the circulation following cell death. The 
correlation between ALT and miR-885-5p adds some support to this hypothesis, 
although the same association was not seen with miR-122-5p. Of note, miR-885-
5p demonstrates the same pattern of deregulation in the PBMC compartment 
and serum of individuals with CHC. This is intriguing, and suggests that PBMCs 
may be an additional source of circulating miR-885-5p in CHC. 
We have demonstrated that miR-885-5p is upregulated in the serum of HCV-
infected individuals, regardless of disease stage. We identified a trend towards 
increased miR-885-5p expression in cirrhotic compared with non-cirrhotic HCV-
infected patients, as seen in the PBMCs (chapter 4.3.4), but this failed to reach 
significance (fold change 9.8 vs 5.0; p=0.160). We also found that miR-885-5p 
correlated with both ALT and CDKN2 transcript expression. 
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MiR-885-5p has tumour suppressor functions (chapter 4.3.6), and elevated 
circulating miR-885-5p expression has previously been described in association 
with liver cirrhosis and HCC (Gui et al., 2011). In CHC, HCC is thought to develop 
as a consequence of chronic inflammation and liver cell proliferation resulting 
from oxidative stress and cytokine signalling (chapter 1.3.1). Cellular 
proliferation is usually tightly regulated, and tumour suppressor genes function 
to limit inappropriate cell growth and metastasis. Mutations in these genes or 
alterations in cancer signalling pathways may result in oncogenesis.  
There is increasing evidence to support a direct role for HCV proteins in 
modulating cancer pathways (Levrero, 2006). Transfection of a hepatoma cell 
line with HCV core protein resulted in marked upregulation of genes involved in 
oncogenic signalling, particularly Wnt-1 and its downstream target gene WISP-2, 
leading to increased proliferation, cell cycle progression and DNA synthesis 
(Fukutomi et al., 2005). MiR-885-5p is able to inhibit Wnt/Β-catenin signalling 
(Zhang et al., 2016) highlighting the importance of its role as a tumour 
suppressor in chronic liver disease, particularly in the context of HCV infection.  
Hepatocarcinogenesis has also been associated with deregulation of a number of 
other pathways regulating cell death or proliferation, including p53 and TGF-Β. 
Mutations and hypermethylation of the p16INK4A gene have also been described 
in HCC (Liew et al., 1999). The risk of HCC is increased by factors including 
alcohol ingestion, metabolic liver disease and co-infection with other 
hepatotropic viruses (chapter 1.3.2).  
The onco-miR miR-21 is thought to play a critical role in suppressing IFN-induced 
apoptosis through downstream targeting of PTEN and AKT. Upregulation of miR-
21 results in a suppression of PTEN expression and increased phosphorylation of 
FAK, a downstream target of PTEN, with consequent deregulation of cell cycle 
progression and cell migration (Meng et al., 2007). Bihrer et al. (2011b) found 
that serum miR-21-5p expression correlated with ALT level, markers of liver 
synthetic expression and hepatic necro-inflammatory activity in CHC. In our pilot 
study, we found that serum miR-21-5p expression was increased in high risk vs. 
low risk subjects. However, we were unable to demonstrate differences in miR-
21-5p expression between groups in our expanded cohort.  
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MiR-122-5p is also upregulated in the serum of cirrhotic HCV-infected individuals 
and appears to weakly correlate with HCV viral load, as described by Kumar et 
al. (2014). Expression was not significantly altered between HCV-infected non-
cirrhotic patients and healthy controls. MiR-122-5p is a commonly described 
biomarker of liver injury, serum expression of which has been shown to correlate 
with hepatic necro-inflammation in both HBV and HCV infection (Waidmann et 
al., 2012b, Bihrer et al., 2011a).  
Similarly to miR-885-5p, miR-122-5p is thought to have tumour suppressor 
properties. MiR-122-5p knockdown in a mouse model results in the development 
of hepatosteatosis and liver tumours resembling HCC (Hsu et al., 2012). MiR-122 
binds to PKM2, resulting in increased apoptosis and reduced cell migration and 
invasion in vitro (Xu et al., 2015). Consistent with the mouse model, miR-122 is 
significantly downregulated in tumour tissue when compared to para-cancerous 
tissue, and low miR-122 expression in HCC is independently associated with poor 
3-year survival (Xu et al., 2015).  
The association of circulating miR-122-5p expression with disease stage is less 
clear; Bihrer and colleagues (2011a) found no association with fibrosis stage 
whereas other groups have described a negative correlation between serum miR-
122 expression and fibrosis stage, as seen in our pilot cohort (Waidmann et al., 
2012c, Marquez et al., 2010, Trebicka et al., 2013). There appears to be a two-
phase pattern of circulating miR-122-5p expression during fibrosis progression; 
miR-122 is elevated during early fibrosis when there is high necro-inflammatory 
activity, and decreased in more advanced ‘burnt-out’ cirrhosis (Trebicka et al., 
2013). It is hypothesised that in advanced cirrhosis, reduced serum miR-122 
expression may reflect a loss of hepatocytes and less functional hepatic 
capacity.  
Analysis of protein-protein interactions suggested that the HIF signalling 
pathway, insulin signalling pathway and the AMPK signalling pathway were 
significantly enriched by genes targeted by miR-122-5p. Hypoxia is a common 
feature of solid tumours, and results in induction of the transcription factor HIF-
1, promoting cell migration and invasion (Ye et al., 2017). Transfection of HCV 
core into a hepatoma cell line resulted in overexpression of HIF-1α and induction 
of VEGF, an important regulator of angiogenesis in neoplasia (Zhu et al., 2014b). 
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Loss of miR-122 in the liver (which correlates with increased serum expression) 
also results in an upregulation of HIF-1α (Ambade et al., 2016), supporting its 
role as a tumour suppressor in CHC.  
HCV infection is known to inhibit the insulin signalling pathway, and promotes IR 
through suppression of PTEN (possibly mediated by increased miR-21-5p 
expression) and increased phosphorylation of IRS-1 (Gao et al., 2015). 
Transfection of Huh7.5 cells with the viral NS5A alone was associated with 
increased phosphorylation of IRS-1 and enhanced expression of molecules 
involved in gluconeogenesis (Parvaiz et al., 2015). IRS-1 phosphorylation results 
in activation of the downstream PI3K and MAPK pathways and suppression of 
apoptosis (Tanaka et al., 1997), promoting cell survival and oncogenesis.  
One striking observation was that non-cirrhotic subjects with higher biological 
age (i.e. increased PBMC CDKN2A expression) behaved similarly to the cirrhotic 
subgroup in terms of pathway enrichment. Our findings suggest that these 
subjects may be at an increased risk of oncogenesis. Consequently, a watchful 
waiting approach may not be appropriate in HCV-infected individuals with a high 
bio-age regardless of liver stiffness. Ongoing clinical monitoring is not currently 
recommended for individuals with normal liver stiffness in whom treatment is 
successful, and who have no additional liver-related comorbidity. It is possible 
that subjects with high biological age may be at ongoing risk of hepatic and 
extra-hepatic disease despite HCV eradication, and may benefit from a period of 
surveillance post treatment. Further study is needed to determine whether 
markers of immunosenescence improve with viral eradication, and whether 
elevated BoA correlate with adverse clinical outcomes.  
We did not identify significant differences between selected miRNA expression in 
the serum of HCV-infected subjects with and without cirrhosis. Additionally, we 
did not demonstrate a difference in miR-21-5p expression between healthy 
controls and HCV-infected subjects with or without cirrhosis. This may reflect 
limited statistical power due to sample size; our study would benefit from the 
inclusion of a greater number of cirrhotic patients and healthy controls. 
However, we were reliant on a previously characterised cohort with limited 
biological material available.  
4-205 
 
We found that the chronological age and BMI were significantly associated with 
cirrhosis. Schwabl and colleagues (2017) previously showed that the presence of 
hepatic steatosis was associated with persistent histological necro-inflammation 
and elevation of fibrogenic and angiogenic biomarkers following SVR in HIV/HCV 
infected subjects. In our study, both BMI and age correlated with CDKN2A 
transcript expression. Our data support previous studies which have 
demonstrated that chronological age has a negative impact on disease 
progression in CHC (chapter 1.3.2.1) (Grebely and Dore, 2011). Interestingly, 
although we had excluded subjects with obesity (BMI > 30kg/m2) and features of 
the metabolic syndrome, we still found that BMI was an independent predictor 
of fibrosis in CHC. This finding is in concordance with that of Friedenberg et al. 
(2003) who demonstrated that BMI was an independent risk factor for fibrosis. 
The finding that even a moderate increase in BMI is significantly associated with 
cirrhosis when compared to BMI within the normal range highlights the 
importance of weight reduction interventions in clinical practice. Furthermore, 
the correlation of BMI with PBMC CDKN2A expression supports the association 
between obesity and immunosenescence. 
Obesity is associated with chronic immune activation, promoting inflamm-aging. 
An increase in adipose tissue is associated with IR, telomere shortening and p53 
activation, leading to an increased incidence of age-associated illness, including 
cancer (Renehan et al., 2008) and atherosclerosis (Ellulu et al., 2017). Obesity is 
also associated with B cell dysfunction and reduced antibody responses, as seen 
with increasing age. Regardless of age, B cells from obese individuals 
demonstrate a pre-activated phenotype and secrete more pro-inflammatory 
TNF-α and IL-6, and less IL-10, in comparison to B cells from lean individuals 
(Frasca et al., 2017).  We did not previously find a correlation between BMI and 
PBMC miR-16-5p or miR-155-5p expression as may have been expected given the 
correlation with B cell dysfunction (Frasca et al., 2015), but this may again 
reflect limited statistical power due to sample size, and the exclusion of 
subjects with BMI > 30 kg/m2.  
Higher BMI is associated with a poorer virologic response to IFN and RBV therapy 
(Bressler et al., 2003), although Todorovska and colleagues (2017) found that 
this signal disappeared when controlling for age, genotype, IR and inflammatory 
change in the liver. The effect of BMI on treatment outcomes with DAAs is less 
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clear, and data are conflicting. Fox and colleagues (2017) failed to demonstrate 
an association between BMI and response rate, whereas BMI > 30kg/m2 was 
found to be significantly associated with virologic failure in the EAP study 
(Cheung et al., 2016). Our findings suggest that immunosenescence secondary to 
chronic immune activation may contribute to the poorer treatment responses 
seen in individuals with a high BMI. Weight loss has been shown to reduce the 
number of senescent cells (Sen-Β-Gal positive) in white adipose tissue in a mouse 
model (List et al., 2016), and caloric restriction has been shown to slow 
measures of biological ageing in humans independent of changes in weight 
(Belsky et al., 2017). Further studies are warranted to explore whether weight 
reduction results in reversal of immunosenescence in individuals with CHC.  
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4.5 Cellular miRNA response to IFN stimulation in vitro 
We have identified changes in the abundance of miRNAs in serum and peripheral 
immune cells that are likely surrogates for changes in the liver. The mechanism 
underlying the higher levels of some miRNAs is not known, but could result from 
HCV infection, modifiable factors and non-modifiable factors.  
It is possible that the host response to infection may drive miRNA expression. 
One of the key host responses to infection is the IFN response (chapter 1.2); HCV 
infection results in the expression of higher levels of ISG transcripts, and it is 
possible that this may drive circulating and hepatic miRNA expression. Given 
that ISG mRNA transcription is altered by the IFN response to infection, we 
developed a model to examine whether miRNAs are regulated by IFN in liver-
derived cells. 
We selected the onco-miR miR-21-5p for the pilot study to explore the feasibility 
of this approach as it is known to be induced by type I IFNs in vitro (Yang et al., 
2015). We also explored whether ISG15, a gene involved in post-translational 
modification, affected the response to IFN stimulation.  
4.5.1 Induction of miR-21-5p by IFN-α in a hepatoma cell line is 
inhibited by ISG15 knockdown 
We analysed miR-21-5p expression in a hepatoma cell line in response to IFN-α 
and poly (I:C) stimulation. We found that expression of miR-21-5p was 
significantly increased in IFN-α and poly (I:C) stimulated cells in comparison to 
mock-treated cells (figure 4-23). This corresponds with previous reports 
demonstrating that miR-21 expression is induced by IFN-α stimulation in a 
number of cell lines (Yang et al., 2010). Interestingly, when we performed the 
same experiment in an ISG15 knockout HepaRG cell line as proof of principle, we 
found that the increase in miR-21-5p in response to IFN-α was abrogated, and 
the response to poly (I:C) treatment was markedly reduced (figure 4-23).  
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Figure 4-23: Expression of miR-21-5p in wild type HepaRG and ISG15-/- HepaRG cell lines in 
response to mock-treatment, IFN-α treatment and poly (I:C) stimulation. Dot plot graphs 
depict mean expression +/- 95% CI; *p<0.05, **p<0.01, ****p<0.0001, ns = non-significant.  
Our data indicate that miR-21 induction is partly dependent on ISG15 signalling, 
as miR-21 induction in response to IFN-α and poly (I:C) stimulation was largely 
abrogated in the ISG15 KO cell line.  
4.5.2 Discussion 
This pilot study has proven the feasibility of studying the miRNA response to IFN 
signalling in vitro, and may be a useful tool for exploring miRNA deregulation in 
host processes.  
ISG15 modulates host antiviral responses through ‘ISGylation’ of viral and host 
proteins and inhibition of virus release, and is thought to result in positive 
regulation of type I IFN signalling. ISG15 also targets many proteins involved in 
the innate immune response to viral infection, including RIG-I, JAK1, STAT1 and 
other ISGs (Morales and Lenschow, 2013). It is dependent on STAT3 for 
induction, similarly to miR-21 (Mahony et al., 2017). In support of an antiviral 
role for ISG15, ISG15-/- mice have been shown to be susceptible to influenza A 
and influenza B, herpes simplex virus and Sindbis virus (Lenschow et al., 2007). 
However, the same susceptibility has not been described with lymphocytic 
choriomeningitis virus or vesicular stomatitis virus (Osiak et al., 2005).  
Counterintuitively, individuals born with inactivating ISG15 mutations do not 
present with increased susceptibility to viral infection, but are susceptible to 
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environmental mycobacterial infection as a consequence of impaired IFN-γ 
immunity, and demonstrate an autoimmune phenotype (Zhang et al., 2015, 
Bogunovic et al., 2012). Cells from ISG15 deficient patients demonstrated 
prolonged induction of ISGs in response to infection with highly pathogenic 
viruses, supporting a proviral role for ISG15 in humans (Speer et al., 2016). 
The role of ISG15 in the response to HCV infection is unclear. Various groups 
have shown that knockdown of ISG15 expression is associated with increased 
HCV replication in a number of cell lines (Jones et al., 2010, Domingues et al., 
2015). In contrast, Broering and colleagues (2010) found that short- or long-term 
knockdown of ISG15 was associated with suppression of HCV replication, and it 
has been proposed that increased ISG15/ISGylation may promote HCV infection 
(Chen et al., 2010). Early PKR-dependent induction of ISG15 may inhibit RIG-I 
ubiquitination, blocking subsequent HCV RNA-mediated RIG-I activation and 
leading to negative regulation of the host immune response and promotion of 
HCV replication (Arnaud et al., 2011).  
Upregulation of miR-21 (Chen et al., 2013) is able to abrogate the type I IFN-
mediated antiviral response through suppression of MyD88 and IRAK1 expression, 
whereas knockdown of miR-21 expression has been shown to sensitise cells to 
IFN-induced antiviral activity against vesicular stomatitis virus (Yang et al., 
2015). MiR-21 blocks PDCD4, a negative regulation of IL-10, resulting in a switch 
to an anti-inflammatory and immunoregulatory environment (Sheedy et al., 
2010). The use of IL-10 therapy has been shown previously to have a proviral and 
anti-inflammatory role in CHC (Nelson et al., 2003). MiR-21 also negatively 
regulates TNF, resulting in regulation of excessive inflammation but facilitating 
cell proliferation and migration (Sheedy, 2015). Infection of hepatocytes with 
HCV has been shown to induce miR-21, which results in promotion of viral 
replication as well as immunomodulation in favour of viral persistence (Chen et 
al., 2013).  
We found that ISG15 is required for IFN-α and poly (I:C) induced upregulation of 
miR-21-5p in a hepatoma cell line. Upregulation of miR-21-5p in liver cells is 
associated with promotion of an immunotolerant cellular environment, and may 
support a proviral role of ISG15 in HCV infection.   
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4.6 Summary 
In this chapter, we have demonstrated that CHC is associated with a distinct 
miRNA signature in the serum and peripheral immune cells.   
We found that pathways in cancer were significantly enriched by target genes of 
miRNAs differentially regulated in the PBMCs of HCV-infected individuals. Of the 
miRNAs upregulated in CHC, we identified a panel that are significantly 
upregulated in HCV-infected subjects with cirrhosis. MiR-16-5p, miR-155-5p, 
miR-885-5p and miR-221-3p correlate with disease stage and markers of immune 
ageing, and are involved in the regulation of clinically relevant signalling 
pathways.  
We also demonstrated that pathways in cancer were significantly enriched by 
the target genes of miRNAs deregulated in the serum of subjects with CHC. 
Moreover, we found that pathway enrichment was similar between HCV-infected 
cirrhotic patients and patients with a normal liver stiffness but high biological 
age. This suggests that decisions regarding treatment prioritisation should not be 
made on the basis of fibrosis stage alone, but should consider factors 
contributing to cellular senescence. 
We found that miR-122-5p and miR-885-5p were significantly elevated in the 
serum of HCV-infected subjects with cirrhosis compared with healthy controls. 
We also showed that circulating miR-885-5p and miR-122-5p performed well as 
biomarkers for CHC, but not HCV-related cirrhosis. Furthermore, chronological 
age and BMI were more significantly predictive of cirrhosis than the selected 
miRNA biomarkers, highlighting the importance of weight loss interventions in 
routine clinical practice. Of the individual biomarkers tested, PBMC CDKN2 
transcript expression was the most significantly associated with the presence of 
cirrhosis. 
We explored an in vitro model to identify the mechanism for altered levels of 
miRNAs. We found that miR-21-5p expression was induced by TLR3 agonism and 
IFN-α stimulation in a hepatoma cell line. We found that this induction was 
largely abrogated in an ISG15 knockout cell line, suggesting that upregulation of 
miR-21-5p in response to IFN-α stimulation is ISG15 dependent, providing further 
tentative insights into the function of ISG15.  
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Our data add to the body of literature surrounding the use of miRNA signatures 
as biomarkers in CHC. We found that PBMC miRNA expression showed promise in 
the diagnosis of cirrhosis in CHC. Analysis of protein-protein interactions for the 
genes targeted by miRNAs significantly deregulated in the PBMCs of patients 
with cirrhosis added mechanistic support to their role in HCV-related 
haematological malignancy. We found that CHC was associated with a distinct 
extracellular miRNA signature, and that serum levels of miR-885-5p and miR-122-
5p show potential as diagnostic biomarkers for HCV infection. Although serum 
expression of miR-885-5p, miR-122-5p and miR-21-5p correlated with CDKN2A 
expression, we failed to demonstrate differences in expression between cirrhotic 
and non-cirrhotic subjects.  
We hypothesised that although the selected extracellular miRNAs did not 
perform well as diagnostic biomarkers for cirrhosis, they may still confer a 
prognostic benefit. We therefore next explored miRNA expression in HCV-
infected subjects with cirrhosis receiving antiviral treatment. 
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5 MiRNAs as prognostic biomarkers for virologic 
and clinical outcomes during treatment of CHC 
5.1 Introduction 
In the absence of treatment, CHC leads to progressive liver fibrosis with an 
increased risk of hepatic decompensation and HCC. Data suggest that 
eradication of HCV is associated with improved clinical outcomes in patients 
with HCV-related cirrhosis (Cheung et al., 2016). Treatment may be beneficial 
even in patients with end-stage liver disease; previous studies of IFN-free 
therapy in HCV infected patients have shown that SVR is associated with a 
reduction in HVPG (Mandorfer et al., 2016), and allows delisting of a significant 
proportion of patients on the waiting list for liver transplantation (Belli et al., 
2016). However, not all patients with cirrhosis benefit from achieving an SVR, 
leading researchers to suggest that there is a ‘point of no return’ in very 
advanced disease (Foster et al., 2016). 
Schwabl et al. (2017) found that over 1/3 of HIV/HCV co-infected patients 
receiving DAA therapy had persistent histological necro-inflammatory activity 
despite achieving an SVR. Mortality in HCV-infected individuals who achieve SVR 
also remains higher than that in the general population; Innes et al. (2017) found 
that Scottish patients who achieve SVR had a mortality rate up to 6-fold greater 
than that of the general population, largely driven by deaths due to drug related 
causes and HCC. They were however less likely to be hospitalised or die for 
another liver-related reason (Innes et al., 2017). Worryingly, a number of recent 
studies have described an increased incidence of both de novo and recurrent 
HCC in cirrhotic patients who achieve SVR with DAAs (Conti et al., 2016, Reig et 
al., 2016). Whilst more recent studies have failed to demonstrate this 
association ('Lack of evidence of an effect of direct-acting antivirals on the 
recurrence of hepatocellular carcinoma: Data from three ANRS cohorts,' 2016), it 
remains a concern for many health care providers. 
Finally, a proportion of patients will fail to respond to treatment or will relapse 
following treatment. Poor response to treatment is associated with a number of 
factors, including advanced liver fibrosis and cellular senescence (chapter 
1.5.2). 
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Robust, non-invasive biomarkers to help characterise individuals at risk of poor 
virologic and clinical outcomes during DAA treatment are required. It is known 
that serum and hepatic miRNA expression differs significantly between patients 
who achieve an SVR with an IFN-α based regimen and those who relapse or fail 
to respond (Butt et al., 2016). The role of miRNAs in predicting response to IFN-
sparing therapy is less well defined (Waring et al., 2016). 
We have identified a panel of miRNAs that are elevated in the serum of patients 
with cirrhosis secondary to CHC, expression of which correlate with previously 
described biomarkers of cellular senescence (chapter 4.4). Other groups have 
shown that serum levels of these miRNAs are upregulated in a number of human 
cancers, including HCC (Gui et al., 2011, Xu et al., 2015, Meng et al., 2007).  
We sought to compare miRNA expression in HCV-infected individuals at baseline 
and end of treatment (EOT) to identify whether the miRNA profile changes 
during DAA therapy. Additionally, we compared baseline miRNA expression in 
individuals who achieved SVR12 and those who relapsed to identify whether 
miRNAs signatures could be used to predict response to DAAs. Finally, we 
examined miRNA expression at baseline in subjects who experienced an adverse 
clinical outcome during DAA treatment despite HCV eradication and those who 
did not, to elicit whether miRNAs could be used to identify individuals who may 
not benefit from antiviral therapy.  
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5.2 Patient selection 
5.2.1 Study design and population 
The NHS England EAP was set up to provide DAA therapy for HCV-infected 
patients with severe liver disease who were at ‘significant risk of death or 
irreversible damage within 12 months due to hepatic or extrahepatic 
manifestations’, irrespective of viral genotype. Eligible patients included those 
with past or current decompensated cirrhosis (defined as ascites, variceal 
bleeding or encephalopathy), Child Pugh score ≥ B7 or extrahepatic 
manifestations of HCV likely to lead to irreversible damage within 12 months. 
Patients were also required to have been intolerant of, or non-responders to, 
IFN-based therapies. Exceptional cases were reviewed by a multidisciplinary 
panel, in line with the Clinical Commissioning Policy Statement. Patients 
received sofosbuvir combined with an NS5A inhibitor (ledipasvir or daclatasvir) 
with or without RBV for a fixed duration of 12 weeks. Choice of NS5A inhibitor 
and inclusion/exclusion of RBV was at physician discretion, with local 
multidisciplinary team input. Patients were enrolled into the HCV Research UK 
(HCVRUK) registry for prospective data collection. Ethical approval for HCVRUK 
was given by the National Research Ethics Service (NRES) committee East 
Midlands – Derby 1 (REC reference 11/EM/0314). Informed consent was obtained 
from all patients included in the study – patients who declined data collection 
were treated but excluded from analysis (Foster et al., 2016).  
In this retrospective, observational cohort study, patients were selected from 
the NHS England EAP cohort in a 1:1:1 ratio. Group 1 consisted of patients who 
achieved SVR12, whose MELD score was unchanged or improved (i.e. decreased) 
from baseline at 12 weeks post therapy and who had no adverse clinical 
outcomes during the study period (SVR12). Group 2 included patients who 
achieved SVR12 but who had an adverse clinical outcome (SVR12-AE), and Group 
3 consisted of responder-relapsers (RR), regardless of clinical outcome. A serious 
adverse event (SAE) was defined as MELD score increase ≥ 2, new 
decompensation event, hospitalisation, death or the development of malignancy 
between EAP baseline and 12 weeks post treatment. Data and clinical samples 
were requested from the HCV Research UK registry. All patients who received 12 
weeks of sofosbuvir + ledipasvir/daclatasvir +/- RBV were eligible for inclusion. 
5-215 
 
Patients were required to have model for end-stage liver disease (MELD) scores 
available at baseline, EOT and 12 weeks post EOT. Additionally, patients were 
required to have stored serum samples available from two time points – baseline 
and EOT. Exclusion criteria included co-infection with HBV (HBsAg +ve) or HIV, 
non-compliance with study medication, and patients with a history of liver 
transplantation or who received a liver transplant during the study period.  
In this pilot study the expected difference between the group means for 
individual miRNAs was not known. Based on sample size calculations, we 
required 20 patients in each group (i.e. ≥ 40 patients for each comparison) to 
have 90% power of demonstrating a difference between groups that was 
significant at the 5% level if the true difference was at least 1.5. 
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5.3 Results 
5.3.1 Patient characteristics 
Baseline characteristics of patients (n=59) are shown in table S14. Only 19 HCV-
infected individuals met the criteria for inclusion in the SVR12-AE group. The 
majority of the patients were male (n = 40, 67.9%) and of white ethnicity (n=47, 
79.7%). Most patients were Gt1- (n=26, 44.8%) or Gt3-infected (n=30, 51.7%) 
although Gt2 (n=1, 1.7%) and Gt4 (n=1, 1.7%) were also represented. HCV 
genotype data was missing for 1 subject. The median age on starting treatment 
was 54 years (IQR 48 - 61 years). The majority of patients received a DAA 
regimen containing ledipasvir (n=41, 69.5%) and RBV (n=52, 88.1%). The median 
ALT level was 54 IU/mL (IQR 37.8 – 70.3) and the median baseline MELD score 
was 11 (IQR 8.8 – 13.3). ALT level at baseline was not significantly different 
between genotypes (p=0.217). Co-morbid DM 2 was common (n=18, 30.5%). 
Characteristics at EOT were also examined. There was a statistically significant 
decrease in ALT over the course of treatment (median ALT 23 IU/mL (IQR 17 – 
30) vs 54 IU/mL (IQR 37.8 – 70.3), p<0.0001). However, there was no significant 
change in MELD score (median MELD score 11 (IQR 10 - 14) at EOT vs 11 (IQR 8.8 
– 13.3) at baseline, p=0.09) (figure 5-1). 
 
Figure 5-1: Serum ALT level and MELD score at baseline and end of 12 weeks’ treatment 
(EOT) with DAAs. Dot plot graphs depict median expression +/- 95% CI; ****p<0.0001, 
ns=non-significant. 
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5.3.2 Serum miRNA expression is significantly altered by DAA 
therapy 
We have previously demonstrated that serum levels of miR-21-5p, miR-122-5p 
and miR-885-5p correlate with markers of immune senescence in CHC (chapter 
4). Immunosenescence is known to be associated with a poorer response to IFN-
based treatment (Hoare et al., 2010b), and we hypothesised that it would be 
associated with poorer outcomes following DAA therapy. We therefore chose to 
explore whether expression levels of these miRNAs were altered during DAA 
treatment, and whether they could be used as prognostic biomarkers for HCV 
treatment-related outcomes.   
We first examined inter-genotypic differences in expression of miR-21-5p, miR-
122-5p and miR-885-5p at baseline. Only Gt1 (n=26) and Gt3 (n=30) infected 
subjects were compared, as they constituted the bulk of the cohort. Gt2 (n=1) 
and Gt4 (n=1) infected subjects were excluded and information on HCV 
genotyping was missing for 1 patient.  
We did not demonstrate significant differences in miR-122-5p or miR-21-5p 
expression at baseline between Gt1 and Gt3 infection. However, miR-885-5p was 
significantly higher in Gt3 infection (p=0.009). This contrasts with our findings in 
the Outcomes cohort (chapter 4.4), in which all 3 miRNAs were expressed at 
similar levels between genotypes. One patient was diagnosed with Gt2 infection; 
this individual had markedly elevated expression of miR-122-5p (ΔCT -8.28) at 
baseline. 
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Figure 5-2: Baseline expression of miR-21-5p, miR-122-5p and miR-885-5p in the serum of 
HCV-infected subjects according to HCV genotype. Dot plot graphs depict mean/median 
expression +/- 95% CI; **p<0.01, ns=non-significant.  
  
 
 
 
 
 
 
5-219 
 
Next, we examined the expression of selected miRNAs at baseline and EOT for 
all patients (n=59). We found that miR-122-5p and miR-885-5p were significantly 
downregulated during DAA therapy (p<0.001). MiR-21-5p was not significantly 
altered over the course of treatment (figure 5-3). 
 
Figure 5-3: Expression of miR-21-5p, miR-122-5p and miR-885-5p in the serum of HCV-
infected subjects at baseline and end of 12 weeks’ treatment (EOT) with DAAs. MiR-122-5p 
and miR-885-5p were significantly downregulated following DAA treatment. Dot plot graphs 
depict mean/median expression +/- 95% CI; ***p<0.001, ns=non-significant.  
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We then stratified the HCV-infected subjects according to treatment outcome, 
and examined the pattern of miRNA deregulation over the course of treatment. 
We found that miR-122-5p and miR-885-5p were significantly downregulated at 
EOT in subjects who achieved viral eradication (SVR12, figure 5-4). MiR-21-5p 
was unchanged over the course of treatment in this group (p=0.168).  
 
Figure 5-4: Before-after chart demonstrating expression of miR-21-5p, miR-122-5p and miR-
885-5p at baseline and EOT in the serum of HCV-infected subjects who achieved viral 
eradication (SVR12). There was a significant decrease in miR-122-5p and miR-885-5p 
expression during treatment in patients who cleared HCV. MiR-21-5p expression was 
unchanged during treatment. *p<0.05; ns = non-significant. 
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We next explored changes in miRNA expression during treatment in subjects who 
experienced a negative clinical outcome despite viral eradication (SVR12-AE, 
figure 5-5). Neither miR-122-5p, nor miR-885-5p were significantly altered during 
treatment in these subjects. In contrast, miR-21-5p was significantly upregulated 
(p=0.029). However, the pattern of miRNA regulation over the course of 
treatment appeared highly variable in this group. 
 
Figure 5-5: Before-after chart demonstrating expression of miR-21-5p, miR-122-5p and miR-
885-5p at baseline and EOT in the serum of HCV-infected subjects who experienced an 
adverse clinical event during treatment (SVR12-AE). There was a significant increase in 
miR-21-5p expression during treatment in patients who experienced a negative clinical 
outcome. *p<0.05; ns = non-significant.  
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All 3 miRNAs were significantly downregulated between baseline and EOT in 
subjects who subsequently relapsed (figure 5-6), and the pattern of miRNA 
deregulation appeared more consistent.  
 
Figure 5-6: Before-after chart demonstrating expression of miR-21-5p, miR-122-5p and miR-
885-5p at baseline and EOT in the serum of HCV-infected subjects who relapsed following 
EOT. There was a significant decrease in miR-21-5p, miR-122-5p and miR-885-5p expression 
during treatment in subjects who subsequently relapsed.  *p<0.05; ****p<0.0001. 
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5.3.3 Baseline miRNA expression predicts virologic relapse 
We next compared the expression of the selected miRNAs at baseline in patients 
who achieved an SVR12 regardless of clinical outcome (n=39), and subjects who 
achieved an EOT response (EOTR) then relapsed (n=20). We found that RRs had 
significantly higher levels of miR-21-5p, miR-122-5p and miR-885-5p at baseline 
compared with patients who achieved virologic clearance (figure 5-7).  
 
Figure 5-7: Expression of miR-21-5p, miR-122-5p and miR-885-5p at baseline in the serum of 
HCV-infected subjects who subsequently achieved a sustained virologic response (SVR12; 
n=39) or relapsed post end-of-treatment (n=20). All miRNAs demonstrated increased 
baseline expression in subjects who experienced virologic relapse post treatment. Dot plot 
graphs depict mean/median expression +/- 95% CI; *p<0.05, ***p<0.001.  
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As previously described (chapter 2.4), we used a two stage approach to identify 
factors associated with relapse in our cohort. Univariate statistical tests were 
performed to assess key risk factors for potential associations (chapter 2.3). 
Multiple logistic regression analyses were then performed for factors significant 
at the 10% level in univariate analysis and models reviewed. As it was not 
possible to express miRNA expression with reference to a healthy control 
population, miRNA expression is expressed as either ‘positive’ or ‘negative’ 
dependent on the ΔCT relative to the mean/median of the cohort. MiRNA 
expression is defined as positive when the ΔCT was lower than the mean/median 
(i.e. increased expression) and negative when the ΔCT is higher than the 
mean/median. 
Choice of NS5A inhibitor and use of RBV did not differ significantly between 
groups (SVR and RR). Additionally, the prescription of DAAs was similar when 
stratified by genotype. The majority of the subjects in each group received a 
ledipasvir containing regimen: of the Gt3-infected subjects in the RR group 
(n=16), 37.5% received daclatasvir (n=6), whereas of the Gt3-infected patients 
who achieved SVR (n=15), 40% received daclatasvir (n=6). Of the Gt1-infected 
individuals who achieved SVR (n=23), and who relapsed (n=4), only a minority 
received daclatasvir (n=4, 17.4% and n=1, 25%, respectively). 
In univariate analysis (table S15), infection with HCV Gt2 or Gt3 was significantly 
associated with likelihood of relapse when compared to infection with Gt1 or 
Gt4 (80% vs 20%; p=0.003). Higher baseline MELD score (median score 13 vs 11, 
p=0.006) was also significantly associated with relapse. Finally, baseline miR-21-
5p positivity was significantly associated with chance of relapse (80% in the RR 
group vs 20% in the SVR12 group, p<0.001). There was a non-significant trend 
towards increased chance of relapse with miR-885-5p and miR-122-5p positivity 
at baseline (p=0.081). There were no differences in gender, age at start of 
treatment, ethnicity or HCV viral load between groups.  
There was significant correlation between miR-21-5p, miR-885-5p and miR-122-
5p expression, all of which were significant at the 10% level in univariate 
analysis. To avoid collinearity bias, models were fitted using each miRNA 
independently and in combination, and found that inclusion of miR-21-5p 
resulted in the best fit, as would be expected from the univariate analysis. A 
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model containing baseline miR-21-5p positivity and HCV genotype correctly 
classified 81% of cases and was statistically significant (Χ2 26.1, p<0.001), 
explaining 50% of the variation in treatment outcome. Inclusion of baseline MELD 
did not significantly improve the fit of the model (p=0.404); baseline miR-21-5p 
and HCV genotype remained significantly associated with relapse when 
accounting for MELD and viral genotype (table S16).  
In conclusion, Gt2- or Gt3-infected patients were significantly more likely to 
relapse than Gt1- or Gt4-infected subjects (OR 7.90, 95% CI: 1.7 – 36.2, 
p=0.008). Positive miR-21-5p expression at baseline was highly associated with 
relapse post EOTR (OR 16.9, 95% CI: 3.5 – 80.9, p<0.001). A ROC curve analysis 
was performed using predicted probabilities for the final model and 
demonstrated an AUC 0.861 (95% CI: 0.766 – 0.956, p<0.001).  
Our data suggest that baseline miR-21-5p expression, independent of HCV 
genotype (and MELD), is highly predictive of virologic relapse following DAA 
therapy and could be used to guide decisions regarding treatment length or 
intensity. It would be interesting to see retreatment data on these patients to 
ascertain whether negative baseline predictive factors could be overcome with 
treatment prolongation or intensification, as is seen with baseline RASs 
(Sarrazin, 2016).  
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5.3.4 MiRNA expression predicts adverse clinical outcome during 
DAA therapy 
Given the concerns about the risk of de novo and recurrent HCC development in 
subjects with HCV-related cirrhosis undergoing DAA treatment, and the idea of a 
‘point of no return’ beyond which subjects fail to benefit from antiviral therapy, 
we were keen to identify a prognostic biomarker to identify such patients. To 
that end, we compared baseline expression of miR-21-5p, miR-122-5p and miR-
885-5p in patients who achieved an SVR12, and those who achieved an SVR12 but 
experienced a negative clinical outcome. A negative clinical outcome was 
defined as worsening MELD score (≥ 2 points), a decompensation event, 
hospitalisation, the development of a malignancy or death. 
We did not find any significant differences in baseline expression of miR-21-5p, 
miR-122-5p or miR-885-5p between the two groups (figure 5-8). However, we 
had previously shown that there is a significant increase in miR-21-5p (p=0.029) 
expression over the course of treatment in subjects who experienced an adverse 
clinical event (SVR12-AE). In contrast, miR-885-5p (p=0.888) and miR-122-5p 
(p=0.837) did not change significantly over the course of treatment in this group 
(figure 5-5). This in itself is interesting, as both miR-885-5p and miR-122-5p were 
significantly downregulated during treatment in the other patient groups (SVR12 
and RR; figure 5-4 and figure 5-6), and may indicate that changes in the 
expression of miR-21-5p, miR-122-5p and miR-885-5p are driven by liver injury 
rather than HCV replication. However, the change in miRNA expression over the 
course of treatment in subjects who experienced negative clinical outcomes was 
highly variable, perhaps reflecting the amalgamated criteria used for the 
definition of SAE.  
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Figure 5-8: Expression of miR-21-5p, miR-122-5p and miR-885-5p in the serum of HCV-
infected subjects who achieved an SVR12 compared with those who achieved an SVR12 but 
experienced an adverse clinical event during treatment. There were no differences in 
baseline miRNA expression between groups. Dot plot graphs depict mean/median expression 
+/- 95% CI; ns=non-significant.  
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In order to identify further potential prognostic biomarkers, we pooled sera from 
patients who achieved an SVR (SVR12, n=20), and those who achieved virologic 
suppression but experienced an adverse event (SVR12-AE, n=19), and used 
TaqMan® MicroRNA Arrau Cards to profile baseline miRNA expression in each 
group. Only 1 additional miRNA (miR-139-5p; RQ 3.96, p=0.031) was found to be 
significantly deregulated at baseline in the serum of patients who experienced 
an adverse outcome (figure 5-9). However, miR-345-5p was also upregulated (RQ 
3.10, p=0.326) and a decision was made to explore both these miRNAs further as 
biomarkers.  
 
Figure 5-9: Volcano plot demonstrating p value against fold change for miRNA deregulated in 
the serum of chronically HCV-infected subjects who experienced a negative clinical outcome 
during treatment compared with subjects who achieved SVR12 with no adverse event. Data 
points in red indicate miRNAs upregulated > 2 fold in CHC, and those in blue indicate > 2 fold 
downregulation. Only miR-139-5p was significantly upregulated.  
MiR-139-5p was not reliably expressed during the validation experiments and 
further investigation was abandoned. However, baseline miR-345-5p expression 
was shown to be significantly higher in patients who experienced a negative 
clinical outcome with treatment (figure 5-10).   
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Figure 5-10: Baseline expression of miR-345 in the serum of HCV-infected subjects who 
achieved an SVR12 compared with those who achieved an SVR12 but experienced an adverse 
clinical event during treatment. MiR-345 was significantly increased at baseline in the serum 
of subjects who experienced a negative clinical outcome. Dot plot graph depicts 
mean/median expression +/- 95% CI; **p<0.01.  
We went on to explore baseline factors associated with negative clinical 
outcomes in more detail. In univariate analysis (table S17), the presence of DM 2 
was significantly associated with an adverse outcome during treatment 
(p=0.022). Baseline miR-21-5p negativity (i.e. expression lower than the cohort 
mean) was also significantly associated with adverse outcome (p=0.048). 
However, we found that low miR-21-5p expression at baseline was significantly 
associated with upregulation of miR-21-5p over the course of treatment 
(p=0.004), suggesting an interaction between the two variables. Neither miR-
122-5p nor miR-885-5p expression at baseline was significantly associated with 
individual or global adverse outcome.  
Higher miR-345 expression was significantly associated with adverse outcome 
during treatment (p=0.037). When looking at individual outcomes in more detail, 
we found that this finding was driven by the association between miR-345-5p 
and the development of malignancy (Χ2=4.234, p=0.04). There was no 
association between baseline miR-345-5p expression and either MELD increase 
(Χ2=0.672, p=0.412) or decompensation (Χ2=1.699, p=0.428).  
All patients who developed a malignancy (both HCC and non-HCC) during 
treatment in the SVR-AE group (n=4) were positive for miR-345-5p at baseline. 
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We also observed an upregulation of miR-21-5p during treatment in these 
patients. Our findings indicate that miR-345-5p may be a more sensitive 
biomarker of malignancy than miR-21-5p, although monitoring the expression of 
miR-21-5p during treatment may also aid diagnosis.  
Interestingly, omission of RBV from the treatment regimen was significantly 
associated with adverse outcome (p=0.03). There were no significant differences 
in age, gender, ethnicity or HCV VL between groups. Choice of NS5A inhibitor 
was similar between groups. More detail on significant adverse events (SAEs) and 
baseline miRNA expression are shown in Table S18. 
Our analysis suggested that an interaction between miR-345 and miR-21-5p was 
influencing the model. Models were therefore tested using each miRNA 
individually, and in combination, with baseline miR-21-5p negativity and miR-
345-5p positivity indicating a positive event. This composite variable was more 
significantly associated with adverse outcome than either of the independent 
variables in univariate analysis (p=0.006). A crosstabulation was performed for 
the composite miRNA variable and the independent adverse events which 
demonstrated that the association between miRNA expression and the 
development of malignancy was again driving this association (Χ2=7.131, 
p=0.008). There was no association between miRNA expression and either MELD 
increase (Χ2=0.154, p=0.694) or decompensation (Χ2=3.630, p=0.163).  
A model containing composite baseline miRNA expression (OR 35.9, 95% CI: 3.5 – 
366.6, p=0.003) and co-morbid DM 2 (OR 43.4, 95% CI: 3.4 – 561.2, p=0.004) 
correctly classified 82.1% of cases (table S19). This model was statistically 
significant (Χ2=20.9, p<0.001) and explained 55.3% of variation in treatment 
outcome. The inclusion of RBV use did not significantly improve the model 
(p=0.206). A ROC curve analysis was performed using predicted probabilities for 
the final model including miRNA expression and DM 2, and demonstrated an AUC 
0.845 (95% CI: 0.717 – 0.972, p=0.001).  
MiR-345-5p and miR-21-5p were explored as individual biomarkers using ROC 
curve analysis. The AUC for miR-345-5p was 0.779 (95% CI: 0.630 – 0.928, 
p=0.003) and for miR-21-5p was 0.692 (95% CI: 0.524 – 0.860, p=0.04). This 
suggests that miR-345-5p may be a useful marker of adverse clinical outcome 
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during antiviral treatment, and is a more accurate predictor of SAE than miR-21-
5p.  
In conclusion, measuring baseline miR-345-5p and miR-21-5p expression may aid 
in risk stratification of patients at risk of adverse clinical outcomes during DAA 
therapy, specifically the development of malignancy, in addition to previously 
described co-morbidities. This is intriguing and suggests that monitoring miRNA 
expression during treatment may aid in the early diagnosis of cancer.  
5.3.5 Functional analysis of miR-345-5p in silico 
MiR-345-5 is not well defined in the literature. We identified only 3 validated 
target genes: CDKN1A, ABCC1 and NTRK3. Predicted protein-protein interactions 
are demonstrated below (figure 5-11). As with the other selected miRNAs, we 
found that KEGG pathways in cancer were highly enriched. The 5 most 
significantly enriched KEGG pathways are the cell cycle, hepatitis B, p53 
signalling pathway, bladder cancer and glioma.  
 
Figure 5-11: Predicted protein-protein interactions for miR-345-5p target genes. Networks 
are clustered according to the Markov cluster algorithm (inflation factor 3); strength of 
association is shown by the line thickness: dotted lines indicate weaker support. Proteins 
involved in the cell cycle pathway are highlighted in red. 
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5.4 Discussion 
The objective of this study was to explore changes in extracellular miRNA 
expression during treatment of CHC with oral DAA regimens, and to identify 
novel prognostic biomarkers for adverse clinical and virologic outcomes during 
the treatment of CHC with DAAs. Overall, we found that the expression of miR-
122-5p and miR-885-5p was significantly downregulated over the course of 
antiviral treatment, whereas miR-21-5p was unchanged. In contrast, when we 
looked only at patients who experienced negative clinical outcomes despite viral 
eradication, we found that the downregulation in miR-122-5p and miR-885-5p 
was abrogated, and miR-21-5p was upregulated.  
We demonstrated that baseline serum levels of miR-21-5p, miR-885-5p and miR-
122-5p were significantly higher in individuals who experienced viral rebound 
when compared to those who achieved SVR12. We found that a model containing 
miR-21-5p expression and HCV genotype accurately predicted virologic relapse 
following DAA treatment. Finally, we showed that upregulation of miR-21-5p 
together with baseline comorbid DM 2 and elevated miR-345-5p expression was 
significantly associated with the development of an adverse clinical outcome 
during antiviral therapy. 
Elevated serum miR-885-5p expression has been proposed as a biomarker for 
cirrhosis and HCC in HCV-infected subjects (Gui et al., 2011). We previously 
observed elevated expression of miR-885-5p in the serum of HCV-infected 
individuals with cirrhosis, and found that miR-885-5p expression positively 
correlated with ALT (chapter 4.4). Serum miR-122-5p has also been shown to 
correlate with histologic necro-inflammatory activity and ALT (Dubin et al., 
2014, Su et al., 2013), although we failed to demonstrate this association in our 
cohort. IFN-free antiviral therapy is associated with significant improvement in 
biochemical parameters, as well as a reduction in liver stiffness as measured by 
TE (Knop et al., 2016). The rapid improvement in liver stiffness measures by TE 
over the 12 week period of treatment suggest that these findings are largely due 
to resolution of necro-inflammation, and to a lesser extent regression of fibrosis. 
Improvement in histological necro-inflammatory activity has also been described 
in the HIV/HCV population following DAA therapy (Schwabl et al., 2017). The 
decrease in miR-885-5p and miR-122-5p levels detected during antiviral 
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treatment correlated with a significant reduction in ALT, and is concordant with 
a reduction in necro-inflammatory activity. The change in miR-122-5p expression 
during treatment may also correspond with the fall in HCV viral load, given the 
positive correlation previously observed (chapter 4.4.3). Conversely, neither 
MELD score nor miR-21-5p fell significantly over the course of treatment. MiR-21-
5p has been described as a biomarker of fibrosis in a number of organs (Lorenzen 
et al., 2015, McClelland et al., 2015, Zhao et al., 2014), whilst the MELD score 
gives a reflection of liver synthetic function. A significant regression of cirrhosis 
would not be expected over 12 weeks, and the fact that these biomarkers 
remain static supports the earlier statement that the change in liver stiffness by 
TE predominantly reflects a reduction in inflammatory activity. 
It has been demonstrated previously that SVR with an IFN-containing regime is 
associated with a significant decrease in serum miR-122-5p levels (Dubin et al., 
2014). Concordant with our study, Waring et al. (2016) also found that miR-122 
was significantly downregulated during DAA therapy, but that levels returned to 
baseline in subjects who relapsed or experienced virologic breakthrough. This is 
in line with our previous observation regarding the association between HCV viral 
load and miR-122-5p expression (chapter 4.4.3). The association between 
baseline miR-122-5p expression and treatment response is complex, and data are 
conflicting. Elevated serum miR-122 has been shown to correlate with the 
favourable INFL3 rs8099917 TT genotype, and to predict SVR with IFN-based 
therapy independently of host INFL3 genotype (Su et al., 2013), whilst lower 
hepatic miR-122-5p levels are described in non-responders to IFN-based therapy 
(Sarasin-Filipowicz et al., 2009). In contrast, Waidmann et al. (2012a) failed to 
demonstrate an association between serum miR-122-5p levels and treatment 
response. Waring and colleagues (2016) did not find that baseline serum miR-
122-5p was predictive of SVR for either Gt1 or Gt3 infection, although the trend 
was for lower baseline serum miR-122 expression in subjects who achieved SVR, 
in line with our findings. However, they did find a significant positive association 
between serum miR-122-5p levels and SVR in Gt2 infected patients. Only one 
patient in our cohort was Gt2-infected; interestingly, this patient achieved an 
SVR and had very high baseline miR-122-5p expression (ΔCT -8.28). The 
association between HCV genotype, serum miR-122-5p expression and response 
to DAA therapy warrants further investigation in a larger cohort.  
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We found that Gt3 infection was significantly associated with relapse following 
EOTR. Our data mirror the findings in the wider EAP cohort; Foster and 
colleagues (2016) found that viral clearance was achieved in 209 of 231 Gt1-
infected subjects (90.5%) compared with only 132 of 192 Gt3-infected subjects 
(68.8%). The association between Gt3 infection and poor outcome is unclear, but 
may relate to a combination of host and viral factors. Steatosis is more common 
in Gt3 infection, where it is thought to relate to direct effects of HCV core 
protein on lipid oxidation and LDL assembly (Rubbia-Brandt et al., 2000). 
Steatosis was found to be an independent predictor of relapse following IFN-
based therapy in Gt3-infected subjects (Restivo et al., 2012), and may have 
contributed to relapse rates in our cohort. It is possible that the choice of NS5A 
inhibitor influenced the likelihood of virologic relapse: the majority of 
individuals in our cohort received a ledipasvir-containing combination, which is 
no longer recommended for individuals with Gt3 infection as a consequence of 
poorer treatment outcomes in comparison to other agents ('EASL 
Recommendations on Treatment of Hepatitis C 2016,' 2016). The use of less 
potent antiviral medications may have led to the development of NS5A 
resistance. However, the proportion of Gt3-infected subjects receiving each 
regimen was similar between treatment responders and RRs, so it is unlikely that 
choice of NS5A inhibitor contributed significantly to the observed association 
between genotype and relapse rates in this cohort.  
In our study, we found that baseline miR-21-5p expression was highly predictive 
of virologic relapse post EOTR, even accounting for HCV genotype and MELD 
score. We have previously shown that miR-21-5p is induced by IFN-α and poly (I: 
C) stimulation, and that this signal was lost in an ISG15 knockout cell line. It has 
also been shown that higher basal ISG expression with higher levels of 
endogenous IFN (as seen with the unfavourable IFNL4 genotype ΔG) is associated 
with treatment failure in response to both IFN-containing and IFN-sparing 
antiviral regimens (Murakawa et al., 2017, Meissner et al., 2014). It is possible 
that the higher miR-21-5p reflects high basal ISG (and ISG15) expression, 
explaining the correlation between miR-21-5p expression and treatment 
outcomes. It has also been demonstrated that miR-21 has a proviral and 
immunomodulatory activity in CHC, promoting viral replication (Chen et al., 
2013). Knockdown of miR-21 expression has been shown to sensitise cells to IFN-
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induced antiviral activity against vesicular stomatitis virus (Yang et al., 2015), 
whereas upregulation of miR-21-5p is associated with promotion of an 
immunotolerant cellular environment. This may also contribute to the increased 
likelihood of virologic relapse in subjects with higher baseline miR-21-5p 
expression. Finally, as described previously, miR-21-5p is a recognised biomarker 
of fibrosis, and elevated levels may reflect more advanced hepatic fibrosis with 
consequent effect on treatment outcome.  
We also explored baseline factors associated with the incidence of adverse 
clinical outcomes during treatment. We found that low baseline miR-21-5p 
expression, high miR-345-5p expression, comorbid DM 2 and omission of RBV 
from the treatment regimen were significantly associated with the development 
of an SAE during treatment in univariate analysis. The association between 
baseline miRNA expression and SAEs during treatment was driven by the 
association between baseline miR-345-5p and miR-21-5p and the development of 
malignancy. 
MiR-345-5p is a promising prognostic biomarker. Upregulation of miR-345-5p has 
been described in association with a number of human cancers, including HCC 
(Cervigne et al., 2009, Guled et al., 2009). HCV core protein has been shown to 
induce miR-345 expression in a hepatoma cell line, resulting in suppression of 
p21 gene expression (Shiu et al., 2013). Deregulation of p21 expression is a 
frequently observed event in human cancers; p21 acts as tumour suppressor 
through negative regulation of the cell cycle. Protein p21 is transcriptionally 
activated by p53, and is able to bind to and inhibit the CDKs, resulting in cell 
cycle arrest (Abbas and Dutta, 2009). Interestingly, p21 may have both pro- and 
anti-apoptotic activity depending on cellular stresses, with paradoxical 
oncogenic activity. Functional analysis of protein-protein interactions for genes 
targeted by miR-345 showed that the p53 pathway was significantly enriched, 
and indicated an important role for miR-345 in regulation of the cell cycle. We 
found that miR-345 demonstrated increased abundance at baseline in all 
individuals who developed a cancer over the course of treatment, supporting its 
role as a biomarker of malignancy. We also observed an upregulation in miR-21-
5p expression over the course of treatment in all patients who were diagnosed 
with malignancy, consistent with its role as an onco-miR in the literature 
(chapter 1.7.3). 
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The association between low baseline miR-21-5p expression and negative clinical 
outcome is less easy to rationalise, particularly as miR-345 and miR-21 are often 
co-expressed in tumour tissue (Cervigne et al., 2009). It is possible that low 
baseline serum miR-21-5p expression (reflecting low hepatic miR-21 expression) 
was associated with enhanced inflammatory activity in response to antiviral 
treatment. However, we also found that low miR-21-5p expression at baseline 
was significantly associated with an upregulation of miR-21-5p during treatment, 
suggesting an interaction between these variables.  
The pattern of miR-21-5p deregulation was significantly different between 
treatment groups; miR-21-5p was upregulated over the course of treatment in 
79% of subjects in the SVR12-AE group, compared with only 40% in the SVR12 
group. MiR-21-5p upregulation has been described in the cerebral cortex of mice 
with hepatic encephalopathy (HE) secondary to acute liver failure (Vemuganti et 
al., 2014), and it has been proposed as a biomarker for inflammatory 
neurological disease in other animal models (Gaitero et al., 2016, Yelamanchili 
et al., 2015). It is possible that extracellular serum miR-21-5p levels may reflect 
aberrant miRNA expression in the brain tissue of subjects with HE. However, a 
rise in miR-21-5p during treatment was only observed in 2 of the 4 patients who 
developed encephalopathy during treatment, suggesting that serum miR-21-5p 
expression is an unreliable biomarker of encephalopathy. The association 
between miR-21, fibrosis and malignancy has been described in detail (chapter 
1.7.3), and an upregulation in miR-21-5p was demonstrated in all subjects who 
developed a malignancy during treatment. The monitoring of miR-21-5p 
expression may improve the sensitivity of current HCC surveillance strategies in 
CHC, and warrants further exploration in a larger cohort. 
We found that DM 2 was significantly associated with adverse clinical outcome 
during treatment, when controlling for miRNA expression and RBV use. Co-
morbid DM 2 is significantly associated with the development of cirrhosis and 
decompensation in CHC (Huang et al., 2014). It has also been associated with an 
increased prevalence of HE in decompensated cirrhosis (Butt et al., 2013), as 
well as increased risk of HCC. In line with our study, Nahon and colleagues 
(2017) found that co-incident metabolic syndrome was associated with ongoing 
risk of HCC in HCV-infected subjects despite viral eradication. There is a high 
prevalence of NAFLD and non-alcoholic steatohepatitis (NASH) among individuals 
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with DM 2 (Firneisz, 2014), and it is conceivable that this contributed to the 
poorer clinical outcomes observed in diabetic subjects. Studies have shown that 
fasting glucose declines rapidly in diabetic HCV-infected subjects receiving DAAs 
(Pavone et al., 2016), and it is also possible that these metabolic changes may 
provoke hepatic decompensation events.  
We found that omission of RBV from the treatment regimen was significantly 
associated with adverse clinical outcome in univariate analysis. However, RBV is 
contraindicated in subjects with decompensated cirrhosis and significant blood 
dyscrasia (Sulkowski et al., 2011). The omission of RBV may in fact have been a 
surrogate marker of advanced disease stage, which may explain the poorer 
clinical outcomes in these subjects.  
As regards to the limitations of this study, it is possible that we have failed to 
adjust our model for other prognostic factors associated with adverse clinical 
and virologic outcomes. Our study would have benefited from the inclusion of 
data on BMI, given the correlation between BMI and disease progression 
identified in our earlier work (chapter 4.4.3). Information on the grade of 
hepatic steatosis would also have been valuable. It is possible that the 
association between co-morbid DM 2 and adverse clinical outcomes identified in 
this study is partly contributed to by an increased incidence of obesity and 
NAFLD in these patients, given the usual association of these features within the 
metabolic syndrome (Magliano et al., 2006). Information on host IFNL4 genotype 
and baseline RASs would also strengthen the study, and we hope to obtain these 
data in the future.  
This study is retrospective and observational, and subjects were selected 
according to known treatment outcomes. Whilst we have attempted to control 
for confounding factors, the possibility of selection bias must be taken into 
consideration, and promising findings ideally require validation in a randomised 
controlled trial. As described previously (chapter 4), there was considerable 
inter-individual variance in miRNA expression, which together with the relatively 
small group sizes may have led to an underestimation of between-group 
differences. This also explains the wide confidence intervals seen in the 
statistical analysis. Finally, we were only able to identify 19 subjects in the 
SVR12-AE group who met the inclusion criteria. As the study was designed to 
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compare groups of ≥ 20 individuals, the final analysis of SAEs is underpowered, 
and findings must be interpreted with caution.  
In conclusion, miRNAs may prove valuable prognostic biomarkers for treatment 
outcomes with DAA therapies. Measurement of selected miRNAs may aid in 
patient stratification prior to DAA initiation, and monitoring the pattern of 
miRNA deregulation over the course of treatment may provide useful 
information on underlying liver disease. Finally, we tentatively present miR-345 
as a novel biomarker of both hepatic and extra-hepatic malignancy in CHC.  
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6 General discussion 
In this study, we aimed to explore factors associated with disease progression in 
CHC using both local and national clinical data. We interrogated 3 cohorts of 
HCV-infected subjects together with healthy controls to identify factors 
associated with spontaneous clearance of CHC, progression of fibrosis, and 
clinical and virologic outcome in response to DAA therapy. We also characterised 
miRNA expression in the PBMCs and serum of HCV-infected individuals in order to 
explore the biological mechanisms underlying HCV pathogenesis, and to identify 
novel biomarkers for cirrhosis and for treatment outcomes with DAAs. 
We found that spontaneous clearance of CHC occurred rarely in our local patient 
population, with an incidence rate of < 0.5 per 100-person-years follow up. In 
line with previous reports, clearance was associated with female gender, co-
infection with HBV, younger chronological age at infection, and lower HCV RNA 
titres (Sagnelli et al., 2009, Scott et al., 2006, Gruener et al., 2002). We present 
the novel finding that spontaneous clearance was negatively associated with 
current IDU. We observed that a proportion of cases occurred in the context of 
significant intercurrent illness and possibly in the context of pregnancy, as had 
been described in the literature (Hattori et al., 2003, Zein et al., 2001, Mora-
Peris et al., 2015). 
We confirmed the findings in the literature that CHC is associated with a distinct 
miRNA expression profile in the serum and immune cells (Shrivastava et al., 
2015, Chang et al., 2014), and observed that pathways in cancer were highly 
enriched by genes targeted by these miRNAs. Importantly, the data indicated 
that non-cirrhotic individuals with elevated biomarkers of immunosenescence 
behaved similarly to cirrhotic subjects, with implications for clinical practice 
and surveillance.  
We demonstrated that HCV-infected subjects with cirrhosis had elevated PBMC 
levels of miR-16-5p, miR-155-5p, miR-221-3p and miR-885-5p compared to non-
cirrhotic patients. MiR-16-5p and miR-155-5p are of particular interest, given 
their association with B cell dysfunction (Frasca et al., 2015) and haematological 
malignancy (Eis et al., 2005, Piluso et al., 2015). However, we also identified a 
number of issues with the PBMC analysis which limited our interpretation of the 
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data. We observed that PBMC storage method affected the quality of the RNA; 
RNA extracted from PBMCs cryopreserved in liquid nitrogen had evidence of 
increased degradation compared to RNA from PBMCs lysed in RLT buffer. We also 
found that a number of miRNAs were expressed at comparatively lower levels in 
cryopreserved PBMCs. Due to limited sample availability, we were required to 
use cryopreserved PBMCs for our analysis, and we hypothesise that poor RNA 
quality may have affected our miRNA expression analysis and contributed to our 
failure to identify a suitable endogenous control miRNA. The source of the 
problem with the cryopreserved PBMCs is not clear, but could arise from the 
presence of cellular RNAses in the samples. It is possible that our findings could 
also impact on transcriptomic studies with cryopreserved PBMCs, again resulting 
in data that may be difficult to interpret. We also observed considerable inter-
individual variance in miRNA expression, which combined with the small cohort 
size, may have limited our ability to demonstrate between-group differences. 
Given the aforementioned limitations, a decision was made not to pursue further 
analysis using a larger bank of PBMC samples. It would be interesting to repeat 
the experiment in a larger cohort using freshly separated PBMCs which had been 
stored directly in lysis buffer, and an exogenous spike-in control.  
We observed that miR-21-5p, miR-122-5p and miR-885-5p were upregulated in 
the serum of HCV-infected subjects compared to healthy controls. 
Unfortunately, we did not find that these miRNAs performed well as serum 
biomarkers of cirrhosis, although miR-885-5p demonstrated a trend towards 
increasing expression in cirrhotic subjects. We did however find that all of the 
selected miRNAs correlated weakly but significantly with CDKN2A mRNA 
expression, and we tentatively suggest that these miRNAs could be explored 
further as BoA in CHC. 
Of the biomarkers tested, CDKN2 mRNA transcript expression was most 
significantly associated with cirrhosis; ALT level (a marker of hepatic 
inflammatory activity) was also significantly associated with cirrhosis. However, 
we found that chronological age and BMI were more strongly associated with 
disease stage than any of the biomarkers explored. Although these findings were 
ultimately disappointing, they remain important for clinical practice. Hepatic 
steatosis and BMI are associated with persistent hepatic necro-inflammatory 
activity in HIV/HCV co-infected subjects following HCV eradication (Schwabl et 
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al., 2017), and hepatic steatosis, together with age and hepatic fibrosis, has 
been associated with an increased incidence of HCC post SVR (Tanaka et al., 
2007). At present, lifestyle modification and dietary advice represent the only 
interventions for hepatic steatosis outwith specific treatment for metabolic 
disorders (Nascimbeni et al., 2013), and should be implemented aggressively. 
One concern regarding the use of short course oral antiviral treatment for HCV 
(as opposed to 24-48 weeks IFN-based therapy) is that healthcare providers have 
less interaction with the patient, and have less opportunity to recommend public 
health interventions. Our findings highlight the need to counsel HCV-infected 
individuals to maintain a healthy weight; elevated BMI remained associated with 
cirrhosis in our cohort even having excluded obesity (chapter 4). 
Interestingly, we also found that metabolic disorders were predictors of adverse 
clinical outcomes during antiviral treatment; co-morbid DM 2 was significantly 
associated with the development of an SAE. The presence of DM 2 may indicate 
more severe baseline liver disease, given its association with other features of 
the metabolic syndrome, including obesity and NAFLD, which have been 
associated with increased hepatic necro-inflammatory activity and incidence of 
HCC (Schwabl et al., 2017, Tanaka et al., 2007). Additionally, it is conceivable 
that decompensation/encephalopathy may be provoked by metabolic changes 
during treatment. 
Circulating miR-122-5p and miR-885-5p levels were significantly downregulated 
over the course of DAA treatment, in concordance with serum ALT level. Neither 
miR-21-5p expression nor MELD score were significantly altered. However, in 
subjects who experienced a negative clinical outcome despite viral eradication, 
miR-122-5p and miR-885-5p levels were unchanged, and miR-21-5p was 
upregulated. This may indicate that serum miRNA expression is driven by host 
rather than viral factors, and prompted us to explore the use of models to study 
miRNA regulation in vitro (chapter 4.5). Interestingly, lower miR-21-5p 
expression at baseline was associated with the development of an SAE during 
treatment in univariate analysis. MiR-345-5p was also associated with adverse 
clinical outcome during treatment, and all individuals diagnosed with a 
malignancy during treatment (both HCC and extra-hepatic disease) were positive 
for miR-345-5p at baseline. This finding corresponds with reports in the 
literature describing upregulation of miR-345-5p in a number of human cancers 
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(Cervigne et al., 2009, Guled et al., 2009), and is supported by our functional 
analysis which indicates an important role for miR-345 in cancer pathways. 
Upregulation of miR-21-5p was also associated with the development of an SAE, 
and was observed in all patients subsequently diagnosed with cancer. 
We used TaqMan® Advanced MicroRNA Assays to quantify selected serum and 
PBMC miRNA expression, and the RT-PCR was performed using the 7500 Fast 
Real-Time PCR system (Applied Biosystems). TaqMan® RT-PCR reagents are used 
routinely in clinical laboratories together with the 7500 machine (Espy et al., 
2006), and serum is readily obtainable from whole blood. As only 150 μL serum is 
required for RNA extraction (which can be automated), sufficient sample could 
be acquired in 1 draw at the pre-treatment clinic appointment when baseline 
bloods and HCV RNA levels are obtained. The use of miRNAs as biomarkers of 
virologic relapse or malignancy could therefore be easily incorporated into 
clinical practice. For instance, HCV-infected subjects with elevated miR-21-5p at 
baseline could be considered for treatment intensification or a prolonged 
treatment duration, and subjects with elevated miR-345-5p expression at 
baseline could be referred for more detailed liver imaging or enhanced 
hepatoma surveillance. Thus, monitoring of selected miRNAs could form part of 
routine surveillance, to aid in the early diagnosis of hepatic decompensation 
events.  
The development of newer DAAs has revolutionised the treatment landscape in 
CHC, and treatment is associated with high SVR rates even in previously ‘hard-
to-treat’ patient groups. As a consequence, biomarkers of treatment response in 
CHC may become increasingly redundant. However, there is ongoing concern 
regarding the risk of HCC post SVR with DAAs, as discussed previously (chapter 
5.1). Data have suggested that there is an increased risk of de novo and 
recurrent HCC with all-oral DAA combinations, thought to relate to the loss of 
immune surveillance previously provided by IFN-containing regimens (Robert, 
2016, Conti et al., 2016). Additionally, it has been demonstrated that a number 
of HCCs are missed through the current surveillance policies (Irving WL, personal 
communication, Aug 7, 2017). Although more recent meta-analyses have failed 
to demonstrate an association between DAA therapy and HCC incidence ('Lack of 
evidence of an effect of direct-acting antivirals on the recurrence of 
hepatocellular carcinoma: Data from three ANRS cohorts,' 2016), early 
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biomarkers of malignancy are urgently needed. MiR-345-5p was found to be 
elevated in all patients at baseline who subsequently developed a malignancy, 
and this finding warrants exploration in a larger patient cohort. 
The miRNAs we have identified do not appear to be specific to HCV-related 
chronic liver disease. They may be relevant to other viral infections, as well as 
playing a role in non-viral liver disease. Pathway analysis suggested that the 
HBV, HTLV and EBV canonical pathways are significantly enriched by genes 
targeted by miRNAs deregulated in CHC. HBV can integrate into the host 
genome, driving oncogenic transformation and hepatocarcinogenesis (Zhao et 
al., 2016). MiR-21-5p is upregulated by HBV X protein, resulting in 
downregulation of PDCD4 and promoting oncogenesis (Qiu et al., 2013). MiR-122-
5p (Wang et al., 2016) and miR-885-5p (Gui et al., 2011) are also upregulated in 
the serum of HBV-infected individuals. It would be of interest to explore 
whether these miRNAs correspond with disease severity and outcomes in non-
HCV related liver disease. 
There are a number of questions still to be answered before miRNA biomarkers 
are transferable as diagnostic tools ‘from bench to bedside’. For instance, this 
study would be strengthened by the inclusion of a larger cohort of healthy 
control patients. If miRNAs are to be developed as biomarkers for virologic and 
clinical outcomes during treatment, then a greater understanding of the 
‘normal’ range of expression is required. There is significant inter-individual 
variation in both PBMC and miRNA expression, thus larger banks of patient 
samples are required. The UK Biobank (http://www.ukbiobank.ac.uk/about-
biobank-uk/) is a rich repository of clinical and genetic data as well as serum 
samples for miRNA profiling, and represents one possible source of further 
samples. Additionally, since the EAP was introduced, the recommendations for 
CHC treatment in Scotland have been updated, with sofosbuvir-velpatasvir and 
elbasvir-grazoprevir now first line as treatment options (Dillon et al., 2017). It 
remains to be seen whether baseline miR-21-5p expression remains significantly 
associated with virologic relapse following EOTR with the newer DAAs. A similar 
question can be asked of the association between miR-345-5p and miR-21-5p 
expression and the risk of significant adverse event during treatment.  
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There were a number of limitations to the studies presented here. We were 
reliant on cohorts established by other researchers, with incomplete data and 
limited sample material available. In our study of spontaneous clearance of CHC 
(chapter 3), the volume of missing data meant that multivariate analysis was not 
deemed appropriate and statistical analysis must be interpreted with caution. 
Additionally, in the Outcomes study (chapter 4), the healthy control population 
consisted partly of non-HCV-infected subjects recruited from Glasgow hospitals. 
Although individuals taking lipid-lowering medications were excluded, we cannot 
exclude the possibility that other co-morbid conditions and lifestyle factors may 
have contributed to the miRNA profile in these subjects. This might have 
contributed to an underestimation of changes in miRNA expression in the HCV-
infected population. In the same study, we found that cirrhotic patients were 
significantly older, and had significantly higher BMIs at baseline. Therefore, we 
cannot exclude the possibility that these baseline demographic factors 
contributed to the elevated miRNA expression in the PBMCs and serum of HCV-
infected subjects with cirrhosis independently of HCV infection. We had 
explored the possibility of setting up a matched cohort of non-HCV infected 
individuals with chronic liver disease secondary to NAFLD to ascertain the 
contribution of HCV infection itself to the miRNA deregulation, but this was not 
deemed possible within the time constraints of the project. It would be of 
interest in the future to interrogate such a cohort, to establish whether miRNA 
deregulation in CHC was driven by HCV infection or chronic liver disease. The 
lack of miRNA response to viral eradication in subjects who experienced 
complications of their liver disease during treatment suggests the latter. Finally, 
as discussed earlier, cohorts in the EAP study (chapter 5) were categorised 
according to known treatment outcomes, and this may have resulted in selection 
bias. Ideally, the findings require validation in a larger, prospective, randomised 
controlled trial in which the investigators are blinded as to study outcome. 
Our study lacks long-term follow up data. In my opinion, one of the most 
powerful observations of this study was that non-cirrhotic individuals with 
elevated biomarkers of immunosenescence demonstrated similar pathway 
enrichment to cirrhotic subjects. It would be of considerable interest to obtain 
long-term outcomes data for these patients to identify whether elevated 
biomarkers of immunosenescence were associated with more rapid disease 
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progression, or an increased incidence of HCC or extra-hepatic malignancy. 
Similarly, we would be keen to ascertain whether persistent elevation of miR-
122-5p, miR-21-5p and miR-885-5p in the EAP cohort was associated with 
subsequent adverse clinical outcome. MiR-345-5p appears to be a promising 
biomarker for malignancy, and requires further investigation in a larger patient 
cohort. The STOP-HCV consortium (http://www.stop-hcv.ox.ac.uk/about-stop-
hcv) was established with the aims of deriving patient stratification models to 
enhance clinical decision making, and of understanding disease mechanisms that 
define patient strata. Work Strand 5 of the STOP-HCV consortium focuses on the 
identification of serum biomarkers associated with treatment response and 
cirrhosis progression, and represents an exciting potential resource through 
which to explore these miRNAs further. 
The association between chronological age at infection and likelihood of 
spontaneous clearance of CHC suggests that senescence may negatively impact 
likelihood of spontaneous clearance, as well as treatment outcomes and disease 
progression (Hoare et al., 2010b). It would be of interest to explore the 
association between immunosenescence, miRNA expression and spontaneous 
clearance in the future. Given the concordance between factors that influence 
disease progression and those we have found to be associated with spontaneous 
clearance of CHC, the prognostic biomarkers we have identified may also have a 
role in predicting likelihood of spontaneous clearance. 
Finally, having developed an in vitro model to study the effect of IFN signalling 
on miRNA expression, it would be interesting to explore the effects of IFNα and 
poly (I:C) stimulation on expression levels of other selected miRNAs. This may 
provide further insight into the mechanisms underlying miRNA deregulation in 
CHC and the role played by host responses to infection. It is known that HCV-
infected patients demonstrate constitutive induction of IFN-regulated genes 
(Robinson et al., 2015), which may also alter miRNA regulation. The preliminary 
study presented in chapter 4.5.1 is the first step in such an analysis. It provides 
an opportunity to link the IFN response to miRNA deregulation, and to explore 
the mRNA targets for deregulated miRNAs. This would allow validation of the in 
silico pathway analyses presented here and open new avenues to explore the 
underlying mechanism for host response to infection. Moreover, there is 
increasing availability of rich host genetic data on HCV-infected subjects (Ansari 
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et al., 2017), which could also be linked to miRNA profiles from our study and 
allow analysis of the impact of host genetic variation on miRNA deregulation. 
In conclusion, we have identified a number of host and viral factors associated 
with disease progression and virologic outcomes in CHC. We found that host 
factors, including older chronological age and elevated BMI, were associated 
with the development of cirrhosis in CHC. Metabolic factors were also important 
in determining outcome following DAA therapy; a diagnosis of DM 2 was 
significantly associated with SAEs during treatment. Serum miR-21-5p expression 
and viral genotype were the most important predictors of DAA-related viral 
clearance of CHC, whilst patient demographic factors (female gender and 
younger chronological age at infection) were significantly associated with 
spontaneous clearance. Co-infection with HBV and low HCV RNA levels were also 
significantly associated with spontaneous clearance of CHC. We observed that all 
patients who were diagnosed with cancer in the EAP cohort had elevated miR-
345-5p expression at baseline, and experienced an increase in miR-21-5p 
abundance during treatment. We suggest that monitoring selected miRNAs may 
aid in the early diagnosis of HCV-related malignancy, or hepatic morbidity, and 
may help identify HCV-infected individuals who require treatment prolongation 
or intensification. Our data suggest that non-cirrhotic HCV-infected individuals 
with high bio-age (as determined by PBMC CDKN transcript status) should be 
managed similarly to cirrhotic patients, and that lifestyle factors contributing to 
immunosenescence, for instance, elevated BMI and metabolic disorders, should 
be targeted aggressively as part of a multi-disciplinary approach to patient care.  
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Tables 
Table S 1: Univariate analysis between case-control status and demographic/clinical factors 
  Late 
spontaneous 
clearance (n=50) 
Chronic infection 
(n=200) 
P value 
Male sex [n (%)] 19 (38) 129 (65) 0.001 
Median age at diagnosis  
[years (IQR)] 
29 (25-36) 33 (28-38) 0.022 
Ethnic group [n (%)] 
     White 
     Asian    
 
48 (96) 
2 (4) 
 
194 (97) 
6 (3) 
0.719 
 
 
Risk group [n (%*)] 
     Intravenous drug use 
     Other 
     Unknown 
 
41 (89) 
5 (11) 
4 
 
161 (90) 
17 (10) 
22 
0.789 
 
 
 
HCV GT [n (%*)] 
     1 
     2 
     3 
     Unknown 
 
7 (41) 
1 (6) 
9 (53) 
33 
 
61 (52) 
5 (4) 
52 (44) 
82 
0.713 
 
 
 
 
Serum HIV IgG [n(%*)] 
     Positive 
     Negative 
     Not tested 
 
2 (5) 
36 (95) 
12 
 
3 (3) 
98 (97) 
99 
0.518 
Serum HBsAg [n (%*)] 
     Positive 
     Negative 
     Not tested 
 
5 (10) 
43 (90) 
2 
 
0 (0) 
99 (100) 
101 
0.001 
Current IDU [n (%*)] 
     Yes 
     No 
     Unknown 
 
15 (38) 
25 (62) 
10  
 
97 (56) 
76 (44) 
27 
0.034 
History of alcohol 
excess/ALD [n (%*)] 
     Yes 
     No 
     Unknown 
 
 
21 (47) 
24 (53) 
5  
 
 
64 (36) 
109 (64) 
27 
0.236 
Cirrhosis [n (%*)] 
     Yes 
     No 
     Unknown 
 
13 (34) 
25 (66) 
12 
 
34 (25) 
104 (75) 
62  
0.238 
 
 
 
Median duration of 
infection [months (IQR)] 
50 (31-81) 50 (19-103) 0.854 
HCV VL (IU/ml) 
     Median 
     Interquartile range 
 
1000** 
1000 - 83293 
 
341142** 
59496 - 1517864 
<0.001 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
**Data on HCV VL only available for 19/50 (38%) patients and 138/200 (69%) patients 
respectively 
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Table S 2: As per Table S1, but where cases are confined to ‘confirmed clearers’ 
 ‘Confirmed’ 
clearance (n=27) 
Chronically 
infected 
(n=200) 
P value 
Male sex [n (%)] 10 (37) 129 (65) 0.006 
Median age at 
diagnosis  
[years (IQR)] 
29 (25-37) 33 (28-38) 0.142 
Ethnic group [n (%)] 
     White 
     Asian    
 
27 (100) 
0 (0) 
 
194 (97) 
6 (3) 
0.362 
 
 
Risk group [n (%*)] 
     IDU 
     Other 
     Unknown 
 
23 (92) 
2 (8) 
2 
 
161 (90) 
17 (10) 
22 
0.803 
 
 
 
HCV GT [n (%*)] 
     1 
     2 
     3 
     Unknown 
 
6 (55) 
0 (0) 
5 (45) 
16  
 
61 (52) 
5 (4) 
52 (44) 
82  
0.784 
 
 
 
 
Serum HIV IgG [n (%*)] 
     Positive 
     Negative 
     Not tested 
 
1 (4) 
23 (96) 
3 
 
3 (3) 
98 (97) 
99 
0.765 
Serum HBsAg [n (%*)] 
     Positive 
     Negative 
     Not tested 
 
1 (4) 
26 (96) 
0  
 
0 (0) 
99 (100) 
101 
0.055 
Current IDU [n (%*)] 
     Yes 
     No 
     Unknown 
 
9 (39) 
14 (61) 
4 
 
97 (56) 
76 (44) 
27 
0.126 
History of alcohol 
excess/ALD [n (%*)] 
     Yes 
     No 
     Unknown 
 
 
11 (44) 
14 (56) 
2 
 
 
64 (36) 
109 (64) 
27 
0.500 
Cirrhosis [n (%*)] 
     Yes 
     No 
     Unknown 
 
7 (29) 
17 (71) 
3 
 
34 (25) 
104 (75) 
62 
0.638 
 
 
 
Median duration of 
diagnosis [months 
(IQR)] 
46 (29-76) 50 (19-103) 0.593 
HCV VL (IU/ml) 
     Median 
     Interquartile range 
 
1000** 
763 - 131242 
 
341142 
59496 - 1517864 
0.001 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
**Data on HCV VL only available for 10/27 (37%) patients 
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Table S 3: Baseline demographics of the Outcomes pilot study cohort 
 Low bio-age 
(n=8) 
High bio-age 
(n=8) 
Cirrhotic 
(n=9) 
Healthy control 
(n=8) 
Male sex [n (%)] 
 
7 (87.5) 6 (75.0) 5 (55.6) 6 (75) 
Age  
[years (IQR)] 
 
39.0  
(33.0 – 42.0) 
43.5  
(38.8 - 47.5) 
49.0 
(41.5 – 55.0) 
41.0 
34.5 – 51.5) 
Age at infection 
[years (IQR)] 
 
17.0  
(15.0 - 28.5) 
18.0 
(9.5 – 23.0) 
24.0 
(16.3 – 44.0) 
- 
Ethnicity [n (%)] 
     White 
     Asian 
 
 
8 (100) 
0 
 
8 (100) 
0 
 
9 (100) 
0 
 
8 (100) 
0 
Source [n (%*)] 
     IDU 
     Other 
     Unknown 
 
 
6 (75.0) 
2 (25.0) 
0 
 
4 (57.1) 
3 (42.9) 
1 
 
5 (55.6) 
1 (11.1) 
3 
- 
HCV Gt [n (%)] 
     1 
     3 
 
 
4 (50) 
4 (50) 
 
4 (50) 
4 (50) 
 
5 (55.5) 
4 (44.5) 
- 
BMI (kg/m2) 
 
 
23.9 
(20.3 - 25.1) 
24.9 
(23.6 – 26.5) 
27.4 
(25.1 – 29.3) 
24.1 
(21.6 – 25.5) 
Current alcohol 
excess [n (%)] 
 
 
1 (12.5) 
 
0 (0) 
 
0 (0) 
 
3 (37.5) 
HCV VL  
[log10 IU/ml (IQR)] 
 
6.2 
(6.0 – 6.5) 
6.2 
(5.5 – 6.6) 
5.7 
(5.2 – 6.2) 
- 
ALT  
[IU/mL (IQR)] 
 
74.5 
(44.0 - 88.8) 
76.0 
(26.5 – 107.8) 
89.0 
(69.5 – 137.0) 
21.5 
(17.5 – 38.2) 
Liver stiffness 
[kPa (IQR)] 
 
6.2  
(5.4 – 6.6) 
5.1 
(4.2 – 6.1) 
31.4 
(21.8 – 36.6) 
- 
CDKN2A 
[RQ (IQR)] 
 
0.8  
(0.7 - 1.0) 
4.2 
(3.1 – 4.7) 
4.6 
(3.6 – 5.3) 
1.2 
(0.8 – 1.4) 
CDKN2B 
[RQ (IQR)] 
 
1.0  
(0.7 – 3.2) 
4.5  
(3.2 - 8.3) 
7.9 
(3.6 – 9.4) 
1.3 
(0.6 – 2.9) 
ARF 
[RQ (IQR)] 
 
0.8  
(0.5 – 1.2) 
7.6  
(5.3 – 9.7) 
9.7 
(8.7 – 9.7) 
1.3 
(0.7 – 1.8) 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
IQR, interquartile range; IDU, injecting drug use; Gt, genotype; RQ, fold change. 
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Table S 4: Baseline demographics of the expanded Outcomes study cohort 
 HCV infected 
(n=36) 
Cirrhotic 
(n=15) 
Healthy control 
(n=10) 
Male sex [n (%)] 
 
30 (83) 9 (60) 6 (60) 
Age  
[years (IQR)] 
 
41.0 
(37.3 – 46.8) 
48.0 
(41.0 – 54.0) 
42.0 
(33.0 – 48.0) 
Age at infection 
[years (IQR)] 
 
21.5 
(17.0 -27.5) 
21.5 
(16.3 – 34.5) 
- 
Ethnicity [n (%)] 
     White 
     Asian 
 
35 (97.2) 
1 (2.8) 
 
 
14 (93.3) 
1 (6.7) 
 
6 (60) 
4 (40) 
Source [n (%*)] 
     IDU 
     Other 
     Unknown 
 
 
26 (83.9) 
5 (16.1) 
5 
 
8 (72.7) 
3 (27.3) 
4 
- 
HCV Gt [n (%)] 
     1 
     3 
 
 
20 (55.6) 
16 (44.4) 
 
7 (46.7) 
8 (53.3) 
- 
BMI  
[kg/m2 (IQR)] 
 
24.3  
(21.4 – 26.0) 
27.4 
(24.7 – 30.0) 
24.3 
(22.2 – 25.6) 
Current alcohol 
excess [n (%)] 
 
 
3 (8.3) 
 
0 (0) 
 
3 (30) 
HCV VL  
[log10 IU/ml (IQR)] 
 
 
6.1 
(5.2 – 6.5) 
5.7 
(5.2 – 6.3) 
- 
ALT  
[IU/mL (IQR)] 
 
70.5 
(45.0 – 98.8) 
92.0 
(77.0 – 144.0) 
24.0 
(17.0 – 44.0) 
Liver stiffness 
[kPa (IQR)] 
 
6.1 
(5.0 -7.3) 
27.2 
(18.7 – 38.5) 
- 
CDKN2A 
[RQ (IQR)] 
 
1.3** 
(1.1 – 3.0) 
3.6*** 
(2.1 – 5.1) 
1.1 
(0.8 – 1.4) 
CDKN2B  
[RQ (IQR)] 
 
2.4** 
(1.1 – 4.6) 
5.7*** 
(2.0 – 9.4) 
1.1 
(0.9 – 2.3) 
ARF 
[RQ (IQR)] 
 
1.4** 
(0.9 – 5.5) 
8.8*** 
(2.5 – 9.7) 
1.2 
(0.9 – 1.7) 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
**Data only available for 27/36 (75%) patients ***Data available for 13/15 (86.7%) patients. 
IQR, interquartile range; IDU, injecting drug use; Gt, genotype; RQ, fold change with respect 
to healthy controls. 
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Table S 5: Expression of miRNA in the PBMCs of HCV-infected subjects compared with 
healthy controls 
MiRNA Fold change P-value 
hsa-miR-136-3p 0.072 0.0001 
hsa-miR-374b-3p 0.306 0.0001 
hsa-miR-629-5p 2.294 0.0001 
hsa-miR-16-5p 2.554 0.001 
hsa-miR-193a-5p 2.774 0.001 
hsa-miR-656-3p 0.184 0.001 
hsa-miR-146b-3p 2.708 0.002 
hsa-miR-323-3p 0.197 0.002 
hsa-miR-155-5p 1.523 0.006 
hsa-miR-374a-3p 0.242 0.006 
hsa-miR-193b-3p 1.849 0.007 
hsa-miR-26a-1-3p 0.263 0.008 
hsa-miR-548c-5p 1.466 0.008 
hsa-miR-532-5p 2.698 0.009 
hsa-miR-1244 2.847 0.01 
hsa-miR-410-3p 0.336 0.01 
hsa-miR-629-3p 2.191 0.01 
hsa-miR-720 2.002 0.01 
hsa-miR-140-3p 2.14 0.011 
hsa-miR-95-3p 2.095 0.011 
hsa-miR-376a-3p 0.349 0.012 
hsa-miR-520f-3p 1.414 0.015 
mmu-miR-93-5p 1.434 0.017 
hsa-miR-199a-3p 0.591 0.022 
hsa-miR-642a-5p 1.66 0.022 
hsa-miR-362-5p 1.551 0.023 
hsa-miR-590-3p 2.404 0.023 
hsa-miR-1270 0.585 0.026 
hsa-miR-1248 2.224 0.027 
hsa-miR-148b-5p 1.732 0.028 
hsa-miR-151-5p 0.346 0.028 
hsa-miR-365a-3p 1.987 0.028 
hsa-miR-628-3p 1.915 0.029 
252 
 
hsa-miR-146b-5p 1.717 0.033 
hsa-miR-222-3p 1.73 0.033 
hsa-miR-345-5p 1.738 0.033 
hsa-miR-138-5p 2.271 0.034 
hsa-miR-502-3p 1.56 0.034 
hsa-miR-29a-3p 1.853 0.037 
hsa-miR-411-5p 0.415 0.037 
hsa-miR-500a-5p 2.117 0.037 
hsa-miR-589-3p 2.354 0.038 
hsa-miR-548d-5p 1.374 0.039 
hsa-miR-20b-5p 1.322 0.04 
hsa-miR-29b-2-5p 1.503 0.045 
hsa-miR-744-3p 0.39 0.047 
hsa-miR-597-5p 0.344 0.049 
hsa-miR-9-5p 0.711 0.049 
hsa-miR-140-5p 1.624 0.049 
hsa-miR-28-3p 1.113 0.051 
hsa-miR-548J-5p 2.15 0.052 
hsa-miR-34a-3p 1.938 0.057 
hsa-miR-301a-3p 0.682 0.061 
hsa-miR-574-3p 1.349 0.065 
hsa-miR-223-3p 1.468 0.069 
hsa-miR-24-3p 1.346 0.069 
hsa-miR-16-1-3p 0.469 0.084 
hsa-miR-616-5p 0.521 0.091 
hsa-miR-449a 2.745 0.092 
hsa-miR-589-5p 1.299 0.094 
hsa-miR-139-5p 0.577 0.097 
hsa-miR-17-5p 1.253 0.101 
hsa-miR-645 2.351 0.101 
hsa-miR-184 1.186 0.106 
hsa-miR-329-3p 0.516 0.107 
hsa-miR-27a-5p 1.863 0.108 
hsa-miR-30a-3p 0.368 0.109 
hsa-miR-191-5p 1.252 0.11 
hsa-miR-376a-5p 0.129 0.116 
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hsa-miR-192-3p 1.407 0.118 
hsa-miR-29c-3p 2.172 0.118 
hsa-miR-454-3p 1.648 0.118 
hsa-miR-181a-5p 1.281 0.12 
hsa-miR-1300 1.434 0.121 
hsa-miR-145-3p 0.3 0.122 
hsa-miR-27b-3p 0.594 0.122 
hsa-miR-146a-5p 1.239 0.123 
hsa-miR-26a-2-3p 0.34 0.129 
hsa-miR-378 1.998 0.132 
hsa-miR-127-3p 0.539 0.134 
hsa-miR-451a 2.308 0.134 
hsa-miR-126-3p 0.594 0.137 
hsa-miR-550a-5p 1.763 0.139 
hsa-miR-103a-3p 1.143 0.141 
hsa-miR-495-3p 0.528 0.144 
hsa-miR-505-5p 1.207 0.15 
hsa-miR-376b-3p 1.198 0.152 
hsa-miR-551b-3p 0.505 0.16 
hsa-miR-369-3p 0.535 0.164 
hsa-miR-152-3p 0.647 0.168 
hsa-miR-370-3p 0.399 0.169 
hsa-miR-15a-3p 0.391 0.174 
hsa-miR-199b-5p 0.587 0.178 
hsa-miR-942-5p 1.134 0.179 
hsa-miR-372-3p 2.766 0.182 
hsa-miR-20a-5p 1.112 0.184 
hsa-miR-154-3p 0.42 0.189 
hsa-let-7g-3p 1.212 0.192 
hsa-miR-515-3p 0.891 0.199 
hsa-miR-30d-3p 0.479 0.2 
hsa-miR-337-5p 0.558 0.201 
hsa-miR-487b-3p 0.615 0.202 
hsa-miR-890  1.341 0.202 
hsa-miR-10a-5p 1.186 0.209 
hsa-miR-411-3p 0.372 0.213 
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hsa-miR-432-5p 0.515 0.214 
hsa-miR-302b-3p 2.484 0.226 
hsa-miR-361-5p 1.085 0.23 
hsa-miR-624-5p 0.399 0.235 
hsa-miR-335-3p 0.351 0.239 
hsa-miR-324-3p 1.197 0.246 
hsa-miR-330-3p 1.25 0.248 
hsa-miR-652-3p 1.272 0.256 
hsa-miR-543 0.635 0.259 
hsa-miR-1a-3p  0.559 0.276 
hsa-miR-192-5p 1.18 0.278 
hsa-miR-93-3p 1.87 0.28 
hsa-miR-27a-3p 0.786 0.287 
hsa-miR-671-3p 1.086 0.288 
hsa-miR-339-3p 1.163 0.297 
hsa-miR-630 0.912 0.299 
hsa-miR-181a-2-3p 0.458 0.3 
hsa-miR-367-3p 0.177 0.302 
hsa-miR-29a-5p 0.617 0.312 
hsa-miR-17-3p 0.469 0.324 
rno-miR-29c-5p 0.959 0.335 
hsa-let-7c-5p 1.045 0.338 
hsa-miR-635 1.514 0.339 
hsa-miR-125a-3p 0.734 0.34 
hsa-miR-409-3p 0.609 0.347 
hsa-miR-377-5p 3.994 0.356 
hsa-miR-221-3p 0.742 0.371 
hsa-miR-548E-3p 1.735 0.379 
hsa-miR-409-5p 0.805 0.381 
hsa-miR-489-3p 0.987 0.388 
hsa-miR-18a-3p 1.277 0.391 
hsa-miR-320a 1.006 0.392 
hsa-miR-542-5p 6.165 0.396 
hsa-miR-376c-3p 0.506 0.399 
hsa-miR-766-3p 0.637 0.402 
hsa-miR-135b-5p 2.34 0.411 
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hsa-miR-580-3p 0.535 0.419 
hsa-miR-503-5p 0.788 0.428 
hsa-miR-590-5p 0.748 0.433 
hsa-miR-491-5p 1.182 0.433 
hsa-miR-206 0.685 0.435 
hsa-miR-128-3p 1.117 0.439 
hsa-let-7f-2-3p 0.818 0.447 
hsa-miR-618 1.053 0.455 
hsa-miR-99b-5p 0.721 0.455 
hsa-miR-204-5p 0.715 0.462 
hsa-miR-31-3p 1.332 0.462 
hsa-miR-494-3p 0.948 0.466 
hsa-miR-744-5p 1.132 0.467 
hsa-miR-1282 0.599 0.469 
hsa-miR-570-3p 1.074 0.473 
hsa-miR-218-5p 1.21 0.476 
hsa-miR-493-3p 0.717 0.479 
hsa-miR-224-5p 0.694 0.497 
hsa-miR-1227-3p 1.322 0.528 
hsa-miR-374a-5p 1.03 0.533 
hsa-miR-106b-5p 1.263 0.545 
hsa-miR-30d-5p 0.794 0.548 
hsa-miR-195-5p 0.938 0.549 
hsa-miR-125b-5p 0.875 0.554 
hsa-miR-186-5p 1.367 0.56 
hsa-miR-19b-3p  1.25 0.566 
hsa-miR-190a-5p 0.656 0.569 
hsa-miR-381-3p 0.671 0.575 
hsa-miR-520c-3p 1.119 0.577 
hsa-miR-30c-5p 0.975 0.578 
hsa-miR-92a-1-5p 0.67 0.59 
hsa-miR-1271-5p 0.705 0.601 
hsa-miR-545-3p 0.8 0.601 
hsa-miR-21-5p 1.321 0.626 
hsa-miR-203-3p 0.637 0.631 
hsa-let-7e-3p 0.634 0.644 
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hsa-miR-424-5p 1.008 0.648 
hsa-let-7i-3p 0.781 0.65 
hsa-miR-185-5p 0.904 0.655 
hsa-miR-320B 1.128 0.658 
hsa-miR-340-3p 0.84 0.66 
hsa-miR-875-5p 0.395 0.675 
hsa-miR-182-5p  1.031 0.677 
hsa-miR-133a-3p 0.686 0.678 
hsa-miR-331-3p 0.998 0.68 
hsa-miR-19b-1-5p 1.01 0.693 
hsa-miR-30b-5p 1.181 0.696 
hsa-miR-28-5p 1.148 0.705 
hsa-miR-29b-3p 0.739 0.711 
hsa-miR-654-3p 0.923 0.711 
hsa-miR-221-5p 1.077 0.731 
hsa-miR-425-5p 0.914 0.732 
hsa-miR-144-5p 0.659 0.733 
hsa-miR-100-5p 0.879 0.739 
hsa-miR-101-3p 1.241 0.742 
hsa-miR-1254 1.126 0.745 
hsa-miR-340-5p 0.911 0.757 
hsa-miR-302a-3p 0.857 0.762 
hsa-miR-19a-3p 0.851 0.767 
hsa-miR-425-3p 0.756 0.767 
hsa-miR-539-5p 0.652 0.772 
hsa-miR-190b 1.073 0.786 
hsa-miR-125a-5p 0.913 0.811 
hsa-miR-197-3p 0.858 0.835 
hsa-miR-375 0.888 0.853 
hsa-miR-130b-3p 1.124 0.857 
hsa-miR-598-3p 1.088 0.862 
hsa-miR-876-3p 0.922 0.863 
hsa-miR-142-3p 1.632 0.864 
hsa-miR-518f-3p 0.744 0.87 
hsa-miR-18a-5p 1.033 0.871 
hsa-miR-362-3p 1.277 0.884 
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hsa-miR-181a-3p 0.758 0.903 
hsa-miR-148a-3p 1.171 0.904 
hsa-miR-30e-3p 1.079 0.905 
hsa-miR-20b-3p 1.05 0.915 
hsa-miR-20a-3p 0.916 0.924 
hsa-miR-548b-5p 1.186 0.926 
hsa-miR-26b-5p 1.062 0.927 
hsa-miR-550a-3p 0.752 0.964 
hsa-miR-19a-5p 0.652 0.98 
hsa-miR-142-5p 1.11 0.988 
hsa-miR-191-3p 0.949 0.997 
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Table S 6: PBMC miRNA expression in HCV Gt3 infection compared with HCV Gt1 infection 
MiRNA Fold change P-value 
hsa-miR-202-3p 0.004 0.09 
hsa-miR-515-3p 0.004 0.127 
hsa-miR-532-5p 0.034 0.0001 
hsa-miR-28-3p 0.119 0.016 
hsa-miR-323a-3p 0.146 0.051 
hsa-miR-142-3p 0.158 0.001 
hsa-miR-451a 0.164 0.002 
hsa-miR-369-5p 0.168 0.028 
hsa-miR-671-3p 0.184 0.0001 
hsa-miR-193b-3p 0.204 0.0001 
hsa-miR-362-3p 0.226 0.013 
hsa-miR-374b-5p 0.232 0.009 
hsa-miR-886-3p 0.239 0.057 
hsa-miR-142-5p 0.248 0.008 
hsa-miR-424-5p 0.253 0.003 
hsa-miR-10a-5p 0.268 0.044 
hsa-miR-296-5p 0.273 0.001 
hsa-miR-193a-5p 0.277 0.0001 
hsa-miR-148a-3p 0.28 0.0001 
hsa-miR-320a 0.283 0.002 
hsa-miR-324-3p 0.291 0.0001 
hsa-miR-423-5p 0.303 0.0001 
hsa-miR-375 0.324 0.011 
hsa-miR-328-3p 0.326 0.0001 
hsa-miR-551b-3p 0.34 0.064 
hsa-miR-652-3p 0.358 0.001 
hsa-miR-502-3p 0.362 0.0001 
hsa-miR-597-5p 0.367 0.012 
hsa-let-7c-5p 0.373 0.008 
hsa-miR-31-5p 0.373 0.216 
hsa-miR-574-3p 0.375 0.012 
hsa-miR-345-5p 0.383 0.004 
hsa-miR-148b-3p 0.393 0.011 
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hsa-miR-744-5p 0.398 0.0001 
hsa-miR-886-5p 0.398 0.185 
hsa-miR-369-3p 0.405 0.08 
hsa-miR-376c-3p 0.41 0.059 
hsa-miR-30b-5p 0.418 0.0001 
hsa-miR-339-3p 0.418 0.025 
hsa-miR-29a-3p 0.426 0.026 
hsa-miR-197-3p 0.426 0.199 
hsa-miR-21-5p 0.43 0.011 
hsa-miR-19b-3p 0.441 0.007 
hsa-miR-181a-5p 0.443 0.013 
hsa-miR-222-3p 0.446 0.048 
hsa-miR-150-5p 0.458 0.015 
hsa-miR-331-3p 0.46 0.002 
hsa-miR-532-3p 0.46 0.066 
hsa-miR-106b-5p 0.462 0.001 
hsa-miR-92a-3p 0.462 0.002 
hsa-miR-221-3p 0.463 0.003 
hsa-miR-372-3p 0.473 0.203 
hsa-miR-324-5p 0.481 0.0001 
hsa-miR-642a-5p 0.482 0.003 
hsa-miR-146b-5p 0.482 0.079 
hsa-miR-484 0.484 0.005 
hsa-miR-589-5p 0.486 0.002 
hsa-miR-101-3p 0.49 0.016 
hsa-miR-25-3p 0.491 0.0001 
hsa-miR-330-3p 0.492 0.019 
hsa-miR-140-5p 0.498 0.031 
hsa-miR-629-5p 0.499 0.002 
hsa-miR-598-3p 0.507 0.012 
hsa-miR-409-5p 0.514 0.117 
hsa-miR-125b-5p 0.521 0.0001 
hsa-miR-485-3p 0.528 0.016 
hsa-miR-146a-5p 0.537 0.039 
hsa-miR-27a-3p 0.548 0.063 
hsa-miR-367-3p 0.55 0.201 
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hsa-miR-301a-3p 0.551 0.002 
hsa-miR-3633p 0.552 0.004 
hsa-miR-182-5p 0.562 0.087 
hsa-miR-431-5p 0.565 0.395 
hsa-miR-18a-5p 0.566 0.029 
hsa-miR-223-3p 0.571 0.09 
hsa-miR-127-3p 0.578 0.077 
hsa-miR-196b-5p 0.584 0.046 
hsa-miR-491-5p 0.603 0.092 
hsa-miR-29c-3p 0.606 0.043 
hsa-miR-200c-3p 0.606 0.106 
hsa-miR-128-3p 0.616 0.102 
hsa-miR-495-3p 0.616 0.323 
hsa-miR-100-5p 0.617 0.954 
hsa-miR-93-5p 0.619 0.036 
hsa-miR-24-3p 0.621 0.018 
hsa-miR-30c-5p 0.622 0.002 
hsa-miR-185-5p 0.64 0.009 
hsa-miR-342-3p 0.643 0.22 
hsa-miR-103a-3p 0.644 0.012 
hsa-miR-192-5p 0.651 0.123 
hsa-miR-15b-5p 0.653 0.036 
hsa-let-7d-5p 0.658 0.025 
hsa-miR-20a-5p 0.658 0.1 
hsa-miR-95-3p 0.674 0.115 
hsa-miR-155-5p 0.679 0.13 
hsa-miR-106a-5p 0.68 0.057 
hsa-let-7e-5p 0.685 0.073 
hsa-miR-381-3p 0.69 0.114 
hsa-miR-545-3p 0.695 0.249 
hsa-miR-152-3p 0.699 0.864 
hsa-let-7g-5p 0.702 0.128 
hsa-miR-191-5p 0.705 0.11 
hsa-miR-199a-3p 0.725 0.035 
hsa-miR-186-5p 0.734 0.073 
hsa-miR-28-5p 0.738 0.054 
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hsa-miR-301b-3p 0.738 0.519 
hsa-miR-654-3p 0.741 0.454 
hsa-miR-138-5p 0.755 0.389 
hsa-miR-17-5p 0.758 0.123 
hsa-miR-361-5p 0.761 0.553 
hsa-miR-16-5p 0.766 0.078 
hsa-miR-758-3p 0.766 0.179 
hsa-miR-370-3p 0.768 0.101 
hsa-miR-376b-3p 0.776 0.274 
hsa-miR-890 0.789 0.345 
hsa-miR-27b-3p 0.794 0.443 
hsa-miR-362-5p 0.797 0.1 
hsa-miR-329-3p 0.808 0.339 
hsa-miR-425-5p 0.839 0.559 
hsa-miR-374a-5p 0.84 0.235 
hsa-miR-20b-5p 0.842 0.238 
hsa-miR-454-3p 0.843 0.114 
hsa-miR-579-3p 0.857 0.836 
hsa-miR-125a-5p 0.903 0.871 
hsa-miR-335-5p 0.907 0.75 
hsa-miR-29b-3p 0.916 0.813 
hsa-miR-224-5p 0.973 0.529 
hsa-miR-337-5p 0.974 0.507 
hsa-miR-708-5p  0.99 0.914 
hsa-miR-26a-5p 1.003 0.772 
hsa-miR-548c-5p 1.016 0.811 
hsa-miR-655-3p 1.077 0.778 
hsa-miR-411-5p 1.087 0.839 
hsa-miR-487b-3p 1.11 0.742 
hsa-miR-410-3p 1.136 0.455 
hsa-miR-493-3p 1.141 0.945 
hsa-miR-340-5p 1.151 0.772 
hsa-miR-218-5p 1.165 0.978 
hsa-miR-140-3p 1.349 0.667 
hsa-miR-518f-3p 1.387 0.714 
hsa-miR-139-5p 1.417 0.512 
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hsa-miR-126-3p 1.422 0.548 
hsa-miR-376a-3p 1.472 0.401 
hsa-miR-135a-5p 1.474 0.769 
hsa-miR-19a-3p 1.516 0.209 
hsa-miR-590-5p 1.561 0.221 
hsa-miR-193a-3p 1.576 0.596 
hsa-miR-628-5p 1.595 0.969 
hsa-miR-539-5p 1.605 0.793 
hsa-miR-548d-5p 1.757 0.026 
hsa-miR-302b-3p 1.826 0.468 
hsa-miR-618 1.843 0.035 
hsa-miR-627-5p 1.843 0.281 
hsa-miR-338-3p 1.844 0.535 
hsa-miR-520f-3p 2.05 0.052 
hsa-miR-548b-5p 2.45 0.066 
hsa-miR-889-3p  2.477 0.55 
hsa-miR-26b-5p 2.496 0.041 
hsa-miR-133a-3p 2.576 0.508 
hsa-miR-141-3p 2.662 0.242 
hsa-miR-422a 2.756 0.01 
hsa-miR-494-3p 3.175 0.005 
hsa-miR-302a-3p 3.339 0.085 
hsa-miR-576-3p 3.518 0.192 
hsa-miR-1-3p 3.637 0.047 
hsa-miR-145-5p 3.723 0.225 
hsa-miR-184 3.754 0.436 
hsa-miR-190a-5p 4.346 0.0001 
hsa-miR-195-5p 4.947 0.0001 
hsa-miR-548c-3p 5.645 0.001 
hsa-miR-136-5p 11.159 0.502 
hsa-miR-483-5p 11.225 0.004 
hsa-miR-885-5p 11.522 0.499 
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Table S 7: Univariate analysis between clinical factors and PBMC biomarkers in cirrhotic and 
non-cirrhotic HCV-infected subjects in the pilot study cohort 
 Non-cirrhotic 
(n=16) 
Cirrhotic 
(n=9) 
P value 
Male sex [n (%)] 13 (81.3) 5 (55.6) 0.170 
Age [years (IQR)] 40.5 (38.3 – 45.8) 49 (41.5 – 55.0) 0.012 
Age at infection 
[years (IQR)] 
17 (12.5 – 25.5) 24 (16.3 – 44.0) 0.179 
Duration of infection 
[years (IQR)] 
22 (16.3 – 38.5) 30 (13.5 – 48) 0.677 
Source [n (%*)] 
     IDU 
     Other 
     Unknown 
 
10 (66.7) 
5 (33.3) 
1 
 
5 (83.3) 
1 (16.7) 
3 
0.688 
BMI [kg/m2 (IQR)] 24.6 (23.4 – 25.5) 27.4 (25.1 – 29.3) 0.027 
HCV VL  
[log10 IU/ml (IQR)] 
6.2 (5.9 – 6.5) 5.7 (5.2 – 6.2) 0.057 
ALT [IU/mL (IQR)] 
 
74.5 (37.8 – 96.0) 89 (69.5 – 137) 0.207 
CDKN2A [RQ (IQR)] 1.3 (0.8 – 4.3) 4.6 (3.6 – 5.3) 0.007 
CDKN2B [RQ (IQR)] 3.4 (0.9 – 4.6) 7.9 (3.6 – 9.4) 0.019 
ARF [RQ (IQR)] 2 (0.8 – 7.9) 9.7 (8.7 – 9.7) 0.006 
miR-16-5p positive 
[n (%)] 
5 (31.2) 8 (100)* 0.001 
miR-155-5p positive 
[n (%)] 
6 (37.5) 9 (100) 0.002 
miR-221-3p positive 
[n (%)] 
3 (18.8) 8 (88.9) 0.001 
miR-21-5p positive 
[n (%)] 
11 (68.8) 4 (44.4) 0.234 
miR-885-5p positive 
[n (%)] 
4 (25) 8 (88.9) 0.002 
miR-195-5p positive 
[n (%)] 
10 (62.5) 2 (22.2) 0.053 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
IQR, interquartile range; IDU, injecting drug use; Gt, genotype; RQ, fold change with respect 
to healthy controls. 
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Table S 8: Expression of miRNA in the serum of HCV-infected subjects compared with healthy 
controls 
MiRNA Fold change P-value 
hsa-miR-122-5p 4.186 0.0001 
hsa-miR-192-5p 4.003 0.0001 
hsa-miR-193a-5p 2.9 0.0001 
hsa-miR-193b-3p 3.816 0.0001 
hsa-miR-21-5p 2.254 0.0001 
hsa-miR-30d-5p 3.2 0.0001 
hsa-miR-34a-3p 3.954 0.0001 
hsa-miR-875-5p 6.47 0.0001 
hsa-miR-885-5p 8.571 0.0001 
hsa-miR-320a 1.569 0.001 
hsa-miR-375 3.55 0.001 
hsa-let-7c-5p 1.694 0.002 
hsa-miR-1291 3.009 0.003 
hsa-miR-363-3p 1.921 0.003 
hsa-miR-455-5p 3.288 0.003 
hsa-miR-625-5p 2.787 0.004 
hsa-miR-671-3p 0.475 0.004 
hsa-miR-411-3p 0.351 0.005 
hsa-miR-125b-5p 1.952 0.008 
hsa-miR-224-5p 2.289 0.009 
hsa-miR-654-3p  0.358 0.009 
hsa-miR-99b-3p 2.834 0.009 
hsa-miR-200b-3p 3.53 0.011 
hsa-miR-146b-3p 3.155 0.012 
hsa-miR-720 0.637 0.013 
hsa-miR-1244 3.823 0.014 
hsa-miR-126-5p 5.183 0.019 
hsa-miR-26a-1-3p 2.938 0.019 
hsa-miR-16-5p 1.64 0.021 
hsa-miR-362-3p 1.963 0.021 
hsa-miR-100-5p 1.975 0.024 
hsa-miR-483-5p 5.771 0.024 
hsa-miR-423-5p 1.328 0.029 
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hsa-miR-26b-5p 1.468 0.031 
hsa-miR-429 1.579 0.031 
hsa-miR-424-3p 1.634 0.035 
hsa-miR-362-5p  1.807 0.036 
hsa-miR-182-5p 2.586 0.037 
hsa-miR-130b-3p  1.396 0.039 
hsa-miR-486-5p 0.363 0.042 
hsa-miR-19a-3p 1.28 0.044 
hsa-miR-133a-3p 1.309 0.046 
hsa-miR-590-5p 1.349 0.046 
hsa-miR-150-5p 1.429 0.047 
hsa-miR-186-5p 1.499 0.047 
hsa-miR-194-5p 1.817 0.049 
hsa-miR-93-3p 0.435 0.049 
hsa-miR-598-3p 1.402 0.05 
hsa-miR-365a-3p 2.053 0.051 
hsa-miR-191-3p 0.594 0.054 
hsa-miR-328-3p 0.731 0.054 
hsa-miR-95-3p 1.305 0.055 
hsa-miR-660-5p 1.501 0.076 
hsa-miR-454-5p 0.241 0.079 
hsa-miR-181c-5p 3.119 0.085 
hsa-miR-190a-5p 1.692 0.086 
hsa-miR-645 0.456 0.09 
hsa-miR-183-5p 1.404 0.093 
hsa-miR-576-3p 0.604 0.094 
hsa-miR-214-5p 0.516 0.109 
hsa-miR-148a-3p 1.773 0.118 
hsa-miR-22-5p 1.2 0.132 
hsa-miR-152-3p 1.563 0.137 
hsa-miR-485-3p 0.488 0.14 
hsa-miR-195-5p 1.298 0.141 
hsa-miR-16-1-3p 0.604 0.146 
hsa-miR-345-5p 1.26 0.158 
hsa-miR-505-5p 1.343 0.161 
hsa-miR-181a-2-3p 0.639 0.163 
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hsa-miR-296-5p 1.285 0.163 
hsa-miR-101-3p 1.466 0.164 
hsa-miR-301a-3p 1.457 0.165 
hsa-miR-629-5p 1.445 0.169 
hsa-miR-155-5p 1.167 0.17 
hsa-miR-134-5p 1.442 0.17 
hsa-miR-203a-3p 1.812 0.172 
hsa-miR-184 1.463 0.173 
hsa-miR-1300 0.409 0.174 
hsa-miR-511-5p 1.916 0.174 
hsa-miR-1274A 0.336 0.18 
hsa-miR-1227-3p 0.493 0.185 
hsa-miR-487b-3p 0.605 0.188 
hsa-miR-130a-3p 1.327 0.189 
hsa-miR-10a-5p 1.528 0.192 
hsa-miR-424-5p 0.592 0.192 
hsa-miR-616-3p 2.263 0.194 
hsa-miR-29c-3p 2.164 0.197 
hsa-miR-590-3p 0.386 0.197 
hsa-miR-548a-3p 1.526 0.2 
hsa-miR-185-5p 1.08 0.203 
hsa-miR-146a-5p 1.288 0.205 
hsa-miR-486-3p 0.172 0.208 
hsa-miR-605-5p 0.634 0.222 
hsa-miR-26b-3p 0.592 0.224 
hsa-miR-103a-3p 0.78 0.227 
hsa-miR-190b 1.298 0.236 
hsa-miR-27b-3p 1.469 0.239 
hsa-miR-616-5p 0.636 0.244 
hsa-miR-148b-3p 0.687 0.256 
hsa-miR-628-5p 0.604 0.258 
hsa-miR-206 1.57 0.261 
hsa-miR-29a-3p 1.227 0.264 
hsa-miR-335-3p 1.343 0.265 
hsa-miR-145-3p 0.585 0.266 
hsa-miR-338-3p 2.519 0.269 
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hsa-miR-597-5p 0.486 0.272 
hsa-miR-320b 1.356 0.277 
hsa-miR-139-3p 1.149 0.28 
hsa-miR-9-3p 1.032 0.28 
hsa-miR-370-3p 0.593 0.281 
hsa-miR-18a-3p 0.441 0.286 
hsa-miR-30d-3p 1.816 0.287 
hsa-miR-339-3p 1.369 0.298 
hsa-miR-579-3p 0.972 0.301 
hsa-miR-491-5p 0.85 0.302 
hsa-let-7e-5p 0.745 0.306 
hsa-miR-548d-5p 2.178 0.31 
hsa-miR-574-3p 1.008 0.311 
hsa-miR-10b-3p 1.027 0.319 
hsa-miR-548c-5p 1.5 0.324 
hsa-miR-886-3p 0.711 0.326 
hsa-miR-629-3p 1.039 0.328 
hsa-miR-1262 0.767 0.335 
hsa-miR-18a-5p 0.704 0.336 
hsa-miR-223-3p 0.708 0.347 
hsa-miR-744-5p  0.792 0.349 
hsa-miR-301b-3p 1.228 0.353 
hsa-miR-636 0.621 0.357 
hsa-miR-31-5p 1.222 0.366 
hsa-miR-411-5p 0.829 0.367 
hsa-miR-886-5p 2.099 0.367 
hsa-miR-652-3p 1.282 0.371 
hsa-miR-484 1.081 0.374 
hsa-miR-1285-3p 0.242 0.376 
hsa-miR-543  0.62 0.378 
hsa-miR-548b-5p 0.375 0.384 
hsa-miR-93-5p 1.044 0.386 
hsa-miR-218-5p  1.221 0.389 
hsa-miR-515-3p 0.258 0.389 
hsa-miR-30e-3p 1.431 0.393 
hsa-miR-140-3p 0.959 0.395 
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hsa-miR-140-5p 0.977 0.395 
hsa-miR-19b-1-5p 0.67 0.396 
hsa-miR-642a-5p 0.9 0.403 
hsa-miR-766-3p 0.883 0.403 
hsa-miR-379-5p 1.745 0.409 
hsa-miR-136-3p 0.724 0.413 
hsa-miR-28-3p 0.638 0.414 
hsa-miR-502-3p 1.165 0.418 
hsa-miR-452-5p 1.153 0.42 
hsa-miR-197-3p 1.06 0.424 
hsa-miR-1303 0.536 0.425 
hsa-miR-758-3p 1.06 0.428 
hsa-miR-15b-5p 0.566 0.438 
hsa-miR-1180-3p 0.685 0.444 
hsa-miR-223-5p 1.422 0.444 
hsa-miR-376b-3p 1.088 0.453 
hsa-miR-132-3p 0.589 0.454 
hsa-miR-92a-1-5p 1.153 0.456 
hsa-miR-589-3p 0.558 0.458 
hsa-miR-432-5p 0.884 0.472 
hsa-miR-342-3p 1.007 0.483 
hsa-miR-28-5p  1.046 0.484 
hsa-miR-27a-3p 1.096 0.491 
hsa-miR-1267 0.24 0.499 
hsa-miR-340-5p 1.149 0.499 
hsa-miR-376c-3p 0.802 0.514 
hsa-miR-523-3p 0.679 0.522 
hsa-miR-30a-3p 1.257 0.532 
hsa-miR-495-3p 0.882 0.533 
hsa-miR-19b-3p 1.137 0.537 
hsa-miR-1254 1.37 0.538 
hsa-miR-374b-5p 0.828 0.538 
hsa-miR-191-5p 1.215 0.543 
hsa-miR-199a-5p  0.736 0.546 
hsa-miR-221-3p 0.903 0.552 
hsa-miR-222-3p 1.038 0.554 
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hsa-miR-361-5p 0.602 0.554 
hsa-miR-550a-5p  1.187 0.556 
hsa-miR-181a-3p 1.634 0.559 
hsa-miR-338-5p 1.214 0.566 
hsa-miR-146b-5p  1.189 0.567 
hsa-miR-205-5p 0.767 0.577 
hsa-miR-500a-5p 0.824 0.579 
hsa-miR-516b-3p 0.859 0.579 
hsa-miR-204-5p 0.946 0.584 
hsa-miR-542-3p 0.417 0.586 
hsa-miR-125a-3p 0.875 0.593 
hsa-miR-24-3p 1.15 0.594 
hsa-miR-124-3p 0.513 0.594 
hsa-miR-151-5p 0.889 0.6 
hsa-miR-505-3p 0.792 0.607 
hsa-miR-127-3p 0.767 0.619 
hsa-miR-324-3p 0.653 0.619 
hsa-miR-425-3p 0.986 0.62 
hsa-miR-577 0.627 0.638 
hsa-miR-628-3p 0.876 0.638 
hsa-let-7e-3p 1.362 0.64 
hsa-miR-15a-3p  0.649 0.64 
hsa-miR-126-3p 1.123 0.641 
hsa-miR-143-3p 0.996 0.651 
hsa-miR-26a-5p 0.911 0.653 
hsa-miR-494-3p 0.93 0.656 
hsa-miR-138-5p 1.07 0.662 
hsa-miR-196b-5p 0.966 0.674 
hsa-miR-17-5p 0.834 0.676 
hsa-miR-409-3p 0.602 0.677 
hsa-miR-1-3p 0.866 0.683 
hsa-miR-181a-5p 0.88 0.685 
hsa-miR-211-5p 0.864 0.685 
hsa-miR-409-5p 0.993 0.692 
hsa-miR-422a 1.027 0.696 
hsa-let-7d-5p 1.13 0.698 
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hsa-miR-889-3p 0.733 0.704 
hsa-miR-200c-3p 0.811 0.707 
hsa-miR-1271-5p 0.906 0.709 
hsa-miR-376a-3p 0.993 0.73 
hsa-miR-493-3p 1.072 0.734 
hsa-miR-942-5p 1.302 0.741 
hsa-miR-576-5p 1.062 0.745 
hsa-miR-128-3p 1.023 0.747 
hsa-let-7g-5p 1.03 0.75 
hsa-miR-433-3p 0.732 0.753 
hsa-miR-92a-3p 0.938 0.772 
hsa-miR-451a 0.997 0.774 
hsa-miR-890 0.943 0.778 
hsa-miR-27a-5p  0.675 0.782 
hsa-miR-517a-3p 0.854 0.786 
hsa-miR-532-5p 0.894 0.799 
hsa-miR-25-3p 0.925 0.801 
hsa-miR-1255b-5p 1.223 0.804 
hsa-miR-425-5p 0.921 0.806 
hsa-miR-142-3p 0.956 0.81 
hsa-miR-584-5p 1.13 0.814 
hsa-miR-548c-3p 1.508 0.817 
hsa-miR-148b-5p 0.419 0.83 
hsa-miR-625-3p 0.911 0.835 
hsa-miR-20b-5p 0.959 0.839 
hsa-miR-331-3p 0.945 0.841 
hsa-miR-1197 0.881 0.846 
hsa-miR-337-5p 1.167 0.848 
hsa-miR-324-5p 0.908 0.853 
hsa-miR-144-5p 1.029 0.856 
hsa-miR-340-3p 1.067 0.857 
hsa-miR-30c-5p 1.048 0.862 
hsa-miR-655-3p 0.819 0.868 
hsa-miR-378 0.975 0.869 
hsa-miR-518f-3p 0.853 0.872 
hsa-miR-769-5p 0.853 0.875 
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hsa-miR-20a-5p  0.911 0.888 
hsa-miR-20a-3p 1.136 0.892 
hsa-miR-374a-5p 0.901 0.896 
hsa-miR-29c-5p 0.853 0.896 
hsa-miR-330-3p 1.026 0.901 
hsa-miR-410-3p 0.812 0.909 
hsa-miR-106b-5p 0.947 0.929 
hsa-miR-139-5p 1.075 0.934 
hsa-miR-519a-3p 0.758 0.936 
hsa-miR-532-3p 1.088 0.937 
hsa-miR-183-3p 1.195 0.947 
hsa-miR-30b-5p 1.1 0.947 
hsa-miR-329-3p 0.865 0.948 
hsa-miR-34b-3p 1.154 0.957 
hsa-miR-539-5p 1.067 0.958 
hsa-miR-125a-5p 0.911 0.964 
hsa-miR-591 0.688 0.972 
hsa-miR-142-5p 0.972 0.975 
hsa-miR-106a-5p 0.973 0.99 
hsa-miR-199a-3p 0.989 0.994 
hsa-miR-454-3p 0.888 0.995 
hsa-miR-99b-5p 0.903 0.996 
hsa-miR-145-5p 1.12 0.997 
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Table S 9: Univariate analysis between clinical factors and biomarkers in cirrhotic and non-
cirrhotic HCV-infected subjects in the expanded Outcomes cohort (n=51) 
 Non-cirrhotic 
(n=36) 
Cirrhotic 
(n=15) 
P value 
 
Male sex [n (%)] 30 (83) 9 (60) 0.073 
White ethnicity [n (%)] 35 (97.2) 14 (93.3) 0.514 
Age [years (IQR)] 41.0 (37.3 – 46.8) 48.0 (41.0 – 54.0) 0.004 
Age at infection  
[years (IQR)] 
21.5 
(17.0 -27.5) 
21.5 
(16.3 – 34.5) 
0.566 
Source [n (%*)] 
     IDU 
     Other 
     Unknown 
 
26 (83.9) 
5 (16.1) 
5 
 
8 (72.7) 
3 (27.3) 
4 
0.647 
HCV Gt [n (%)] 
     1 
     3 
 
20 (55.6) 
16 (44.4) 
 
7 (46.7) 
8 (53.3) 
0.562 
IFNL3 Gt [%*)] 
     CC 
     Non CC 
     Unknown 
 
9 (26.5) 
25 (73.5) 
2 
 
4 (36.4) 
7 (63.6) 
4 
0.529 
BMI [kg/m2(IQR)] 24.3 (21.4 – 26.0) 27.4 (24.7 – 30.0) 0.005 
Alcohol excess 
[n (%)] 
3 (8.3) 0 (0) 0.249 
HCV VL  
[log10 IU/ml (IQR)] 
6.1 (5.2 – 6.5) 5.7 (5.2 – 6.3) 0.408 
 
ALT [IU/mL (IQR)] 70.5 (45.0 – 98.8) 92.0 (77.0 – 144.0) 0.082 
miR-21-5p [RQ (IQR)] 0.7 (0.4 – 2.8) 1.4 (0.5 – 5.6) 0.408 
miR-122-5p [RQ (IQR)] 2.1 (0.2 – 8.9) 2.6 (0.9 – 6.5) 0.664 
miR-885-5p [RQ (IQR)] 5.0 (1.1 – 12.1) 9.8 (3.7 – 16.6) 0.160 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
IQR, interquartile range; IDU, injecting drug use; Gt, genotype; RQ, fold change with respect 
to healthy controls.  
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Table S 10: Multiple logistic regression for variables significant at the 10% level in the 
univariate analysis between clinical factors and biomarkers in cirrhotic and non-cirrhotic 
HCV-infected subjects in the expanded Outcomes cohort (n=51). *p<0.05 
 Model 1 Model 2 
Variable B SE OR B SE OR 
Constant -17.01 5.34 0.00 -18.45 5.89 0.00 
Age 0.17* 0.07 1.19 0.19* 0.08 1.20 
BMI 0.34* 0.14 1.40 0.36* 0.15 1.42 
ALT    0.00 0.00 1.00 
-2LL 43.84 42.93 
Nagelkerke R2 40.4% 42.3% 
 Χ2 = 16.52; df 2; p<0.001 Χ2 = 17.43; df 3; p=0.001 
Hosmer & 
Lemeshow 
p=0.721 p=0.234 
Classification 
accuracy 
81.6% 85.7% 
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Table S 11: Univariate analysis between clinical factors and biomarkers in non-cirrhotic and 
cirrhotic HCV-infected subjects; analysis restricted to subjects with data available on CDKN2 
locus transcript expression (n=40) 
 Non-cirrhotic 
(n=27) 
Cirrhotic 
(n=13) 
P value 
 
Male sex [n (%)] 22 (81.5) 8 (61.5) 0.172 
White ethnicity [n (%)] 27 (100) 12 (92.3) 0.144 
Age [years (IQR)] 41.0 (38.0 – 46.0) 48.5 (41.0 – 54.3) 0.002 
Age at infection  
[years (IQR)] 
20.0 
(16.3 -26.8) 
18.0 
(16.3 – 33.8) 
0.660 
Source [n (%*)] 
     IDU 
     Other 
     Unknown 
 
20 (80) 
5 (20) 
2 
 
6 (66.7) 
3 (33.3) 
3 
0.648 
HCV Gt [n (%)] 
     Gt1 
     Gt3 
 
17 (63.0) 
10 (37.0) 
 
5 (38.5) 
8 (61.5) 
0.145 
IFNL3 Gt [n (%*)] 
     CC 
     Non CC 
     Unknown 
 
5 (18.5) 
22 (81.5) 
0 
 
4 (44.4) 
5 (55.6) 
4 
0.120 
BMI [kg/m2(IQR)] 24.9 (22.7 – 26.3) 27.5 (25.2 – 30.0) 0.003 
Alcohol excess [n (%)] 3 (11.1) 0 (0) 0.211 
HCV VL  
[log10 IU/ml (IQR)] 
6.0 (5.4 – 6.4) 5.8 (5.2 – 6.4) 0.289 
ALT [IU/mL (IQR)] 70.0 (39.0 – 85.0) 90.5 (75.5 – 133.5) 0.012 
CDKN2A [RQ (IQR)] 1.3 (1.1 – 3.0) 3.1 (1.9 – 5.0) 0.007 
CDKN2B [RQ (IQR)] 2.4 (1.1 – 4.6) 4.1 (1.1 – 9.4) 0.142 
ARF [RQ (IQR)] 1.4 (0.9 – 5.5) 8.0 (1.6 – 9.7) 0.006 
CDKN2 expression 
     High 
     Low 
 
11 (40.7) 
16 (59.3) 
 
11 (85.7) 
2 (14.3) 
0.009 
miR-21-5p [RQ (IQR)] 0.7 (0.3 – 2.2) 1.2 (0.6 – 3.8) 0.360 
miR-122-5p [RQ (IQR)] 2.2 (0.6 – 8.9) 2.6 (0.8 – 14.7) 1.000 
miR-885-5p [RQ (IQR)] 4.8 (0.8 – 9.7) 9.4 (3.2 – 14.8) 0.168 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
IQR, interquartile range; IDU, injecting drug use; Gt, genotype; RQ, fold change with respect 
to healthy controls.  
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Table S 12: Multiple logistic regression for variables significant at the 10% level in the 
univariate analysis between clinical factors and biomarkers in cirrhotic and non-cirrhotic 
HCV-infected subjects in the expanded Outcomes cohort; analysis restricted to subjects with 
data available on CDKN2 locus transcript expression (n=40). *p<0.05 
 Model 1 Model 2 
Variable B SE OR B SE OR 
Constant -34.76 12.76 0.00 -33.66 13.02 0.00 
Age 0.28* 0.13 1.32 0.25 0.32 1.28 
BMI 0.73* 0.30 2.07 0.71* 0.32 2.03 
ALT 0.03 0.01 1.03 0.03* 0.01 1.03 
CDKN2    1.54 1.27 4.67 
-2LL 22.31 20.71 
Nagelkerke R2 69.4% 72.3% 
 Χ2 = 26.5; df 3; p<0.001 Χ2 = 28.1; df 4; p<0.001 
Hosmer & 
Lemeshow 
p=0.532 p=0.992 
Classification 
accuracy 
92.1% 84.2% 
 
 
Table S 13: Diagnostic power of individual biomarkers for cirrhosis in CHC 
Biomarker AUC 95% CI P value 
ALT 0.656 0.483 – 0.828 0.082 
CDKN2A RQ 0.764 0.609 – 0.918 0.008 
CDKN2B RQ 0.645 0.444 – 0.846 0.141 
ARF RQ 0.765 0.612 – 0.918 0.007 
miR-21-5p RQ 0.574 0.402 – 0.706 0.206 
miR-122-5p RQ 0.539 0.373 – 0.705 0.912 
miR-885-5p RQ 0.626 0.467 – 0.785 0.088 
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Table S 14: Baseline demographics of the EAP study population (n=59) 
 All 
(n=59) 
SVR12 
(n=20) 
SVR-AE 
(n=19) 
RR 
(n=20) 
Male sex  
[n (%)] 
 
40 (67.9) 12 (60) 13 (68) 15 (75) 
Age 
[years (IQR)] 
54 
(48 - 61) 
51.5 
(45.5 – 60.8) 
59 
(47 – 62) 
54 
(49.3 – 58.8) 
Ethnicity [n (%*)] 
    White  
    Asian  
    Unknown 
 
47 (83.9) 
9 (16.1) 
3 
 
15 (83.3) 
3 (16.7) 
2 
 
14 (77.8) 
4 (22.2) 
1 
 
18 (90) 
2 (10) 
0 
HCV Gt [n (%*)] 
     1 
     2 
     3 
     4 
     Unknown 
 
26 (44.8) 
1 (1.7) 
30 (51.7) 
1 (1.7) 
1 
 
9 (45) 
1 (5) 
9 (45) 
1 (5) 
0 
 
13 (72.2) 
- 
5 (27.8) 
- 
1 
 
4 (20) 
- 
16 (80) 
- 
0 
DM 2 [n (%)] 18 (30.5) 2 (10) 8 (42) 8 (40) 
HCV VL [log10 
IU/ml (IQR)] 
 
5.5 
(4.9 – 6.0) 
5.6 
(4.3 – 6.1) 
5.2 
(4.8 – 6.0) 
5.4 
(5.0 – 6.0) 
Use of RBV  
[n (%)] 
52 (88.1) 20 (100) 15 (78.9) 17 (85) 
NS5Ai [n (%)] 
     Ledipasvir 
     Daclatasvir 
 
41 (69.5) 
18 (30.5) 
 
14 (70) 
6 (30) 
 
14 (73.7) 
5 (26.3) 
 
13 (65) 
7 (35) 
ALT  
[IU/mL (IQR)] 
 
54.0 
(37.8 – 70.3) 
61.0 
(45.0 – 80.0) 
47.0 
(27.3 – 71.0) 
60.0 
(39.3 – 67.0) 
MELD 
[n (IQR)] 
11 
(8.8 – 13.3) 
10.5 
(8.0 – 12.0) 
11.0 
(7.0 – 12.0) 
13.0 
(11.3 – 15.0) 
*Percentage related to the actually recorded data. SVR12, sustained virologic response 12 
weeks post end of treatment; AE, adverse event; IQR, interquartile range; Gt, genotype; 
RBV, ribavirin; NS5Ai, NS5A inhibitor; ALT, alanine aminotransferase; MELD, model for end-
stage liver disease. 
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Table S 15: Comparison of the baseline clinical characteristics, laboratory parameters and 
biomarkers in treatment responders (n=39) and RRs (n=20). 
 SVR12 - all 
(n=39) 
RR 
(n=20) 
P-value 
Male sex [n (%)] 25 (64.1) 15 (75) 0.396 
Age [years (IQR)] 55 (47 – 61) 54 (49.3 – 58.8) 0.317 
Ethnicity [n (%*)] 
     White 
     Asian 
     Unknown 
 
29 (80.6) 
7 (19.4) 
3  
 
18 (90) 
2 (10) 
0 
0.356 
HCV Gt [n (%*)] 
     1 or 4 
     2 or 3 
     Unknown 
 
23 (60.5) 
15 (39.5) 
1 
 
4 (20) 
16 (80) 
0 
0.003 
DM 2 [n (%)] 10 (25.6) 8 (40) 0.257 
HCV RNA  
[log10 IU/mL (IQR)] 
5.5  
(4.8 – 6.0) 
5.4  
(5.0 – 6.0) 
0.543 
NS5Ai [n (%)] 
     Ledipasvir 
     Daclatasvir 
 
28 (71.8) 
11 (28.2) 
 
13 (65) 
7 (35) 
0.592 
 
Use of RBV [n (%)] 35 (89.7) 17 (85) 0.594 
ALT [IU/mL (IQR)] 51.5  
(33.8 – 72.5) 
60  
(39.3 – 67) 
0.525 
MELD score [n (IQR)]
  
11 (7.8 – 12) 13 (11.3 – 15) 0.006 
miR-21-5p +ve [n (%)] 12 (30.7) 17 (85) <0.001 
miR-122-5p +ve [n (%)] 16 (41.0) 13 (65) 0.081 
miR-885-5p +ve [n (%)] 16 (41.0) 13 (65) 0.081 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
SVR, sustained virologic response 12 weeks post end of treatment; AE, adverse event; IQR, 
interquartile range; Gt, genotype; NS5Ai, NS5A inhibitor; RBV, ribavirin; ALT, alanine 
aminotransferase; MELD, model for end-stage liver disease 
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Table S 16: Multiple logistic regression for variables significant at the 10% level in the 
univariate analysis between baseline clinical factors and biomarkers in treatment responders 
(n=39) and RRs (n=20) in the EAP cohort. **p<0.01, ***p<0.001 
 Model 1 Model 2 
Variable B SE OR B SE OR 
Constant -3.56 0.90 0.03 -4.71 1.55 0.01 
miR-21-5p 2.83*** 0.80 16.88 2.90** 0.85 18.22 
HCV Gt 2 or 3 2.07** 0.78 7.90 2.18** 0.83 6.85 
MELD score    0.10 0.12 1.10 
-2LL 48.65 44.64 
Nagelkerke R2 50.0% 55.2% 
 Χ2 = 26.1; df 2; p<0.001 Χ2 = 29.2; df 3; p<0.001 
Hosmer & 
Lemeshow 
p=0.706 p=0.932 
Classification 
accuracy 
81% 82.5% 
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Table S 17: Comparison of baseline clinical characteristics, laboratory parameters and 
biomarkers in treatment responders who did (SVR-AE, n=19) and did not (SVR12, n=20) 
experience adverse clinical outcomes in the EAP cohort 
 SVR12 
(n=20) 
SVR12 - AE 
(n=19) 
P-value 
Male sex [n (%)] 12 (60) 13 (68.4) 0.584 
Age [years (IQR)] 51.5 (45.5 – 60.8) 59 (47 – 62) 0.461 
Ethnicity [n (%*)] 
     White 
     Asian 
     Unknown 
 
15 (83.3) 
3 (16.7) 
2 
 
14 (77.8) 
4 (22.2) 
1 
0.674 
HCV Gt [n (%*)] 
     1 or 4 
     2 or 3 
     Unknown 
 
10 (50) 
10 (50) 
0 
 
13 (72.2) 
5 (27.8) 
1 
0.162 
DM 2 [n (%)] 2 (10) 8 (42.1) 0.022 
HCV RNA  
[IU/mL (IQR)] 
5.6  
(4.3 – 6.1) 
5.2  
(4.9 – 5.8) 
0.409 
NS5Ai [n (%)] 
     Ledipasvir 
     Daclatasvir 
 
14 (70) 
6 (30) 
 
14 (73.7) 
5 (26.3) 
0.798 
 
Use of RBV [n (%)] 20 (100) 15 (78.9) 0.030 
ALT [IU/mL (IQR)] 61 (45 – 80) 47 (27.3 – 71) 0.196 
MELD score [n (IQR)] 10.5 (8 – 12) 11 (7 – 12) 0.806 
miR-21-5p +ve [n (%)] 9 (45) 3 (15.8) 0.048 
miR-122-5p +ve [n(%)] 9 (45) 7 (36.8) 0.605 
miR-885-5p +ve [n (%)] 9 (45) 7 (36.8) 0.605 
miR-345 +ve [n (%)] 7 (35) 13 (68.4) 0.037 
Composite miR [n (%)] 4 (20) 12 (63.2) 0.006 
*Percentage related to the actually recorded data; missing data handled by listwise deletion. 
SVR, sustained virologic response 12 weeks post end of treatment; AE, adverse event; IQR, 
interquartile range; Gt, genotype; NS5Ai, NS5A inhibitor; RBV, ribavirin; ALT, alanine 
aminotransferase; MELD, model for end-stage liver disease
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Table S 18: Details of significant adverse events in the SVR12-AE group (n=19).  
Age Gender Ethnicity Gt ALT DM 
2 
Baseline 
MELD 
MELD ↑ HCC Ca Decomp Other miR-345 miR-21 miR-122 miR-885 miR-21↑ 
62 Female Asian Gt3 30 Yes 7 Yes No No Past Anaemia Pos Neg Neg Neg Yes 
58 Male White Gt1 34 No 11 No No No Current HE Pos Neg Neg Neg Yes 
55 Female White Gt3 21 No 13 No No No Current Ascites Pos Neg Pos Pos Yes 
59 Male White Gt1 52 Yes 6 Yes No No Current NA Neg Neg Neg Neg Yes 
47 Male 
 
Gt1 15 No 15 No No Yes Past HE Pos Neg Neg Neg Yes 
38 Male White Gt1 212 Yes 11 No No No Never Endoscopy Neg Pos Pos Pos No 
61 Female Asian Gt3 71 Yes 
  
No No Past HE Pos Pos Pos Pos No 
60 Male White Gt1 33 No 9 Yes No No Never NA Pos Neg Neg Neg Yes 
53 Male White Gt1 51 No 11 No No No Never Variceal 
bleed 
Pos Neg Pos Pos Yes 
64 Male White Gt3 148 No 7 No Yes Yes Past Ascites Pos Neg Neg Pos Yes 
61 Female White Gt3 28 No 6 Yes No No Current NA Neg Neg Neg Neg Yes 
59 Female White Gt1 10 No 6 No No No Past NA Pos Neg Neg Pos Yes 
75 Male White Gt1 25 No 11 No No Yes Current NA Pos Neg Pos Pos Yes 
50 Female Asian 
 
71 Yes 12 
 
No No Current HE Pos Pos Neg Neg No 
38 Male White Gt1 101 No 12 No No No Past NA Pos Neg Neg Neg No 
62 Male White Gt1 43 Yes 24 No No No Current Ascites Pos Neg Neg Neg Yes 
39 Male Asian Gt1 
 
Yes 11 Yes No No Current Ascites Neg Neg Neg Neg Yes 
40 Male White Gt1 56 No 10 No Yes Yes Past NA Pos Neg Neg Neg Yes 
67 Male White Gt1 61 Yes 8 Yes No No Current NA Neg Neg Pos Neg Yes 
Gt, genotype; DM 2, diabetes mellitus type 2; MELD, model for end stage liver disease; HCC, hepatocellular carcinoma; Ca, malignancy other than HCC; 
Decomp, decompensation event; Pos, positive; Neg, negative; HE, hepatic encephalopathy; NA, not applicable
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Table S 19: Multiple logistic regression for variables significant at the 10% level in the 
univariate analysis between treatment responders who did (SVR12-AE, n=19) and did not 
(SVR12, n=20) experience adverse clinical outcomes in the EAP cohort. *p<0.05, **p<0.01 
 Model 1 Model 2 
Variable B SE OR B SE OR 
Constant -2.66 1.03 0.07 -2.66 1.03 0.07 
DM 2 3.77** 1.31 43.36 3.08* 1.37 21.74 
Composite miR 3.58** 1.19 35.92 3.58** 1.19 35.91 
RBV    20.30 18153 655306328 
-2LL 33.13 30.87 
Nagelkerke R2 55.3% 59.7% 
 Χ2 = 20.91; df 2; p<0.001 Χ2 = 23.17; df 3; p<0.001 
Hosmer & 
Lemeshow 
p=0.991 p=0.991 
Classification 
accuracy 
82.1% 82.1% 
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